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Abstract 
Thl or Th2 type immune responses are an important feature of many human diseases, 
including several lung pathologies. Multiple factors are involved in determining 
whether a naïve CD4+ T cell differentiates into a Thl or Th2 effector cell and several 
lines of evidence point towards an important role for the interaction between the T cell 
receptor (TCR) and its peptide ligand. A previous study showed that highly polarised 
Th2 CD4+ T cells selected under Th2 polarising conditions favour a structurally 
distinct TCR with an elongated TCR a chain complimentarity determining region 3 
(CDR3), while those selected under Thl polarising conditions favour a shorter TCR 
CDR3 a chain. Molecular modelling predicted that this elongated TCR a chain 
results in a less optimal (lower avidity) interaction between the TCR and peptide/MHC 
complex. In this thesis, clonotypic analysis was used to identify dominant TCR 
chains from established Thl and Th2 polarised T cell lines. Dominant TCR a chains 
were cloned into TCR transgenic expression vectors and lines of mice with transgenic 
expression of these chains were identified. In vitro and in vivo studies were used to 
investigate T cell responses in these transgenic lines and the data suggests that 
expression of the Th2 derived TCR a chain can cause an inherent bias in CD4+ T cell 
phenotype. A long term aim of this work is to use the Thl and Th2 TCR transgenic 
animals to develop novel mouse models of lung disease and this thesis also describes 
the generation of transgenic mice that express the Thl and Th2 TCR cognate epitope, 
PLP 56-70, inducibly and specifically in the lung. Also implicated in the pathogenesis 
of many lung diseases is the CXC chemokine, interleukin 8. The final chapter of this 
thesis describes the generation of transgenic mice overexpressing this human protein 
constitutively in the lung and reports initial characterisation of protein expression and 
consequent lung inflammation in these animals. 
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Chapter 1  
Introduction 
1.1 The afi T cell receptor 
The af3 T cell receptor (TCR) is a transmembrane heterodimer expressed on the 
surface of CD4+ and CD8 + T lymphocytes. TCRs on CD4+ and CD8+ T cells 
recognise peptides bound to class I or class II major histocompatibility complex 
(MHC) molecules respectively and engagement of the TCR with peptide and MHC 
can result in activation of the T cell and initiation of an adaptive immune response. 
The TCR protein was first identified in the early 1980's using antibodies raised against 
lymphomas or T cell clones (Allison et al., 1982 and Haskins et al., 1983). It was 
noted that these antibodies, specific for a component of the T cell, could block antigen 
recognition and that this blocking or binding did not occur when the antibodies were 
used against T cells of different antigen specificities. Precipitation of the proteins 
bound by these antibodies revealed a dimer of approximately 80 kilodaltons (kD), 
which, on reduction of disulphide bonds, could be separated into two monomers of 39 
and 41 kD. Tryptic peptide analysis of the two TCR monomers, now known as the 
alpha chain and the beta chain, began to reveal the basis of TCR clonality and 
peptide/MHC specificity (Kappler et al., 1983), with comparisons of peptides derived 
from TCRs of different specificities suggesting the presence of constant and variable 
regions in both chains. Understanding of the genetic basis for these constant and 
variable regions of the TCR became possible following the isolation of alpha and beta 
chain cDNA (Chien et al., 1984 and Hedrick et al., 1984) which showed the TCR 
chains to be composed of rearranged variable (V), diversity (D), joining (J) and 
constant (C) region sequences, a concept previously encountered in studies of the B 
cell antigen receptor immunoglobulin genes (Hozumi and Tonegawa, 1976). 
24 
Following the discovery of the a13 TCR, another TCR molecule, known as the y8 
TCR, was also described (Brenner et al., 1986). 
1.2 T cell receptor gene rearrangement 
There are three distinct TCR loci in the genome of both humans and mice, Tcrb, 
Tcra/Tcrd and Tcrg, containing the V, D, J and C genes necessary for assembly of af3 
and y8 T cell receptors. An outline of the murine germline configuration of genes 
within the Tcrb and Tcra/Tcrd loci is shown in figure 1.1. The process of gene 
rearrangement and the joining of V, D, J and C genes to form a functional TCR chain 
occurs in the thymus during lymphocyte development and utilises highly conserved 
recombination signal sequences (RSS) that flank each gene segment (Akira et al., 
1987). The recombination signals consist of conserved heptamer and nonamer 
sequences that flank relatively non-conserved 12 bp (12RSS) or 23 bp (23RSS) 
spacers. Point mutations in the conserved sequences, or changes in the length of the 
spacers, drastically reduce recombination efficiency (Akira et al., 1987) and, although 
non-conserved, changes in the sequence of the spacer regions have also been shown to 
have an impact (Montalbano et al., 2003). Recombination between gene segments 
occurs via a mechanism of double strand breaks (Roth et al., 1992) and is mediated by 
the recombination activating genes, RAG1 and RAG2 (McBlane et al., 1995). Mice 
deficient in either RAG1 or RAG2 fail to develop mature T cells, due to an inability to 
initiate V(D)J recombination (Mombaerts et al., 1992a and Shinkai et al., 1992), and 
as such, transgenic expression of rearranged TCR alpha and beta chain genes can 
restore T cell development in these animals (Shinkai et al., 1993). The RAG proteins 
control the specificity of cleavage events during recombination by binding to the 
conserved RSS motifs, but also control the configuration in which gene segments can 
be joined together, by dictating that a gene with a 5' 23RSS can only be joined to a 
gene with a 3' 12RSS and vice versa (van Gent et al., 1996). This is known as the 
12/23 rule of recombination (Akira et al., 1987). However, this seemingly simple 
mechanism of control over the configuration of TCR genes cannot account for the 
25 
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Figure 1.1 TCR a and 13 loci gene arrangement and recombination. (a) Schematic 
diagrams of the arrangement of V, D, J and C genes and enhancer elements at the 
murine Tcra/d and Tcrb loci are shown. (b) Gene segments are combined by a 
mechanism of double strand breaks, mediated by the RAG recombinase protein 
complex. Junctional diversity during the joining together of gene segments is brought 
about by random nucleotide (N) addition by the Terminal deoxynucleotidyl transferase 
(TdT) enzyme. (c) The order in which gene segments are combined is strictly 
controlled with DP-J(3 recombination occurring before VP-DP joining. Points at 
which N nucleotide addition creates junctional diversity in the a and [3 TCR chains are 
marked (N). 
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strict control imposed on the order in which different genes and indeed different 
chains are rearranged. Figure 1.1 outlines the basic mechanism of the V(D)J 
recombination reaction and also shows the order in which gene segments for each 
TCR chain are recombined. According to the 12/23 rule direct VP-J13 rearrangement 
should be possible. However, DP-JP rearrangements are found to occur preferentially, 
followed by VP - D.43 (Born et al., 1985). A greater level of control than simply 
12RSS or 23RSS is now known to reside with the recombination signal sequence 
itself. A study using a modified TCR (3 locus containing just one DP gene segment 
and one JP gene cluster demonstrated that the 12RSS of the JP was unable to substitute 
for the 12RSS of the DP in allowing recombination with VP gene segments (Bassing 
et al., 2000). However, although this finding sheds more light onto how the 
configuration of gene segments in TCR chains may be controlled, the complex 
temporal regulation of gene rearrangement is still unexplained. Temporal control of 
TCR gene rearrangement is important not only in determining the order in which 
genes of a single chain are rearranged (Born et al., 1985), but also in controlling 
rearrangement of (3 or y chains prior to rearrangement of a or 8 chains (Raulet et al., 
1985) and in controlling allelic exclusion of the TCRP locus, where productive 
rearrangement of one TCR (3 allele impedes further gene rearrangement on another 
(Uematsu et al., 1988). To explain these processes, the concept of locus accessibility 
has emerged whereby multiple mechanisms are employed to alter the accessibility of 
genes within a TCR locus to the RAG V(D)J recombinase. Experiments have shown 
the presence of nucleosomes (the simplest form of chromatin packaging) around RSSs 
to be inhibitory to cleavage by the V(D)J recombinase (Golding et al., 1999) and 
changes in the chromatin accessibility of VP genes, as measured by sensitivity to 
DNase I digestion and levels of histone acetylation have been observed upon transition 
of developing T cells from double negative (DN) to double positive (DP) (Tripathi et 
al., 2002). As well as acetylation, chromatin accessibility is also affected by 
methylation. Increased levels of methylation as a consequence of deletion of the 
promoter PD(31 (figure 1.1) from the TCR (3 locus results in decreased D131 gene 
rearrangement, although D(32 rearrangement is unaffected (Whitehurst et al., 2000). 
This suggests that chromatin remodelling may be one mechanism by which promoters 
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within TCR loci exert control over local rearrangements. Longer range control over 
chromatin structure has been observed for the enhancer sequence (EP) of the TCR P 
locus (figure 1.1), deletion of which significantly reduces chromatin accessibility 
throughout the DpJP region (Oestreich et al., 2006). This study also reported direct 
physical contact between EP and PD131, implying that different control elements 
within a TCR locus can interact to exert control over TCR gene rearrangement during 
T cell development. 
1.3 T cell receptor sequence diversity 
Mathematical estimates of the number of different TCR sequences that can potentially 
exist are in the range of 1012-1015 (Davis and Chien, 1999). However, through the 
need for self tolerance, and the processes of negative and positive selection in the 
thymus, estimates of the number of different aP T cell receptor sequences present in 
the periphery range from 2 x 106 for a naive mouse (Casrouge et al., 2000) to 2 x 107 
in human peripheral blood (Arstila et al., 1999). Diversity of TCRs is achieved in one 
of three ways. As already discussed, the genomic locus of each TCR chain contains 
many different V, D and J gene segments which recombine to generate a functional 
TCR chain. There are therefore many possible combinations of gene sequences that 
can exist following recombination. Secondly, each TCR is composed of an a and a P 
chain. Diversity is therefore amplified by receptor heterodimerisation where, for 
example, a particular p chain sequence is able to form a functional receptor with 
multiple TCR a chain partners (Listman et al., 1996). The third mechanism by which 
TCR sequence diversity is achieved is by imprecise joining of gene segments during 
the recombination process itself. Following cleavage of the TCR locus, coding ends 
of gene segments, brought into close proximity by the RAG V(D)J recombinase 
complex, must be joined together to create a functional TCR chain. During the joining 
phase of rearrangement reactions, random nucleotides (N) are added in a template 
independent fashion onto the 3' OH ends of the combining gene segments by the 
terminal deoxynucloetidyl transferase (TdT) enzyme. Regions of N nucleotides at the 
junctions of gene segments are absent in the TCRs of T lymphocytes that lack this 
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enzyme (Komori T et al., 1993) and the size of the a(3 TCR repertoire in TdT null 
mice has been estimated to be just 10% of the size of a normal wild-type animal 
(Cabaniols et al., 2001). However, immune responses appear relatively unimpaired in 
these animals, which remain able to mount robust responses against a range of 
different antigens (Gilfillan et al., 1995). Regions of each TCR chain sequence that 
are subject to N region addition are marked on figure 1.1 and lie in a region termed the 
CDR3a or CDR313 of the TCR a and 13 chains respectively. The CDR3, along with 
the germline encoded CDR1 and CDR2 regions of the TCR, plays an important role in 
peptide specificity and in binding of the TCR to peptide/MHC and will be discussed in 
more detail in a later section. 
1.4 T cell receptor assembly 
The assembly of a functional a(3 TCR on the surface of a mature T cell is an ordered 
process that is subject to strict control measures at multiple stages during T cell 
development. A schematic diagram of the different stages of T cell development in 
the thymus and the timing of al3 TCR assembly is shown in figure 1.2. The main 
requirements of a TCR on the surface of a T cell, exiting the thymus to join the 
peripheral immune system, are that it should be able to recognise peptides bound to 
self-MHC molecules but that it should not be reactive to peptides derived from self-
proteins. The nature of TCR gene rearrangement in promoting extensive TCR 
sequence diversity, as discussed in the previous section, means that there is estimated 
to be potential for the generation of 1012 — 1015 different TCRs. However many of 
these will not satisfy the self MHC / self peptide requirements mentioned above and so 
processes of positive and negative selection are employed in the thymus to reduce and 
restrict the peripheral TCR repertoire to those molecules which will be functional, but 
not self reactive. 
During T cell development, the TCR (3 chain is rearranged before the a chain (Raulet 
et al., 1985) and indeed use of a TCR p chain transgene in scid mice (Bosma et al., 
1983), which carry a mutation in a DNA repair enzyme and so cannot carry out VDJ 
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Figure 1.2 Timing of TCR gene rearrangement and T cell selection during 
normal thymocyte development. The main stages of normal thymocyte development 
are shown, along with cell surface markers used to distinguish each immature cell 
population. TCR (3 gene rearrangement and cell surface expression occurs before that 
of the TCR a chain and the TCR (3 chain is stabilised at the cell surface by binding to a 
surrogate a chain (pTa). Formation of a pTa complex at the cell surface mediates 
transition of thymocytes from the DN stage to the DP stage and following allelic 
exclusion at the TCR (3 locus, TCR a gene rearrangement and expression is permitted. 
On formation of a stable a13 heterodimer, positive and negative selection events ensure 
that mature SP T cells exiting the thymus are able to recognise foreign peptides bound 
to self MHC, but are not reactive to peptides derived from self proteins. 
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recombination, demonstrated expression of the TCR (3 chain on the cell surface of DN 
thymocytes in the absence of the a chain (Hiroyki et al., 1991). Stable cell surface 
expression of the 13 chain is permitted by the formation of a heterodimer with a 33 kDa 
glycoprotein known as the pre-TCR a chain (Groettrup et al., 1993). af3 T cell 
development is found to be severely impaired in animals that lack the pre-TCR a gene 
(Fehling et al., 1995), with T cell development blocked at the transition between DN 
and DP thymocytes (figure 1.2), although the block is incomplete compared to that 
seen in the absence of the 13 chain (Mombaerts et al., 1992b). This finding implies that 
proteins other than the pre-TCR a (pTa) are able to facilitate transition of thymocytes 
from DN to DP and indeed in pTa deficient mice, a13 TCR complexes can rescue T 
cell development and promote maturation and expansion of T cells expressing a 
productively rearranged (3 chain (Buer et al., 1997). However, the a chain cannot act 
as a direct substitute for pTa, as T cells manipulated to express a TCR a chain at the 
point of normal pTa gene expression, but lacking endogenous pTa, demonstrate 
impaired development, proliferation and differentiation (Borowski et al., 2004). In 
this study, inefficiencies in T cell development and survival were partly overcome by 
expression of a hybrid TCR a chain, containing the cytoplasmic domain of pTa, and 
multiple lines of evidence now point to an important role for pTa in mediating 
signalling events that promote T cell development and allelic exclusion at the TCR p 
locus. pTa is a type 1 transmembrane protein (Saint-Ruf et al., 1994) which pairs 
with the TCR p chain via a disulphide bond. The extracellular portion of the protein is 
an immunoglobulin (Ig) like domain and the intracellular cytoplasmic tail contains 
several potential phosphorylation sites and a Src homology 3 (SH3) domain binding 
sequence. Mutation studies of this cytoplasmic tail have demonstrated an important 
role in T cell development (Aifantis et al., 2002) and in intracellular Ca2+ mobilisation, 
an important mediator of intracellular signalling events which has been shown to 
increase, alongside activation of the transcription factors NF-KB and NFAT, during 
constitutive signalling through the pre-TCR complex (Aifantis et al., 2001). The 
process by which a developing lymphocyte expressing a pre-TCR (TCR (3 / pTa) 
complex is permitted to move from the DN to DP compartment of the thymus, thereby 
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undergoing proliferation and escape from apoptosis, is known as p selection and is 
accompanied by allelic exclusion at the TCR (3 locus, ensuring that each developing T 
cell expresses a single TCR (3 chain. Signalling through the pre-TCR is known to be 
important in this allelic exclusion as thymocytes from mice lacking pTa show an 
increased number of cells with two rearranged TCR (3 alleles (Aifantis et al., 1997), a 
finding also observed in mice lacking the signalling pathway adapter, SH2 Domain-
containing Leukocyte Protein (SLP)-76 (Aifantis et al., 1999). These SLP-76 
knockout mice also show a block at the DN stage of thymocyte development, which 
cannot be overcome by expression of TCR a and p chain transgenes. However, 
signalling through the pre-TCR during (3 selection does not occur in isolation and other 
signalling pathways, such as those initiated by the Notch receptor and its ligands have 
also been shown to play a role (Ciofani et aL, 2004). 
One of the functional outcomes of pre-TCR signalling, leading to allelic exclusion at 
the TCR (3 locus, is the down regulation of the RAG genes responsible for gene 
rearrangement (Wilson et al., 1994). Expression levels of RAG-1 and RAG-2 are high 
at two stages during lymphocyte development. The first is early in DN thymocytes, 
prior to (3 chain selection, and the second later in DP thymocytes, permitting 
rearrangement at the TCR a locus (figure 1.2). Unlike the TCR (3 locus, both alleles 
of the TCR a locus are permitted to undergo rearrangement simultaneously and this 
rearrangement is not inhibited by expression of an aP TCR at the cell surface 
(Borgulya et al., 1992). As such, rearrangement at the TCR a locus continues until an 
a(3 pair on the surface of the T cell successfully engages with a major 
histocompatibility complex molecule and results in positive selection and 
downregulation of RAG gene expression (Brandle et al., 1992). A single TCR a allele 
is able to make multiple rearrangements, so that if the first rearrangement does not 
result in a functional TCR when paired with the TCR (3 chain expressed by that T cell, 
the TCR a locus can excise the first rearrangement and recombine different V and J 
genes upstream and downstream of the original rearrangement respectively in a 
process termed TCR a chain revision (Marolleau et al., 1988). Mice engineered to 
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express a modified TCR a locus containing a very limited number of V and J genes, 
which cannot undergo effective TCR cc chain revision, show a reduced number of a(3 
T cells in the periphery (Huang et al., 2005), highlighting the importance of this 
process in normal T cell development. At the point of TCR a chain rearrangement 
and expression, the pre-TCR complex is downregulated from the cell surface via a 
mechanism of competitive displacement (Trop et al., 2000). Immature double positive 
thymocytes (TCRI') often express two cell surface TCR a chains, derived from each 
TCR a, allele, both forming pairs with the same TCR 13 chain (Alam et al., 1995). 
However, most mature thymocytes and peripheral T cells express just one cc(3 TCR 
and this process of selection of one TCR cc chain over another is known as allelic 
exclusion, although the functional rearrangement of both TCR cc chain alleles that can 
precede exclusion makes it a functionally different process from that previously 
described for allelic exclusion at the TCR (3 locus. Several different hypotheses have 
been proposed to explain allelic exclusion of TCR a chains. The first proposes that 
competition between the chains for pairing with a limited number of TCR (3 chain 
molecules dictates which pair becomes dominant. This is supported by experiments 
demonstrating good expression of both chains intracellularly, despite the presence of 
just one on the cell surface, arguing against a mechanism of downregulation of one 
chain (Alam and Gascoigne, 1998). However, T cells engineered to express two 
independent TCRs, i.e. with different cc and (3 chains, still preferentially express just 
one receptor at the cell surface, although both TCR proteins can be detected 
intracellularly and the receptor which dominates is not fixed between T cell clones 
(Sant'Angelo et al., 2001). This finding makes the competition hypothesis harder to 
rationalise, but does point to a post-translational mechanism of control. A second 
hypothesis proposes an active mechanism of exclusion whereby signalling events are 
required to select one a(3 pair over another. In a study using immature thymocytes 
expressing two TCR cc chains with different peptide specificities, allelic exclusion was 
achieved upon ligand recognition with subsequent loss of the non-ligated receptor in 
mature T cells (Boyd et al., 1998). This receptor specific signal for allelic exclusion 
was also found to be CD45 dependent, implicating a mechanism of signalling through 
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the TCR, a finding subsequently supported by studies involving other mediators of the 
TCR signalling pathway (Niederberger et al., 2003). 
1.5 Thymic selection 
The process of positive selection, whereby an ocr3 TCR demonstrates binding and 
recognition of self-MHC, occurs in the thymic cortex. Interactions between T cells 
and cortical thymic epithelial cells (cTECs) have been shown to be dependent upon 
MHC (Bousso et al., 2002) and lead to the migration of thymocytes towards the 
thymic medulla, a process mediated by the upregulation of chemokine receptors, such 
as CCR7, and their ligands (Kwan and Killeen, 2004). In the thymic medulla T cells 
interact with other cell types, such as dendritic cells (DCs) and medullary thymic 
epithelial cells (mTECs), which present a diverse array of peptide/MHC complexes 
with peptides derived from ubiquitously expressed, but also tissue specific proteins 
(Sospedra et al., 1998). A high affinity interaction between an a(3 TCR and a self 
peptide/MHC complex results in negative selection and deletion of the thymocyte 
bearing the autoreactive TCR (Kappler et al., 1987) thus establishing tolerance to self 
proteins. A recent study highlighting the importance of negative selection in 
establishing tolerance used mice able to express an MHC molecule (IA") bound to just 
a single peptide, permitting positive selection of thymocytes but severely impairing the 
process of negative selection. The authors demonstrated that mature T cells specific 
for this MHC molecule were highly cross reactive, not only recognising other peptides 
bound to IA", but also binding other MHC alleles (Huseby et al., 2005). 
Expression of peripheral antigens in the thymus was found to be a function of mTECs 
(Derbrinksi et al., 2001) and in this study, expression of a peripheral protein in these 
cells was found to be sufficient for the generation of peripheral tolerance. However, 
although expression of the tissue specific antigen is a function of mTECs, they are not 
necessarily the cell type that ultimately presents the antigen to the developing 
lymphocyte. A study of antigen presentation in the thymus, using mice in which 
mTECs could express ovalbumin (OVA) but not MHC class I, demonstrated that DCs 
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in the thymus could generate tolerance to this protein via a mechanism of indirect 
antigen presentation (Gallegos and Bevan, 2004). Expression of tissue specific 
antigens in mTECs is now known to be primarily mediated by the transcription factor 
AIRE (Anderson et al., 2002), although some genes can still be upregulated in the 
absence of this protein (Derbinski et al., 2005). Humans with mutations in the AIRE 
gene suffer from systemic autoimmunity (Finnish-German APECED Consortium, 
1997), as do AIRE deficient mice (Anderson et al., 2002). More recently, variations 
between individuals in thymic expression levels of autoantigens controlled by the 
AIRE protein, such as insulin, have been correlated with susceptibility to disease 
(Taubert et al., 2007). However, thymic expression of a protein does not necessarily 
result in efficient negative selection and tolerance. A study investigating tolerance 
versus autoimmunity to the membrane protein H+/K+ ATPase, the main autoantigen of 
autoimmune gastritis, found that although one subunit of the protein (H/Ka) is 
expressed in the thymus, T cells specific for this molecule are not deleted (Allen et al., 
2005). The reason for this failure of negative selection was found to be the absence of 
the (3 subunit (H/K(3), which is required to stabilise the H/Ka subunit in the 
membrane. Many proteins are also expressed differentially between tissues as 
different splice variants of the same gene. This can mean that, despite induction of 
gene expression in the thymus during T cell development, the epitope associated with 
disease is not encountered by autoreactive T cells until they reach the periphery (Klein 
et al., 2000). Therefore, although the expression of tissue specific antigens in the 
thymus is critical for the generation of self-tolerance, tolerance may be harder to 
achieve for more complicated proteins with multiple subunits or complex genetic 
expression mechanisms. 
The main mechanism of central tolerance induction in the thymus is negative selection 
by apoptosis. T cells deficient in two key pro-apoptotic proteins, Bak and Bax 
demonstrate impaired thymocyte development, including an impaired ability to 
undergo negative selection (Rathmell et al., 2002), and NOD mice, which display a 
general susceptibility to autoimmunity, have been shown to have reduced expression 
of another mediator of apoptosis, the bim protein (Liston et al., 2004). However, an 
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alternative mechanism of central tolerance, where T cells bearing autoreactive TCRs 
are induced to acquire a regulatory T cell (CD4+CD25±) phenotype has also been 
described (Jordan et al., 2001). T cells proceeding along this pathway of selection 
have been shown to require a high affinity interaction with their peptide/MHC 
complex. That a high affinity interaction between a TCR and self/peptide MHC in the 
thymus can result in development of a regulatory T cell phenotype in some cases, but 
apoptosis and negative selection in other cases, and that a low affinity interaction 
spares the T cell from deletion resulting in positive selection (Alam et al., 1996), 
raises important, but yet broadly unanswered questions about how the T cell interprets 
a signal through the TCR to generate different functional outcomes. This issue will be 
explored further in later sections discussing TCR structure, TCR signalling and T cell 
differentiation. 
1.6 Dual TCR expression 
Although most mature CD4+ and CD8+ T cells express just a single type of al3 TCR at 
the cell surface, allelic exclusion, particularly at the TCR a locus, is not always 
complete. This results in the expression of two TCR a chains, each pairing with the 
same TCR p chain to form two independent receptors (Padovan et al., 1993). It is 
estimated that as many as 30% of peripheral human T cells (Padovan et al., 1993) and 
10-30% of peripheral mouse T cells (Elliott and Altmann, 1995 and Sarukhan et al., 
1998) may carry dual a chains and although dual TCRs are most commonly associated 
with incomplete allelic exclusion at the a locus, very low frequencies of T cells 
expressing two p chains have also been reported (Padovan et al., 1995). Since the 
demonstration of dual TCR expression on the surface of a single T cell in the 
periphery, much attention has focussed on the potential implication of this finding in 
terms of antigen specificity and autoimmunity. It has been postulated that autoreactive 
TCRs may escape negative selection in the thymus by being expressed at low levels on 
the surface of a T cell which is then subsequently positively selected based on low 
affinity self peptide/MHC recognition by a second, more highly expressed, TCR. This 
idea was supported by a study using dual TCR transgenic mice where one receptor, 
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specific for the natural self-antigen C5, was rescued from negative selection in the 
thymi of C5+ mice by expression of a second unrelated TCR. Both TCRs were 
present on the surface of mature T cells in the periphery, but levels of the autoreactive 
TCR were very low and these CD8+ T cells were only able to mediate killing of a C5 
carrying target cell when activated via the second TCR (Zal et al., 1996). That this 
phenomenon may then lead to increased susceptibility to autoimmunity also has some 
experimental support (Sarukhan et al., 1998). In this study a TCR transgenic model of 
autoimmune diabetes was used to demonstrate that, in the context of an active central 
tolerance mechanism, T cells expressing low levels of autoantigen specific TCR could 
still be found in the periphery and that these cells also expressed a second TCR 
molecule and were capable of causing disease. However, other studies in different 
disease systems using mice hemizygous for the TCR a locus and therefore unable to 
express dual TCRs have not always supported this link (Elliott and Altmann, 1996 and 
Corthay et al., 2001). Another proposed implication of dual TCR expressing cells is 
that they may serve to increase the repertoire of TCRs in the periphery which are 
capable of binding to foreign peptides by rescuing from deletion those TCRs which do 
not bind self peptide/MHC with high enough affinity to be positively selected in the 
thymus (He et al., 2002). 
1. 7 TCR editing and revision 
Although discussions of negative selection in the thymus usually refer to deletion of a 
T cell bearing an autoreactive TCR, there is some evidence that T cell apoptosis is not 
always the default pathway for removing these receptors from the repertoire. As an 
alternative, a mechanism of receptor editing has been proposed to occur whereby 
autoreactive TCRs are internalised and further rearrangement at the TCR a locus is 
permitted (McGargill et al., 2000). This was demonstrated using a transgenic TCR 
specific for a peptide of OVA in a mouse expressing this peptide specifically in the 
thymus. Why the binding of some autoreactive TCRs may activate this receptor 
editing pathway of negative selection compared to the apoptotic pathway initiated by 
others is not currently understood, but does seem to be an outcome intrinsic to the 
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TCR and antigen being recognised. When a different TCR (2C) and ligand (HY) were 
used in the system described above, deletion was the main outcome (Mayerova and 
Hogquist, 2004) and the choice between receptor editing and deletion was found to be 
unaffected by the cell type involved in presentation of the antigen within the thymus. 
When a T cell exits the thymus and enters the peripheral immune system, the TCR(s) 
it bears on the cell surface are generally considered to be fixed, i.e. no further changes 
in TCR sequence occur. However, a study using a TCR Vp5 transgenic mouse 
demonstrated that the RAG genes could be re-expressed in peripheral CD4+ T 
lymphocytes, and that active V(D)J recombination was detectable in these cells 
(McMahan and Fink, 1998). In this study, this process of receptor revision was seen 
to occur over time, with numbers of V135+ cells in the periphery decreasing as mice 
aged, but it has also been reported to occur in response to stimulation with 
superantigen (Huang et al., 2002) and the notion that receptor revision is restricted to 
recent thymic emigrants still undergoing secondary rearrangement events has also 
been challenged (Cooper et al., 2003). Any changes in the TCR of a T cell once in the 
periphery and out of reach of thymic selection could be potentially dangerous to self 
as, although receptor revision may serve as a mechanism of peripheral tolerance and 
deletion, the generation of autoreactive TCR is also a possibility. In one study using 
non-obese diabetic (NOD) mice, which are susceptible to autoimmune diabetes, a 
population of peripheral, autoagressive, CD40+ T cells were seen to express RAG 
genes and alter their surface expression of Va (Vaitaitis et al., 2003). However, a 
good understanding of the importance of TCR revision in relation to disease 
mechanisms, peripheral tolerance or TCR repertoire expansion is still lacking. 
1.8 Structure of the TCR/CD3 signalling complex 
As previously discussed, the ar3 and y8 TCRs are both transmembrane heterodimers 
whose individual subunits are composed of rearranged V, D, J and C region 
sequences. Many crystal structures for both al3 TCRs and yo TCRs have now been 
solved (e.g. Garcia et al., 1996 and Allison et al., 2001). Each TCR chain is revealed 
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to form 2 immunoglobulin (Ig) like domains on the extracellular side of the cell 
membrane, one composed of rearranged V, D and J sequences and the other formed 
from part of the C region, although the Ig fold formed by the Ca region is atypical due 
to the absence of a top (3 sheet. A connecting peptide, the transmembrane domain and 
a short cytoplasmic tail are also encoded by the C regions and the two chains of each 
TCR are joined together by disulphide bonds. Cell surface expression of the TCR 
heterodimer is stabilised by, and is indeed dependent upon, association with another 3 
protein dimers (CD3ye, CD38E and CD3t) and a TCR molecule at the cell surface in 
association with these additional polypeptides is known as the TCR/CD3complex 
(Samelson et al., 1985, Sussman et al., 1988 and Geisler, 1992). The extracellular 
domains of the y,E, and 8 chains also form Ig folds (Arnett et al., 2004 and Kjer-
Nielsen et al., 2004) while the extracellular domains of the chains are only 9 amino 
acids in length and are of unknown structure. A schematic diagram of the 4 protein 
dimers that make up the TCR/CD3 complex is shown in figure 1.3. However, 
although the identity of the components of the complex are now fairly well 
established, the lack of a crystal structure for the complex in its entirety means that our 
understanding of the three dimensional organization of the complex is still incomplete. 
Although precise interactions between subunits, particularly the extracellular portions 
are ill defined, acidic and basic charged residues in the transmembrane helices of TCR 
and CD3 subunits, which are highly conserved, are known to play an important role in 
complex assembly (Call et al., 2002). In this study, isolation of radiolabelled 
assembly intermediates from the cell endoplasmic reticulum (ER), and a mutagenesis 
approach, allowed the exact transmembrane residue requirements of each intermediate 
to be determined. It was found that the intermediates of (TCRa - CD38E), (TCR(i - 
CD3yE) and (TCRa - CD3) all required one basic and two acid residues for 
assembly with the basic residues provided by transmembrane regions of the TCR 
chains and acidic residues by transmembrane regions of the CD3 chains. This study 
also provided evidence that each TCR/CD3 complex contained just a single TCR aP 
heterodimer, a concept that has been controversial, with other groups reporting 
evidence of multiple aP molecules per complex (Fernandez-Miguel et al., 1999). To 
date, the exact stoichiometry of the TCR/CD3 complex is still debated, but more 
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Figure 1.3 Signalling pathways downstream of the T cell receptor. This schematic 
diagram shows the major components of the intracellular signalling pathways of T cell 
activation but does not cover all known proteins and interactions. Phosphorylation of 
ITAM motifs in the intracellular domains of the CD3 proteins by Lck results in 
recruitment and activation of ZAP-70. ZAP-70 phosphorylates the adaptor molecule 
LAT, which is then able to recruit a multitude of other adapter proteins and enzymes 
ultimately leading to activation of the transcriptional activation by the transcription 
factors AP-1, NF-xl3 and NFAT 
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recent evidence points towards the existence of both monovalent and multivalent 
complexes on the cell surface (Schamel et al., 2005) a finding that may have important 
implications for current models of TCR signalling. 
Much is now known about the nature of the intracellular signalling events that occur 
following ligation of the TCR with a peptide/MHC complex (pMHC). A review of all 
of the different kinases, phosphatases and adapter molecules currently known to be 
involved in the propagation of a productive TCR signal will not be attempted here, but 
the main components of the signalling cascade are shown in figure 1.3. The earliest 
signalling events following TCR ligation are phosphorylation of immunoreceptor-
tyrosine-based activation motif (ITAM) tyrosines in the intracellular domains of CD3 
chains by the Src family kinases Lck and Fyn, although the contribution of Fyn under 
normal physiological conditions is thought to be minimal as it is largely unable to 
compensate for the loss of a functional Lck molecule (Straus and Weiss, 1992). The 
CD3 y, 8 and 6 chains each contain 1 ITAM while the CD3 chain contains 3 and 
phosphorylation of these motifs creates docking sites for the Src homology 2 (SH2) 
domains of the Syk family kinase ZAP-70 (Chan et al., 1991). Expression of the 
ITAM containing region of the CD3 chain as a chimeric transmembrane protein that 
is oligomerized by an extracellular stimulus such as a monoclonal antibody (Irving and 
Weiss, 1991) or the aggregation of chimeric proteins bearing ZAP-20 and Fyn as their 
intracellular components (Kolanus et al., 1993) are both able to transduce normal 
activation signals by themselves, independently of the rest of the TCR complex. 
Recruitment of ZAP-70 to the TCR/CD3 signalling complex results in 
phosphorylation of ZAP-70 by Lck at position Tyr-493 (Chan et al., 1995) and the 
critical importance of this molecule in normal T cell function is clear from the severe 
immunodeficiencies in both CD8÷ and CD4+ responses in patients which lack a 
functional ZAP-70 protein (Elder et al., 1994). Activated ZAP-70 then itself 
phosphorylates the adapter protein LAT (linker for activation of T cells) (Zhang et al., 
1998), the multiple phosphotyrosine residues of which act to recruit the many other 
enzymes and linker proteins involved in the main Ras and Ca2+ mediated pathways of 
cell signalling (Zhang et al., 1999). Activation of these signalling pathways ultimately 
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lead to the activation of transcription factors such as AP-1 and NFAT (figure 1.3) 
which then act, often cooperatively (Jain et al., 1992) to direct the expression of the 
many different genes known to be upregulated during T cell activation. Binding sites 
for these transcription factors were originally identified in regulatory regions upstream 
of the interleukin-2 (IL-2) gene (Serfling et al., 1989 and Shaw et al., 1988) but a role 
in regulation of expression of many other proteins, particularly cytokine genes, is now 
known. Mice with T cells that lack the main lymphocyte NFAT proteins, NFAT1 and 
NFAT2, show deficiencies in many of the main effector outcomes of T cell activation 
(Peng et al., 2001) such as cytotoxicity, due to failure to upregulate effector molecules 
such as CD40 ligand and Fas ligand, and cytokine production, with production of 
cytokines such as IL-2, interferon-y (IFN-y), IL-4, IL-10, IL-5, and tumor necrosis 
factor-a (TNF-a) all severely impaired in these animals. The question of whether 
these generic T cell activation transcription factors can influence the effector 
phenotype of an activated T cell, for example in determining whether a T cell 
differentiates to become a Thl cell, producing predominantly IL-2 and IFN-y, or a Th2 
cell, producing cytokines such as IL-4, IL-5 and IL-13, has been much debated. The 
processes governing Thl and Th2 T cell differentiation will be discussed in more 
detail in a later section, but important studies addressing this issue include those 
utilising mice deficient in one or other of the NFAT1 and NFAT2 proteins. Mice 
lacking NFAT1 show impaired IFN-y production by activated T cells (Kiani et al., 
2001), are more susceptible to infections that rely on the development of a Thl 
effector cell response (Kiani et al., 1997) and show exacerbated Th2 type responses 
(Ranger et al., 1998a). Conversely, NFAT2 deficient T cells show impaired IL-4 
production (Yoshida et al., 1998) and reduced titres of the IL-4 dependent antibody 
isotypes IgG1 and IgE (Ranger et al., 1998b). However, from more recent data, the 
simplistic explanation of these knockout studies, that NFAT1 positively regulates Thl 
cell differentiation but negatively regulates Th2 cell differentiation and that NFAT2 is 
required for Th2 cell differentiation, has not held true. Expression of constitutively 
active forms of NFAT1 and NFAT2 are both able to induce transcription of Thl 
(Porter and Clipstone, 2002) and Th2 cytokines (Monticelli and Rao, 2002) and 
cooperative binding of NFAT1 with Thl and Th2 lineage specific transcription factors 
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has been demonstrated in vivo at the promoter regions of both the IFN-y and IL-4 
genes (Avni et al., 2002). 
Although the TCR signalling cascade discussed in brief above was described as being 
mediated by a series of phosphorylation events, effective control over TCR signalling 
also requires the coordinated action of tyrosine phosphatases. Upon TCR engagement, 
increased protein tyrosine phosphorylation within the cell is detectable within a matter 
of just a few seconds (June et al., 1990). However, to be a well controlled signalling 
mechanism, the tyrosine residues in question must be kept in an unphosphorylated 
state prior to TCR ligation. In keeping with this, treatment of T cells with 
pervanadate, a protein tyrosine phosphatase inhibitor, results in activation of some of 
the tyrosine kinase mediated signalling events normally associated with ligation of the 
TCR, such as activation of Lck, and the induction of some effector outcomes of TCR 
signalling, such as production of IL-2 (Secrist et al., 1993). In relation to T cell 
signalling, the most well studied tyrosine phosphatase protein to date is CD45 (Tonks 
et al., 1988). CD45 is a membrane bound protein expressed on the surface of all 
nucleated hematopoietic cells, a deficiency in which results in profound defects in T 
cell development and function (Mee et al., 1999 and Weaver et al., 1991). Perhaps 
counter intuitively to the findings of the pervanadate experiment described above, 
CD45-/- T cells show an increase in the strength of the TCR stimulus that is required 
for TCR signalling (Mee et al., 1999). This can be explained by the action of CD45 
phosphatase activity on the protein tyrosine kinase, Lck. CD45 activity was found to 
keep Lck in an easily activated form by removal of a tyrosine phosphate that 
negatively regulates the kinase activity of this protein (Mustelin et al., 1989). The 
balance between phosphorylation and dephosphorylation of proteins that make up and 
surround the TCR/CD3 signalling complex is therefore of paramount importance in 
dictating whether or not a TCR mediated signalling event is propagated into the T cell. 
How ligation of the TCR leads to the triggering of these signalling events and how the 
nature of ligand binding to TCR is interpreted by the signalling machinery to lead to 
different T cell effector outcomes is still very poorly understood and multiple different 
models of TCR triggering have been proposed. 
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1.9 pMHC binding by TCR 
Although the way in which the TCR activation signal is propagated from TCR ligation 
to initiation of intracellular signalling events is poorly defined, better understood is the 
nature of the physical interaction between the TCR and its pMHC, studies of which 
have helped to shed some light on possible mechanisms of TCR triggering. Despite 
the technical difficulties involved in crystallising complexes of multiple, multimeric, 
transmembrane proteins, the crystal structures of at least 24 TCRs bound to either 
class I or class II pMHC complexes have been solved (Garcia et al., 1996 and 
Reinherz et al., 1999). In terms of the pMHC structure being recognised by the TCR, 
the general architecture of class I and class II MHC molecule peptide binding grooves 
are quite similar, with the floor of the groove formed by a seven stranded (3 sheet and 
sides of the groove by two long a helices. However, differences in the pMHC surface 
which must be bound by TCR are brought about by the different lengths of peptide 
bound preferentially by each class of MHC, with class I molecules tending to bind 
shorter peptides than those bound by class II molecules (Stern and Wiley, 1994). 
Class I MHC molecules generally bind peptides of 8-10 residues in length, the termini 
of which are anchored into the peptide binding groove by conserved, MHC allele 
specific, pockets (Colbert et al., 1993). These conserved pockets mean that allele 
specific motifs in peptides binding to a particular MHC molecule have also been 
identified (Falk et al., 1991). The anchoring of peptide termini in MHC class I 
complexes results in longer peptides being forced to bulge out of the binding groove 
(Speir et al., 2001) and, along with generally shallower binding of peptide in the 
groove, means that peptide residues in MHC class I complexes are generally more 
accessible to the TCR. However, as the termini of peptides bound to MHC class II 
molecules are not fixed, and class II molecules are able to bind peptides of 
significantly longer length, peptide termini extending from the ends of MHC class II 
peptide binding grooves can also play a major role in interacting with the TCR 
(Carson et al., 1997). Despite recognition of different MHC molecules bound to 
peptides of different lengths and conformations, the general orientation of the TCR, 
with respect to pMHC, upon binding is seen to be relatively similar between 
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complexes. Generally the TCR molecule binds such that its orientation is diagonal 
with respect to the MHC peptide-binding groove. The Va and VP domains of the 
TCR lie over the N and C terminal portions of the peptide respectively and the 
majority of peptide contacts are made via the hypervariable CDR3a and CDR.3(3 
loops. Contacts with the MHC a helices that form the walls of the peptide binding 
groove are made predominantly by the less variable and germline encoded CDR1 and 
CDR2 regions, although peptide contacts with these loops have also been noted 
(Garcia et al., 1996). Although, from the structural data obtained to date for different 
TCR/pMHC complexes, this diagonal mode of binding is by far the most commonly 
observed, there are notable exceptions. For example, recently solved structures of two 
autoimmune TCRs binding to their pMHC ligands revealed that compared to other 
conventional TCR binding positions, these MBP specific autoimmune TCRs were not 
centred over the pMHC surface, but were shifted towards the N terminus of the 
peptide (Hahn et al., 2005 and Li et al., 2005). Determining whether an unusual 
binding pattern is a general feature of autoreactive TCRs requires the resolution of 
many more structures, not least because the features of a TCR or pMHC that define 
conventional binding are still not clear. Although at the level of each individual 
TCR/pMHC whose structure has been solved, the precise residues involved in binding 
of the TCR in this orientation can be identified, there are as yet no general rules to 
describe the location and identity of residues involved in this docking and resultant 
MHC restriction of TCR. Indeed, different TCRs recognising the same pMHC 
complex have been shown to use assume the same orientation, yet use completely 
different TCR amino acids for binding (Ding et al., 1998) and in a recent study, the 
same TCR was shown to utilise different binding residues and adopt an altered 
orientation when binding to a self versus a foreign MHC molecule (Colf et al., 2007). 
This data argues against the presence of conserved residues in TCR molecules that 
dictate binding orientation, although some amino acid positions are suggested to make 
more frequent contacts than others and analysis of TCR reactivity to MHC from T 
cells which had not undergone negative or positive selection suggested that MHC 
reactivity is indeed an inherent feature of TCR germline sequences (Zerrahn et al., 
1997). More convincing data to explain MHC restriction comes from study of 
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residues in the MHC molecule itself. When all known structures are compared, 
several MHC residues are consistently observed to make important contacts, for 
example residues a65 and a155 of MHC class I molecules. These residues were also 
recently shown to be 2 of only 3 residues involved in binding to TCR in a complex 
with a highly bulged peptide which severely restricted possible TCR/MHC 
interactions (Tynan et al., 2005). The authors of this study proposed binding via these 
residues to comprise the minimal "generic footprint" of MHC restriction, but in the 
absence of many more conserved TCR and MHC contacts other mechanisms that drive 
the docking of the TCR with a pMHC complex have been proposed. To reconcile the 
need for a TCR to scan many different pMHC complexes on the surface of an APC but 
then to initiate signalling and T cell activation only when specific binding is achieved, 
a two step mechanism of TCR binding to pMHC has been put forward (Wu et al., 
2002). This study, using a mutagenesis approach and measurement of TCR/pMHC 
binding interactions using surface plasmon resonance, demonstrated that mutation of 
MHC contact residues had a profound effect on initial association of the TCR with 
pMHC but that these residues contributed very little to the overall stability of the 
interaction. Conversely, mutations of peptide contacts profoundly influenced the 
stability of the complex, affecting off rates of binding, but made only a minor 
contribution to complex association. The model therefore proposes that initial 
interactions between the TCR and MHC guide and position the receptor over the 
peptide ligand and that the TCR, most likely using the CDR3 loops, then forms a more 
stable interaction with its ligand which, if of sufficiently high affinity, will allow 
transmission of a positive signal and activation of the T cell. 
1.10 TCR binding affinity and conformational change 
Interactions between TCRs and pMHC are usually characterised as being of relatively 
low affinity with slow association rates and faster dissociation rates (Matsui et al., 
1994). That the low affinity of this interaction may be due to insufficient contacts 
between the TCR and the pMHC is not supported by extensive interactions revealed 
by structural studies. Instead, the demonstration that the kinetics of binding becomes 
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faster with increased temperature (Boniface et al., 1999) led to an induced fit model of 
TCR binding where productive binding required the TCR to overcome a large energy 
barrier. Calculation of binding energies showed that binding was associated with 
unfavourable changes in entropy (Willcox et al., 1999), which suggests an increase in 
molecule ordering. This could be brought about by conformational changes, and as a 
consequence reduced flexibility, of a part of the TCR/pMHC complex itself, or by the 
incorporation of ordered water molecules at the binding interface. As water molecules 
are excluded from the TCR/pMHC interface upon binding this does not seem a likely 
explanation for unfavourable entropy. Instead, structural studies support a model in 
which parts of the TCR, particularly the CDR3 loops, undergo a conformational 
change on binding, such that a greater number of contacts are made with the peptide 
and stability of the complex is increased (Garcia et al., 1998 and Reiser et al., 2002). 
However, a more recent analysis of the well studied LC13 TCR, specific for an 
Epstein-Barr virus (EBV) peptide, showed that not all TCR/pMHC interactions 
conform to this thermodynamic model of binding (Ely et al., 2006). In this study, 
CDR loops were found to be well ordered in the unliganded state suggesting that in 
this case, although a conformational change did occur on binding, binding was 
entropically favoured rather than disfavoured. Another study with the same TCR 
molecule used mutagenesis and surface plasmon resonance to examine the 
contribution of binding energy from the CDR1, CDR2 and CDR3 loops of this 
receptor. Contrary to the two-step mechanism of binding described above, the CDR1 
and CDR2 loops were found to contribute only minimally to ligand binding with 
stabilization of the complex mediated mainly by the CDR3 loops (Borg et al., 2005). 
Despite increasingly apparent differences in the binding mechanisms employed by 
different TCR/pMHC complexes, the important contribution made by the CDR3 loops 
to binding affinity and specificity, but also degeneracy, is clear. That the flexibility of 
the CDR3 loops, and therefore their ability to undergo conformational change on 
ligand binding, could explain how a single receptor is able cross react with multiple 
peptides, has been demonstrated using structural studies where the structure of a single 
TCR was solved in complex with different peptides bound to the same MHC molecule 
(Reiser et al., 2003). CDR3 loops were found to adopt very different conformations 
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depending on the ligand bound, although changes in other parts of the molecule were 
also observed. Indeed, specificity of binding has recently been shown to be influenced 
by residues of the pMHC molecule that do not make any direct contacts with the TCR 
molecule at all (Huseby et al., 2006). 
Despite the ability of many TCRs to bind multiple ligands, the affinity of this binding 
is invariably not the same. That this is because the TCR molecule is flexible only up 
to a point was addressed in a recent study using a single TCR recognising 3 
structurally distinct peptides (Mazza et al., 2007). Although overall binding 
orientations in the 3 structures were comparable, different peptide structures forced 
some adaptation of the TCR molecule which, when combined with the retention of 
many TCR/MHCa helix contacts, resulted in suboptimal and lower affinity binding 
interactions with some peptides compared to others. Suboptimal binding was 
associated with impaired effector outcomes of T cell activation, such as reduced 
proliferation and IL-2 production. The observation that TCR/pMHC interactions of 
different affinity can result in different functional outcomes for the T cell is a well 
documented one (Sykulev et al., 1994, Matsui et al., 1994). Studies linking TCR 
binding affinity to effector outcome have been used to investigate processes such as 
thymocyte positive selection (Alam et al., 1996) and many different groups have 
reported the ability to generate receptors with increased affinity for pMHC by 
mutating residues of the TCR, most commonly in the CDR1, CDR2 or CDR3 regions 
(Chlewicki et al., 2005 and Manning et al., 1999). However, as mentioned previously, 
the way in which information about the affinity of the TCR binding interaction is 
transmitted into the cell to initiate the TCR signalling machinery, and how different 
biological outcomes might arise from the transmission of this information is still 
poorly understood. Some of the different mechanisms that have been proposed to 
explain the process of TCR triggering are discussed below. 
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1.11 TCR triggering 
The two earliest models of TCR triggering were based on the concepts of 
multimerization and conformational change. The multimerization model proposed 
that specific pMHC binding by TCRs would result in clustering of pMHC/TCR 
complexes at the cell surface, bringing intracellular signalling molecules into close 
proximity with one another and allowing signalling to be initiated. Evidence was 
provided by the demonstration that, in solution, TCR/pMHC complexes could 
oligomerise upon ligand binding (Reich et al., 1997). However, these results were 
subsequently disputed (Baker and Wiley, 2001) and, as this model requires the 
simultaneous ligation of multiple TCR molecules, the observation that a T cell could 
be activated by just a single pMHC could not be explained (Sykulev et al., 1996 and 
Irvine et al., 2002). To resolve this problem variants of the multimerization model 
have been proposed (Trautrnann and Randriamampita, 2003), such as the 
heterodimerization model, where triggering is initiated by simultaneous pMHC 
binding of the TCR and its CD4 or CD8 co-receptor (Delon et al., 1998), and the 
pseudo-dimerisation model, where TCR oligomers form by engagement of both 
specific peptide and self peptide MHC (Irvine et al., 2002). 	As for the 
multimerization model however, some data remains unexplained by these 
mechanisms. Mice that lack co-receptors are still able to mount effector T cell 
responses (Schilham et al., 1993) and the same is true for T cells with greatly reduced 
expression of self-peptide MHC (Sporri and e Sousa, 2002). Conformational change 
has been another mechanism proposed to explain TCR triggering. Small scale 
conformational changes that occur in the TCR molecule, particularly the CDR loops, 
upon ligand binding have now been noted from comparisons of non-ligated and ligated 
structures of several TCRs (Garcia et al., 1998 and Reiser et al., 2002). However, 
with the exception of one study, where upon ligand binding a conformational change 
in the TCRa constant domain was observed (Kjer-Nielsen et al., 2003), large 
conformational changes in the extracellular domains or constant regions of the TCR 
have not been seen and so argue against a mechanism of signal transduction by 
conformational changes through the TCRaf3 heterodimer itself. In support of a 
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conformational change mechanism though, thermodynamic data of TCR binding does 
find a relationship between flexibility at the TCR/pMHC interface and T cell 
activation (Krogsgaard et al., 2003) and more recently attention has focused on the 
idea that binding induces changes in the structural relationship between the TCRar3 
heterodimer and CD3 components of the signalling complex. A study using a yeast 
two-hybrid approach, to identify molecules that bind to the CD3 subunits of the 
signalling complex during T cell activation, showed that an adaptor protein, Nck, 
binds to a proline-rich sequence present in the cytoplasmic tail of CDR. This 
sequence was only available for Nck binding following ligation of the TCR and was 
proposed to be exposed as a consequence of a conformational change induced by 
ligand binding (Gil et al., 2002). 	Studies subsequently showed that this 
conformational change occurred in thymocytes upon presentation by MHC of both 
positively and negatively selecting peptides (Gil et al., 2005) although more recently 
conformational change was found to be more associated with thymocytes undergoing 
negative selection than positive selection (Risueno et al., 2006) suggesting that rather 
than being an all or nothing event, conformational change could be a mechanism by 
which the T cell could transmit information about the strength of TCR/pMHC 
interactions. It remains to be seen whether the cytoplasmic tails of other CD3 proteins 
may show similar rearrangements upon TCR ligation, and the normal T cell 
development observed in mice that lack this proline rich sequence of CDR has called 
into question the real importance of this conformational change in the mechanism of 
TCR triggering (Szymczak et al., 2005). 
A third model of TCR triggering also gaining experimental support is the kinetic 
segregation model (van der Merwe et al., 2000). This model hypothesises that, in a 
resting cell, phosphorylation of signalling molecules is maintained at a low level by 
tyrosine phosphatases such as CD45 and CD148 and signalling is therefore not 
initiated. Upon ligation of the TCR, proteins at the cell surface passively segregate 
according to size, with larger molecules such as CD45, CD148 and LFA-1 becoming 
separated from the smaller proteins that comprise the TCR signalling complex. The 
exclusion of bulky phosphatases from around TCR signalling molecules means that, 
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once phosphorylated, they are more likely to remain that way and, as TCR/pMHC 
binding would be likely to prohibit the diffusion of signalling complexes away from 
these small contact zones, a TCR signal can be potentiated. The advantage of this 
model over those already discussed is that it is able to explain observations of ligand-
independent triggering, for example where CTLA-4 is able to inhibit T cell activation 
in the absence of its ligand, B7 (Chikuma et al., 2005), as the presence or absence of 
phosphatases around the signalling machinery is mediated by passive diffusion rather 
than a specific ligation signal. In support of this kinetic segregation model both CD45 
and CD148 are found to be excluded from sites of TCR triggering (Bunnell et al., 
2002 and Lin and Weiss, 2003). In the study involving CD148 (Lin and Weiss, 2003), 
chimeric proteins were used to demonstrate that exclusion was mediated, in large part, 
by presence of the bulky extracellular domain of the protein and that if the intracellular 
phosphatase domain was targeted to the immune synapse by creating a fusion protein 
with the adapter molecule LAT, signalling through the TCR could be inhibited. 
Further evidence that the segregation of molecules is dependent upon the sizes of their 
extracellular domains and that this process is important in TCR triggering was also 
provided by a study in which the size of an MHC class I extracellular domain was 
increased using immunoglobulin spacers. A larger MHC molecule was associated 
with reduced TCR triggering with very little depletion of CD45 at the site of cell 
contact, but no effect on ligation of the TCR with pMHC was observed (Choudhuri et 
al., 2005). That protein segregation alone is sufficient to mediate TCR triggering has 
yet to be demonstrated and it is possible that several of the proposed mechanisms 
discussed here may act together in controlling this process. Indeed a recent study 
examining the requirement of the CDR conformational change for activation has 
reported that the conformational change induced in this subunit must be accompanied 
by TCR/pMHC clustering in order to be productive (Minguet et al., 2007). 
Whatever the answer to the question of how TCR triggering is initiated, a slightly 
separate issue is one of how the TCR signalling complex interprets the variable 
binding properties of different pMHC ligands in order to generate different effector 
outcomes, whether that be positive versus negative thymic selection (Alam et al., 
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1996) or other effector decisions such as CD4+ T cell differentiation (Lezzi et al., 
1999). Differences in phosphorylation states of TCR signalling molecules in response 
to different ligands have been well documented (Sloan-Lancaster et al., 1994 and 
Madrenas et al., 1995) but several hypotheses exist for how these different signalling 
patterns may be achieved. The idea that conformational changes may occur in the 
signalling complex to different extents depending on the nature of the TCR/pMHC 
binding interaction has been mentioned above, but currently there is very little data to 
support this idea. More widely accepted is the view that information about binding is 
transmitted into the cell via serial triggering events (Lanzavecchia et al., 1999) and 
that signalling is therefore dependent upon the half-life or "dwell time" of the 
TCR/pMHC complex. This model proposes that a threshold number of TCRs must be 
engaged for T cell activation and that each pMHC can serially engage multiple TCRs. 
The shorter the half-life of a pMHC, the less efficient the triggering will be and the 
longer it will take to reach the required threshold. Equally however, if the half-life of 
a complex exceeds the time required to trigger the TCR, efficiency of signalling will 
also be decreased as less serial engagements will occur within a given time period. 
Consistent with this theory were the findings of a mutagenesis study where mutations 
in the antigen binding site of a TCR were used to increase or decrease the half-life of 
the TCR/pMHC complex (Kalergis et al., 2001). Mutations that resulted in decreased 
and increased half-lives of TCR/pMHC complexes, as measured by binding to pMHC 
tetramers, both resulted in impaired T cell activation. Additional evidence that 
TCR/pMHC complexes with a short half-life have been associated with incomplete 
phosphorylation of the CD3 chain also supports this hypothesis (Kersh et al., 1998) 
highlighting the importance of binding kinetics and serial phosphorylation events in 
TCR signalling. Some data however remains unexplained by this model, such as the 
observation that the binding of TCR/pMHC complexes with very similar half-lives can 
result in very different functional outcomes (Baker et al., 2000). 
Although the preceding discussion has addressed the central role of the TCR and its 
associated signalling molecules in T cell activation, in a normal biological setting, the 
complex does not act alone and many other molecules and mechanisms interact to 
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elicit the final effector outcome for the T cell. T cell contact with an antigen 
presenting cell (APC) can last for many hours (Stoll et al., 2002). During this time 
TCR/pMHC complexes, but also other receptor/ligand pairs including co-stimulatory 
molecules (e.g. CD28-B7) and adhesion molecules (e.g. LFA-1-ICAM-1) accumulate 
and adopt a defined arrangement at the T cell-APC interface which is now referred to 
as the "immune synapse" (Monks et al., 1998). Although formation of the immune 
synapse is dependent upon signalling through the TCR, the myriad of other molecules 
present at this interface serves to highlight the many other mechanisms that must be 
considered when deciphering the pathway to a functional outcome of T cell activation. 
This thesis will attempt to define the role that cq3 TCR structure has in influencing the 
outcome of CD4+ T cell differentiation into T cells of different effector phenotypes. 
The nature of the signal that a T cell receives through its TCR is known to have some 
influence over this process, but many other factors and signalling pathways have also 
been implicated. The process of CD4÷ T cell differentiation and the mechanisms that 
may be involved in its control are discussed below. 
1.12 CD4+ T cell phenotype 
The two major lineages of cq3 TCR bearing T cells that emerge from the thymus are 
classified according to their expression of co-receptors. Cells bearing the co-receptor 
CD8 are termed CD8+, but when activated are also referred to as cytotoxic T cells due 
to their primary function in killing infected target cells (Blanchard et al., 1987). CD8+ 
T cells will not be discussed further here, but instead attention focussed on cells 
bearing the co-receptor CD4, termed CD4+ T cells. CD4+ T cells are also known as T 
helper (Th) cells and have been shown to play a role in many different types of 
immune response, mainly through their ability to co-ordinate the actions of other cell 
types into a response appropriate to the initial insult or infection. This functional 
diversity of CD4+ T cells was partly explained by the findings of Mosmann et al. that 
mouse CD4+ T cell clones could be classified into distinct populations (named Thl 
and Th2) on the basis of their patterns of cytokine production. It was subsequently 
53 
found that these different cytokine patterns could be linked to the different functional 
properties of these cells (Mosmann and Coffman, 1989). Thl cells produce mainly 
IL-2 and IFN-y, are involved in cell mediated inflammatory reactions such as those in 
response to bacterial infections (Andersen et al., 1995) and have been implicated in a 
variety of autoimmune diseases (Trembleau et al., 1995). Th2 cells can produce IL-4, 
IL-5, IL-9, IL-10 and IL-13 and are involved in expulsion of extracellular parasites 
(Bancroft et al., 1994) as well as strong antibody reactions and allergy (Robinson et 
al., 1992). This fundamental role of Thl and Th2 cells in adaptive immunity, and the 
finding that populations of these highly polarised cells can be identified in a variety of 
disease states means that there is much interest in understanding the mechanisms 
involved in their generation. The many factors now known to be involved in Thl 
versus Th2 differentiation, including the hypothesis that the structure of the ap TCR 
may be important, are discussed in the section below. However, since the original 
classification of CD4+ T cells into one or other of these subsets, other populations of 
CD4+ T cells that are distinct from Thl or Th2 have also been identified. 
Aside from Thl and Th2 effector cells, the CD4+ T cell subset on which the most 
attention has been focused in recent years is the regulatory CD4+ T cell (Treg). Most 
commonly, Tregs are now defined by the expression of CD4 and CD25 at the cell 
surface and by their ability to downregulate the immune responses mediated by other 
T cell subsets. Depletion of lymph node cells and splenocytes of CD4+CD25+ T cells, 
and then transfer of the remaining cells into nude BALB/c mice, results in the 
development of spontaneous autoimmune pathologies (Sakaguichi et al., 1995). 
However, the mode of action of T„g cells remains ill defined. Cytokines that have 
been implicated in the suppressive mechanisms of CD4+CD25+ T cells include IL-10 
and transforming growth factor p (TGF(3). CD4+CD25+ T cells have been shown to 
produce IL-10 in vivo (Annacker et al., 2001) and IL-10 production by these cells 
mediates suppression of some forms of autoimmunity, although others are IL-10 
independent (Surf-Payer and Cantor, 2001). For TGFP there is little evidence to 
suggest that CD4+CD25+ T cells mediate suppression of CD4+ T cells via this 
cytokine, but TGFP mediated suppression of CD8+ T cells has been documented 
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(Chen M et al., 2005). Other proposed modes of action are based on mechanisms of 
direct cell-cell contact as T cells deficient in the co-stimulatory molecules CD80 and 
CD86 are resistant to suppression (Paust et al., 2004). That regulatory T cells may 
develop during the process of thymic selection has already been mentioned and central 
to this process is TCR signalling. Mice deficient in two downstream molecules of 
TCR signalling, Bc1-10 and PKC-O have reduced numbers of Treg cells (Schmidt-
Supprian et al., 2004) and understanding the signalling mechanisms and genetics of 
Treg lineage commitment was greatly advanced by the identification of the supposed 
CD4+CD25+ T cell specific transcription factor, Foxp3 (Hori et al., 2003 and Fontenot 
et al., 2005). A recent study in which the Cre recombinase system of gene targeting 
(discussed later) was used to ablate Foxp3 expression specifically in Treg cells resulted 
in an altered cytokine expression profile towards Thl cytokines such as IL-2 and IFN-
y, an altered pattern of gene expression where genes known to be controlled by Foxp3 
such as Socs2 and Ctla-4 were downregulated, and a loss of suppressor function 
(Williams and Rudensky, 2007). Many gene targets of the Foxp3 transcription factor 
are now being identified and the recent identification of other transcription factors that 
cooperate with Foxp3 (Wu et al., 2006 and Ono et al., 2007) should enable rapid 
identification of the patterns and sequences of gene expression that are required to 
bestow regulatory cell phenotype and function. 
Another CD4+ T cell lineage specific transcription factor recently identified is RORyt, 
reported to be expressed by the newly described Th17 subset of CD4+ T cells (Ivanov 
et al., 2006) that have been associated with inflammatory responses such as those seen 
in autoimmunity (Langrish et al., 2005). Th17 cells were identified as a subset of T 
cells whose differentiation could be induced by the cytokine IL-23 (Aggarwal et al., 
2003) and it is known that mice deficient in IL-23 are resistant to several autoimmune 
diseases, such as experimental autoimmune encephalomyelitis (EAE) (Cua et al., 
2003). 	This link with IL-17 producing cells and the demonstration that 
proteolipoprotein (PLP) specific, IL-17 producing T cells could induce EAE when 
transferred into naive mice while classical Thl cells could not (Langrish et al., 2005) 
helped to explain why previous data regarding the pathogenicity of Thl responses was 
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confusing. Data showing that ablation of Thl responses can in fact worsen 
autoimmune disease (Ferber et al., 1996) can now be reconciled with data showing a 
reciprocal relationship between Thl, Th2, Th17 and indeed Treg cells where cytokines 
promoting the development of one subset act to prevent the development of others 
(Park et al., 2005 and Bettelli et al., 2006). This concept of antagonistic development 
of one subset by another will be discussed further in the section below in relation to 
Thl and Th2 cell differentiation, but it is becoming ever clearer that the original 
classification of CD4+ T cells into either Thl or Th2 is no longer by any means the 
whole picture and it is likely that in the future, important roles of other subsets of 
CD4+ T cells, in addition to the ones discussed here, will be elucidated. 
1.13 Thl and Th2 cell differentiation 
One of the most important and well described factors influencing CD4+ T cell 
differentiation is local cytokine environment. Among the most well characterised Thl 
promoting cytokines is IL-12. IL-12 is a heterodimer composed of p40 and p35 
subunits, and is produced primarily by antigen presenting cells, including 
macrophages, monocytes and dendritic cells (Macatonia et al., 1995). Mice deficient 
in IL-12 are impaired, although not completely lacking, in their ability to produce 
IFN-y and mount an effective Thl response (Magram et al., 1996) and exogenous 
addition of this cytokine is now used extensively in vitro as a means to generate a Thl 
phenotype in primary T cells. IL-12 acts via the signal transducer and activator of 
transcription 4 (STAT4), following binding to the IL-12 receptor on the surface of the 
T cell and, primarily, activation of this signalling pathway leads to the upregulation of 
IFN-y expression (Thierfelder et al., 1996). The residual IFN-y production in IL-12 
deficient mice also points towards the importance of other cytokines in the 
development of Thl responses and IFN-y itself, as well as other cytokines such as IL-
18, IL-27 and IFN-a have all been implicated (Schmitt et al., 1994, Kohno et al., 
1997 and Hibbert et al., 2003). Important in the understanding of Thl phenotype 
development was the discovery of the Thl lineage specific transcription factor, Tbet. 
T-bet is a member of the T-box family of transcription factors and the antagonistic 
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nature of Thl versus Th2 differentiation is exemplified by the demonstration that IFN-
y production can be induced, and IL-4 and IL-5 production repressed, by the 
introduction of Tbet into T cells that were defined as having a Th2 phenotype (Szabo 
et al., 2000). In addition, mice lacking Tbet spontaneously develop a phenotype 
similar to that seen in human asthma, a predominantly Th2 mediated disease (Finotto 
et al., 2002). Lineage specific transcription factors identified in Th2 cells include 
GATA-3 and c-maf (Zheng and Flavell, 1997 and Ho et al., 1996) and as observed for 
T-bet, ectopic expression of GATA-3 can induce Th2 cytokine production in 
committed Thl cells (Lee et al., 2000). GATA-3 expression is induced in Th2 
differentiating cells by the transcription factor STAT6, which is activated by T cell 
binding of the main Th2 promoting cytokine, IL-4. Additionally very recent data 
suggests that GATA-3 expression is additionally regulated by Notch signals (Fang et 
al., 2007). T cells from IL-4, STAT6 and GATA-3 knockout mice are all greatly 
impaired in their ability to undergo differentiation into Th2 cells (Kopf et al., 1993, 
Shimoda et al., 1996 and Pai et al., 2004). Less is known about the regulation of the 
c-maf transcription factor, but more recently signalling via IL-6 and the TCR were 
both implicated (Yang et al., 2005). A schematic diagram of the main cytokines and 
transcription factors involved in the differentiation of Thl and Th2 cells is shown in 
figure 1.4. As well as the action of Thl and Th2 associated transcription factors in 
directly promoting the expression of some cytokines and repression of others, 
epigenetic mechanisms involving chromatin remodelling and locus accessibility have 
been proposed to explain the fixed phenotype of fully differentiated T cells and the 
heritability of phenotype as cells proliferate and clonally expand during the course of 
an immune response. In support of this, additional DNase I hypersensitivity sites 
(HS), indicators of increased locus accessibility, appear at the 114 locus and Ifng locus 
in Th2 and Thl differentiating cells respectively (Agarwal and Rao, 1998) and 
changes in acetylation and methylation, other markers of chromatin remodelling, have 
also been observed (Avni et al., 2002 and Lee et al., 2002). There is evidence that 
lineage specific transcription factors are involved in mediating these epigenetic 
changes, with ectopic expression of GATA-3 able to mediate chromatin remodelling at 
the 114 locus, even in Thl cells (Lee et al., 2000). However, a direct role for T-bet in 
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Thl CD4+ T cell 
	 Th2 CD4+ T cell 
Figure 1.4 Cytokine environment and CD4+ T cell differentiation. Cytokines IL-
12 and IL-4 promote Thl and Th2 cell differentiation respectively. Intracellular 
signalling pathways activated by TCR and cytokine receptor ligation result in 
activation of the Stat protein and lineage specific transcription factors Tbet, GATA3 
and cMaf. These transcription factors drive the expression of genes for Thl and Th2 
CD4+ T cell differentiation, including the cytokines IFN-y and IL-4 which act to 
potentiate the development of Thl and Th2 cell lineages respectively. 
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modifications at the Ifng locus has recently been questioned with evidence suggesting 
that previously observed remodelling events at this locus maybe an indirect 
consequence of GATA-3 downregulation by the Thl transcription factor (Usui et al., 
2006). 
With the clear importance of cytokines in the process of CD4+ T cell differentiation, it 
follows that APCs, as the primary source of these cytokines during the initiation phase 
of an immune response, should also have an important role to play. The types of 
cytokines that an APC produces are greatly dependent upon the type of pathogen or 
stimulus that it meets. For example, dendritic cells mature into Th2 promoting 
effectors (DC2s) in the presence of protein extract from the parasite Schistosoma 
mansoni, but Thl promoting effectors (DC1s) result from exposure to toxins from 
intracellular bacteria (de Jong et al., 2002). Differential activation of Toll like 
receptors (TLRs) is proposed as one mechanism by which these different APC 
phenotypes arise. In one study, using an OVA based disease induction protocol, TLR2 
ligation was associated with promotion of a Th2 type immune response, but TLR9 
ligation with a more Thl type response (Redecke et al., 2004) and dendritic cells 
isolated from BALB/c mice infected with Chlarnydia show increased expression of 
TLR9 and can inhibit in vivo allergic responses to OVA when adoptively transferred 
(Han et al., 2004). However, understanding the possible effects of TLR ligation on 
differentiation are complicated by the presence of TLRs on T cells as well as APCs 
and a recent study has linked direct ligation of TLR2 on T cells to activation of Thl 
effector functions in already differentiated T cells (Imanishi et al., 2007). Also to be 
considered is the timing, cytokine environment and location of APC activation. 
Highlighting the temporal and historic importance of APC activation, one study 
showed that mice infected with Influenza virus 30 days before exposure to allergen 
developed more severe allergic disease than control animals (Dahl et al., 2004). The 
cytokine environment of the APC itself at the time of activation was also shown to 
have an influence on T cell differentiation in a murine model of Leishmania infection. 
BALB/c mice are normally susceptible to this pathogen as a result of a dominant Th2 
immune response. When IL-4 was present in vivo during initial activation of DCs, 
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rather than during T cell priming, mice developed a Thl response and were resistant to 
disease (Biedermann et al., 2001). Other evidence suggests that the site at which the 
APC encounters antigen is also important and several studies have shown that antigen 
encountered by APC at mucosal sites, such as the lung and the intestine, preferentially 
induce Th2 cell differentiation, even in mouse strains that are strongly biased towards 
the development of Thl CD4 T cells (Constant et al., 2000 and Iwasaki and Kelsall, 
1999). That some mouse strains, such as C57BL/6 and BALB/c are biased towards 
developing Thl and Th2 responses respectively suggests an important genetic 
component. Studies in this area have mainly focussed on MHC genotype (Murray et 
al., 1992), although a locus on murine chromosome 11 has also been implicated 
(Gorham et al., 1996). 
As previously mentioned, the immune synapse that develops at the site of T cell-APC 
contact during activation contains many more proteins than just those of the 
TCR/pMHC complex. Co-stimulation is an important component of T cell activation 
and acts not only to deliver a second signal to the T cell on top of the signal received 
through the TCR, but also to increase the avidity (strength) of the T cell-APC 
interaction. The two main co-stimulatory molecules upregulated on APCs following 
encounter with antigen are B7-1 (CD80) and B7-2 (CD86) (Reiser et al., 1992 and 
Freeman et al., 1993). CD86 has been shown to preferentially induce IL-4 production 
(Freeman et al., 1995) and distinct regions in the cytoplasmic domain of CD28, the 
receptor for CD80 and CD86 on the surface of the T cell, that are required for Th2 
differentiation have now been identified (Andres et al., 2004). There is also evidence 
that the co-stimulatory molecule OX40 as well as the CD4 molecule itself can play a 
supportive role in Th2 development (Ohshima et al., 1998 and Fowell et al., 1997). 
With the large array of other proteins on the surface of, and secreted by, both T cells 
and APCs, other molecules proposed to influence CD4+ T cell differentiation are 
continually being identified (Oosterwijk et al., 2007 and Lund et al., 2007 and Fang et 
al., 2007), but the challenge will be how to fit these into an already complex picture of 
decision making at the time of T cell priming. 
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1.14 The TCR and CD4+ T cell differentiation 
Despite the importance of co-stimulation, key to the overall avidity of a T cell-APC 
interaction is the binding of TCR to its pMHC ligand, and there are now multiple lines 
of evidence pointing towards a role for both avidity and affinity of TCR/pMHC 
interactions in influencing CD4+ T cell differentiation. Indeed, some recent data 
tentatively suggests that for some TCR/pMHC interactions, TCR mediated signals 
alone, in the absence of co-stimulation, or Thl promoting cytokines and even T-bet, 
are sufficient to drive development of Thl cells (Ariga et al., 2007). That the strength 
of the signal received through the TCR can influence T cell effector outcome was 
supported by data on the duration of TCR signalling, where prolonged stimulation of 
naïve CD4+ T cells in vitro with pMHC and an anti-CD28 antibody was required to 
induce a Th2 phenotype (Lezzi et al., 1999). It can be imagined that the most simple 
way in which TCR/pMHC interactions could influence avidity of T cell-APC binding 
would be the number of binding interactions occurring at any given time, with a 
greater number of binding events increasing binding avidity. In support of this, both 
peptide dose and the density of MHC molecules on the surface of an APC have been 
shown to be important (DiMolfetto et al., 1998). Data on antigen dose are slightly 
conflicting and depend upon the antigen used in the study but, in general, very high 
and low doses of antigen elicit Th2 responses, while moderate and high antigen doses 
favour Thl responses (Constant et al., 1995 and Hosken et al., 1995). Alternatively, 
strength of TCR signalling could be influenced by the kinetics of binding and affinity 
for pMHC of each individual TCR molecule, i.e. at the level of structural interactions 
between the TCR and its pMHC ligand. Early evidence that this may be true came 
from studies using altered (mutated) peptide ligands (APLs). It was observed that 
amino acid substitutions in peptide ligands, usually by as little as just a single residue, 
could shift the effector cell phenotype of CD4+ T cells responding to this antigen from 
Thl to Th2 (Pfeiffer et al., 1995 and Tao et al., 1997). That these switches in T cell 
phenotype can alter disease outcome has also been seen in several studies involving 
the Thl mediated murine autoimmune disease, EAE (Brocke et al., 1996 and 
Nicholson et al., 1995). In the study by Nicholson et al. SJL mice, normally 
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susceptible to EAE induction using a peptide of PLP (PLP 139-151), were prevented 
from developing, or displayed greatly reduced severity of disease when immunised 
with an altered peptide ligand (Q144). Disease could be prevented by immunising 
with APL alone or in combination with the wild-type peptide and the adoptive transfer 
of T cell lines specific for APL Q144 could also confer protection. T cells isolated 
from mice immunised with Q144 were found to secrete the Th2 type cytokines IL-4 
and IL-10 and were able to proliferate in response to both Q144 and the native peptide. 
This suggested that T cells were able generate productive TCR signals in response to 
the mutated peptide and that Q144 was not simply acting as a competitive MHC 
blocker inhibiting productive TCR/pMHC interactions. The mutated residue of this 
APL was known to be the primary contact residue in TCR binding and a subsequent 
study revealed that the primary contact points of APL Q144 had shifted to residues 
141 and 142, towards the N terminal end of the peptide (Das et al., 1997). Others had 
demonstrated APLs, described as antagonistic in these studies, to have reduced affinity 
for TCR (Lyons et al., 1996) and the generation of altered affinity TCR/pMHC 
interactions by mutating residues in the TCR itself has already been discussed. A link 
between mutations in TCR structure and CD4+ T cell differentiation came with the 
demonstration that a change in a single amino acid in the CDR2 region of a TCR could 
shift the immune response from Thl to Th2 (Blander et al., 2000). Taken together, all 
of this data leads to a hypothesis which suggests that the structure of a TCR and, as a 
consequence, the binding interaction between TCR and pMHC can bias CD4+ T cell 
differentiation, with high affinity interactions promoting Thl development and lower 
affinity interactions favouring a Th2 response. 
However, despite this data, all of which involves manipulation of TCR interactions 
artificially in vitro, what is the relevance in vivo to any role that TCR structure may 
have in determining the CD4+ T cell phenotype of populations of T cells with a normal 
and diverse repertoire of TCRs? The finding that TCRs with relatively high affinity 
can be selected and come to dominate the repertoire during the course of an immune 
response has been observed both in vivo and in vitro. In an in vitro study, PCR 
mutagenesis was used to mutate the CDR3a regions of TCRs and through successive 
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rounds of in vitro selection using a yeast expression system, high affinity mutants were 
found to become dominant (Holler et al., 2000). In vivo, pMHC multimers have been 
used to demonstrate expansion of both MHC class I and MHC class II restricted, high 
affinity TCRs, during development of an immune response to pathogen in mouse 
models of infection (Busch and Pamer, 1999 and Malherbe et al., 2000) and high 
affinity TCRs, sequences of which are conserved between patients, have also been 
seen in studies assessing T cell clonal dominance to human cytomegalovirus (HCMV) 
(Trautmann et al., 2005). In the study by Malherbe et al. looking at expansion of 
MHC class II restricted CD4+ T cells in mice during the course of infection with the 
Leishmania major parasite, T cell populations expanding in a resistant strain of mice 
(D10.D2), which develop a Thl type immune response to the pathogen, were found to 
bind pMHC with higher affinity and have a different pattern of Va and CDR3a usage 
to T cell populations expanding in the susceptible BALB/c strain of mouse, which 
develop a predominantly Th2 type response. Other studies have also observed 
selection of preferred CDR3 motifs during immune responses (McHeyzer-Williams et 
al., 1999). In this study, CDR3 sequences from T cells present at time points 
throughout the course of an immune response to whole pigeon cytochrome c (PCC) 
protein were analysed. By day 3, 40% of cells analysed were using CDR3 sequences 
containing at least 6 of 8 conserved features identified, for example a CDR3a length 
of 8 amino acids or a serine residue at position a95, and this rose to more than 80% 
after 2 weeks. In a subsequent memory response to PCC, 96% of T cells were using a 
restricted TCR. As, unlike B cells, T cells do not undergo affinity maturation 
(mutation of CDR amino acids to generate higher affinity ligand binding), the 
dominant sequences must have been selected from the original starting repertoire of 
pMHC specific TCRs. Combined, this data led to the idea that not only could 
preferred structural motifs be selected for during an immune response, but that the 
structural features selected may bear some relation to the phenotype of the cells 
responding, i.e. structural features of TCR selected during a Thl immune response 
may be different from those selected during a Th2 immune response. This question 
was addressed by a study in our laboratory, published in 2002, which determined the 
TCR gene usage, CDR3a and CDR313 sequences from T cell clones and lines selected 
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under Thl versus Th2 polarising conditions in vitro (Boyton et al., 2002). This study 
found that CD4+ T cell clones selected under Th2 polarising conditions favoured an 
elongated TCR CDR3a chain and from modelling studies predicted that these 
elongated TCR a chains may result in less optimal (lower affinity) interactions 
between the pMHC complex, which in this case was a PLP peptide (PLP 56-70) 
complexed to the MHC class II molecule I-Ag7, and CDR loops of the TCR. No clear 
V gene bias between Thl and Th2 cell derived TCRs was observed and there were no 
differences in the lengths of CDR3(3 regions. In short term Thl and Th2 polarised T 
cell lines, dominant Thl and Th2 TCR CDR3a sequences could be identified, and 
when oligonucleotides of these CDR3a sequences were radiolabelled and used to 
probe cDNA libraries of CDR3a sequences, it was found that the longer Th2 derived 
CDR3a motif was present only in Th2 lines while the shorter Thl CDR3a motif 
seemed to be permissible in both, although was more dominant in the Thl lines. 
The hypothesis that emerged from this study was that, if structurally distinct TCRs 
arising from Thl and Th2 polarised T cells, i.e. a TCR bearing an elongated CDR3a 
region from a Th2 cell and a shorter CDR3a region from a Thl cell, are expressed 
transgenically, an inherent bias towards Thl or Th2 will be observed in CD4+ T cell 
responses from these animals. Chapters 3 and 4 of this thesis describe the generation 
and characterisation of such transgenic animals. Further to this hypothesis is a second 
question of whether these Thl and Th2 transgenic animals could be used to create new 
models of Thl and Th2 mediated disease. The lung is one organ in which 
understanding Thl and Th2 type responses is of much interest. The roles played by 
Thl and Th2 CD4+ T cells in human lung diseases are discussed below, and chapter 5 
of this thesis describes the generation of a new transgenic model that could be of use 
in the modelling of these diseases in the mouse. 
1.15 Thl and Th2 responses in human lung disease 
CD4+ T cells in the lung are an area of major interest, as a number of lung diseases are 
believed to be associated with a bias for either Thl or Th2 type responses. Pulmonary 
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sarcoidosis is an example of a chronic lung disease that has been associated with a 
predominantly Thl type immune response (Moller et al., 1996) while asthma, 
bronchopulmonary aspergillosis and cryptogenic fibrosing alveolitis are among other 
diseases thought to be predominantly Th2 mediated (Robinson et al., 1992, Kurup et 
al., 1994 and Wallace et al., 1995). In most cases the underlying cause, or nature of 
the initiating insult to the lung, is not well understood and other major challenges still 
remaining include a good understanding of the regulation of lung inflammation, and 
the long term processes of repair and lung remodelling that occur in the context of 
prolonged, chronic, inflammatory responses. 
Allergic asthma is probably the best studied lung disease thought to be associated with 
Th2 type responses. Many different allergens have been associated with asthma, but 
among the most common and well studied include proteins from the house dust mite, 
grass pollen and cat dander. 	Allergic asthma is characterised by airway 
hyperreactivity, which for the most part is reversible, high levels of IgE antibodies and 
airway inflammation. The main cell types found in the asthmatic lung are CD4+ T 
cells, eosinophils, mast cells, basophils and neutrophils, and cytokines found to be 
elevated in the lungs of asthmatics are predominantly of the Th2 type (Robinson et al., 
1992). Since the discovery of a role for CD4+ T cells and Th2 cytokine production in 
allergy, much effort has gone into understanding the mechanisms by which they act to 
cause disease. A major function of IL-4 and IL-13 is to mediate IgE antibody class 
switching by B cells (Lebman and Coffman, 1988 and Punnonen et al., 1993). These 
cytokines function though activation of the transcription factor STAT6, which can 
synergise with the transcription factor NF-KB to promote germline transcription of 
IgE. The process of IgE transcription is also mediated by signalling through CD40 
(Kawabe et al., 1994), the ligand for which is transiently expressed on T cells 
following antigen stimulation, and polymorphisms in the IL-4, IL-13 and CD40 genes 
have all been associated with high IgE levels in patients with asthma (Suzuki et al., 
2000, Hunninghake et al., 2007, Park et al., 2007). IgE class switching is a process 
mediated by a germline recombination event, similar to those described above for 
TCR gene rearrangement, although it is RAG independent (Lansford et al., 1998). It 
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is proposed to occur predominantly in lymphoid tissue (Muramatsu et al., 1999) 
although active class switching in the bronchial mucosa of asthmatics has also been 
demonstrated (Takhar et al., 2007). IgE acts by binding to high affinity receptors 
(FCERI) on the surface of mast cells and basophils, and crosslinking of this IgE by 
specific antigens leads to the release of inflammatory mediators such as histamine, 
leukotrienes, enzymes and cytokines (Segal et al., 1977). Mast cell and basophil 
degranulation, and the release of these inflammatory mediators by specific IgE 
crosslinking in the lungs of asthmatics upon exposure to allergen, is proposed to be the 
initiating sequence of events in an asthmatic response. Consequences include mucus 
secretion, smooth muscle contraction and the recruitment of other effector cells to the 
lung, some of which contribute to the observed increase in airway 
hyperresponsiveness (AHR) that is synonymous with asthma. In keeping with an 
essential role for IgE in the early phase of an asthmatic response, administration of an 
anti-IgE antibody to asthmatic patients has been shown to inhibit allergen induced 
AHR (Fahy et al., 1997), although mouse models of asthma have demonstrated 
development of AHR and eosinophilia in the absence of IgE (Mehlhop et al., 1997). 
As such, the exact nature of the mechanisms behind the development of AHR are not 
yet fully understood and the roles played by inflammatory cells, such as the 
eosinophil, are still controversial. Recruitment of eosinophils to the lung is mediated 
by chemokines such as eotaxin (Ganzalo et al., 1996), and cytokines such as IL-5. 
Mice deficient in IL-5 fail to develop lung eosinophilia and AHR (Foster et al., 1996), 
and although this may be interpreted as evidence for a role for IL-5 and eosinophils in 
AHR development this has been complicated by the subsequent demonstration that 
this effect was dependent upon the genetic background of the IL-5-/- mice (Hogan et 
al., 1998). The key roles of the prototypic Th2 cytokines, IL-4, IL-5, and IL-13 
discussed so far in the context of asthma serves to highlight the important role of Th2 
type, allergen specific, CD4+ T cells in the pathogenesis of this disease, and with 
evidence that Thl cytokines are antagonistic towards the development of T cells with 
a Th2 phenotype (Wynn et al., 1995), the prospect that promotion of a Thl type 
environment may ameliorate Th2 mediated disease in the lung has provoked much 
interest. However, results have been conflicting and while some groups have 
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demonstrated reduced airway inflammation and AHR upon transfer of antigen specific 
Thl T cells in established mouse models of asthma (Huang et al., 2001), others have 
not, but have instead seen enhanced inflammatory cell recruitment to the lung (Hansen 
et al., 1999). In a recent study where IFN-y was overexpressed in the mouse lung, 
levels of IL-5 and IL-13 were found to be increased upon induction of allergic airway 
inflammation (Koch et al., 2006). Some studies have reported increased number of T 
cells expressing IFN-y in the lungs of patients with asthma (Krug et al., 1996) and 
viral infections, immune responses to which are predominantly Thl mediated, have 
been associated with an increased risk of developing this disease (Sigurs et al., 2005). 
In the Thl associated lung disease of pulmonary sarcoidosis, although the pathology 
of the disease is well characterised in terms of the presence of granulomas, 
accumulation of activated CD4+ T lymphocytes and macrophages and production of 
Thl type cytokines (Moller et al., 1996), the antigen(s) to which the immune system is 
responding is not yet known. The presence of activated CD4+ T cells at the sites of 
disease has led to much research to try to identify the antigens for which these T cells 
are specific but, although some studies have reported some V gene bias in the TCRs of 
these lymphocytes, with bias being linked to MHC class II genotype (Grunewald et 
al., 2002), the activating peptides remain elusive. Some studies have pointed towards 
mycobacterial antigens as possible targets of T cell responses in sarcoidosis (Song et 
al., 2005 and Hajizadeh et al., 2007), although attempts to identify mycobacterium 
tuberculosis in sarcoid biopsies have been unsuccessful (Marcoval et al., 2005) and the 
possibility that Thl T cells in sarcoidosis may be responding to endogenous rather 
than bacterial antigens still remains. Additionally, the finding that patients with 
sarcoidosis are deficient in, or have greatly reduced numbers of, a recently described 
subset of CD 1 d-restricted NKT cells, which have immunoregulatory functions, has 
also led to the suggestion that defects in immune regulation may play a role in the 
development of this disease (Ho et al., 2005). 
Despite the Thl type nature of immune responses during development of sarcoidosis, 
severe fibrosis is a common end point (Moller, 2003). Fibrosis is more commonly 
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associated with Th2 type responses, with cytokines IL-4, IL-5 and IL-13 all implicated 
in pathogenesis and in a common mouse model of fibrosis, promotion of Thl type 
immunity using IL-12 was seen to markedly reduce fibrotic disease development 
(Wynn et al., 1995). How the Thl environment of sarcoidosis may then lead to 
fibrosis is therefore unclear, although other pro-fibrotic mediators such as TGF-p are 
found to be expressed in the sarcoidosis lung (Zissel et al., 1996) and more recently 
polymorphisms in the gene for TGF-133 have been implicated in progression to fibrosis 
in sarcoid patients (Kruit et al., 2006). Fibrosis is a mechanism of tissue repair and 
occurs when connective tissue grows in place of normal parenchymal tissue. If limited 
to small areas of an organ, fibrosis is beneficial, as it can reverse tissue damage. 
However, if the process of fibrosis becomes continuous and progressive, organ 
function, particularly of those such as the lung, where tissue architecture is delicate, 
can become severely compromised and can ultimately cause organ failure. 
A common fibrotic lung disease in humans is cryptogenic fibrosing alveolitis, one of a 
group of interstitial lung diseases that are characterised by lung inflammation and 
fibrosis. Lung infiltrates include activated T cells, macrophages, B cells and, in 
keeping with the Th2 nature of the disease, eosinophils and a Th2 like pattern of 
cytokines (Haslam et al., 1980 and Wallace et al., 1995). Similar to sarcoidosis, the 
exact nature of the lung antigens that initiate the disease process is unknown, however, 
the inflammatory pathways that lead to fibrosis are becoming better defined. Key 
roles for the cytokines IL-13 and TGF-P have been proposed. Overexpression of both 
of these cytokines in transgenic animals leads to severe fibrosis (Sime et al., 1997 and 
Zhu et al., 1999), while neutralisation can attenuate disease (Belperio et al., 2002). 
That this is not just a feature of all Th2 type cytokines was demonstrated by the lack of 
airway fibrosis seen in transgenic mice that overexpressed IL-4 (Rankin et al., 1996). 
Signalling pathways that mediate fibrosis and are initiated by these cytokines are still 
being elucidated, but IL-13 has been proposed to act in both a TGF-p dependent (Lee 
et al., 2001) and independent manner (Kaviratne et al., 2004). Signalling molecules 
shown recently to be upregulated by IL-13 include the chemokine receptor CCR5 and 
IL-11Ra and blocking the functions of both of these receptors ameliorated IL-13 
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induced inflammation and fibrosis (Ma et al., 2006 and Chen Q et al., 2005). The 
Smad3 signalling pathway has been implicated in TGF-13 mediated pulmonary fibrosis, 
with Smad3 mice shown to be resistant to the severe fibrosis induced by 
overexpression of TGF-13 in the lung (Bonniaud et al., 2004) and more recently, 
importance of the mitochondrial mediated pathway of apoptosis, involving the 
apoptosis proteins Bax and Bid has also been suggested (Kang et al., 2007). This 
demonstration of a link between TGF-I3 signalling and pathways of apoptosis provide 
an explanation for the dependence on epithelial cell apoptosis previously observed for 
TGF-13 induced fibrosis (Lee et al., 2004). Although fibrosis is the main pathology 
observed in lung diseases such as cryptogenic fibrosing alveolitis, that it is observed as 
a chronic component of other lung diseases, such as sarcoidosis, COPD and asthma, 
serves to highlight the interrelated nature of the many inflammatory and repair 
processes that can be initiated in the lung in response to a wide range of insults. 
There is therefore still much to be learnt about the consequences of Thl and Th2 type 
immune responses in the lung and it is becoming increasingly clear that, far from 
being exclusively one type or the other, the pathogenesis of many lung diseases, 
particularly those that are chronic in nature, probably involves interplay between many 
different Thl and Th2 cytokine mediated mechanisms. A further level of complexity 
now arises from the description of Treg cells and more recently Th17 cells, a subset of 
CD4÷ T cells whose development can be antagonised by both Thl and Th2 type 
cytokines, and there will undoubtedly be many examples in the coming months of how 
these other T cell subsets may play a role in lung inflammation. IL-17 mRNA has 
been reported to be elevated in the sputum of asthmatic patients (Bullens et al., 2006) 
and in a study using Tbet /- mice discussed previously as having a spontaneous asthma 
like phenotype, increased neutrophilia in the airways of these mice has now been 
linked to a greater propensity of T cells from these mice to develop into IL-17 
producing cells (Fujiwara et al., 2007). As a result, effective treatments for many of 
these diseases are unlikely to be achieved by blocking a single pathway. However, 
much of what is currently known about lung inflammation, and the apparent 
dependence of some pathologies on single mediators, has come from mouse models 
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using manipulation of single entities using transgenesis or monoclonal antibodies, and 
the induction of disease through conditions that may be far from physiologically 
normal. Some of the mouse models commonly used in the study of human lung 
disease are discussed below. 
1.16 Mouse models of human lung disease 
Many different mouse models now exist for the study of human lung disease. Some 
mimic specific disease pathologies such as granuloma formation, while others have 
achieved modelling of multiple disease outcomes, such as the AHR, lung 
inflammation and the high IgE levels that result from antigen challenge in several 
mouse models of asthma. The disease outcomes associated with the chronic Thl type 
and IFN-y mediated lung inflammation of diseases such as sarcoidosis and 
bronchiectasis have proved the hardest to model. Bronchiectasis is characterised by 
irreversible airway dilation and is found in association with chronic bronchial 
infection and inflammation. There are currently no good animal models of 
bronchiectasis, and while bacterial lung infection can be easily induced in the mouse 
(Cole et al., 2005), the irreversible changes in lung structure that occur in humans over 
long periods of time have proved harder to mimic. No spontaneous models have been 
described and our lack of understanding surrounding the processes involved in chronic 
airway structural change makes it difficult to arrive at a starting point in trying to 
establish an in vivo model. Likewise, there are currently no good models of 
sarcoidosis, although some protocols to induce granuloma formation in the mouse 
have been described. Early models investigated the use of human sarcoid tissue itself 
as an inducing agent, with granuloma formation in mice observed following 
inoculation with sarcoid tissue homogenate (Mitchell et al., 1976). However, results 
were not consistent, with others reporting similar granulomas when control tissue 
homogenates were used (Belcher and Reid, 1975) and this model as since fallen out of 
favour. Other approaches include the intravenous injection of complete Freund' s 
adjuvant in rats (Bergeron et al., 2001) and Schistosome mansoni or 
Propionibacterium acnes infection in mice (Wynn et al., 1993 and Nishiwaki et al., 
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2004). However, the mechanisms of granuloma formation in these models remain 
poorly defined and indeed elucidation of mechanisms that are occurring in response to 
antigens irrelevant to the human disease of sarcoidosis may be misleading. This may 
be particularly true of Schistosome mansoni infection, where formation of granulomas 
is seen to be accompanied by a Th2 type pattern of cytokine expression (Wynn et al., 
1993). However, in keeping with the Th2 nature of this disease model, S. mansoni 
infection is also used as a model of fibrosis (Wynn et al., 1995). In the S.mansoni 
model, fibrosis and granuloma formation occur in the liver. To model fibrosis in the 
lung, the most common protocols involve the infliction of lung injury using toxins or 
drugs. The antibiotic bleomycin is used most commonly (Adamson and Bowden, 
1974) but the acute nature of the fibrotic disease caused by these agents raises doubts 
over whether they are faithful mimics of the slower but progressive tissue remodelling 
observed in diseases such as idiopathic pulmonary fibrosis. Another infection model 
that has been used to cause fibrosis in the lung uses Aspergillus fumigatus (Blease et 
al., 2002). Models using this pathogen are of particular interest as this fungus is 
known to be the cause of allergic bronchopulmonary aspergillosis and is associated 
with asthma. As such, many features of human asthma, such as AHR, eosinophilia 
and high levels of IgE, can be modelled in mice by exposure to this pathogen (Kurup 
et al., 1992). 
Aside from the aspergillosis model, several different and well characterised murine 
systems now exist for the study of the more acute phases of allergic lung immune 
responses. The most commonly cited of these is the ovalbumin (OVA) model of 
murine asthma (Kung et al., 1994). Protocols for disease induction using the OVA 
model vary slightly, but the overall scheme of sensitisation to OVA by intraperitoneal 
(i.p) injection followed by exposure of the airways to the allergen, either as an aerosol 
or by intranasal administration, 2 or 3 weeks after the initial priming, is similar across 
most studies. Strains of mouse commonly used are BALB/c and C57BL/6 and mice 
sensitised and challenged with antigen demonstrate airway hyperresponsiveness, lung 
infiltrates dominated by allergen specific CD4+ T cells and eosinophils, Th2 type 
cytokines in the BAL and lung such as IL-4, IL-5 and IL-13, and high levels of 
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allergen specific serum IgE. The existence of transgenic mice that express a TCR 
(D011.10), specific for a peptide of OVA (OVA323-339)  (Murphy et al., 1990) has 
made the use of this model even more widespread. These TCR transgenic mice have 
facilitated the development of adoptive transfer models of lung inflammation where 
lymphocytes from immunised TCR transgenic mice are cultured in vitro, often in Thi 
or Th2 polarising conditions, before being transferred by intravenous injection to naïve 
mice that are subsequently challenged with OVA (Randolph et al., 1999). In this way, 
allergen specific T cells can be tracked in vivo and this approach has allowed for a 
better understanding of the role of both Thl and Th2 CD4+ T cells in the development 
of allergy. In the context of human asthma, and indeed murine allergy, as no natural 
mouse allergens have been described, OVA is an irrelevant protein. The success of 
the model in generating a Th2 type disease profile is mediated in part by the inclusion 
of the Th2 promoting adjuvant, alum, in the priming stages of disease induction (Grun 
and Maurer, 1989). In this way, the OVA model of asthma is non-ideal as it 
predisposes the immune response towards a Th2 phenotype in a way that is 
independent of allergen, which in the case of OVA is also physiologically irrelevant to 
the human disease. The non-physiological nature of the immune response is also 
highlighted by the large doses of protein, administered over a period of many days, 
that are required to induce significant disease, compared to the relatively small doses 
of antigen that human asthmatics are proposed to be exposed to (Arshad et al., 1998). 
In order to more closely mimic human disease, other models that use human allergens 
have been developed, for example, the house dust mite allergen, DerP1 (Lee et al., 
1999). However, disease induction protocols with DerP1 also require priming with 
alum and high antigen doses. More complicated attempts to create humanised mouse 
models of asthma have also used house dust mite allergy as their basis, with SCID 
mice reconstituted with peripheral blood mononuclear cells (PBMCs) from house dust 
mite allergic patients showing evidence of human cell inflammatory infiltrates and 
specific human IgE responses following challenge with antigen (Duez et al., 1996). 
Another drawback of original OVA and DerP1 disease induction protocols is that they 
fail to mimic the progressive fibrotic and remodelling processes that are seen to occur 
over the long term in the lungs of patients with more severe asthma. To try to model 
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these changes, existing protocols have been modified to include extended periods of 
allergen challenge. Signs of airway remodelling, such as goblet cell hyperplasia and 
collagen deposition, have been observed (McMillan and Lloyd, 2004) although similar 
to criticisms of acute airway inflammation, in these models, the doses of antigen 
required to elicit these pathologies in the murine lung are extremely high and unlikely 
to be physiologically similar to the human disease. 
In addition to the use of exogenous agents, such as pathogens, drugs or proteins, 
transgenic mice have been used extensively, both in combination with the models so 
far described, and alone, to decipher more specifically the roles of individual 
molecules or pathways in the mechanisms and potential treatments of disease. For 
example, most of the cytokines associated with CD4+ T cell immune responses have 
now been overexpressed in the lung. Overexpression of IL-4, IL-5, IL-13, and IL-9 all 
result in spontaneous recruitment of inflammatory cells, particularly eosinophils and 
lymphocytes, to the airways and are also associated with other pathologies such as 
mucus hypersecretion, airway hyperresponsiveness, collagen deposition and fibrosis to 
varying degrees (Rankin et al., 1996, Lee et al., 1997, Zhu et al., 1999, and Temann et 
al., 1998). Overexpression of IFNI leads to infiltrates of macrophages and 
neutrophils, and alveolar enlargement, characteristic of emphysema, is also observed 
(Wang et al., 2000). The opposite approach has been to knockout proteins of interest. 
The spontaneous asthma like phenotype of Tbefi" mice has already been discussed 
(Finotto et al., 2002), as has the lack of eosinophilia and AHR in IL-5-/- animals 
(Foster et al., 1996), and a great many molecules have now been manipulated in these 
ways. However, results should be interpreted with caution, bearing in mind potential 
genetic background effects and also the presence or absence of these proteins from 
birth, which could result in abnormal lung or lymphoid tissue development. To 
circumvent the problems of abnormal lung development and enable genetic 
intervention purely at the point of disease induction, inducible transgenic animals are 
now being increasingly employed (Cheng et al., 2007). However, having stated this 
caveat to the timing of gene overexpression, the phenotypes observed when IL-13 is 
73 
inducibly targeted to the lung are found to be very similar to those that result in mice 
that express this cytokine constitutively (Zheng et al., 2000). 
Chapter 5 of this thesis describes the generation of an inducible transgenic model of 
lung disease, where induction results not in the overexpression or ablation of 
endogenous protein but in the expression of a peptide antigen for CD4+ T cells. The 
peptide in question is the cognate antigen for the T cell receptors used in the 
generation of the TCR transgenic animals described in chapters 3 and 4 of this thesis. 
Commonly employed strategies in the generation of transgenic animals, along with the 
transgenic approaches that have been used in the generation of the mouse models in 
this thesis are discussed in the section below. 
1.17 Approaches to transgenesis 
Transfer of foreign DNA into the mouse genome by injection of a plasmid into the 
pronuclei of fertilised mouse oocytes, a technology now known as transgenesis, was 
first achieved in 1980 (Gordon et al., 1980). That this transfer of genetic material 
could lead to an altered phenotype in genetically modified animals was demonstrated a 
couple of years later (Palmiter et al., 1982) and since this time, the use of transgenic 
mice in research has become widespread and routine. Improvements in transgene 
design have led to better and more predictable expression levels of the proteins of 
interest, but pronuclear injection of oocytes remains the most common technique by 
which genetic modification of the mouse is achieved, and it has now been employed in 
many other species of animal including rats, rabbits, sheep, pigs and cows. Other 
approaches to DNA integration that have been tried and which are becoming more 
widely used include the use of transposons (DNA sequences that trigger integration) 
(Dupuy et al., 2002) and the use of retroviral vectors (Lois et al., 2002). Of these 
approaches, retroviral vectors probably hold the most promise, and very high 
efficiencies from low titre preparations of virus are now being reported (Ritchie et al., 
2007). Although random recombination events are the most straightforward way to 
introduce new genetic material into the genome, modification of endogenous gene 
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function by gene knockout or mutation cannot be achieved in this way. This approach 
requires a homologous recombination event at the endogenous loci of the gene of 
interest and is achieved using embryonic stem (ES) cells as, in these cells, for 
unknown reasons, homologous recombination is the most efficient. Although more 
efficient in ES cells, homologous recombination is still a rare event and cells in which 
this has occurred must be selected and further used to generate a living embryo. Only 
two mouse lines have proven useful in the development of chimeric embryos, which 
then transmit the recombined gene to their progeny, and most chimeric mice have been 
generated using 129/SV ES cells. The difficulty of this technique is additionally 
highlighted by the failure to date to achieve transgenesis by homologous 
recombination in any species other than the mouse. 
One of the benefits of homologous recombination over random integration of a 
transgene is that factors influencing transgene expression are better understood. If the 
position of the transgene in the genome is known and controlled, then so are the 
corresponding promoter and enhancer elements surrounding the integrated DNA. 
When a transgene is integrated randomly into the genome, control over expression 
may be mediated not only by the promoter that has been engineered into the transgene 
itself, but also by promoter, enhancer and silencer elements that now surround it 
(Cranston et al., 2001). Approaches to minimise the influence of surrounding genetic 
elements have included the use of so called insulator sequences (Taboit-Dameron et 
al., 1999) and the inclusion of long genomic DNA fragments in the transgene itself 
(Giraldo and Montoliu, 2001), but removing bacterial sequences prior to pro-nuclear 
injection and the inclusion of intronic sequences immediately before coding sequences 
are among some straight forward rules now employed in the design of transgenes to 
aid correct expression. Aside from the coding sequence of the gene of interest, crucial 
to the function of the transgene is the choice of promoter. The promoter used will 
determine the timing and tissue specificity of transgene expression and the use of a 
wide variety of different promoters have been reported in transgenic mice, from 
ubiquitous and constitutive, such as the chicken (3 actin promoter (Wiekowski et al., 
2001a) to the tissue specific and developmentally controlled, such as the CD4 
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promoter (Salmon et aL, 1996). There is also a growing interest in inducible gene 
expression technology, where tissue specific or ubiquitous gene expression/ablation 
can be exogenously controlled at the most appropriate time point for the scientific 
question being addressed. For gene knockout studies this approach was demanded by 
the embryo lethal phenotype of many constitutive knockouts and in overexpression 
studies it has become important to separate abnormal developmental processes from 
those really involved in the biological pathway of interest. Several systems for 
inducible gene targeting have now been described with the tetracycline and Cre 
systems being the most commonly employed and schematic diagrams that outline the 
mechanistic basis behind these two approaches are shown in figure 1.5 
In the tetracycline system of inducible gene targeting a ubiquitous or tissue specific 
promoter directs expression of a reverse tetracycline transcriptional activator (rtTA). 
Temporal control is achieved because this molecule can only initiate transcription of 
the target gene by binding an upstream tetracycline operator (tetO) sequence in the 
presence of doxycycline (Zhu Z et al., 2002). The main drawback to this approach has 
been the low baseline levels of target gene expression found in the absence of 
induction, as rtTA can exhibit a degree of residual affinity to tetO in the absence of the 
drug. To minimise this problem, some groups have used another transgene coding for 
a transcriptional silencer (rTS). rTS binds to tetO only in the absence of doxycyline 
and so transcriptional repression is lifted on administration of the drug (Zhu et al., 
2001). An additional problem with this system was highlighted more recently in a 
study of rtTA transgene use in the lung (Sisson et al., 2006). This study found that 
expression of simply the rtTA protein alone in the lung, in the absence of any target 
gene, could cause pulmonary pathology consistent with an emphysema like phenotype 
in these mice. This study highlights one of the many dangers of interpreting data 
derived from transgenic animals and makes a strong case for the need to control for all 
aspects of a particular genetic manipulation. 
The Cre/lox system involves a mechanism of site-specific recombination that derives 
from bacteriophage P 1. Cre recombinase recognises, and catalyses recombination 
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Figure 1.5 The mechanistic basis of reverse tetracycline-controlled 
transcriptional activator (rtTA) and Cre/Lox systems of inducible gene targeting. 
In both systems, spacial control is achieved with the use of one or more tissue specific 
promoters. (a) In the tetracycline system a transcriptional activator (rtTA) is only 
active in the presence of the tetracycline derivative, doxycycline. Upon binding to 
doxycycline, rtTA can bind an operator sequence (tet0) and activate target gene 
expression. (b) In the Cre/Lox system, the Cre recombinase mutated oestrogen 
receptor complex must bind tamoxifen and translocate to the cell nucleus in order to 
activate target gene expression. Gene expression is permitted by the excision of a 
translational stop sequence. Alternatively, engineering of loxP sites to flank the gene 
of interest itself can result in temporal control over gene ablation. Cre mediated 
recombination is prevented in the absence of tamoxifen by Hsp90 retention of the 
MerCreMer complex in the cytoplasm. 
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between, 34 base pair sequences known as loxP sites. Excision of a stretch of DNA 
located between two loxP sites can either knockout a gene or permit expression of an 
adjacent gene (figure 1.5) and the system becomes inducible when two mutated 
hormone-binding domains of the murine oestrogen receptor are engineered to flank the 
Cre protein (MerCreMer) (Metzger et al., 1995). These hormone binding domains 
complex with Hsp90 to retain the Cre recombinase in the cell cytoplasm until 
administration of the drug tamoxifen. On binding tamoxifen the MerCreMer complex 
is able to move to the cell nucleus and mediate recombination. Spatial control over 
this system can be achieved by tissue specific expression of Cre and/or the gene of 
interest and it has been suggested that further control over specificity may be possible 
by expressing the Cre protein as two halves, under the control of two different 
promoters (Casanova et al., 2003). Cre toxicity is the most widely reported problem 
of this system (Loonstra et al., 2001). It occurs because mammalian genomes contain 
pseudo loxP sites whose sequence can deviate considerably from the consensus loxP 
sites present in the transgene, but which can still act as functional recognition sites for 
the Cre protein. The inducible MerCreMer system does minimise this problem by 
reducing the amount of time for which cells are exposed to the Cre protein, but the 
possibility of phenotypes arising from cell toxicity means that proper experimental 
controls, where animals carry the Cre transgene but not the target gene, should always 
be included. 
An emerging area in the field of gene targeting is the use of RNA interference (RNAi) 
and a recent study has combined RNAi technology with the inducible tetracycline 
system of gene expression to achieve inducible, tissue specific and reversible gene 
knockdown in transgenic mice (Dickins et al., 2007). In this study, a short hairpin 
RNA (shRNA) targeting the mouse Trp53 gene was expressed transgenically under 
the control of a tetracycline responsive CMV promoter with rtTA under the control of 
a liver specific promoter. Efficient, tissue specific and reversible knockdown of Trp53 
was observed upon administration of doxycycline that could be demonstrated to have 
functional consequences in an established model of tumoregenesis, where knockdown 
of Trp53 led to more rapid disease progression. The Cre system of gene targeting does 
not led itself so well to this approach as induction is not reversible, but the use of the 
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tetracycline system and RNAi in this way represents a promising new approach to 
controlling endogenous gene expression in vivo. 
Chapter 5 of this thesis describes the use of the MerCreMer system of inducible gene 
targeting to create a transgenic system in which a T cell epitope (PLP 56-70) is 
expressed inducibly and specifically in the lung. There are currently no reports in the 
literature of other peptides being targeted for expression in the lung in this way, but 
the inducible targeting of proteins to cardiac tissue (Xiong et al., 2007) and tumor cells 
(Spiotto et al., 2003) are examples of other studies that have successfully employed 
the MerCreMer system of gene expression. 
The peptide (PLP56-70), used in the inducible mouse model described in chapter 5, is 
the cognate epitope for the T cell receptors used for the generation of the TCR 
transgenic animals described in chapters 3 and 4. TCR transgenic animals were first 
described in 1988, when mice bearing transgenes encoding the a and (3 chains of a 
TCR specific for the male H-Y antigen were generated (Kisielow et al., 1988). 
Studies with these animals served to answer important questions about T cell tolerance 
and thymic selection. The authors observed that, while in female mice peripheral 
CD8+ T cells bearing the transgenic TCR were capable of lysing male target cells, 
fewer transgenic TCR bearing cells were present in the periphery of male mice, and 
those that were present were unable to react to antigen. Since the publication of these 
first TCR transgenic animals, a great many more TCR transgenic models have been 
described, serving to answer many more questions about T cell development and 
function as well as providing valuable new disease models. The integral role that TCR 
transgenic animals have played in the understanding of T cell development has been 
discussed earlier in this thesis. Expression of a and (3 chain transgenes, both 
independently and together, was pivotal to understanding the way in which TCR 
molecules are assembled (Uematsu et al., 1988) and these models have also played an 
important role in our understanding the role of the TCR in, and the timing of, negative 
selection in the thymus (Douek et al., 1996). In this study by Douek et al., the timing 
of negative selection in several different TCR transgenic lines were compared. The 
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site at which negative selection occurred in the thymus, i.e. thymic cortex or thymic 
medulla, was found to be influenced by the nature of the antigen recognised by the 
TCR. Negative selection as a consequence of superantigen recognition was found to 
occur in the medulla, while presentation of cognate self-peptide could induce deletion 
in either compartment. TCR transgenics have also been used to answer important 
questions about T cell function in the periphery and there are now numerous examples 
in the literature of the use of TCR transgenics to investigate T cell function in the 
context of a disease. The use of mice bearing a transgenic TCR (D011.10) specific for 
an epitope of the ovalbumin protein, in combination with the commonly used 
ovalbumin model of allergic airways disease, has already been described in the context 
of mouse models of lung disease. Other examples of the use of TCR transgenesis in 
disease models include mouse models of multiple sclerosis (MS) (Ellmerich et al., 
2005) and autoimmune gastritis (Candon et al., 2004). In the study by Ellmerich et 
al., the TCR in question was a human sequence derived from myelin basic protein 
specific T cells of MS patients and was used in conjunction with a human HLA class 
II transgenic mouse. Mice expressing both the human TCR and human HLA class II 
were shown to develop spontaneous MS like pathologies. The TCR transgenic mice 
described in chapters 3 and 4 of this thesis have been used to try to answer basic 
biological questions about the role of the TCR in determining CD4+ T cell phenotype, 
but are also linked to the inducible transgenic model described in chapter 5, which 
uses the MerCreMer inducible system of gene expression. A long-term aim of the 
work in this thesis is to combine the TCR transgenic models (chapters 3 and 4) with 
the inducible lung gene expression system (chapter 5) to create a new mouse model of 
lung inflammation. 
1.18 Interleukin 8 
Previous discussion surrounding lung diseases and attempts to understand the 
processes of lung inflammation has included the mention of many proteins that have 
been both ablated and overexpressed in the lung. One cytokine not normally directly 
associated with Thl or Th2 type immune responses per se, but nevertheless implicated 
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in the pathogenesis of several human lung diseases, is IL-8. To date there are no 
reports in the literature of IL-8 having been overexpressed in the mouse lung and 
chapter 6 of this thesis, along with discussion in the following sections, describes 
current understanding of this cytokine in the context of lung inflammation and the 
generation of transgenic mouse lines with lung targeted, but constitutive, expression of 
IL-8. 
Interleukin-8 (IL-8) was first identified in 1987 through its role as a neutrophil 
activating cytokine. Identification of this protein by several different groups at around 
the same time meant that it was assigned different names, being referred to as 
monocyte derived neutrophil chemotactic factor (MDNCF) (Yoshimura et al., 1987), 
monocyte derived neutrophil activating peptide (MONAP) (Schroder et al., 1987) and 
neutrophil activating factor (NAP) (Walz et al., 1987). The name IL-8 was 
subsequently proposed and adopted but since that time a whole family of structurally 
related cytokines, known also as chemokines, have been identified, and in much of the 
current literature IL-8 is referred to as CXCL8. Chemokines are so called because of 
the leukocyte chemotactic properties displayed by most. Members of this family are 
low molecular weight proteins with cysteine residues at well conserved positions and 
it is these cysteine residues that define their nomenclature (Zlotnik and Yoshie, 2000). 
IL-8 belongs to the CXC subgroup of chemokines, which are so called because the 
first two cysteine residues at the N terminus of the functional protein are separated by 
a single amino acid. This is compared to 3 amino acids or adjacent cysteine residues 
in the CX3C and CC subgroups respectively. CXC chemokines can be further 
classified into ELR+ or ELR- based on the presence or absence of a tripeptide motif 
(Glu-Leu-Arg) directly before the first cysteine residue at the N terminus of the 
protein. IL-8 is an ELR+ chemokine (appendix 29) that correlates with a potent 
chemotactic effect, particularly on neutrophils, (Yoshimura et al., 1987), angiogenic 
activity (Strieter et al., 1995) and high affinity binding to the chemokine receptors 
CXCR1 and CXCR2 (Holmes et al., 1991 and Murphy and Tiffany, 1991). 
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The cDNA of IL-8 encodes a 99 amino acid precursor protein (appendix 29), the N 
terminal signal sequence of which is cleaved extracellularly to yield predominantly 77 
or 72 amino acid versions of the protein (Matsushima et al., 1988). Processing is 
carried out by extracellular proteases and the form that dominates depends upon the 
cellular environment. In vitro cultures of fibroblasts and endothelial cells produce 
mainly the 77 amino acid form, while the 72 amino acid form is produced by 
leukocytes (Padrines et al., 1994, Hebert et al., 1990 and Nakagawa et al., 1991). 
Different forms of the protein exhibit different neutrophil chemoattraction activities 
with the 72 amino acid form more potent than the 77 amino acid protein and it is the 
72 amino acid protein that is identified at sites of inflammation in vivo (Ko et al., 
1993). Crystallographic studies revealed that at high concentrations IL-8 exists as a 
homodimer (Baldwin et al., 1991), however at nanomolar concentrations, which most 
likely reflects conditions in vivo, this cytokine is predominantly monomeric (Burrows 
et al., 1994) and indeed mutation of the protein to prevent dimerization does not 
prevent receptor binding or neutrophil activation (Rajarathnam et al., 1994). 
IL-8 can be produced by leukocytes such as T cells, monocytes, neutrophils and 
natural killer (NK) cells but also by somatic cells such as endothelial cells, fibroblasts 
and epithelial cells. However, expression is not generally constitutive and production 
is induced by inflammatory cytokines such as IL-1 and TNF-a (Matsushima et al., 
1988). Bacterial proteins and viruses can cause upregulation of IL-8 expression 
(Martich et al., 1991 and Johnston et al., 1997), as well as environmental conditions 
such as hypoxia (Xu et al., 1999), and the transcription factors NF-K13 and AP-1 have 
been shown to bind the IL-8 gene, implicating these proteins in the control of IL-8 
gene transcription (Murayama et al., 1997 and Thompson et al., 2006). The biological 
activities of IL-8 are mediated through binding to the G protein coupled receptors, 
CXCR1 and CXCR2. These receptors are more than 80% homologous at the amino 
acid sequence level and differ only in their NH2 terminal portions, giving rise to 
slightly different binding specifies of other chemokines. Binding of IL-8 induces 
receptor internalisation, although receptors are subsequently recycled to the cell 
surface (Samanta et al., 1990) and signalling is mediated by the receptor coupled G 
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proteins which activate pathways such as those mediated by PI3K-y and MAPK 
(Hirsch et al., 2000 and Km11 et al., 1996). CXCR1 and CXCR2 receptors have been 
identified on the surface of several different cell types such as neutrophils, monocytes 
and NK cells (Morohashi et al., 1995), and while the role of IL-8 in NK cell migration 
remains slightly controversial, with some studies reporting IL-8 to be chemotactic to 
NK cells and others not (Campbell et al., 2001 and Loetscher et al., 1996), neutrophil 
chemotaxis in response to IL-8 is better defined. In order for IL-8 produced by a 
tissue, for example in response to a bacterial infection, to attract neutrophils, the 
cytokine is first internalised by vascular endothelial cells, transcytosed and then 
presented to neutrophils at the luminal surface of the vessel (Middleton et al., 1997). 
This transcytosis and presentation on the luminal surface is mediated by the C terminal 
end of the protein, and cleavage of this C terminal region by a Streptococcus pyogenes 
bacterial proteinase has been proposed as a mechanism of immune evasion by this 
pathogen (Edwards et al., 2005). On binding to the CXCR1 and CXCR2 receptors on 
the surface of passing neutrophils, IL-8 induces the shedding of adhesion molecule L-
selectin and alters the expression levels and avidity of integrins such as CD11 b and 
CD1 1 c, stimulating migration across endothelial and epithelial cell layers (Detmers et 
al., 1990, Huber et al., 1991 and Mul et al., 2000). Additionally, IL-8 can activate 
some of the effector mechanisms employed by neutrophils, such as degranulation and 
the respiratory burst (Walz et al., 1987) and migration of other cell types such as 
basophils, eosinophils and T cells, both directly and indirectly, has also been reported 
(Geiser et al., 1993, Bruijnzeel et al., 1993, Larsen et al., 1989 and Chertov et al., 
1996). 
1.19 Neutrophil function 
High levels of IL-8 protein are found to be associated with several different diseases 
(discussed later), often in conjunction with large neutrophil infiltrates. With the potent 
chemotactic and neutrophil activating properties of IL-8, and the important role that 
neutrophils are known to play in innate defence mechanisms and in direction of the 
adaptive immune response, there is much interest in the relevance of the high levels of 
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IL-8 protein and neutrophils in these disease pathologies. Neutrophils are most 
commonly thought of as phagocytes that accumulate at, and are rapidly recruited to, 
sites of bacterial infection where they ingest and kill invading microbes. Neutrophils 
produce a wide variety of antimicrobial compounds which are stored within the cell to 
kill ingested pathogens, but which are also secreted during the processes of 
degranulation and the respiratory burst, which occur as a result of neutrophil 
activation. Neutrophil granules contain many antimicrobial molecules, such as 
lactoferrin, lysozyme and matrix metalloproteinases (Faurschou and Borregaard, 2003) 
and products of the respiratory burst, such as hydrogen peroxide, hypochlorous acid 
and reactive oxygen intermediates are also toxic to invading pathogens. First to be 
discharged upon activation of the neutrophil are the peroxidase-negative secondary 
and tertiary granules. As well as the matrix metalloproteinases MMP8, MMP9 and 
MMP25, which are thought to have an important role in facilitating neutrophil 
recruitment and tissue breakdown (Faurschou and Borregaard, 2003), these granules 
contain the antimicrobial proteins lactoferrin, lipocalin, lysozyme and LL37, which act 
to kill microorganisms. Lactoferrin, for example, is an iron binding protein that acts to 
sequester iron thereby removing an essential microbial growth factor from the 
extracellular environment, and transgenic mice that overexpress the human form of 
lactoferrin are found to have enhanced immune responses to bacterial infection 
(Guillen et al., 2002). Following the release of secondary and tertiary granules, next 
to be released by the neutrophil are the peroxidase-positive primary granules. These 
contain additional antibiotic proteins, such as cathepsin G, neutrophil elastase, 
protease 3, and Azurocidin (Campanelli et al., 1990) as well as myeloperoxidase. 
Myeloperoxidase is an iron containing enzyme that converts hydrogen peroxide into 
the much more powerful antiseptics, hypochlorous acid, hypobromous acid and 
hypoiodous acid. 	The hydrogen peroxide that serves as a substrate for 
myeloperoxidase derives from production of reactive oxygen intermediates by the 
neutrophil, the primary mediator of which is a phagocyte oxidase (phox). A 
deficiency of this enzyme is fatal as patients are unable to control bacterial infection 
(Good et al., 1968). Neutrophils are therefore an essential and powerful first line of 
defence against invading pathogens, but the chemicals that they release are also 
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damaging to host cells and if uncontrolled can cause enormous damage to the local 
tissue. A small level of tissue damage around a site of infection is probably beneficial 
to the host as it may help to isolate microbes and prevent spread of infection, however, 
in the longer term neutrophils also generate signals to suppress their own activation, 
promote apoptosis and initiate repair processes. Anti-inflammatory compounds 
secreted by neutrophils include lipoxins, and both neutrophils and macrophages 
secrete the anti-inflammatory factor, secretory leukocyte protease inhibitor (SLPI) (Jin 
et al., 1997) that acts to neutralise some of the antimicrobial proteases secreted during 
the process of neutrophil degranulation. This protease inhibitor also acts to protect the 
epithelial-cell-growth-promoting cytokine, proepithelin, from neutrophil elastase 
thereby enabling repair processes to be initiated. If proepithelin is instead degraded by 
neutrophil elastase, products of this degradation act to promote IL-8 release by 
epithelial cells and the recruitment of activated neutrophils to the site of injury 
continues (Zhu J et al., 2002). 
Neutrophils are produced continuously by the bone marrow and traffic though the 
peripheral blood stream until recruited to sites of infection by chemokines such as IL-
8. As such, they are one of the first cell types to be found at the site of a wound and 
there is growing interest in the role that neutrophils may have in directing later stages 
of the immune response. That activated neutrophils themselves can be a source of IL-8 
has already been mentioned, but other examples include TNF-a, B lymphocyte 
stimulator (BLys) and IFN-y. TNF-a drives DC and macrophage differentiation and 
activation (Bennouna et al., 2003) and neutrophils can additionally mediate DC 
activation by cell-cell contact through engagement of the CD11 b integrin on 
neutrophils by the DC specific adhesion molecule, DC-SIGN (van Gisbergen et al., 
2005). BLys secretion by neutrophils promotes the activation of B cells and in a 
recent study, levels of BLys secreted by neutrophils from patients with rheumatoid 
arthritis were found to be greater than those from healthy control subjects (Scapini et 
al., 2005). Incidentally, rheumatoid arthritis is an example of a human disease that has 
been associated with elevated levels of IL-8 at the site of disease (Troughton et al., 
1996). A further link between neutrophils and the adaptive immune system comes 
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from the demonstration that in the presence of IL-12, neutrophils can produce IFN-y 
(Ethuin et al., 2004) and as well as through the secretion of inflammatory mediators, 
another way in which neutrophils may act to initiate adaptive immune responses was 
reported in a recent study using a Mycobacterium bovis strain Bacille Calmette-Guerin 
(BCG) model of infection (Abadie et al., 2005). In this study by Abadie et al. they 
used transgenic BCG expressing enhanced green fluorescent protein to show that 
neutrophils rather than dendritic cells carried BCG from a site of infection in the skin 
into the draining lymph node. However, there are also examples in the literature of 
neutrophils functioning to suppress rather than activate the adaptive immune response 
(Schmielau and Finn, 2001) and so a picture is emerging of a role for neutrophils in 
both the positive and negative regulation of many aspects of the immune response to a 
pathogen, some aspects of which are likely to be intimately linked to the presence or 
absence of IL-8 at the site of inflammation. 
1.20 Interleukin-8 and human lung disease 
High levels of IL-8 are found in association with several human lung diseases. One 
well studied example is bronchiectasis (Richman-Eisenstat et al., 1993). 
Bronchiectasis is characterised by irreversible airway dilation and is found in 
association with chronic bronchial infection and inflammation. As the respiratory 
organ of the body, the lung is constantly exposed to airborne microbes and as such has 
had to develop a multitude of innate and adaptive defence mechanisms to deal with 
these pathogens. To allow for sufficient and efficient gas exchange, the epithelial 
surface of the lung is vast and, in humans, much of this epithelial surface is covered by 
a layer of mucus. Mucus acts to trap incoming bacteria, and these can then be cleared 
from the lung by the action of motile cilia which line the surface of airway epithelial 
cells. It therefore follows that an impairment in mucus production, or the function of 
cilia, will result in susceptibility to infection, and in the diseases of cystic fibrosis (CF) 
and primary ciliary dyskinesia (PCD), which are both known causes of bronchiectasis, 
this is indeed the case (Matsui et al., 2006 and Bush et al., 1998). In this recent study 
by Matsui et al. the concentrated airway mucus that results from the deficiencies in ion 
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transport seen in CF was found to not only impede clearance of mucus from the 
airways, but also provide a favourable environment for bacterial growth and biofilm 
formation. In some cases of bronchiectasis, such as those caused by CF and PCD, the 
cause of persistent infection is understood. In many cases however, the disease is 
idiopathic (of unknown cause). Failure to clear bacteria from the airways in the first 
instance by ciliary movement results in bacterial contact with, and activation of, the 
lungs innate defence system of which neutrophils are an important component. The 
main mechanisms by which neutrophils clear invading microbes has been discussed in 
the previous section and the importance of the multitude of antimicrobial peptides 
secreted by these cells during a bacterial infection are highlighted by various disease 
models such as the disease protection conferred on mice manipulated to express 
lysozyme constitutively in the lung (Akinbi et al., 2000), and more recently by the 
impaired bacterial clearance observed in mice deficient in this protein (Cole et al., 
2005). It is the persistent nature of infection that lies behind the pathophysiology of 
bronchiectasis, as sustained inflammatory responses inevitably lead to tissue damage, 
impairing the ability of the lung to fight infection, and creating a vicious cycle of IFN-
y mediated immunity. 
As previously mentioned, CF patients suffer from chronic bacterial infections and 
elevated levels of IL-8 protein have been found in BAL, sputum and in the bronchial 
epithelial cells of these patients (Muhlebach et al., 1999, Sloane et al., 2005 and 
Muhlebach et al., 2004), along with pronounced neutrophilic infiltrates (Konstan et 
al., 1994). Whether the observed high levels of IL-8 are purely a function of chronic 
inflammatory reactions occurring in the lung, increasing IL-8 expression as a 
consequence of high levels of inflammatory cytokines and bacterial proteins, or 
whether the reason for high IL-8 expression is intrinsic to CF itself is not quite clear. 
However, two recent studies have suggested that the mutation in CF transmembrane 
conductance regulator (CFTR) gene alone, proposed to be the genetic basis for 
disease, is sufficient to cause elevated IL-8 gene expression in the airways (Perez et 
al., 2007 and Chan et al., 2006). 
87 
Another lung disease characterised by large neutrophil infiltrates and high levels of IL-
8 is acute respiratory distress syndrome (ARDS). Caused by a variety of direct or 
indirect insults to the lung such as pneumonia, smoke inhalation or surgery, several 
groups have reported a correlation between neutrophilia and levels of IL-8 in patients 
with ARDS (Aggarwal et al., 2000) and indeed an association between high levels of 
IL-8 and an increased risk of subsequently developing this condition has also been 
reported (Donnelly et al., 1993). A role for IL-8 in mediating the pathogenesis of this 
acute disease, aside from simply recruiting and activating the neutrophils which 
amplify lung inflammation and cause tissue damage, has been suggested to be 
mediated by anti-interleukin-8 autoantibodies (Kurdowska et al., 2001). This group 
reported a significant correlation between concentrations of IL-8:anti-IL-8 antibody 
complexes in the lung and the onset of ARDS. More recently, they have also 
demonstrated that these IL-8:anti-IL-8 antibody complexes are indeed attached to 
FcyRIIa receptors and are therefore likely to be mediating pro-inflammatory signals in 
the lung (Allen et al., 2007). 
Other diseases for which IL-8 has been found to be a marker of disease severity 
include idiopathic pulmonary fibrosis (IPF), COPD and diffuse panbronchiolitis 
(DPB) (Cane et al., 1991, Yamamoto et al., 1997 and Koga, 1993). Indeed, anti-IL-8 
therapy has been suggested as a possible therapeutic approach for the treatment of 
COPD (Mahler et al., 2004). Aside from neutrophil recruitment, additional roles for 
IL-8 in the pathogenesis of each of these diseases is currently unclear, but 
polymorphisms in the IL-8 gene have been reported in association with DPB (Emi et 
al., 1999) and in the COPD study by Yamamoto et al. IL-8 levels were closely 
correlated with lung function measurements. A more recent study has attempted to 
elucidate a role for IL-8 in directly affecting airway structure and function 
(Govindaraju et al., 2006). In this study, smooth muscle cells from human airways 
were analysed for expression of the IL-8 receptors, CXCR1 and CXCR2. Both 
receptors were found to be present on the surface of these cells and blocking of the 
receptors using neutralising antibodies could prevent changes in intracellular Ca2+ 
observed upon IL-8 stimulation. IL-8 was also found to cause contraction of the 
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muscle cells as well as stimulating cell migration. This data suggests that the lung 
function changes observed in many of the lung diseases discussed here could, in part, 
be mediated by the high levels of IL-8 found within the lung. 
Although asthma is normally considered to be associated with eosinophilic lung 
infiltrates, neutrophil influx is found to be a common feature of persistent asthma and 
this neutrophilia has also been associated with elevated levels of IL-8 (Gibson et al., 
2001). Increased levels of IL-8 have also been found in sputum samples directly 
before late phase exacerbations in acute asthma (Kurashima et al., 1996) and in 
keeping with the more recent results of the airway smooth muscle study by 
Govindaraju et al., IL-8 inhalation has been shown to directly provoke 
bronchoconstriction in guinea pigs, which was observed in the absence of any 
leukocyte recruitment into the airways (Fujimura et al., 1999). A positive role for IL-
8 in the regulation of asthma has been proposed following the finding that IL-8 can 
selectively inhibit IL-4 induced IgE production (Kimata et al., 1992) and the treatment 
of human lungs with IgE results in the release of IL-8 (Erger and Casale, 1998). 
However, there must then be a trade off between IgE downregulation and the 
neutrophil and eosinophil chemoattractant properties of this cytokine. Aside from IgE, 
the reason for elevated IL-8 levels in the airways of asthmatic is not yet clear, but that 
the initial source of this cytokine maybe the airway epithelium in response to allergen 
is supported by the finding that pulmonary epithelial cells can produce high levels of 
IL-8 in the presence of diesel exhaust particles (Takizawa et al., 1999). However the 
wide range of toxic chemicals present in diesel exhaust fumes means that this finding 
is not necessarily applicable to other more classical allergens. 
The neutrophilia observed in many human lung diseases, the central role of IL-8 in 
neutrophil recruitment and also emerging roles for IL-8 in disease pathogenesis that 
are separate from neutrophil recruitment and activation, all make IL-8 an attractive 
target for manipulation in animal models of lung disease. There are currently no 
reports in the literature of IL-8 having been overexpressed in the airways of mice, 
although this may not be an intuitive experiment as in the mouse genome, the IL-8 
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gene and the gene for its receptor, CXCR1, have been deleted. However, the CXCR2 
receptor is expressed, and this receptor is able to mediate neutrophil chemotaxis in 
response to the two proposed murine homologues of IL-8, KC and MIP-2 as well as in 
response to human IL-8 itself (Bozic et al., 1994). The chemoattractant properties of 
human IL-8 have been demonstrated using neutrophils for a variety of different 
species, including monkeys, rabbits, dogs and mice (Rot, 1991). Although the potency 
of human IL-8 varied between species and was lower than that observed for human 
neutrophils, these findings nevertheless suggest that interleukin-8, if expressed in the 
murine lung, should be biologically active. Various studies have manipulated the 
mouse CXCR2 receptor and its ligands in vivo and in keeping with the role of IL-8 and 
its receptors in human studies, mice overexpressing KC in a variety of tissues, 
including the lung, do show evidence of neutrophil infiltrates (Lira, 1996). Mice 
overexpressing KC in the lung also demonstrate increased resistance to infection (Tsai 
et al., 1998), while neutralising the CXCR2 receptor results in increased disease 
susceptibility (Tsai et al., 2000). These studies suggest that, as in humans, ELR+ CXC 
chemokines are critical mediators of neutrophil mediated host defence mechanisms. 
However, as has been discussed in this section, there is increasing evidence that IL-8 
mediates lung pathology in ways other than those involving neutrophil recruitment and 
additionally, to study potential therapeutic approaches to IL-8 mediated lung 
pathology in the mouse, using the human IL-8 protein rather than the mouse 
homologues, which are similar but not equivalent, would be preferable. There is 
therefore merit in the approach to overexpress human IL-8 in the murine lung and the 
generation and initial characterisation of such transgenic animals is described in 
chapter 6 of this thesis. 
1.21 Aims of this thesis 
Much of the discussion in this chapter has centred around the T cell receptor molecule 
and around the Thl and Th2 type immune responses that are an important feature of 
many human diseases, including several lung pathologies. Multiple factors are 
involved in determining whether a naive CD4+ T cell differentiates into a Thl or Th2 
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effector cell and several lines of evidence point towards an important role for the 
interaction between the T cell receptor (TCR) and its peptide ligand. A previous study 
by Boyton et al. (Boyton et al., 2002) showed that highly polarised Th2 CD4+ T cells 
selected under Th2 polarising conditions favour a structurally distinct TCR with an 
elongated TCR a chain complimentarity determining region 3 (CDR3), while those 
selected under Thl polarising conditions favour a shorter TCR CDR3 a chain. 
Molecular modelling predicted that this elongated TCR a chain results in a less 
optimal (lower avidity) interaction between the TCR and peptide/MHC complex and 
gave rise to the hypothesis that, if structurally distinct TCRs arising from Thl and Th2 
polarised T cells, i.e. a TCR bearing an elongated CDR3a region from a Th2 cell and 
a shorter CDR3a region from a Thl cell, are expressed transgenically, an inherent bias 
towards Thl or Th2 will be observed in CD4+ T cell responses from these animals. 
Much of the data in this study by Boyton et al. was derived from T cell responses of 
H2-E transgenic NOD (NOD.E) mice to the peptide epitope PLP 56-70. PLP 56-70 is 
an epitope used to induce EAE in NOD and NOD.E mice. A deletion in the promoter 
region of the I-E a chain gene means that NOD mice only express the MHC class II 
molecule I-A and are known to spontaneously develop type 1 diabetes. However, 
expression of an I-E a chain transgene protects NOD.E mice from diabetes (Lund et 
al., 1990), but makes them more susceptible to EAE (Tackas et al., 1995). In this 
study by Tackas et al. I-E expression in NOD.E animals was associated with a shift 
away from IL-4 production and towards greater IFN-y production in T cell responses 
to PLP 56-70, suggesting an association between Thl responses and disease in this 
model, whilst describing Th2 responses in association with protection. In the study by 
Boyton et al., multiple NOD.E T cell lines and clones specific for the peptide PLP 56-
70 were grown and polarised in vitro towards a Thl or Th2 phenotype. In all cases, 
the peptide response was found to be I-Ag7 rather than I-E restricted. It is Thl and Th2 
T cell lines grown during the course of this study, which are specific for the peptide 
epitope PLP 56-70, that serve as the starting point for the work described in chapters 3 
and 4 of this thesis, where the aim is to express dominant TCRs from Thl and Th2 
polarised T cell lines transgenically to determine whether a structurally distinct TCR 
can cause an innate bias in CD4+ T cell phenotype (figure 1.6) 
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Further to this hypothesis is a second question of whether these Thl and Th2 TCR 
transgenic animals could be used to create new models of Thl and Th2 mediated 
disease. The lung is one organ in which understanding Thl and Th2 type responses is 
of much interest and a second aim of this thesis is to establish a mouse model whereby 
the peptide epitope for these Thl and Th2 TCRs (PLP 56-70) can be expressed 
inducibly and specifically in the lung. Chapter 5 of this thesis describes the generation 
of this model using a lung specific promoter and the MerCreMer system of inducible 
gene expression and a schematic diagram detailing the way in which these mice would 
be used to generate novel lung disease models is shown in figure 1.6. 
The final aim of this thesis is to generate another mouse model of lung disease, where 
lung pathology is as a consequence of overexpression of the human cytokine IL-8 
(figure 1.6). Elevated levels of IL-8 protein are found associated with several different 
human lung diseases, but the precise role that IL-8 plays in the pathologies of these 
diseases has yet to be elucidated. Chapter 6 of this thesis describes the generation of 
mice overexpressing the human IL-8 protein in the lung and initial characterisation of 
lung pathology in these animals. 
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Figure 1.6 Transgenic strategies of this thesis. A schematic diagram of the transgenic strategies proposed for the three main 
aims of this thesis. (a) The use of TCR transgenics to answer questions about a possible role for the TCR in determining CD4+ T 
cell phenotype. (b) The targeting of antigen inducibly and specifically to the lung to generate, in combination with the TCR 
transgenics, models of Thi and th2 type lung inflammation. (c) Targeting of human interleukin 8 to the lung to elucidate the role 
of this cytokine in lung inflammation and pathology. 
Chapter 2  
Materials and methods  
2.1 Genomic DNA extraction 
400 µ1 of digestion buffer (appendix 1) and 10 [,t1 of 20 mg/ml proteinase K (Sigma-P-
6556) were added to each tissue sample and samples incubated at 56°C overnight. 
After complete digestion, 200 µ1 of 6M (saturated) NaC1 were added and the sample 
mixed well by vigorous shaking before centrifuging at 16000 x g for 15 minutes. The 
supernatant was removed to a fresh tube and DNA precipitated by the addition of 600 
µI of isopropanol. The sample was mixed well by inversion and spun at 16000 x g for 
10 minutes to pellet the DNA. The DNA pellet washed once in 70 % EtOH before 
being briefly air-dried and dissolved in 50-80 1_11 of TE buffer (appendix 1). Samples 
were incubated briefly at 56°C for 15 minutes to ensure the DNA pellet was fully in 
solution and samples were then stored at 4°C for up to one week or -20°C for more 
long term storage. 
2.2 RNA extraction 
For tissue samples or samples of greater than 5 x 106 cells, RNA was extracted using 
Trizol (Invitrogen-15596-018) a phenol and guanidine thiocyanate based extraction 
reagent. Prior to addition of Trizol reagent, tissue samples were homogenized using a 
manual glass-glass homogenizer. Samples were lysed by repeated pipetting with 1 ml 
of Trizol reagent. If not processed to RNA immediately, samples were stored at 4°C 
overnight or at -20°C for up to 1 month. Following cell lysis, 2000 of chloroform 
was added, the sample mixed by vigorous shaking for 30 seconds and then incubated 
on ice for 5 minutes. Samples were centrifuged at 12,000 x g for 15 minutes at 4°C 
and the upper aqueous layer removed to a new tube. RNA was precipitated by 
addition of 500 Ill of isopropanol. Samples were mixed by inversion and incubated at 
room temperature for 10 minutes before centrifugation at 12,000 x g to pellet the 
RNA. RNA pellets were washed once with 75% EtOH, air-dried briefly and dissolved 
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in 20-30 t1,1 of RNase free water (Sigma-W4502). RNA samples were stored at -20°C 
in the presence of 20 U RNase OUT (Invitrogen-10777-019). 
RNA from cell line samples of less than 5 x 106 cells was extracted using an RNA 
binding spin column (Stratagene-400805). 
2.3 DNase treatment of RNA samples 
To remove contaminating DNA from some RNA preparations prior to cDNA 
synthesis, samples were treated with an RNase free DNase (Promega-M610A). 3-51.1g 
of RNA in a reaction volume of 20 tx1 containing 2 Ill 10X reaction buffer (400 mM 
Tris-HC1 pH 8.0, 100 mM MgSO4 and 10 mM CaC12) and 1 U of DNase per Rg of 
RNA were incubated at 37°C for 30 minutes. The DNase was then removed from the 
sample by phenol:chloroform (Sigma-P1944) extraction. All traces of phenol were 
removed by an additional chloroform:isoamylalcohol (24:1) extraction and RNA 
precipitated using 2.5 volumes of 100% EtOH. RNA pellets were washed once with 
70% EtOH before being briefly air-dried and dissolved in 10 µ1 of RNase free water. 
cDNA synthesis reactions were then set up both with and without the reverse 
transcriptase enzyme to ensure that subsequent PCR results obtained were not due to 
contaminating DNA. 
2.4 cDNA synthesis 
RNA was quantitated by spectrophotometer and 10Ong - ltA,g used per cDNA reaction. 
The RNA in a volume of 13 1A.1 of sterile water containing 50 ng random hexamers 
(Invitrogen-48190-011) and 1 IA of 10 mM dNTPs (Invitrogen-18427-013) was heated 
to 65°C for 5 minutes and then placed on ice. 4 iil of 5X cDNA synthesis buffer 
(Invitrogen-18080-044), 1 !Al of 0.1M DTT (Invitrogen-18080-044), 40 U of RNase 
OUT and 200 U of Superscript III (Invitrogen-18080-044) were added. The mixture 
was heated at 25°C for 5 minutes, followed by 50°C for 60 minutes and 70°C for 15 
minutes. 1 [11 of completed cDNA reaction mixture was used as a template for each 
subsequent PCR reaction. cDNA was stored at -20°C. 
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2.5 Polymerase Chain Reaction (PCR) 
A general PCR protocol is described below. All oligonucleotide primer sequences, 
reaction product sizes and any reaction conditions that varied from those described in 
this section are listed in appendices 6, 7 and 8. 
PCR reactions were carried out in a reaction volume of 25 µI containing 50-100 ng of 
template DNA, 16 mM (NH4)2SO4, 67 mM Tris-HC1 (pH 8.8), 0.01% Tween-20, 1.5 
mM MgC12, 200 µM dATP, dCTP, dGTP, and dTTP (Bioline-BIO-39025), 0.5 ILIM of 
each oligonucleotide primer (Sigma Genosys) and 0.6 units of Taq polymerase. The 
reaction mixture was incubated at 95°C for 5 minutes, 30 cycles of 95°C for 1 minute, 
55°C for 1 minute, and 72°C for 1 minute, and a final cycle at 72°C for 8 minutes. The 
result of each PCR was then determined by running the reaction on a 1% agarose TAE 
(appendix 1) gel stained with EtBr (Sigma-E1510). 
2.6 Restriction enzyme digest 
Restriction enzyme digests were carried out in a volume of 20 µI containing 0.5-2 µg 
of plasmid DNA, 1 U of appropriate restriction enzyme(s), and 2µl of 10X buffer 
(appendix 3). Reactions were incubated at 37°C or 50°C (appendix 3) for at least 1 
hour. Digests were run alongside a DNA ladder with markers of known molecular 
weight (Promega-G5711) on 1% agarose TAE gels at 90V. 
2.7 Preparation ofXL-Gold competent cells 
XL-Gold cells from a previous preparation were streaked onto a Luria-Bertani (LB) 
agar (Sigma-L2897) plate containing 50 µg/m1 tetracycline (Sigma-T8032) and 
incubated at 37°C overnight. The following day a single XL-Gold colony was 
inoculated into 10 ml of LB broth (Sigma-L3022) containing 50 lag/m1 tetracycline 
and incubated at 37°C overnight on a shaker (225 rpm). The 10 ml overnight culture 
was inoculated into 200 ml of LB broth containing 0.015M MgC12 and grown until the 
optical density Q = 600 nm) of the culture reached 0.6. The culture flask was then 
placed on ice for 10 minutes before spinning 100 ml of the culture in a pre-cooled 
96 
centrifuge (4°C) at 1600 x g for 10 minutes. The supernatant was discarded and the 
remaining culture volume spun down in the same tubes. The cell pellets were 
resuspended by swirling and gentle pipetting in a total volume of 60 ml of ice cold 
solution A (appendix 1) and incubated on ice for 20 minutes. Samples were then 
centrifuged again, the supernatant discarded, and the pellets resuspended in a total 
volume of 12 ml of ice cold solution B (appendix 1). Competent cells were stored at -
80°C in 200 µ1 aliquots. 
2.8 E-coli transformation 
All transformations were performed using XL-Gold (see above) or INVaF' competent 
cells (Invitrogen-C2020-03). The same transformation protocol was used for both 
strains. 2111 of a ligation reaction or 1µl of a plasmid preparation were added to 50 [al 
of competent cells. The mixture was incubated on ice for 30 minutes before heat 
shock at 42°C for 30 seconds. 250 pi of SOC medium (supplied with INVaF' 
competent cells) or LB broth warmed to room temperature were added and the cells 
were then incubated with shaking (225 rpm) at 37°C for 1 hour. Bacteria were spread 
onto LB agar plates containing 50 µg/ml of ampicillin (Sigma-A9518). Plates were 
inverted and incubated at 37°C overnight. For TA cloning ligations, plates were also 
spread with 40 ial of a 40 mg/ml stock solution of 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-Gal) (Bioline-Bio37035) and 8R1 of a 100 mM stock solution of 
Isopropyl 13-D-1-thiogalactopyranoside (IPTG) (Sigma-16758) 30 minutes before 
plating of the bacteria. This allowed successfully ligated plasmids to be identified by 
blue/white screening of the bacterial colonies. Colonies containing a plasmid with a 
PCR product correctly ligated appear white. 
2.9 Standard cloning and ligation protocol 
With the exception of one step, which used a synthetic oligonucleotide insert, the 
fragments for all other cloning steps were obtained by single or double restriction 
enzyme digests of the appropriate plasmids. These restriction digests were carried out 
overnight in a volume of 40 111. For single enzyme digests it was necessary to 
dephosphorylate the ends of the vector fragment after digestion to prevent re-ligation. 
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This was achieved by adding 0.01 U of Calf Intestinal Alkaline Phosphatase (CIAP) 
(Promega-M1821) per pmol of DNA ends in the reaction (where 1 !is of 1000 bp 
DNA = 3.03 pmol of DNA ends) and incubating at 37°C for 1 hour. All DNA 
fragments used for cloning were purified by separation on a 1% agarose (Sigma-
A9539) TAE gel followed by gel extraction using silica beads (Qbiogene-1001-600). 
The amount of each purified fragment recovered was quantitated by running 1 [xl of 
each sample on an agarose gel alongside a quantitative DNA ladder (Bioline-
BI033025). As optimal ligation conditions for each cloning step were unknown, a 
number of reactions using different ratios of vector to insert were set up each time. 
The amount of each fragment required to achieve each ratio was calculated using the 
equation below. 
amount of vector (ng) x size of insert (bp) x molar ratio of insert = amount of insert (ng)  
size of vector (bp) 	 vector 
Standard ratios of vector to insert used were 1:1, 1:3, 1:6 and 1:12. Control reactions 
of 1:0 and 1:0 with no ligase added were also set up to assess levels of re-ligated and 
uncut vector respectively. Ligation reactions were set up in a volume of 10 [AI 
containing 5 U of T4 DNA ligase (Promega-M1801) and 2 [11 of 5 x reaction buffer 
(250 mM Tris-HC1 pH 7.6, 50 mM MgC12, 5 mM ATP, 5 mM DTT and 25% w/v 
polyethylene glycol-8000). Reactions were incubated at 16°C overnight before 
transformation into XL-Gold E-coli (see above). 
2.10 Blunt end generation 
A restriction digest (see above) of the appropriate plasmid and restriction enzyme was 
inactivated by heating to 65°C for 15 minutes. Blunt ends were generated using T4 
DNA polymerase (Promega-M4211). The reaction volume of the original restriction 
digest was increased to 50 1,t1 using sterile water, and contained 6 U of T4 DNA 
polymerase, 100 mM of each dNTP and 3 ill of promega 10X multi-core buffer (250 
mM Tris acetate, pH 7.8, 1 M potassium acetate, 100 mM Magnesium acetate and 10 
mM DTT). Reactions were incubated at 37°C for 5 minutes before inactivation at 
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75°C for 10 minutes. The plasmid was then purified by agarose gel extraction and 
blunt ends ligated using T4 DNA ligase. 
2.11 Oligonucleotide annealing 
Each oligonucleotide was made up to a concentration of 1 mg/ml in sterile water. 1 121 
of each oligonucleotide was then added to 18 itil of TE buffer and the mixture heated at 
70°C for 5 minutes. The tube was placed into a beaker of water at 65°C and left to 
cool to room temperature before placing on ice. No further purification of this 
annealed product was required before ligation. 
2.12 TA cloning of PCR products 
PCR products amplified using Taq polymerase (Bioline-BIO-21040) were cloned into 
the plasmid pCle2.1 by TA cloning (Invitrogen-K2000-01). Vector DNA did not 
require any purification before ligation, but PCR products were separated by agarose 
gel electrophoresis and gel purified using a silica matrix protocol to preserve the A 
overhangs. 10-20 ng of PCR product were ligated into 25 ng of pCle2.1 vector in a 
reaction volume of 10 pi containing 4 U of T4 DNA ligase (Invitrogen-15224-041) 
and 1 1,t1 of 10 x reaction buffer (60 mM Tris-HC1 pH 7.5, 60 mM MgC12, 50 mM 
NaCl, 1 mg/ml BSA, 70mM (3-mercaptoethanol, 1 mM ATP, 10 mM spermidine and 
20 mM DTT). Ligation reactions were incubated at 16°C overnight. 
2.13 Preparation and screening of plasmid DNA 
Successfully transformed bacterial colonies were picked from agar plates using sterile 
pipette tips and grown up in 8 ml of LB broth containing ampicillin (50 p.g/m1) at 
37°C overnight. Bacteria were pelleted by spinning at 1500 x g for 4 minutes and 
plasmid DNA extracted and purified by alkaline lysis (Qiagen-27106 or Sigma 
PLN350). Successfully ligated plasmids were identified by restriction enzyme digest 
and PCR. 
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2.14 T cell receptor PCR analysis 
T cell receptor (TCR) a and (3 chain cDNA transcripts were amplified using sets of 
primers previously described by Candeias et al. (Candeias et al., 1991). Three rounds 
of PCR are required to obtain a chain products while two rounds are required for (3. 
The 5' primers for both a and 13 are degenerate and designed to bind all TCR families. 
5' primers for a and (3 chain amplification are NW36, NW37, NW38 and NK121, 
NK122, NK123 respectively. They were used as an equimolar mixture for all rounds 
of amplification. 3' primers are derived from a and (3 constant regions. For the a 
chain, 3' primer NJ108 was used in the first round of amplification, followed by 
NJ109 and NJ110. For the (3 chain, MQ284 was the first 3' primer used, followed by 
MS175. Primer sequences are listed in appendix 4. All PCR rounds were set up as 
described in the section above using an annealing temperature of 53°C for 2 minutes 
and amplifying for 28 cycles. Products obtained were 300-400 bp in size and were TA 
cloned as described. Successfully ligated PCR products were identified by EcoR1 
digestion of plasmid DNA and sequenced using the M13 primer (appendix 4). 
2.15 Sequencing and T cell receptor sequence analysis 
All sequencing reactions were performed at the Natural History Museum sequencing 
facility. Plasmid DNA containing the sequence of interest was sequenced using a 
sequence specific primer and the Big Dye Terminator v1.1 Cycle Sequencing Kit 
(Applied Biosystems). Sequencing reaction products were analysed on an Applied 
Biosystems 3130x1 DNA analyser and sequence data obtained was manipulated using 
GeneJockeyll software. Raw sequence data files were read by EditView (Perkin 
Elmer). 
T cell receptor sequences and CDR3 region lengths were identified based on the 
classifications of the International Immunogenetics (IMGT) information system 
database (http://imgt.cines.fr) (Ruiz et al., 2000). CDR3 length was taken as the 
number of amino acids between, and not including, the conserved cysteine residue (C) 
at the 3' end of the V gene segment and the conserved phenylalanine residue (F) at the 
5' end of the J segment. 
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2.16 TCR CDR3 Spectratyping 
The sequences of the specific Vf3 gene primers and the constant Cr3 primer conjugated 
to the fluorescent dye 6-carboxyflurorescein-amino-hexy (6-FAM) are shown in 
appendix 5. PCR reactions were set up as described above with a final MgCl2  
concentration of 3.5 mM. For a given cDNA template, each V13 primer was set up as a 
separate PCR reaction with the constant C13-6FAM primer. PCR reaction mixtures 
were incubated at 95°C for 10 minutes followed by 36 cycles of 94°C for 20 seconds, 
55°C for 40 seconds, 72°C for 40 seconds and a final extension step of 72°C for 5 
minutes. 10 til of each PCR reaction was run on a 1% agarose TAE gel to confirm 
that the reaction had been successful before proceeding. PCR products were then run 
on an ABI Prism 3100 Genetic Analyzer in ABI Prism 96 well optical reaction plates 
(Applied Biosystems-403012) where each well of the plate contained 5 IA of PCR 
product, 1011,1 of Hi-Di Formamide (Applied Biosystems-4311320) and 0.50 of a 
Genescan 500 ROX standard (Applied Biosystems-401734). Data was collected and 
analysed by Gene Mapper ID Software version 3.2 (Applied Biosystems). 
2.17 Real- time PCR 
RNA and cDNA were prepared as described. 500 ng of DNase treated RNA was used 
as a template in each cDNA reaction. PCR reactions were carried out in a volume of 
20 Ill containing 1 !al of cDNA, 8 [Al of RNase free water, 1µ1 of 20x gene specific 
primer mix (Applied Biosystems — Assays-on-DemandTM Gene Expression Assay) 
(appendix 8) and 10 ttl of 2x TaqMan® Universal PCR Master Mix (Applied 
Biosystems - 4304437). Reactions were incubated at 50°C for 2 minutes, 95°C for 10 
minutes and then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. PCR 
reactions were set up in triplicate for each set of primers used, and CT values (the PCR 
cycle number at which the fluorescence passes a fixed threshold) were obtained using 
a Stratagene MX3000P real-time PCR machine and software. Variability in the 
amount of RNA used for each cDNA reaction was controlled for by running a PCR for 
18s RNA for each sample. PCR of a dilution series of a single sample showed the 18s 
and all other primer sets to have different amplification efficiencies. It was therefore 
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not possible to use the 2-mc` mathematical expression for fold change. CT values for 
PCR reactions were instead converted to numerical values, using the equation for the 
appropriate efficiency curve before normalising each gene of interest value with 
respect to the 18s value for the same sample. The sample with the lowest level of gene 
expression was assigned a value of 1. Levels of gene expression in all other samples 
were expressed as a value relative to 1. 
2.18 Preparation of DNA for oocyte pronuclear injection 
Plasmid DNA purified using a commercial alkaline lysis based purification kit 
(Qiagen-12162) was digested overnight with the appropriate restriction enzyme. 
Restriction digests were performed in a volume of 60 Ill containing 15 [t.g of plasmid 
DNA and at least 30 U of restriction enzyme. The required band was separated by 
running the sample on a 0.8% low melting point agarose (Promega-V2831) TAE gel at 
70 V for 6 hours. The fragment for injection was excised and gel purified using a 
DNA binding column (Qiagen-28704). An additional wash step of 5 minutes was 
added to the recommended protocol. DNA was eluted from the column in embryo 
grade water (Sigma—W1503) and the DNA solution sterilised by passing though a 
0.22um Costar spin filter (Fisher Scientific —MPA150010C). Purified DNA fragments 
were quantitated using a spectrophotometer (Nanodrop® ND-1000) and by running 
of the preparation on a 1% agarose TAE gel alongside a quantitative DNA ladder. 
Purified DNA fragments were stored at 4°C until the day of injection when they were 
diluted to a concentration of 2-4 ng/p,1 in embryo grade water in a final volume of 50 
pl. Oocyte pronuclear injections were performed at the Nuffield Department of 
Medicine (University of Oxford) or the MRC Clinical Sciences Centre (Hammersmith 
campus of Imperial College London) 
2.19 Genotyping 
Genomic DNA from a small sample of tail tissue was extracted using a high salt DNA 
extraction method (see above). Mice were assigned a number for identification based 
on cage number and ear marking at the time of tail biopsy. Mice carrying the 
transgene of interest were identified by PCR. The genotypes of transgenic founder 
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animals and of animals used for subsequent breeding were also confirmed by Southern 
blot (see below). 
2.20 Southern blotting 
Restriction digests of genomic DNA were carried out in a reaction volume of 50 0 
containing 10-15 [tg of genomic DNA, 50 U of appropriate restriction enzyme, 5 !al of 
10X buffer supplied with enzyme (appendix 3), 1 mM Spermidine (Sigma-S2501), 
100 µg/ml Ribonuclease A (Sigma-R4875) and 100 µg/ml BSA (Promega-R396D). 
Reactions were incubated at 37°C overnight. Digests were run alongside a standard 
ladder on a large 1% agarose TAE gel for 18 hours at 45V. Prior to blotting, the gel 
was photographed alongside a ruler to allow determination of band size on the final 
blot. Size markers and excess gel were trimmed away and the remaining gel incubated 
in depurination solution (appendix 1) for 10 minutes at room temperature. Following 
a brief wash in distilled water the gel was incubated in denaturing buffer (appendix 1) 
for 45 minutes at room temperature and then in neutralising buffer (appendix 1) for a 
further 45 minutes. The DNA was blotted overnight onto Hybond N+ (Amersham 
Biosciences RPN203B), a positively charged nylon transfer membrane, using 20X 
SSC (appendix 1) as the transfer buffer. DNA was irreversibly bound to the 
membrane by exposure to UV light for 2 minutes. The membrane could then be 
washed briefly in distilled water to remove any excess agarose, air-dried and stored at 
4°C. 
2.21 Southern blot Digoxigenin (DIG) probe labelling, hybridisation and detection 
DNA fragments to be DIG labelled and used as Southern probes were generated by 
PCR from plasmid DNA using primers specific to each transgene. PCR products were 
purified by gel extraction and quantitated by running on a 1% agarose TAE gel 
alongside a quantitative DNA ladder. 1-3 pg of DNA template was made up to a 
volume of 16 0 with sterile water and boiled for 10 minutes to separate strands before 
placing immediately on ice. 4 1A1 of DIG high prime mix (Roche-1 585 606) 
containing digoxygenin labelled dUTP was added and the reaction incubated at 37°C 
for 20 hours. The mixture was cleaned using a spin column (Bioline-BIO-28030) after 
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labelling to remove any unincorporated labelled nucleotides that could cause high 
background. The amount of probe successfully labelled was quantitated by dot 
blotting a dilution series of the probe, along with a dilution series of control labelled 
DNA (Roche-1 585 738) onto a nylon membrane, cross linking with UV and then 
carrying out the detection procedure described below. 
The Southern blotted genomic DNA membrane was incubated with 10 ml of pre-
warmed DIG Easy Hyb hybridisation solution (Roche-1 796 895) with gentle rotation 
at 42°C for 30 minutes. This solution was then discarded and the membrane incubated 
at 42°C overnight with 8 ml of pre-warmed hybridisation solution containing 20 ng/ml 
of denatured probe. The probe was denatured by boiling in 20 iil of water for 5 
minutes and then placing immediately on ice. This hybridisation solution could be re-
used by storing at -20°C and heating to 68°C for 10 minutes immediately before use. 
Following hybridisation the membrane was washed twice for 5 minutes in 2X SSC 
containing 0.1% SDS at room temperature and then twice for 20 minutes in 0.5X SSC 
containing 0.1% SDS at 65°C with gentle agitation. 
For detection of the labelled probe, the membrane was rinsed briefly in maleic acid 
wash buffer (appendix 1) before incubation in blocking solution (Roche-1 096 176) for 
30 minutes with gentle agitation at 37°C. This blocking solution was discarded and 
the membrane incubated for a further 30 minutes in blocking solution containing a 
1:10,000 dilution of an anti-digoxigenin alkaline phosphatase conjugated antibody 
(Roche-1 093 274). The membrane was washed twice for 15 minutes in maleic acid 
wash buffer and then the membrane adjusted to the correct pH by equilibration for 5 
minutes in detection buffer (appendixl). The membrane was then placed between two 
sheets of soft plastic and 1 ml of the alkaline phosphatase chemiluminescent substrate, 
CSPD, (Roche- 1 755 633) applied drop wise to the surface of the membrane. The 
membrane was covered with the plastic sheet to distribute the substrate evenly over 
the surface and then incubated for 5 minutes at room temperature before removing all 
air bubbles and sealing the edges of the plastic by heat. The membrane was exposed 
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to light sensitive film (Sigma-Z37351650EA) for 15-120 minutes to achieve the 
desired signal strength. 
2.22 Tamoxifen induction 
Cre nuclear localisation in MerCreMer (Bm70) transgenic animals was induced using 
Tamoxifen (Sigma-T5648). 	Tamoxifen was administered at a dose of 1 
mg/mouse//day for 5 consecutive days and was prepared by combining 10 mg 
tamoxifen with 100 d EtOH and 2 ml of sunflower oil (Tesco pure sunflower oil). 
The mixture was incubated in a sonic water bath at room temperature for 30 minutes. 
200 [1,1 per mouse of the sonicated mixture was administered by i.p injection each day. 
2.23 Footpad /flank peptide immunisation 
The peptide PLP 56-70 (DYEYLINVIHAFQYV) was used for immunisation and in 
vivo priming of T cell responses in NOD.E mice (Lund et al., 1990 and Takacs et al., 
1995). 50 IA.g of peptide, as an emulsion with either Complete Freund's Adjuvant 
(CFA) (Sigma-F5881) or Incomplete Freund's Adjuvant (IFA) (Sigma-F5506), was 
administered per immunisation in the footpad or the flank. 50 µ.1 or 100 pi of peptide 
emulsion were injected into the footpad or flank respectively. Emulsions were a 1:1 
mixture of peptide solution and CFA or IFA and were prepared by vortexing for 30 
minutes, followed by incubation in an iced sonic water bath for 1 -2 hours. 
2.24 Immediately ex vivo T cell proliferation assay 
10 days (unless otherwise stated) after immunisation with peptide, the draining lymph 
node (s) (DLN) and spleen were harvested. The popliteal lymph node drains from the 
footpad and the inguinal lymph node drains from the flank. Single cell suspensions 
were prepared in HL-1 medium (Cambrex-BE344017) supplemented with 2 mM L-
glutamine (Gibco-25030024), 25 Wm' Penicillin G (Gibco-15070063) and 25 µg/m1 
Streptomycin sulfate (Gibco-15070063). Cells were counted using a haemocytometer 
and were cultured in triplicate in 96- well plates (SLS-161093) with 3 x 105 cells per 
well in the presence of different concentrations of peptide PLP 56-70 
(DKEKLINVIHAFQYV). A substituted (Y-'K) version of the peptide PLP 56-70 
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was used for in vitro assays as the un-substituted peptide is very insoluble. After 2 
days of culture, 100 Ill of supernatant was removed from each well. Supernatants 
from triplicates were pooled and stored at —20 °C for subsequent cytokine analysis by 
ELISA. 100 µ1 of fresh HL-1 culture medium was added to each well along with 5 
[Xi of [3H] Thymidine (MP-2405905). Cells were cultured for an additional 18 hours 
before plates were harvested (MACH III M Harvester 96) for beta scintillation 
counting (Wallac 1450 microbeta TRILUX). 
2.25 Culture of T cell lines 
T cell lines from immunised footpad draining lymph nodes were set up with 3 x 106 
DLN cells / ml in the presence of 25 [tg/ ml of PLP 56-70 (substituted). After 48 
hours, IL-2 (10 IU/ml) (R&D systems-402-ML-020) was added to the culture medium 
and the cultures incubated for an additional 8 days. Cells were then resuspended in 
RPMI 1640 medium containing 10% Foetal Calf Serum (FCS) (Globepharm-batch 
F30610), 50 I_LM beta mercaptoethanol (Sigma-M7522), 2 mM L-Glutamine 50 U/ml 
Penicillin G and 50 µg/ml Streptomycin sulfate, and restimulated with 25 µg/ml of 
peptide in the presence of 3 x 106 /ml of irradiated NOD.E splenocytes. The ratio of T 
cells to irradiated APC in restimulation cultures was 1:25. Splenocytes were irradiated 
by exposure to 3000 RADs of gamma radiation (Gammacell® 3000 Elan, Nordion 
International Inc.). All T cell lines were repeatedly restimulated every 9-11 days and 
maintained in 10 IU/ml IL-2. Proliferation assays were set up for each line at each 
restimulation to check peptide specificity and cytokine production. Proliferation 
assays were performed as described above with 3 x 105 irradiated splenocytes and 2 x 
104 T cells in RPMI 1640 medium per well. RNA was also isolated from each cell 
line at each restimulation. 
2.26 Measurement of bronchial hyperreactivity (BHR) 
Measurement of BHR was performed by recording respiratory pressure curves by 
whole body plethysmography, calculated as Penh (Enhanced Pause, Buxco, USA). 
Mice were placed, fully conscious, into individual plethysmograph chambers and 
changes in air pressure between these chambers and a control chamber measured by a 
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differential pressure transducer to give a lung function measurement for each 
individual mouse. Penh is a calculated value, which correlates with measurement of 
airway resistance, impedance, and intrapleural pressure in the same mouse 
(Hamelmann et al., 1997). Penh = ((Te-Tr)/Tr x PEP/PIP (Te = expiration time, Tr = 
relaxation time, PEP = peak expiratory pressure, PIP= peak inspiratory pressure). 
Following a baseline measurement, Penh measurements were taken for each mouse in 
response to increasing doses (3, 10, 30 and 100 mg/ml) of methacholine (Sigma-
A2251). 
2.27 Measurement of Resistance (R) and Compliance (Cdyn) 
Mice were anaesthetised by sub-cutaneous (s.c) injection of 100 ILL1 of a 1:0.55:0.42 
mix of PBS, Medetomidine hydrochloride (Pfizer-Domitor®) and ketamine (Fort 
Dodge Animal Health Ltd-Ketaset®). After 15 minutes, a further 150 RI of anaesthetic 
was administered by intra-muscular (i.m) injection before cannulation of the trachea. 
Mice were placed onto an artificial ventilator and, following a baseline reading, 
resistance and compliance measurements taken (Buxco, USA lung function 
equipment) in response to PBS and increasing doses (3, 10, 30 and 100 mg/ml) of 
methacholine. 
2.28 Collection of Bronchoalveolar lavage (BAL) and serum 
Unless mice had already undergone resistance and compliance lung function 
measurement, in which case they were already unconscious, mice were anaesthetised 
by intra-peritoneal (i.p) injection of 80 pi of a 2:1 mix of ketamine (Fort Dodge 
Animal Health Ltd-Ketaset®) and xylazine (Bayer-Rompune). 	Mice were 
exsanguinated by cardiac puncture followed by cannulation of the trachea. Lungs 
were lavaged 3 times with 0.4 ml Phosphate Buffered Saline (PBS) (Invitrogen-10010-
015) using a 1 ml syringe and all BAL fluid for each mouse was pooled. BAL fluid 
was centrifuged at 260 x g for 8 minutes. The supernatant was removed to a new tube 
and stored at —80 °C for subsequent cytokine analysis by ELISA (see below). Blood 
collected from cardiac puncture was left to coagulate at room temperature overnight 
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before centrifugation at 12,000 x g and collection of the serum fraction. Serum was 
stored at -80 °C for subsequent analysis by ELISA. 
2.29 Cell extraction from whole lung lobe 
One lung lobe was finely chopped and placed into 5 ml of RPMI 1640 medium 
(Gibco-31870-025) containing 0.15 mg/ml Collagenase D (Roche-11088858001) and 
25 lig/m1DNase I (Roche-11284932001). The lung tissue was incubated with shaking 
for 1 hour at 37°C and the mixture passed through a 70 pan cell strainer. Cells were 
washed twice in RPMI 1640 medium before differential cell counting (see below). 
2.30 Differential cell counting 
Following centrifugation of BAL fluid or lung cells, cells were re-suspended in 250 .d 
of RPMI culture medium. A small aliquot of this cell suspension was diluted 1:2 in 
Turks stain (appendix 1) to lyse red blood cells, and white blood cells were counted on 
a haemocytometer. Samples were adjusted to 5 x 105 cells / ml and 100 1A,1 (5 x 104 
cells) spun onto a polysine glass microscope slide (VWR-6310107). Cytospins were 
performed by centrifugation (Shandon-Cytospin 3) at 400 rpm for 4 minutes. Slides 
were allowed to air dry for 5 minutes before fixing in methanol for 3 minutes. Wright 
Giemsa staining of BAL cytospins allowed different cell types to be distinguished on 
the basis of morphology (appendix 9). Slides were stained by immersing in Wright 
Giemsa stain (Sigma-WG16) for 1 minute, followed by distilled water for 6 minutes 
without agitation. Slides were rinsed briefly in running distilled water to stop stain 
development and then allowed to air dry before addition of a cover slip and cell 
counting. A total of 300 cells were counted on each slide and the total number of each 
cell type recovered calculated by multiplying the percentage of each cell type by the 
total number of cells isolated in each sample. 
2.31 Lung homogenate 
One lung lobe was weighed and placed into Hank's Balanced Salt Solution (HBSS) 
without MgC12 or CaC12 (Invitrogen-14175-046), containing a mixture of protease 
inhibitors (Roche-11836153001), at a concentration of 100 mg of lung per 1 ml of 
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HBSS solution. The lung was homogenised using an electric homogeniser before 
centrifugation (1500 x g) and collection of the supernatant for analysis by ELISA. If 
it was not possible to process the lung tissue immediately after harvesting, lung lobes 
were snap frozen using liquid nitrogen and stored at -80 °C. 
2.32 Lung histology - Tissue preparation 
Lungs and heart were removed from the chest cavity en bloc prior to lung inflation or 
harvesting of lung for RNA / cell extraction. If lung tissue was required for RNA or 
cell extraction it was necessary isolate and prevent inflation of several lobes by tying 
main bronchi with sewing cotton. Remaining lobes were inflated by intra-tracheal 
infusion of a 1:1 mixture of PBS and Optimal Cutting Temperature (OCT) embedding 
medium (Cell Path-KMA010000A). Inflated lung tissue was snap frozen in OCT 
using a dry ice/isopentane (BDH-103614T) slurry and stored at -80°C. Sections were 
cut on a cryostat (Bright) at a thickness of 5 IAM and mounted onto polysine glass 
microscope slides. Sections were allowed to air dry for 15 minutes before staining or 
storage at -20°C. 
2.33 Haematoxylin and Eosin (H+E) staining 
Slides were immersed in Harris Haematoxylin (VWR-351945S) for 20 seconds and 
then held in running tap water until the sections were visibly blue. Slides were then 
immersed in 1% Eosin (VWR-341973R) for 5 seconds before dehydration and cover 
slip mounting. Sections were dehydrated by immersing, consecutively, for 30 seconds 
with gentle agitation, in 70%, 90%, 100% and 100% Industrial Methylated Spirit 
(IMS) (Fisher Scientific-M/4400/17) followed by 3 x 5 minute incubations in 
Histoclear (National Diagnostics-HS200). Cover slips were applied with DPX 
mountant (BDH-360294H). 
2.34 Periodic Acid Schiff (PAS) staining and scoring 
Immediately after sectioning, lung tissue was fixed by incubating slides in ice-cold 
acetone for 15 minutes. Slides were allowed to air dry at room temperature before 
oxidising for 5 minutes in 1% periodic acid (MP Biomedicals-102595). Slides were 
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rinsed briefly in distilled water and then immersed in Schiff's reagent (Fisher 
Scientific-J/7300/PB08), in a fume hood, for 15 minutes. Slides were rinsed again in 
distilled water and then held under running tap water for 5 minutes to terminate the 
reaction. Nuclei were counterstained with Haematoxylin before dehydration and cover 
slip mounting (see above). To score PAS stained sections, the percentage of cells 
surrounding the lumen of each airway that were positively staining with PAS was 
calculated. Each airway was assigned a score from 0 to 4 where: 
0 = less than 5% of cells are positively stained 
1 = 5-25% of cells are positively stained 
2 = 26-50% of cells are positively stained 
3 = 51-75% of cells are positively stained 
4 = greater than 75% of cells are positively stained 
The average airway score in each section was then calculated. 
2.35 Immunohistochemistry - tissue fixation 
A hydrophobic barrier (Vector-H4000) was drawn around each tissue section to allow 
incubation of the section in small volumes (100-150 µl per section) of staining 
solutions. Tissue sections were fixed using 4% paraformaldehyde (Sigma-P6148) 
made up in PBS (Sigma-P4417). Sections were incubated with this fixative for 10 
minutes before washing twice for 10 minutes in PBS. Peroxidase based or 
fluorescence antibody staining was then performed. 
2.36 Peroxidase based immunohistochemistry 
Following fixation with paraformaldehyde, sections were incubated in 0.5% H202 
(BDH laboratory supplies-101284N), made up in PBS, for 10 minutes. Sections were 
washed twice for 10 minutes with PBS and then incubated in blocking solution 
(appendix 1) for 30 minutes before rinsing in PBS. Sections were incubated for 15 
minutes in Avidin block (Vector—SP2001) and 15 minutes in Biotin block (Vector-
SP2001), rinsing with PBS in between, before application of the primary antibody. 
The primary and biotinylated secondary antibodies used for the detection of Cre, 
CC10, IL-8 and myeloperoxidase proteins are shown in appendix 2. Antibodies were 
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diluted in block solution and sections incubated at room temperature overnight. 
Sections were washed twice for 10 minutes in PBS and the secondary antibody applied 
for 40 minutes at room temperature. Sections were washed twice for 10 minutes in 
PBS, followed by application of an avidin/biotinylated peroxidase enzyme complex, 
solution ABC (Vector-SP2001) for 30 minutes, and two further PBS washes. To 
visualise antibody staining, solution AEC (Vector-SP2001) containing a peroxidase 
enzyme substrate was applied and colour development monitored under a light 
microscope. When the desired staining intensity was achieved, AEC solution was 
removed and slides washed several times in distilled water to terminate the reaction. 
Sections were then counterstained with hematoxylin to allow visualisation of tissue 
morphology and cover slips mounted using a glycerol based mounting medium 
(DAKO-00563). Images of tissue sections were captured using a light microscope 
and digital camera (Leica MPS 60 with IM1000 software). 
2.37 Immunofluorescence tissue staining 
Following fixation in paraformaldehyde, sections were incubated in block solution for 
30 minutes. Sections were washed twice for 10 minutes in PBS before application of 
the primary antibody overnight at room temperature. Primary antibodies used for 
fluorescence staining were as described for peroxidase staining. Sections were washed 
twice for 10 minutes in PBS and then incubated with secondary antibody for 1 hour at 
room temperature. For Cre staining, a TRITC conjugated donkey anti-rabbit antibody 
(SantaCruz-SC2095) was used at a dilution of 1:400. For CC10 staining, a FITC 
conjugated donkey anti-goat antibody (Jackson-705-095-147) was used at a dilution of 
1:50. When double staining the same section for both Cre and CC10, the CC10 
primary antibody was applied for 4 hours before incubation with the Cre primary 
antibody overnight. Secondary antibodies were also applied sequentially for 1 hour 
each, with the CC10 secondary antibody being applied first. Sections were washed 
twice for 10 minutes in PBS and cover slips mounted using Vectashield (Vector-
H1200) to preserve the fluorescence lifetime. Images of fluorescence staining were 
captured using a fluorescence microscope and digital camera (Leica MPS 60 with 
IM1000 software). 
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2.38 Inflammatory cell scoring 
The same inflammatory scoring system was used to assess levels of inflammation 
around bronchi and blood vessels in both H+E and MPO stained lung sections. Each 
airway and blood vessel in a section was assigned a score from 0 to 3 where: 
0 = Bronchi or blood vessel is not surrounded by any inflammatory cells 
1 = Bronchi or blood vessels is surrounded by the occasional inflammatory cell 
2 = Inflammation completely surrounds and is 1-4 cells in diameter from the edge of 
the bronchi or vessel 
3 = Inflammation completely surrounds and is 5 or more cells in diameter from the 
edge of the bronchi or vessel 
Examples of bronchi and blood vessels assigned each score are shown in appendix 30. 
The average score for all bronchi and the average score for all blood vessels in a 
section was then calculated. 
2.39 Induction of allergic airway disease using ovalbumin (OVA) 
Groups of hIL-8 transgenic and littermate control mice were sensitised by i.p injection 
of OVA (Sigma -A5503) (0.01 mg / mouse) in 0.3 ml of alum (Au-Gel-S, Serva 
Electrophoresis, Heidelberg, Germany) (AMS Biotechnology-12261.01) on days 0 and 
12. Control mice received the same volume of PBS in alum. All mice were 
challenged on days 19, 20, 21, 22 and 23 with a 5% solution of OVA in PBS, 
administered as a 20 minute aerosol (PART Medical Ltd — TurboBoyN compressor). 
BHR was measured on day 24. Resistance and compliance measurements were taken 
on day 25 and lung tissue and peripheral blood were harvested for analysis. 
2.40 Enzyme Linked ImmunoSorbant Assay (ELISA) 
Levels of cytokine production in cell culture supernatants and BAL were determined 
by ELISA, measuring against linear standard curves. 100 1A,1 of capture antibody 
(appendix 2) were added to wells of an ELISA plate (SLS-442404), the plate sealed 
and incubated overnight at room temperature. The next day, wells were washed 3 
times with 400 [11 of wash buffer (appendix 1) and plates blotted against paper towel to 
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remove all liquid. 300 11,1 of block solution (appendix 1) were added to each well and 
plates incubated at room temperature for 1 hour. Wells were washed again and 50 pi 
of the appropriate dilution of standard (appendix 2) or sample added. Plates were 
covered and incubated at room temperature for 2 hours. Wells were washed again and 
100 µ1 of the appropriate biotinylated detection antibody (appendix 2) added to each 
well. Plates were covered and incubated at room temperature for another 2 hours 
before another wash and addition of 100 !al of a 1/200 dilution of streptavidin Horse 
Radish Peroxidase (HRP) (R&D systems-DY998). Plates were incubated with 
streptavidin HRP for 20 minutes at room temperature before another wash step and 
addition of 100m1 of substrate solution (R&D systems-DY999). Plates were incubated 
at room temperature in the dark for 20-25 minutes before terminating the reaction with 
of 50 µl of stop solution (1M H2SO4). The optical density of each well at 450nm was 
determined using an ELISA plate reader (TECAN Sunrise) with wavelength correction 
set to 570 nm. 
2.41 Flow cytometric analysis 
Fluorescence activated cell sorting (FACS) was performed on a BD Biosciences 
FACSCalibur, with CellQuest software (Becton Dickinson UK LTD) and 
fluorochrome-labelled antibodies. 	Single cell suspensions of thymocytes and 
splenocytes were prepared and washed once with PBS containing 10% FCS. Red 
blood cells in splenocyte preparations were lysed by resuspending briefly in distilled 
water followed by an additional PBS wash. Cells were stained with Phycoerythrin 
(PE) conjugated anti-mouse CD4 (eBioscience-12004183) and Fluorescein 
isothiocyanate (FITC) conjugated anti-mouse CD8 (eBioscience-11008182) or with 
FITC conjugated anti-mouse TCR 	(eBioscience-115961-81). Isotype matched 
controls, FITC Rat IgG2a (eBioscience 11-4321-81) and PE Rat IgG (eBioscience 12-
4301-81) were also used. Cells were stained for 45 minutes in the dark at 4 °C and 
washed twice with PBS containing 10% FCS before analysis. 
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Chapter 3  
Generation of Thl and Th2 TCR a chain transgenic lines  
Results  
3.1 Determination of a and /3 TCR gene usage in Thl and Th2 lines specific for PLP 
56-70 
Short term Thl and Th2 polarised T cell lines derived from NOD.E mice and specific 
for the peptide epitope PLP 56-70 had been previously generated in our laboratory. 
The Thl line was maintained in IL-2 (330 IU/ml), IL-12 (100 IU/ml) and anti-IL-4 (10 
µg/ml). The Th2 line was maintained in IL-2 (330 IU/ml), IL-4 (100 IU/ml) and anti-
IFN-y (10 µgimp. The lines were strongly polarised and highly peptide specific and 
both had undergone three restimulations with NOD.E splenocytes and PLP 56-70. 
cDNA from both lines was available for analysis. 
TCR gene usage in the Thl and Th2 cell lines described above was determined using a 
PCR strategy first described by Candeias et al. (Candeias et al., 1991). This strategy 
uses sets of degenerate primers, designed to bind all known TCR a and TCR p 
sequences, in combination with primers specific for the TCR constant regions. The 
strategy allows all TCR a or TCR 13 genes expressed by a population of T cells to be 
identified from a single nested PCR experiment. The PCR strategy and PCR products 
obtained from the Thl and Th2 T cell line cDNA are shown in figure 3.1. 
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Figure 3.1 The PCR strategy used to determine a and p TCR gene usage in 
Thl and Th2 line cDNA. (a) A nested PCR strategy was used, involving 3 rounds of 
amplification for the TCR a chain and 2 for the TCR 13 chain. V region primers for 
both TCR a and TCR (3 chains are degenerate oligonucleotides designed to bind all 
known V genes. These primers were used in all PCR rounds. For the (3 chain, the C 
region primer MQ284 was used in the 1st round of amplification, followed by 
MS175. For the a chain, C region primers NJ108, NJ109 and NJ110 were used 
successively. The gel photos in (b) and (c) show the PCR products obtained from 
Thl and Th2 line cDNA using the TCR a chain and TCR p chain PCRs respectively. 
These PCR products are approximately 300bp in length and were TA cloned and 
sequenced in order to determine TCR gene usage for each T cell line. 
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TCR gene sequences amplified by PCR were identified by TA cloning and 
sequencing. 29 TCR a clones were sequenced for both the Thl and Th2 T cell lines. 
30 and 31 TCR p clones were sequenced for the Thl and Th2 lines respectively. 
Dominant TCR a sequences were found in both cell lines. 48% of a clones sequenced 
from the Thl line were identified as using the a chain variable region gene TRAV1OD 
with the a chain joining region gene TRAJ58 (table 3.1). The CDR3 region of this 
TCR a chain was 12 amino acids in length (CAASREGTGSKLSF). 31% of a clones 
sequenced from the Th2 line were identified as using the a chain variable region gene 
TRAV17 with the a chain joining region gene TRAJ50 (table 3.2). The CDR3 region 
of this TCR a chain was 14 amino acids in length (CALEGIASSSFSKLVF). These 
dominant Thl and Th2 TCR a chains were selected for transgenic expression. 
Although both lines had a dominant TCR a chain sequence, the gene usage and CDR3 
region sequences were more heterogeneous in the Th2 line. 6 different combinations 
of variable and joining a chain genes and 6 different CDR3 a sequences were 
identified in the Thl line compared with 9 different gene combinations and 12 
different CDR3 a sequences in the Th2 line (figure 3.2). In keeping with the data 
previously published by our laboratory (Boyton et al., 2002), there was a statistically 
significant difference in CDR3 a length between Thl and Th2 derived sequences. The 
Thl line had a mean CDR3 a length of 11.4 + 0.2 compared to 12.5 + 0.2 for the Th2 
line. Comparison of these two mean values gives a P value of <0.0005. 
There was no statistical difference in CDR3 p length between Thl and Th2 derived 
sequences, which had mean values of 12.3 + 0.2 and 12.4 + 0.3 respectively (P = 
0.974). No TCR p chain appeared dominant in either line (tables 3.3 and 3.4), 
although as seen for the a chain genes, p gene usage and CDR3 region sequences were 
more heterogeneous in the Th2 line (figure 3.2). The lack of a dominant TCR p chain 
in either line made it impossible, at this stage, to determine which 13 chain was pairing 
with the dominant Thl and Th2 TCR a chains. Indeed the heterogeneity of the 13 
chains, particularly in the Th2 line, suggests that the dominant a chains are able to pair 
with more than one (3. 
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Previously published data (Boyton et al., 2002) suggested that the dominant 14 amino 
acid CDR3 a motif identified in the Th2 line would not be present in the Thl line, but 
that the shorter, Thl derived, 12 amino acid CDR3 a motif would be permissible in 
both Thl and Th2 cells. PCR primers specific to these CDR3 regions were used to 
confirm this finding in these cell lines (figure 3.3). This data confirmed the selection 
of these Thl and Th2 derived dominant TCR a chains as good candidates for 
transgenic expression. No beta chain pair for either TCR a chain had been 
determined. Therefore, only transgenes for expression of TCR a chains were 
constructed. The intent was to identify beta chain pairs for each a chain in vivo and 
also to use these animals to answer questions about the impact of the structurally 
different Thl and Th2 a chains alone on T cell responses and beta chain selection. 
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Table 3.1 TCR a sequences from a Thl polarised NOD.E T cell line against PLP 
(56-70) 
TA clone TRAV CDR3a amino acid sequence 	TRAJ CDR3 length 
Th1 
A1.5 10D CAASREGTGSKLSF 58 12 
A1.10 
A1.11 
A1.16 
A1.19 
A1.20 
A1.33 
A1.42 
A1.43 
A1.44 
A1.47 
A1.48 
A1.61 
A1.62 
A1.23 CAASKPNNRIFF 31 10 
A1.4 17 CALEGRGGRALIF 15 11 
A1.15 
A1.18 
A1.34 
A1.45 
A1.46 
A1.49 
A1.51 
A1.9 4D-3 CAALPGTGSNRLTF 28 12 
A1.17 
A1.55 
A1.8 CAAETNSAGNKLTF 17 
A1.27 CAADSNYQLIW 33 9 
A1.60 
Mean Thl CDR3a length = 11.4 + 0.2 (SE) 
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Table 3.2 TCR a sequences from a Th2 polarised NOD.E T cell line against PLP 
(56-70) 
TA clone TRAY 	CDR3a amino acid sequence 	TRAJ CDR3 length 
Th2 
A2.13 17 CALEGIASSSFSKLVF 50 14 
A2.15 
A2.16 
A2.20 
A2.21 
A2.33 
A2.39 
A2.41 
A2.54 
A2.10 12-2 CALSDANNYAQGLTF 112-2 13 
A2.31 
A2.38 
A2.42 
A2.32 13-4 CAMERQDNYAQGLTF 
A2.3 6-6 CALGEDTNAYKVIF 30 12 
A2.17 CALVRDTGYQNFYF 49 
A2.49 
A2.53 CALGFQGGRALIF 15 11 
A2.48 CALGSQGGRALIF 
A2.22 10 CAASRGNMGYKLTF 9 12 
A2.25 
A2.58 
A2.14 3-3 CAVRGTNAYKVIF 30 11 
A2.40 
A2.55 
A2.34 CAAGDTNTGKLTF 27 
A2.35 
A2.36 CAALNTNTGELTF 
A2.43 CAALNTNTGKLTF 
Mean Th2 CDR3a length = 12.5 + 0.2 (SE) 
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Table 3.3 TCR 3  sequences from a Thl polarised NOD.E T cell line against PLP 
(56-70) 
TA clone TRBV CDR3P amino acid sequence 	TRBJ 	CDR3 length 
Thl 
B1.14 2 CASSQGPLSNERLFF 1.4 13 
B1.36 
B1.41 
B1.81 
B1.82 
B1.83 
B1.98 
B1.57 CASSKAGTGEDTQYF 
B1.1 CASSQEMQGQDTQYF 
B1.94 
B1.95 
B1.37 CASSQQGDQDTQYF 12 
B1.60 CASSQEGTGVQDTQYF 14 
B1.3 , CASSRDWGDTQYF 11 
B1.21 
B1.85 
B1.90 
B1.70 CASSPWGVQDTQYF 2.5 12 
B1.93 
B1.10 : CASSQAGTDTQYF 11 
B1.18 19 CASSRSGDQDTQYF 12 
B1.58 
B1.88 
B1.92 
B1.96 
B1.97 
B1.77 16 CASSNQNYAEQFF 2.1 11 
B1.84 CASSLAGQGARSQNTLY] 2.4 16 
B1.89 CASSSRDWGDEQYF 2.7 12 
B1.8 15 CASSLVGAEQFF 2.4 10 
Mean Thl CDR3p length = 12.3 + 0.2 (SE) 
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Table 3.4 TCR 13 sequences from a Th2 polarised NOD.E T cell line against PLP 
(56-70) 
TA clone TRBV CDR3[3 amino acid sequence TRBJ CDR3 length 
Th2 
B2.2 16 CASSFQTGGAETLYF 2.3 13 
B2.7 
B2.5 CASSVRDWGDTQYF 2.5 12 
B2.84 CASSLRGHTEVFF 1.1 11 
B2.53 CASSLRNTEVFF 10 
B2.4 : CASSQEAGGVDTQYF 13 
B2.8 
B2.56 CASSQEGWGPYEQYF 2.7 
B2.61 CASSQGLGNYAEQFF 2.1 
B2.66 CASSQEGTGGYAEQFF 14 
B2.82 CASSQDGTGGYAEQFF 
B2.78 CASSLGTGDAEQFF 12 
B2.30 CASSPANSDYTF 1.2 10 
B2.46 CASSQGIYEQYF 2.7 
B2.74 CASSLRDNGDTQYF 2.5 12 
B2.13 19 CASSPRTTSGNTLYF 1.3 13 
B2.71 
B2.31 CASSSPTGGWNAWQFF 2.1 14 
B2.50 CASSSPTGGWNAEQFF 
B2.86 
B2.76 CASSPPTGSPNERLFF 1.4 
B2.79 
B2.85 CASSIEDSGTEVFF 1.1 12 
B2.26 4 CASSPRGLYAEQFF 
B2.43 CASSNYAEQFF 9 
B2.68 13-3 CASSGRTTANTEVFF 13 
B2.75 20 CGARDLWGGKNTLYF 2.4 
B2.83 
B2.80 1 CTCSADGSYEQYF 2.7 11 
B2.24 17 CASSSGGFAETLYF 2.3 12 
B2.63 CASRDWGETLYF 10 
Mean Th2 CDR3(3 length = 12.4 + 0.3 (SE) 
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Figure 3.2 A comparison of TCR a and gene usage in Thl and Th2 T cell 
lines in order to select chains for transgenic expression. TCR gene usage in a Thl 
and Th2 T cell line are shown in (a) and (b) respectively. Each segment of a pie chart 
represents an individual CDR3 sequence, while V-J gene combinations are 
differentiated by colour. The percentage of each a repertoire made up by the most 
dominant TCR chain is also shown. The dominant a chains for both the Thl and Th2 
lines were selected to be expressed transgenically, but diverse gene usage and CDR3 
regions in TCR 13 chain repertoires meant that (3 chain pairs could not be identified. 
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Figure 3.3 Presence or absence of the dominant Thl and Th2 CDR3 a motifs in 
Thl and Th2 lines. Primers specific for the dominant Thl 12 amino acid CDR3 
motif and Th2 14 amino acid CDR3 a motif were used with C region primer NJ108 
to determine presence of these motifs in Thl and Th2 line cDNA. The shorter Thl 
motif is present in both Thl and Th2 lines, while the longer Th2 motif is only present 
in the Th2 line. 
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3.2 Construction of Thl and Th2 TCR a chain transgenes. 
Several different cassette vectors have been used to achieve transgenic expression of 
TCR genes. Promoter sequences that have been used in these vectors to drive TCR 
expression include CD2 (McHugh et al., 2001) and MHC class I (Kb) (Mendel et al., 
2004). However, as expression of TCR genes is not an endogenous function of these 
promoters, TCRs under the control of these vectors can be subject to abnormal timing 
and regulation of expression. The vector used in this study (pTa) was designed by 
Kouskoff et al. (Kouskoff et al., 1995) and utilises endogenous mouse TCR 
promoter and enhancer elements. As such, the vector contains many kilobases of non-
coding sequence cloned from regions upstream and downstream of the mouse TCR 
locus. The aim is to ensure that TCR expression is, as far as possible, under the control 
of its natural regulatory elements. The vector also contains the mouse TCR Ca gene 
and associated regulatory sequences. To express a TCR a chain transgenically it is 
necessary to clone into the vector the rearranged V-J coding sequence of interest. 
Many TCR transgenics have been created using TCR a or I chain cDNA. However, 
although in the genome of a T cell, TCR genes have been rearranged and spliced 
together, some intronic sequences remain. Intronic sequence is present at the 5' and 3' 
ends of the rearranged V-J segment, but also separates a coding leader sequence from 
the remainder of the V gene (figure 3.4). To express a TCR a chain using the pTa 
cassette vector it is essential to include a short section of intronic sequence 3' to the 
rearranged J gene. This allows splicing of the V-J coding segment to the Ca gene also 
present in the vector. It is unknown exactly what role the other intronic sequences 
may play in the regulation and processing of the TCR, but it is thought advisable to 
include them in the construct. Therefore, the T cell genomic configuration of the V-J 
segment, rather than that found in cDNA should be used to create the TCR transgene. 
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Figure 3.4 The different states of arrangement of TCR a genes. (a) No 
rearrangement of TCR a genes occurs in non-T cells. Germ-line configuration is 
maintained. (b) In the thymus, rearrangement of TCR a genes occurs in T cells such 
that a V gene is spliced to a J gene at the level of genomic DNA, to create a variable 
CDR3 a region. Intronic sequence remains between the V leader region (LP1) and the 
rest of the V gene and also between the J and C regions. (c) These intronic sequences 
are removed by splicing at the level of mRNA prior to expression of a functional TCR 
a chain on the surface of the T cell. (d) To express a TCR a chain transgenically, the 
arrangement of TCR a genes should resemble that found in the T cell genome, as 
intronic sequences present in this configuration facilitate correct processing and 
expression of the TCR. 
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For the T cell lines and T cell receptor sequences being used in this study, only cDNA 
samples were available. It was therefore not possible to obtain the correct T cell 
genomic configuration of the Thl and Th2 TCR V-J segments by a single PCR 
strategy. 
The only region of each required TCR a V-J segment not present in non-T cell 
genomic DNA was the junction between the rearranged V and J gene (CDR3 region). 
The CDR3 region is present in cDNA and so it was possible to create the required 
configuration of each V-J segment by cloning together fragments derived from non-T 
cell NOD.E genomic DNA and Thl or Th2 line cDNA. The cloning strategies, 
including PCR primers and restriction enzyme sites, used for both the Thl and Th2 
TCR a chain constructs are shown in figures 3.5 and 3.6. 
Three PCR fragments were used to create each TCR a V-J segment. The 2 intron 
containing fragments were derived from non-T cell NOD.E genomic DNA and 
fragments containing the rearranged 12 amino acid and 14 amino acid CDR3 regions 
were derived from Thl and Th2 cDNA respectively. The sequences of all PCR 
primers used for these cloning strategies, along with the PCR conditions and product 
sizes are shown in appendix 6. The PCR products cloned, and the joining together of 
these PCR fragments to create the Thl and Th2 TCR a transgenes, are shown in figure 
3.7. For both the Thl and Th2 strategies it was necessary to create a Hind III 
restriction site in the J region in order to join the PCR fragments. In both cases the 
change was a single base pair mutation from G to T, introduced using the PCR primers 
used to obtain the PCR fragments. Mutations were silent and resulted in the creation 
of an alternative codon for the amino acid leucine. All fragments generated by PCR 
were verified by sequencing prior to proceeding with subsequent stages of the cloning 
strategy. The nucleotide and amino acid sequences of the Thl and Th2 TCR a V-J 
segments are shown in appendices 17 and 18 and appendices 19 and 20 respectively. 
126 
Xma I 
	 11..2MAI 
V Nco I 	Hind III 
VIO 	J58 LP1 
(b) 
Fragments 
joined using 
Hind III 
(ii) 	 (iii) 
NOD.E genomic DNA 	Thl line cDNA 	 NOD.E genomic DNA 
TRA V10 
Xma 1 
 
Nco I 
ThlintronF 
Nco- I 	Hind III 
HindIIITh IF 
Hind -III 
 
Sac II 
    
           
           
           
LP1 	V10 	 V10 	J58 
	 J58 
Th1LP1/2IntronR 
	
ThlHindIIIR 	 TRAJ58 
Fragments 
joined using 
Nco I 
(c) 
Xma I 	 Nco I 
I
immi Hind III 	Sac II 
LP1 	V10 	J58 
Complete Thl VI 0/J58 
fragment cloned into the pTa 
expression vector using Xma I 
and Sac II 
(d) 	 Sal I 
Xma I 
Sac II 
pTa 
Sal I cassette vector --......, 
Thl a construct is linearised for injection using Sal I 
Figure 3.5 A schematic diagram showing the cloning strategy used to create the 
Thl a chain construct. It was only possible to obtain the correct CDR3 a region 
from Thl line cDNA. However, cDNA derived TCR sequence does not contain the 
required intronic regions (figure 3.4). (a) The TCR a chain was therefore created using 
2 intron containing fragments (i) and (iii) derived from NOD.E genomic DNA and one 
CDR3 a containing fragment (ii) obtained by PCR from Thl line cDNA. (b) The 5' 
intronic fragment and that containing the CDR3 region were cloned together using a 
unique and endogenous NcoI site. (c) It was necessary to introduce a unique HindIII 
site into the sequence of J58 by PCR in order to join the 3' intronic fragment. The 
G-*T mutation introduced does not alter the amino acid sequence of the final protein. 
(d) XmaI and SacII sites were introduced by PCR at the 5' and 3' ends of the a chain 
respectively to allow directional cloning into the pTa cassette vector. Bacterial 
sequences were removed from the vector, by digestion with Sall, prior to pronuclear 
injection. All PCR primers and conditions are shown in appendix 6. 
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Figure 3.6 A schematic diagram showing the cloning strategy used to create the 
Th2 a chain construct. It was only possible to obtain the correct CDR3 a region 
from Th2 line cDNA. However, cDNA derived TCR sequence does not contain the 
required intronic regions (figure 3.4). (a) The TCR a chain was therefore created 
using 2 intron containing fragments (i) and (iii) derived from NOD.E genomic DNA 
and one CDR3 a containing fragment (ii) obtained by PCR from Th2 line cDNA. (b) 
The 5' intronic fragment and that containing the CDR3 region were cloned together 
using a unique and endogenous Sad site. (c) It was necessary to introduce a unique 
HindIII site into the sequence of J50 by PCR in order to join the 3' intronic fragment. 
The G---*T mutation introduced does not alter the amino acid sequence of the final 
protein. (d) XmaI and SacII sites were introduced by PCR at the 5' and 3' ends of the 
a chain respectively to allow directional cloning into the pTa cassette vector. 
Bacterial sequences were removed from the vector, by digestion with Sall, prior to 
pronuclear injection. All PCR primers and conditions are shown in appendix 6. 
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To enable each complete V-J segment to be inserted into the pTa cassette vector, 
XmaI and SacII restriction sites were introduced by PCR at the 5' and 3' ends 
respectively (figure 3.7). Screening for successfully ligated clones by restriction 
enzyme digest was possible due to the difference in size between the V-J a segment 
being removed and that being introduced (figure 3.8). The large size of the pTa 
cassette vector, and the tendency of this plasmid to undergo rearrangements and 
deletions during manipulation, meant that it was also necessary to check patterns of 
digest with other restriction enzymes, such as EcoRl (figure 3.8). Observation of the 
same patterns of digest before and after manipulation meant that the cassette vector 
was intact. That the Thl and Th2 TCR a V-J segments were correct within the final 
constructs was also confirmed by sequencing. Plasmid maps of the Thl and Th2 TCR 
a constructs are shown in appendices 10 and 11 respectively. 
Introducing bacterial sequences from the cloning vector into the mouse genome during 
transgenesis is not recommended and can result in greatly reduced levels of transgene 
expression or even no expression of the transgene at all. (Kjer-Nielsen et al., 1992). 
Bacterial sequences of the pTa cassette vector were therefore removed from both the 
Thl and Th2 TCR a constructs, by digestion with Sal I, prior to pronuclear injection. 
The 15,000 bp fragment of each construct purified for injection is shown in figure 3.8. 
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Figure 3.7 Assembly of Thl and Th2 TCR a chain constructs. All gel lane labels 
refer to fragments described in figures 3.5 and 3.6 for Thl and Th2 constructs 
respectively. (a) and (b) show the 3 PCR fragments required for assembly of the Thl 
and Th2 TCR a chains respectively. (c) and (d) show the joining of these fragments 
and the successful introduction of XmaI and SacII sites at either end of these 
constructs. All construct fragments shown in (c) and (d) are in the cloning vector 
pCRe2.1, and within this vector are flanked by EcoR1 sites. 
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Figure 3.8 Complete Thl and Th2 TCR a constructs. Thl and Th2 VJ fragments 
were inserted into the pTa cassette vector by directional cloning using XmaI and 
SacII. (a) XmaI/SacII digests of the final Thl and Th2 constructs show the presence of 
the respective VJ regions (661 and 622 bp) replacing a larger VJ fragment (approx. 
950 bp) used previously in this vector. The pTa vector is very large (20,000 bp) and 
so can be prone to rearrangements during manipulation. EcoRI digests of the Thl and 
Th2 constructs, and of the original vector, demonstrate that no rearrangements or 
deletions have occurred. (b) It was necessary to remove the 5000 bp bacterial 
sequence from the Thl and Th2 vectors prior to pronuclear injection. This was 
achieved for both constructs by digestion with Sall and purification of the upper 
15,000 bp band. 
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3.3 Identification of Thl and Th2 TCR a chain transgenic founder animals. 
The inbred mouse strains used most frequently for pronuclear injection are FVB/N and 
C57BL/6. These strains respond well to super-ovulation and pronuclear embryos are 
generally larger and less fragile than those of other mouse strains, making them 
technically easier to inject and giving better rates of embryo survival and transgene 
integration (Brinster et al., 1985). However, the Thl and Th2 cell lines, from which 
the transgenic TCR a chains were identified, were originally derived from NOD.E 
mice. In NOD and NOD.E mouse strains, the peptide epitope for which the TCR a 
chains are specific, PLP 56-70, is presented in the context of the MEIC class II 
molecule I-Age. Transgenic mice carrying either TCR a chain transgene must 
therefore also express I-Age in order for T cell responses to PLP 56-70 to be studied, 
and TCR I chain pairs to be identified in these animals. To circumvent the need to 
cross the transgenic founder animals onto a NOD.E background, the Thl and Th2 
TCR a chain transgenes were initially injected into NOD oocytes. Despite their 
fragility, NOD oocytes have successfully been used to generate transgenic lines 
(O'Shea et al., 2006 and Birk et al., 1996). However, multiple attempts to inject the 
TCR constructs into these pronuclear embryos failed to generate any litters. 
Therefore, to achieve transgenesis, it was necessary to use C57BL/6 or FVBN oocytes. 
48 potential founder animals obtained from pro-nuclear injection of FVB/N oocytes at 
the Nuffield department of Medicine in Oxford were screened for the presence of the 
Th2 TCR a chain transgene. An initial PCR screen, using genomic DNA extracted 
from a tail biopsy, identified 2 founder animals (figure 3.9). These founder animals 
are subsequently referred to as Th2 a line 20 and Th2 a line 34, based on numbers 
assigned to each animal at the point of tail biopsy. The transgenic status of these two 
founder animals was confirmed by Southern blotting. The entire rearranged V-J 
segment present in the construct was used to probe genomic DNA that had been 
digested using the restriction enzyme EcoRI (figure 3.9). EcoRl does cut within the 
construct itself, but sites are only 3' to the V-J segment with the most 5' site 3013 bp 
from the 5' end of the construct. Integration of a transgene into the genome can occur 
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at one or multiple sites and at each site, multiple copies of the transgene are often 
found as head to tail concatamers. On the Th2 TCR a line Southern blot, bands 
present in transgenic and littermate samples are due to binding of the probe to 
endogenous, unrearranged, TRAV17 and TRAJ50 sequences. Bands that are 
differential between the two transgenic lines represent different sites of integration 
into the genome, while the most intense band, which is 6 kilobases in size, is due to 
the head to tail concatamers present at one or more of the integration sites. 
23 potential founder animals obtained from pronuclear injection of C57BL/6 oocytes 
at the MRC Clinical Sciences Centre, Imperial college, were screened for the presence 
of the Thl TCR a chain transgene. An initial PCR screen identified 1 founder animal, 
Thl a line 30 (figure 3.10). The transgenic status of this animal was confirmed by 
Southern blot using the same strategy as that described for the Th2 TCR a chain, but 
using the Thl rearranged V-J segment as a probe (figure 3.10). 
The sequence and product sizes of all PCR and Southern primers used for screening of 
Thl and Th2 TCR a chain transgenic founder animals are shown in appendix 6. 
NOD.E mice were used as breeding partners for subsequent breeding of all TCR a 
chain transgenic founder animals. New generations of each line were also backcrossed 
onto NOD.E. As NOD.E mice are homozygous for the MHC class II molecule I-M7, 
all TCR a chain transgenic animals subsequent to the founder will express the 
transgene and I-Ag7. 
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Figure 3.9 Identification of Th2 TCR a chain transgenic founder animals. 
Transgenic founders were identified by PCR and by Southern blot. The location of 
primers used for PCR screening (Th2lntronF and Th2HindIIIR) and for generation of 
the Southern probe (TRAV17 and TRAJ50) are shown in (a). Two transgenic animals 
were identified from an initial PCR screen of 48 potential founders (b). The transgenic 
status of these two animals (numbers 20 and 34) was then confirmed by Southern blot 
(c). The restriction enzyme used to digest genomic DNA for Southern blotting was 
EcoRI (E). This enzyme only cuts the integrated construct on the 3' side of the V-J 
region being used as a probe (c), giving information about construct integration sites 
and copy number. 
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Figure 3.10 Identification of the Thl TCR a chain transgenic founder animal. 
The transgenic founder was identified by PCR and by Southern blot. The location of 
primers used for PCR screening (ThllntronF and Thl HindIIIR) and for generation of 
the Southern probe (TRAV10 and TRAJ58) are shown in (a). One transgenic animal 
was identified from an initial PCR screen of 23 potential founders (b). The transgenic 
status of this animal (number 30) was then confirmed by Southern blot (c). The 
restriction enzyme used to digest genomic DNA for Southern blotting was EcoRI (E). 
This enzyme only cuts the integrated construct on the 3' side of the V-J region being 
used as a probe (c), giving information about construct integration sites and copy 
number. 
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3.4 Determination of TCR a chain transgene expression. 
The TCR a chain transgenes contain multiple regions of intronic sequence as well as 
coding regions for the Thl and Th2 rearranged V-J segments and the mouse Ca gene. 
For correct expression, all intronic regions should be removed and the V-J coding 
segment spliced to the Ca gene. 
A PCR strategy was used to demonstrate that correct processing of the transgenic TCR 
a chain, by removal of intronic sequence, and expression of the TCR a chain coding 
sequence, at the level of mRNA, was occurring in T cells from both of the Th2 TCR a 
chain transgenic lines (figure 3.11) and the Thl TCR a chain transgenic line (figure 
3.12). Removal of the intronic sequence at the 5' end of the V gene results in a shorter 
V-J segment and therefore a smaller PCR product when cDNA is used as a template 
compared to genomic DNA. 
Correct splicing of the TCR a V-J segments to the Ca gene present in the transgene 
was demonstrated by using the nested PCR strategy described in figure 3.1 to look at 
TCR a chain usage in these animals. The strategy uses primers specific for mouse V 
genes in combination with a primer specific for the mouse Ca gene. In the transgene, 
the J region and C region are separated by many kilobases of intronic sequence. A 
PCR product of the correct size will only be obtained if splicing has occurred. 
Splenocyte cDNA was used as a template for PCR and the sequences obtained from 
each line are shown in tables 3.5 and 3.6. From Th2 a line 20, all a sequences 
obtained were transgenic. From Th2 a line 34, most sequences were transgenic but a 
small number of endogenous TCR a sequences were also seen. From Thl a line 30 
the percentage of the repertoire made up by the transgenic TCR alpha chain was more 
variable. In one animal 16% of the sequences obtained were transgenic compared to 
54% for another. This data suggest that in the Th2 a chain transgenic lines levels of 
expression of the transgenic TCR are high, but are not completely exclusive of 
endogenous TCR. In the Thl a chain transgenic line expression levels may be more 
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variable and a significant number of T cells bear endogenous T cell receptors in these 
animals. 
Although data presented thus far confirms correct processing and high levels of 
expression of the TCR a chain transgenes at the level of mRNA, they do not provide 
evidence for expression of the TCR chains at the surface of the T cell. Direct evidence 
for this is difficult to obtain as no antibodies exist against either TRAV10 or TRAV17. 
Other single TCR a chain transgenic models do exist and studies with these mice have 
demonstrated that mice expressing a TCR a chain transgene have an increased 
percentage of double negative (DN) thymocytes compared to wild-type mice (Huang 
and Kanagawa, 2004). During normal thymocyte development, the TCR p locus is the 
first to rearrange (Mombaerts et al., 1992b). Successfully rearranged p chains then 
pair with a surrogate a chain known as the pre-TCR a. This pre-TCRa/r3 complex 
mediates the differentiation of the thymocyte from CD4-CD8- (double negative) to 
CD4+CD8÷ (double positive) (Fehling et al., 1995). Studies of TCR a chain 
transgenic mice suggest that premature expression of a rearranged a chain at the DN 
stage of thymocyte development precludes the formation of pre-TCRa/f3 complexes. 
This results in less efficient transition of thymocytes from DN to DP and an increased 
percentage of DN thymocytes. Staining of thymocytes with antibodies against CD4 
and CD8 showed this to be true for both lines of Th2 TCR a chain transgenic mice 
(figure 3.13). Additional evidence for altered TCR expression at the cell surface also 
comes from the observation that Th2 TCR a chain transgenic animals have a reduced 
CD4+: CD8+ ratio in the thymus. However, this difference in ratio was not observed in 
splenocytes (P = 0.9977 and P = 0.1999 for lines 34 and 20 compared to littermates 
respectively) and so the CD4+: CD8+ ratio of T cells in the periphery seems to be 
unaffected by Th2 TCR a chain transgene expression. An increased percentage of 
double negative thymocytes was also observed in Thl TCR a chain transgenic mice 
(figure 3.14). However, there was no change in the CD4+: CD8+ ratio in the thymi or 
splenocytes of these animals. 
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Despite high levels of transgene expression in Th2 TCR a chain transgenic animals, 
and significant levels of expression in some Thl TCR a chain transgenics, staining of 
splenocytes with an antibody directed against the constant region of the TCR 
demonstrated normal levels of a/13 TCR at the cell surface (figure 3.15). 
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Figure 3.11 Demonstration of correct Th2 TCR a chain transgene processing and 
expression by PCR. Splicing out of intronic sequence should occur during correct 
processing and expression of the TCR a chain transgene. PCR using primers shown 
in (a) and (b) should demonstrate a size difference in PCR product between the 
genomic configuration of the construct (a) and that obtained from transgenic T cells 
where intronic sequence has been removed (b). An HPRT control PCR demonstrates 
successful reverse transcription from transgenic and littermate control splenocyte 
RNA (c). Expression of the transgene and correct splicing of intronic sequence has 
been demonstrated by PCR from splenocyte cDNA in both Th2 TCR a chain 
transgenic lines (d). 
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Figure 3.12 Demonstration of correct Thl TCR a chain transgene processing and 
expression by PCR. Splicing out of intronic sequence should occur during correct 
processing and expression of the TCR a chain transgene. PCR using primers shown in 
(a) and (b) should demonstrate a size difference in PCR product between the genomic 
configuration of the construct (a) and that obtained from transgenic T cells where 
intronic sequence has been removed (b). (c) Expression of the transgene, and correct 
splicing of intronic sequence, has been demonstrated by PCR in the Thl TCR a chain 
transgenic line using splenocyte cDNA. A low level of expression of this V10/J58 
TCR sequence was also detected in the littermate cDNA sample. 
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Table 3.5 TCR a chain sequences from splenocytes of Th2 TCR a chain 
transgenic and littermate control animals. 
TA clone 	TRAV CDR3a amino acid sequence TRAJ CDR3 length 
Th2 a line 20 
20-2 Al 17 CALEGIASSSFSKLVF 50 14 
20-2 A3 
20-2 A4 
20-2 A8 
20-2 A9 
20-2 A10 
20-2 All 
20-2 Al2 
20-2 A13 
20-2 A14 
Th2 a line 34 
34-20 AI 17 CALEGIASSSFSKLVF 50 14 
34-20 A2 
34-20 A4 
34-20 A5 
34-20 A7 
34-20 A10 
34-20 All 
34-20 A6 4D-3 CAAVNYGGSGNKLIF 32 13 
34-20 A9 CASSGSWQLIF 22 9 
Littermate 
34-21A15 4D-3 CAAETNTDKVVF 34 10 
34-21A16 CAAPDSNYQLIW 33 
34-21A17 CAAYIASSSFSKLVF 50 13 
34-21 A3 CAADNTNTGKLTF 27 11 
34-21 A2 4D-4 CAAGLPNYNVLYF 21 
34-21Al2 CAARNSGYNKLTF 11 
34-21 A5 4-4 CAAENTGNYKYVF 40 
34-21 A9 CAAEITGNTRKLIF 37 12 
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Table 3.6 TCR a chain sequences from 2 Thl TCR a chain transgenic animals. 
TA clone 	TRAY CDR3a amino acid sequence 	TRAJ CDR3 length 
Thl a line 30 
Th1-56 Al4 	10D 	CAASREGTGSKLSF 	58 	12 
Th1-56 A8 
Th1-56 A5 	 CAALGAGNTRKLIF 	37 
Thl-56 A6 
Thl-56A4 4D-3 CAAPPNYGNEKITF 	 48 
Th1-56 Al6 	 CAAETGTGGYKVVF 12 
Th1-56 Al7 CAAEATRGNNKLTF 	56 
Th1-56 A3 	4-3 	CAAEIMGTYQRF 	 13 	10 
Th1-56 Al5 CAAEGVNTGNYKYVF 	40 13 
Th1-56 Al 	4D-4 	CAAVNTGNYKYVF 	 11 
Th1-56 A7 	4-4 	CAAEAKNTGYQNF 49 	13 
Thl-56A10 	4-2 	CAAEDANNRIFF 	 31 10 
Th1-63 A2 	10D 	CAASREGTGSKLSF 	58 	12 
Thl-63 A3 
Thl-63 A8 
Thl-63 All 
Thl-63 Al2 
Thl-63 A13 
Thl-63 A16 
Th1-63 Al 	4-4 	CAAEAGGADRLTF 	 45 	11 
Th1-63 A20 
Th1-63 Al9 	 CAAEKDSGTYQRF 	 13 
Th1-63 A4 	4D-3 
Th1-63 Al8 CAAEEDMGYKLTF 	 9 
Th1-63 Al0 	 CVAEDYGGSGNKLIF 32 	13 
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Figure 3.13 An increased percentage of double negative thymocytes and a 
decreased CD4:CD8 ratio suggests expression of the Th2 a chain transgene at 
the cell surface early in thymocyte development. (a) Thymocytes from both lines 
of Th2 TCR a chain transgenic animals and littermate control animals were stained 
with CD4-PE and CD8-FITC antibodies. FACS analysis showed an increased 
percentage of double negative thymocytes in transgenic animals compared to controls 
(b). The CD4:CD8 ratio was also decreased in thymocytes from transgenic animals 
(c) but no change in CD4:CD8 ratio was observed in splenocytes (d). Data points for 
individual animals are shown and mean values + SD are also marked. The statistical 
significance of differences between transgenic and littermate groups were tested using 
a non-paired t test, ***P < 0.001, **** P < 0.0001, and data shown is representative 
of two independent experiments. 
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Figure 3.14 An increased percentage of double negative thymocytes suggests 
expression of the Thl a chain transgene at the cell surface early in thymocyte 
development. (a) Thymocytes from Thl TCR a chain transgenic and litter mate 
control animals were stained with anti CD4 PE and anti CD8 FITC antibodies. FACS 
analysis showed an increased percentage of double negative thymocytes in transgenic 
animals compared to controls (b). There was no difference in the CD4:CD8 ratio 
observed between the two groups in either thymocytes (c) or splenocytes (d). Data 
points for individual animals are shown and mean values + SD are also marked. The 
statistical significance of differences between transgenic and littermate groups were 
tested using a non-paired t test, **P < 0.01, and data shown is representative of a 
single experiment. 
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Figure 3.15 Transgenic expression of Thl or Th2 T cell receptor a chains does 
not affect the levels of TCR at the cell surface. Splenocytes from TCR oc chain 
transgenic and littermate control animals were stained with an anti TCR [3 chain FITC 
conjugated antibody. No differences in levels of TCR at the cell surface were 
observed in either Th2 TCR a chain transgenic line (a) or the Thl TCR a chain 
transgenic line (b) when compared to littermate control animals. 
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Discussion 
Many factors are known to influence CD4+ T lymphocyte differentiation and there is a 
growing body of evidence to suggest that the avidity and affinity of the TCR/pMHC 
interaction is important. Most studies suggest that a low affinity interaction between 
the TCR and pMHC complex will favour a Th2 response, while a high affinity 
interaction promotes Thl development (Malherbe et al., 2000). A study from our 
laboratory in 2002 observed that CD4+ T cells selected under Th2 polarising 
conditions favoured an elongated TCR CDR3a chain and predicted that these 
elongated TCR a chains may result in less optimal (lower affinity) interactions 
between the class II pMHC complex and CDR loops of the TCR (Boyton et al., 2002). 
As a continuation of this work, the aim of this study was to express these elongated 
Th2 and shorter Thl TCR a chains transgenically to determine if TCR structure can 
cause an inherent Thl or Th2 bias in CD4+ effector cell phenotype. This chapter has 
described identification of TCR a chains derived from polarised T cell lines and the 
generation of Thl and Th2 TCR a chain transgenic mice. 
A PCR strategy was used to determine the profile of TCR a and TCR r3 gene usage in 
the cDNA of short term polarised NOD.E Thl and Th2 cell lines, both of which were 
specific for an antigen (PLP 56-70) used in the previous study. Dominant TCR a 
chains were present in both cell lines and there was a statistically significant difference 
in CDR3a length between Th 1 and Th2, with the CDR3a regions of the Th2 line 
being longer than those of the Thl. This data is in keeping with the findings of the 
original study from which these lines derive, as was the observation that there was no 
significant difference in CDR3 (3 length and that the Th2 CDR3 motif could not be 
identified in the Thl line by PCR. No clonal expansion of a dominant TCR p chain 
was observed in either line, suggesting that the dominant TCR a chains were able to 
form peptide specific heterodimers with more than one p chain. However, as the 
dominant TCR a chains identified made up a significant proportion, but the not the 
entirety, of each line no single TCR (3 chain partner for either a chain could be 
146 
confidently identified. Selective expansion of TCR sequences, which then become 
dominant during the course of an immune response has been well documented in 
studies of both mice and humans and for both CD4 and CD8 responses (Wedderburn 
et al., 1993, Fasso et al., 2000 and Zhong and Reinherz, 2004). However, these 
studies mostly report the presence of dominant TCR a and p chain pairs or have 
observed narrowing of the TCR (3 chain repertoire. That a TCR a chain, using a 
conserved CDR3 a region, i.e. not just a V gene bias, should come to dominate a TCR 
repertoire in the absence of any simultaneous TCR p sequence expansion is perhaps 
unexpected. During normal T cell development in the thymus, TCR p chain 
rearrangement and cell surface expression occurs before that of the a chain (Kishi et 
al., 1991). Transition of thymocytes from double negative to double positive denotes 
successful (3 chain rearrangement and selection and is accompanied by cell 
proliferation (Hoffman et al., 1996). Many T cells bearing the same TCR p chain with 
an identical CDR3 (3 region will therefore be present in the thymus, and populations of 
mature T cells exiting the thymus with the same TCR (3 chain, but pairing with 
different TCR a chains are likely. However, that exactly the same TCR a chain will 
be generated by different T cells as they undergo TCR a chain rearrangement is a 
random event and therefore T cells exiting the thymus carrying the same TCR a chain 
but different TCR p chains are likely to occur at a much lower frequency. The TCR a 
chain bias observed in the lines used for this study may therefore be of great 
significance, in terms of providing peptide specific structural features to the TCR 
heterodimer that are selected for under Thl or Th2 polarising conditions, and lends 
further weight to the argument that an inherent bias may be observed upon transgenic 
expression of these TCR a chains. However, transgenic expression of the TCR a 
chain alone is unlikely to yield an inherent peripheral repertoire of T cells with the 
correct antigen specificity. One approach to finding TCR (3 chain partners that formed 
antigen specific receptors with the expanded a chains would have been to use a T cell 
transfection technique. In vitro expression and analysis of TCRs has been described 
by many other groups (Sugiyama et al., 2004) and transfecting T cells lacking 
endogenous TCR with the Thl and Th2 TCR a chains, along with TCR (3 chains 
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identified from the diverse repertoire of each line, would have allowed identification 
of [3 chain partners which were able to form stable heterodimers with the required 
specificity for the antigen PLP 56-70. However, given the unexpected, but striking, 
TCR a chain bias observed in both Thl and Th2 cell lines, further questions arise 
about whether indeed the dominant TCR a chains alone could be responsible for any 
observed phenotype bias. As such it was decided that the Thl and Th2 TCR a chains 
should be expressed transgenically in the absence of an identified antigen specific 
TCR 13 chain pair, and that pairing would be subsequently established from in vitro 
and in vivo studies of these TCR a chain transgenic mice. 
Following construction of transgenes for both Thl and Th2 TCR a chains, mice 
transgenic for each chain were identified by both PCR and Southern blot. 2 lines of 
mice for the Th2 TCR a chain were established, and one line of mice carried the Thl 
TCR a chain. Founder animals were crossed, and then each subsequent generation 
backcrossed, onto the NOD.E strain of mice as this strain expresses the MHC class II 
molecule, I-Ag7, to which the peptide specificity of the original Thl and Th2 cell lines 
was restricted. At each generation, mice for subsequent breeding were identified by 
both PCR and Southern blot, as germline transmission of transgenes can sometimes 
result in loss of transgene copies (Kim et al., 2004). As it was not practical to examine 
levels of transgene expression in each line at each new generation, transgene copy 
number by southern blot was taken as a surrogate marker that the new generation was 
the same as the previous. 
The most straightforward way to determine expression of a TCR transgene would be 
to use a V region specific antibody. However, although many antibodies exist against 
V(3 sequences, very few Va antibodies are available. Cell surface staining of T cells 
from transgenic animals was therefore not possible as a means of determining 
transgene expression in these mice. Direct observation of transgene expression at the 
level of cDNA was possible however, and a PCR strategy demonstrated transgene 
expression, and indeed correct splicing out of intronic sequences present in the V 
region of each transgene, for each line of transgenic mice. Transgenes for both Thl 
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and Th2 TCR a chains were derived from endogenous mouse TCR a promoter and 
enhancer elements contained within the transgenic cassette vectors designed by 
Kouskoff et al. (Kouskoff et al., 1995), NOD.E genomic DNA and Thl or Th2 cell 
line cDNA. In using these endogenous elements from the TCR a locus, as far as 
possible, expression patterns of the transgenic TCR chains should be normal. 
However, it is well documented that mice expressing a TCR a chain transgene have an 
increased percentage of DN thymocytes compared to wild-type mice (Huang and 
Kanagawa, 2004). This is a consequence of the necessity to include pre-rearranged V 
and J gene segments in the transgenic construct and altered percentages of thymocyte 
populations result from early expression of the transgenic TCR a chain compared to 
endogenous a chains. This consequence of TCR a chain transgenesis was alluded to 
in the original paper by Kouskoff et al. where the transgenic vectors used in this study 
were first described. In this study, high expression levels of transgenes were 
documented in double negative thymocytes. The impact of this premature TCR 
expression on T cell development and selection was addressed in a recent study by 
Baldwin et al. In this study, correct timing of TCR a chain expression was achieved 
using the Cre/lox system of conditional gene targeting where Cre was expressed under 
the control of the CD4 promoter/enhancer and a TCR a chain transgene was under the 
control of a constitutively active promoter, but preceded by a foxed stop sequence 
(Baldwin et al., 2005). TCR a chain expression was therefore restricted to DP and SP 
thymocytes. The authors report that, when the TCR a chain was expressed in DP 
thymocytes, no perturbations of thymocyte DN and DP populations were observed 
and, by using a well characterised HY TCR transgenic line, they demonstrated that in 
male mice negative selection of HY specific thymocytes occurred at the single positive 
(SP) stage of thymocyte development rather than at the DP stage reported in 
conventional HY transgenic animals. Thus, the unphysiological expression pattern of 
TCR a chains observed in studies using conventional TCR expression vectors are non-
ideal and potential consequences for normal T cell development and selection should 
be born in mind. However, in this study, the expected block in thymocyte 
development observed serves to answer an important question regarding transgene 
expression. Increased percentages of double negative thymocytes were observed in all 
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3 lines of TCR a chain transgenic animals and because thymocyte development is 
perturbed by early expression of the TCR a chain at the cell surface, that the Thl and 
Th2 TCR a chain transgenes are indeed being expressed at the cell surface can be 
surmised. 
As both the Thl and Th2 TCR a chains were derived from CD4+ T cells, which are 
restricted to antigen recognition in the context of MHC class II molecules, a shift 
towards the dominance of CD4+ T cells in the periphery may have been predicted. 
Other studies using a13 transgenic mice have seen a large shift in ratio towards CD4+ 
or CD8+ T cells both in the thymus and the periphery depending on whether the TCR 
in question was MHC class II or MHC class I restricted respectively (Lobito et al., 
2002). This was observed in the study by Lobito et al. using an MHC class II 
restricted TCR, although they reported a small increase in CD8+ T cells when the TCR 
a chain of the receptor was expressed alone. In our study, no statistically significant 
shift in CD4/CD8 ratio was observed in the periphery of either Th 1 or Th2 TCR a 
chain transgenic animals, although a small apparent shift towards CD8+ T cells in the 
Th2 TCR a transgenics, particularly line 20, may have become more apparent if more 
mice were included in the analysis. There is however, a significant shift towards 
CD8+ T cells in the thymi of these mice. That the same shift is not observed in the 
Thl TCR a chain transgenic line suggests that this difference is inherent to the 
different TCR a chains being expressed rather than a consequence of transgene 
expression per se, but the lack of CD4+ T cell bias in either line suggests that MHC 
class restriction is not mediated by either TCR a chain alone and that the transgenic 
TCR a chains are likely to be present on the surface of both CD4+ and CD8+ T cells. 
In the absence of an antibody and despite some evidence that both TCR a chain 
transgenes were being expressed at the cell surface, levels of transgene expression in 
the periphery could only be assessed by TCR sequence analysis. However, for all 3 
transgenic lines, normal levels of TCR expression on peripheral T cells, whether 
endogenous or transgenic, were demonstrated using an antibody specific for the 
constant region of the TCR. This finding is particularly important in light of findings 
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about T cell phenotype and is discussed in chapter 4. Sequence analysis of TCRs 
expressed by peripheral T cells from splenocytes of both Th2 TCR a chain transgenic 
lines and the Thl TCR a chain transgenic line revealed the presence of transgenic 
sequences in all samples. However, the percentage of the repertoire comprising the 
transgenic sequence was very different between Thl and Th2 animals. From Th2 
TCR a chain transgenic animals, almost all sequences obtained derived from the 
transgene, with only the occasional endogenous sequence identified. In contrast, no 
more than 50% of sequences from Thl TCR a chain transgenic animals were 
transgenic and percentages between animals were highly variable. There are several 
possible reasons for these variations. Expression levels of transgenes are known to be 
highly variable depending on the site of transgene integration (Robertson et al., 1995) 
and so the Thl TCR a chain transgene may be integrated into a locus of the genome 
permitting weaker expression of the transgene than those in which the Th2 a chain 
transgene has integrated. However, if the block at the DN stage of thymocyte 
development is any indication of the level of transgene expression, then the 
thymocytes of Thl and Th2 transgenic animals appear to be very similar. Another 
possibility is that many T cells bearing the transgenic Thl TCR a chain are negatively 
selected in the thymus and therefore do not proceed to become part of the peripheral T 
cell repertoire. The Thl a chain was originally identified from a highly specific, but 
also highly polarized T cell line, whose TCRs were predicted to display a high affinity 
for pMHC. T cells with a high affinity for self pMHC are known to be negatively 
selected in the thymus (Alam et al., 1996) and it may be that T cells bearing this 
shorter CDR3 a region of the Thl TCR a chain are more likely to make high affinity 
interactions with self pMHC compared to those bearing the longer CDR3 a region of 
the Th2 TCR a chain. This hypothesis would be most easily tested by sorting 
different populations of T cells as they proceed through the different stages of T cell 
development, i.e. DN, DP, SP and mature T cells and analysing the repertoire of TCR 
a chains at each stage, although the picture will be complicated by the appearance of 
endogenous TCR a at a different time point to that of the transgene. Perhaps a cleaner 
system in which to analyse thymic selection of this TCR a chain would be to use mice 
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in which the endogenous TCR a locus is disrupted. Also a possibility is transgene 
deletion as there is some evidence that TCR transgenes can become deleted in 
peripheral T cells (Komori S et al., 1993). This issue could be resolved by single cell 
sorting of peripheral T cells and using PCR to detect the presence or absence of the 
transgene at the level of genomic DNA and cDNA. A final explanation for apparent 
low levels of expression in the Thl TCR a chain transgenic line is that many T cells 
are expressing the transgenic a chain as well as endogenous a chains, i.e. that there 
are many dual a expressing cells in these animals. This may equally apply to 
endogenous TCR a sequences detected in samples from Th2 TCR a chain transgenics. 
Again, single cell sorting could determine whether some T cells from these animals 
were expressing two TCR a chains. These latter two possibilities would also help to 
explain the variability observed between animals of the same line. 
Data in this chapter has described the identification of dominant Th 1 and Th2 cell 
derived TCR a chains and the strategy used to express these TCR chains 
transgenically. In vitro and in vivo studies using these animals to try to determine 
antigen specific TCR 13 chain pairing, and to determine whether T cells expressing 
these chains display any inherent effector phenotype bias are described in the next 
chapter. 
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Chapter 4  
TCR 6 chain selection and cytokine phenotype in Thl and Th2 TCR 
a chain transgenics  
Results 
4.1 Analysis of TCR /3 chain usage in unprimed Th2 TCR a chain transgenics. 
Previous analysis of TCR a chain usage in the Th2 TCR a chain transgenic animals 
had shown that, in both transgenic lines, most T cells in the periphery bear the 
transgenic TCR a chain (table 3.5). Using the PCR strategy described previously 
(figure 3.1) splenocytes from unprimed mice were used to examine TCR 13 chain usage 
in these animals (figure 4.1). The aim was to determine whether dominance of this 
transgenic TCR a chain generates any innate bias in the TCR (3 chain repertoire of 
these animals in the absence of exogenous priming with the antigen (PLP 56-70) for 
which the TCR, from which the a chain derives, was specific. However, no 
preference for a particular TCR (3 chain was observed in either line, and the pattern of 
TCR (3 chain genes used was very similar between transgenic and littermate samples. 
There were also no differences in the length of CDR3 regions seen in the TCR (3 
chains. From this sequence data it seems that the peripheral TCR (3 chain repertoire is 
unaffected by the dominant expression of the transgenic Th2 TCR a chain. However, 
as the number of sequences obtained for any one sample represent just a tiny fraction 
of TCR (3 chains present in the periphery, any subtle impact of the Th2 TCR a chain 
on the 13 chain repertoire may be hard to detect using this approach. CDR3 spectratype 
analysis was therefore used in order to build a more global picture of TCR (3 chain 
usage in the periphery of these animals. CDR3 spectratype analysis was originally 
developed and described by Pannetier et al. (Pannetier et al., 1993). It uses TRBV 
gene specific primers in combination with either a fluorescently labelled constant 
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region primer or fluorescently labelled TRBJ gene specific primers to amplify all TCR 
p chain sequences in a given sample. Products from each PCR reaction are then 
analysed according to size. A typical profile of product sizes for any given primer 
combination usually consists of 4 or more discrete peaks, spaced 3 nucleotides apart, 
that follow a Gaussian (normal) distribution. Clonal expansion or bias towards a 
particular TCR p chain is observed as a dominant peak or skewing of the peak profile 
away from a normal Gaussian distribution. To analyse TCR p chain usage in the 
periphery of the Th2 TCR a chain transgenic animals, TRBV gene specific primers 
were used in combination with a fluorescently labelled constant region primer. 
Profiles obtained for each TRBV gene were then compared between transgenic and 
littermate animals (figure 4.2). No major differences were observed between the 
spectra of transgenic and littermate animals. There was also no evidence of clonal 
expansion for any TRBV gene, with all spectra displaying a normal distribution of 
product sizes. Good spectra were not obtained for all TRBV genes. These genes (e.g. 
TRBV 23, TRBV 21, TRBV 30 and TRBV 24) were also never observed from 
sequence analysis of transgenic or littermate splenocytes samples and so as a 
consequence of genetic background are probably poorly represented in the periphery 
of these animals. It is not possible from this spectratyping data to determine the CDR3 
lengths represented by individual peaks as they represent combinations of each TRBV 
gene with many different TRBJ genes, but the similarity in spectra between transgenic 
and littermate samples suggests that there are no differences in average TCR I CDR3 
length or TRBV gene usage as a consequence of transgenic Th2 TCR a chain 
expression. 
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TA clone 	TRBV CDR3(3 amino acid sequence TRBJ CDR3 length 
Th2 a line 20 
20-2 B1 
20-2 B7 
20-2 B9 
20-2 B2 
20-2 B5 
20-2 B4 
20-2 B6 
20-2 B8 
20-2 B10 
Mean CDR3 length  
2 	CASSQDSQNILYF 	2-4 	11 
CASSPDRGRNTLYF 12 
CASSQGQGSYEQYF 	2-7 
20 CGARLGLNQDTQYF 2-5 
13-2 CASGDAGFNQDTQYF 
	
13 
CASGDWGSGNTLYF 	1-3 
	
12 
16 	CASSFRDRGF 	 2-7 8 
17 	CASSPDNYEQYF 
	
10 
19 	CATLGQNYAEQF F 	2-1 
	
11  
11.2 
Th2 a line 34 
34-23 B1 
34-23 B9 
34-23 B3 
34-23 B10 
34-23 B8 
34-23 B5 
34-23 B6 
34-23 B2 
34-23 B11 
34-23 B7 
Mean CDR3 length  
17 	CASSRTGGQDTQYF 	2-5 	12 
CASSRLGTGDTQYF 
2 	CASSQERRINQDTQYF 	 14 
13-2 CASGDARWGGSQDTQl 15 
19 	CASSILTGSNQDTQYF 	 14 
CASSILSQNTLYF 	2-4 	11 
15 	CASSSGQQNTLYF 
29 	CASGTNTEVFF 	 1-1 
	
9 
CASSPPTGRSAETLYF 2-3 14 
4 	CASSSGQGDNQAPLF 	1-5 
	
13  
12.5 
Littermate 
20-31 B1 
20-31 B12 
20-31 B6 
20-31 B2 
20-31 B3 
20-31 B11 
20-31 B4 
20-31 B8 
20-31 B9 
20-31 B10 
Mean CDR3 length 
29 	CASSSRQGMDSPLYF 	1-6 
CASRDQGANTGQLYF 2-2 
CASSRTGYEQYF 	2-7 
15 	CASSLDRDEQYF 
13-1 CASSLWGNQDTQYF 2-5 
CASSDWGASYEQYF 	2-7 
2 	CASSQDRDYEQYF 
13-3 CASGVLGGGAETLYF 2-3 
16 	CASSLGTGGYEQYF 	2-7 
13 
10 
12 
11 
13 
12  
11.8 
 
  
Figure 4.1 TCR 13 chain sequences from splenocytes of unprimed Th2 TCR a 
chain transgenic and littermate control animals. A PCR strategy (figure 3.1) was 
used to determine TCR (3 chain usage in Th2 TCR a chain transgenic and littermate 
splenocytes. 
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Figure 4.2 Spectratype analysis of TCR 13 chain gene usage in splenocytes of unprimed Th2 TCR a chain transgenic and 
littermate control animals. TRBV gene specific primers were used with a fluorescently labelled constant region primer to 
amplify TCR (3 chain sequences from splenocyte cDNA. Analysis of product sizes obtained from each PCR reaction showed no 
major differences in spectra obtained for transgenic compared to littermate control animals and no evidence of clonal expansion 
for any TCR (3 chain in the presence of a dominant Th2 TCR a chain. Numbers at the top of each spectra indicate the size of PCR 
product in base pairs. Data shown is representative of 2 animals per group. 
4.2. Analysis of TCR fi chain usage in Th2 TCR a chain transgenics in the context of 
antigen specificity. 
The data from unprimed animals suggests no bias in TCR 13 chain repertoire in the 
context of a dominant transgenic Th2 TCR a chain and that the transgenic a chain is 
able to form a functional TCR with many different TCR 13 chains with different 
lengths of CDR3. However, the TCRs present in the periphery of the animals used to 
generate this data have an enormous range of antigen specificities. Structural 
constraints on which TCR 13 chains may be able to pair with the transgenic Th2 TCR a 
chain may be more apparent in the context of an antigen specific response. PLP (56-
70) is the antigen for which the original TCR, from which the transgenic Th2 TCR a 
chain was derived, was specific. Th2 TCR a chain transgenic and littermate animals 
were immunised in the footpad with PLP 56-70. The peptide was administered as an 
emulsion with Complete Freund's Adjuvant (CFA) in order to generate an immune 
response and 10 days after immunisation, popliteal draining lymph nodes from these 
animals were harvested and peptide specificity and TCR [3 chain usage determined. 
Good proliferation in response to antigen was seen from both transgenic and littermate 
lymph node T cells, but neither sequence analysis (figure 4.3) nor CDR3 spectratype 
analysis (figure 4.4) showed any evidence of clonal expansion, TRBV gene bias or 
differences in TRBV gene usage and CDR3 length between Th2 TCR a chain 
transgenic and littermate animals. 
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20-131311 13-2 CASGSGGPNQDTQYF 2-5 13 
20-13B13 CASGDAGGRDTQYF 12 
20-13 B5 CASGGLGDEQYF 2-7 10 
20-13 B9 CASGDALGASAETLYF 2-3 14 
20-13 B1 19 CASSPDSAETLYF 11 
20-13 B4 CASRQTGGDQDTQYF 2-5 13 
20-13 B7 13-1 CASSDGGGPEVFF 1-1 11 
20-13 BIO CASSPGENTLYF 2-4 10 
20-13 B6 31 CAWTTGGTTGWLYF 2-2 12 
20-13 B8 4 CASSWDWEQDTQYF 2-5 
Mean CDR3 11.8 
Th2 a line 34 
34-3 BIO 16 CASSPRQGENTGQLYF 2-2 14 
34-3 B11 CASSLVDAANSDYTF 1-2 13 
34-3 B7 CASSLTGGVQDTQYF 2-5 
34-3 B8 15 CASSLAPGLGKDTQYF 14 
34-3 B9 CASSRQGNTEVFF 1-1 11 
34-3B12 13-1 CA SSDAYRGGTEVFF 13 
34-3 B1 CASSDEGYTLYF 2-4 10 
34-3 B3 5 CASSQQGEQYF 2-7 9 
34-3 B5 19 CASSIEDQGARTERLFF 1-4 15 
Mean CDR3 12.4 
Littermate 
34-1 B7 13-2 CASGGRDRASERLFF 1-4 13 
34-1B11 1-4 
34-1 B2 13-1 CASSDVWDWGYEQYF 2-7 
34-1 B15 CASSDGQGDNQAPLF 1-5 
34-1 B8 CASSDSRLGGAETLYF 2-3 14 
34-1 B13 CASSDQGANTEVFF 1-1 12 
34-1 B3 2 CASSQDLSNQAPLF 1-5 
34-1 B5 CASSQQNSDYTF 1-2 10 
34-1 B6 20 CGARDWGGAYAEQFF 2-1 13 
34-1 B14 19 CASSILGGEETLYF 2-3 12 
Mean CDR3 12.5 
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Th2 a line 20 
Figure 4.3 TCR I  chain sequences from primed draining lymph node of Th2 
TCR a chain transgenic and littermate control animals. Mice were primed with 
the peptide PLP 56-70 by footpad immunisation. The draining popliteal lymph node 
was harvested at day 10 and peptide specificity of T cells determined by proliferation 
assay. TCR (I chain usage was determined by PCR. The proliferation data shown 
corresponds to the draining lymph node from which each set of sequence data is 
derived. 
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Figure 4.4 Spectratype analysis of TCR 13 chain gene usage in primed draining lymph node T cells of Th2 TCR a chain 
transgenic and littermate control animals. TRBV gene specific primers were used with a fluorescently labelled constant region 
primer to amplify TCR 13 chain sequences from draining lymph node cell cDNA. Analysis of product sizes obtained from each 
PCR reaction showed no major differences in spectra obtained for transgenic compared to littermate control animals and no 
evidence of clonal expansion for any TCR [3 chain in the context of a dominant Th2 TCR a chain and PLP peptide specificity. 
Numbers at the top of each spectra indicate the size of PCR product in base pairs. Data shown is representative of 2 animals per 
group. 
4.3. Analysis of PLP (56-70) specific Th2 TCR a chain transgenic T cell lines. 
The lack of a dominant TCR (3 chain in the draining lymph nodes of PLP 56-70 
immunised transgenic animals suggests that a single priming with antigen and 10 days 
between priming and harvesting of the lymph node was not sufficient for a clonal 
expansion to occur. Antigen specific T cell lines were therefore established from Th2 
TCR a chain transgenic and littermate draining lymph nodes and grown in vitro over 
many weeks with repeated exposure to antigen and APC in growth medium containing 
10U/m1 IL-2. T cell lines were restimulated with antigen (PLP 56-70) every 9-11 days 
and splenocytes from NOD.E mice were used to present the peptide at each 
restimulation, as APCs from this mouse strain carry the MHC class II molecule I-Ag7, 
against which the original Th2 TCR was restricted. TCR p chain usage in these PLP 
56-70 specific cell lines was analysed over successive restimulations. Figure 4.5 
shows TCR p chain sequence data for Th2 TCR a chain transgenic (derived from 
transgenic line 20) and littermate T cell lines grown over 6 restimulations. A clonal 
expansion of a TCR (3 chain was apparent at the 4th  restimulation of the transgenic T 
cell line and this 13 chain (TRBV 31 / TRBJ 2-3) with a CDR3 p length of 12 amino 
acids, comprised 100 % of all sequences obtained at the 6th restimulation. In contrast, 
the littermate derived line showed no evidence of clonal expansion at the 4th 
restimulation and the most significant expansion at the 6th restimulation comprised just 
21% of the sequenced repertoire. However, despite the major differences in TRBV 
gene usage between the two lines, CDR3 (3 lengths remained similar throughout. 
The rapid narrowing of the TCR p chain repertoire in the transgenic line compared to 
the littermate line was also seen from CDR3 spectratyping data (figure 4.6). For each 
of the TRBV genes shown, even at the 2nd restimulation, the number of peaks in each 
spectra was greater in the littermate line than in the transgenic line where all spectra 
rapidly narrow or disappear completely. Narrowing of the repertoire was also evident 
in the littermate line by the 6th restimulation but for this line the kinetics of this change 
in (3 chain usage was much slower. 
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2°d restimulation 4th restimulation 6th restimulation 
  
     
TA clone TRBV CDR3IO amino acid sequence TRBJ CDR3 length TA clone TRBV CDR30 amino acid sequence TRBJ CDR3 length TA clone TRBV CDR313 amino acid sequence TRIM CDR3 length 
Th2 a transgenic 
2°20814 
2°  20 1316 
2° 20 135 
2°20 B13 
2°20818 
2° 20 B8 
2° 20021 
2° 20 B4 
2°20 B23 
2°20 B17 
2° 20 Ell 
2° 20 1312 
2°  20 B20 
2° 2082 
2° 20 B22 
2° 20 B7 
2 
13-2 
13.1 
4 
31 
29 
CAS SQRL VNQDTQYF 
CA S S LGT ANTGQLYF 
CAS S LGT ANTGQP YF 
CASSQEERTNSDYTE 
CAS SQDGQFLNERLFF 
CASGDPD W TETLY F 
CASGDRDRGNNSPLYF 
CAS SAGTNSNERLFF 
CAS S DAGD 1NNQAPLF 
CASSDAWGQGNTEVFF 
CAS SGTGGNTLYF 
CALGHRINERLFF 
CA S SPGTGVDTQYF 
2-5 
2-2 
1-2 
1-4 
2-3 
1-6 
1-4 
1-5 
1-1 
2-4 
1-4 
2-5 
13 
14 
12 
14 
13 
14 
12 
Th2 a transgenic 
4° 20 131 
4°2003 
4° 20 136 
4° 20 B8 
4120E19 
4° 20 1310 
4° 20811 
4°20013 
020B14 
4° 20E16 
4° 20 B21 
4°20137 
4° 20 1317 
020 1318 
4°20E123 
4°20 B2 
4°2004 
(201320 
31 
13-1 
13-3 
5 
CAWS LGGGAETLYF 
CASSDAWGQGNTEVFF 
CAS SG PPGQSSGNTLYF 
CAS RRDNQAPLF 
CASSQTFLNSDYTF 
2-3 
1.1 
1-3 
1-5 
1-2 
12 
14 
15 
10 
12 
Th2 a transgenic 
6°20131 
e20B2 
6°20 B3 
6°2084 
6°  20 B5 
6° 20 B6 
e 20 87 
6'2088 
6°  20 B9 
(201310 
6°20611 
(20 B12 
e 20 513 
6°20814 
6°20E115 
e 20 1316 
6°201317 
6°20 BIS 
6°201320 
6'20521  
31 CAWSLGGGAETLYF 2.3 12 
Mean CDR3 12.8 Mean CDR3 12.6 
Littermate 
2° WT B3 
2° WT1320 
2°WTB1 
2°  WT B2 
2° WT B13 
2° WT B17 
2° WT B4 
2° WTB11 
2° WT B14 
2° WT B6 
2° WT B12 
21  WT 139 
2° WT B21 
2° WT B20" 
2° WT B24 
2° WT 137 
2° WT B18 
rwr 819 
16 
13-1 
2 
19 
24 
31 
CASSTTSYEQYF 
CASS LDGT TNSDY TF 
CAS S LQGA 1 S NEGLEF 
CAS SLVGSNERLF F 
CASSSDWGSTLYF 
CAS S DEWGETDTQYF 
CAS S DAGTGSYEQY F 
CASSALGGRSYEQYF 
CAS RPDWG GAGAEQFF 
CASSDAGGARDAETLYF 
CASSQDRDFYAEQFF 
CAS SQEGGVG AEQFF 
CAS S PRDNQ NTLY F 
CA S S QDM GGAHQDTQYF 
CASTPGQGNSPLYF 
CA SSPSGTGGNTL YF 
CAWSPGGGAETLYF 
2-7 
1-2 
1-4 
2-4 
2-5 
2-7 
2-1 
2-3 
2-I 
2-4 
2-5 
1-6 
2-4 
2-3 
10 
13 
14 
12 
11 
13 
13 
13 
14 
15 
13 
13 
12 
15 
12 
13 
12 
Littermate 
e wrm 
WT B12 
4° WT131 
4° WT 86 
WT Bit 
4° WT 820 
WT BIO 
4° WT BI6 
4° WT B2 
4°WT 114 
4° WT 135 
WT B21 
4° 337 813 
4° W1"1314 
4°WT 87 
WT 89 
4° WT 1317 
4° s/17 B15 
(WT1119 
WT BR 
13-1 
15 
17 
16 
12-2 
2 
14 
31 
20 
13-2 
CASSDAGGARDAETLYF 	2-3 	15 
CAS SPRTTSQNTLYF 	2-4 	13 
CAS R PDWGGAGAEQ IF 	2-1 14 
CASSLGGSGNTLYF 	1-3 	12 
CASSSRDNQDTQYF 	2-5 	12 
CAS SLELGQSNQDTQYF 	 15 
CAS RDWGSNTGQLYF 	2-2 	13 
CASSLGGVTEVFF 	 1-1 1 
CASSLDDANTEVFF 12  
CASSRDWGDEQYF 	2-7 	II 
CASSLVIFSNE RIFF 1-4 13
2  CASSLDNNQDTQYF 	2-5 
CASSQEGLGETQYF 
CASSSREDTQYF 	 10 
CAWSSRDWGDKQYF 	2-7 	12 
CGARDRDWGDEQYF 
CASGGDWGLALYF 	2-4 	II 
Mean CDR3 12 
Littermate 
(IVT134 
6° WT 136 
6° Wr 07 
ewTBI9 
6°Avr 85 
6° WT 03 
6" WT139 
6° WT BIO 
6° 18T1315 
6°  WT 1318 
6" WT1320 
eurrI311 
6° WT 82 
6° WT 822 
6° 1118817 
WT 131 
ex7521 
61%71316 
6° WT138 
16 
2 
13-1 
13-2 
29 
CASSRDWGDEQYF 
C AS SLE WG DEQ VF 
CASSRDWGDTQYF 
CASSLDDANTEVFF 
C AS S FQG YNE RL FF 
CASSLv1FSNF.RLFF 
CASSQEGTGGAGAEQFF 
CASSDAGGARDAETLYF 
CAS SD VG KDTE VFF 
CASGESANTEVFF 
CAS CPT ANTE VFF 
C AS GDAGG AET L CF 
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1-4 
2.1 
2-3 
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14 
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Figure 4.5 Rapid clonal expansion of TCR over successive restimulations of a Th2 TCR a chain transgenic T cell line. 
T cell lines were established from PLP 56-70 primed draining lymph nodes of transgenic and littermate control animals. T 
cells were restimulated with peptide in the presence of NOD.E splenocytes every 9-11 days. RNA was extracted from cell 
lines at each restimulation and TCR beta usage determined by PCR. A clonal expansion in the transgenic T cell line is 
apparent from the 4th restimulation and this TCR comprises 100% of the repertoire by the 6th restimulation. No significant 
expansion was observed in the littermate line. 
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Figure 4.6 Spectratype analysis of Th2 a chain transgenic and littermate derived 
T cell lines through successive restimulations. T cell lines were restimulated every 
9-11 days with peptide (PLP 56-70) and NOD.E splenocytes. RNA was extracted 
from cell lines at each restimulation. TRBV gene specific primers were used with a 
fluorescently labelled constant region primer to amplify TCR 13 chain sequences from 
T cell line cDNA. Analysis of product sizes obtained from each PCR reaction showed 
narrowing of the TCR 13 chain repertoire in both T cell lines over successive 
restimulations. Narrowing of the repertoire was more rapid in the Th2 a chain 
transgenic line with complete disappearance of some TRBV genes by the 6th 
restimulation. 
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Given the enormous differences observed in TCR usage, proliferation in response to 
antigen and cytokine phenotype of the two lines were examined. Proliferation assays 
with multiple doses of peptide at each restimulation showed that both cell lines were 
highly peptide specific and that rates of proliferation in response to antigen were 
roughly equivalent between the two lines (figure 4.7). However, cytokine profiles 
revealed marked differences. In the Th2 TCR a chain transgenic line levels of the Thl 
cytokine IFN-y were decreased between the 2❑d  and the 6th  restimualtion while levels 
of the Th2 cytokines IL-4 and particularly IL-5 were increased. In the littermate 
control line IFN-y production remained high and IL-4 and IL-5 remain low throughout 
the timecourse. This apparent phenotype difference between the two lines was also 
seen at the level of Thl and Th2 transcription factors by real time PCR for Tbet (Thl) 
and GATA3 (Th2) transcripts (figure 4.8). At all time points, levels of Tbet 
transcripts were higher in the littermate line than in the transgenic line and, from the 
4th restimulation, levels of GATA3 transcripts show the opposite trend. Taken 
together, the sequence, cytokine, and real time PCR data suggest that, by the 6th 
restimulation, the Th2 TCR a chain transgenic T cell line has undergone a rapid clonal 
expansion such that the line now comprises a dominant TCR and that the line has a 
Th2 type phenotype compared to the more heterogeneous TCR repertoire of the 
littermate line which has a predominantly Thl type phenotype. 
The original hypothesis of this study asked whether the structure of the TCR could 
cause an inherent Thl or Th2 bias in T cell phenotype. As it was not possible to 
identify a TCR (3 chain pair for the Th2 TCR a chain used to make the transgenics in 
this study, it would be necessary to use the a chain only transgenic lines to identify a 13 
chain that pairs with this alpha chain in the context of peptide specificity and a Th2 
phenotype. The data for the transgenic cell line described here suggested that the 
clonally expanded TRBV 31/TRBJ 2-3 TCR (3 chain may be a suitable P chain pair for 
transgenic expression. The picture of TCR usage and cytokine profile over 6 
restimulations of this transgenic T cell lines is a rapidly changing one. However, if 
cytokine phenotype here is linked to the clonal expansion of the TCR you would 
expect that once a single TCR is present, the cytokine phenotype should remain stable. 
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The cell lines were therefore grown over many more restimulations. Figure 4.9 shows 
the cytokine phenotype and relative abundance of Tbet and GATA3 transcripts for the 
transgenic and littermate T cell lines after 15 restimulations with antigen. The 
transgenic T cell line was still producing high levels of Th2 cytokines IL-4 and IL-5, 
but low levels of IFN-y while the littermate line produced only IFN-y. Levels of Tbet 
transcripts were still higher in the littermate line while GATA3 transcripts were more 
abundant in the transgenic line. The Th2 type phenotype of this Th2 TCR a chain cell 
line therefore appears to be stable. 
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Figure 4.7 Cytokine phenotype of Th2 TCR a chain transgenic and littermate T 
cell lines over successive restimulations. Th2 TCR a chain transgenic (a) and 
littermate (b) T cell lines were restimulated every 9-11 days with peptide (PLP 56-70) 
and NOD.E splenocytes. At each restimulation, proliferation assays were performed 
with multiple doses of antigen. After 48 hours of culture, supernatants were harvested 
and wells pulsed with [3H] thymidine to determine proliferation. Cytokines in cell 
culture supernatants were quantitated by ELISA. 
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Figure 4.8 Real time PCR analysis of GATA3 and Tbet transcripts in Th2 TCR 
a chain transgenic and littermate T cell lines over successive restimulations. T 
cell lines were restimulated every 9-11 days with peptide (PLP 56-70) and NOD.E 
splenocytes. RNA was extracted from cell lines at each restimulation. Real time PCR 
analysis was used to compare levels of GATA3 (a) and Tbet (b) transcripts between 
the Th2 TCR a transgenic line (grey bars) and the littermate line (black bars) at each 
restimulation. RNA levels in each sample were normalised to 18s. At each time 
point, and for each gene of interest, the sample with the lowest level of gene 
expression was assigned a value of 1 and gene expression levels in other samples 
expressed as a value relative to 1. 
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Figure 4.9 Cytokine phenotype of Th2 TCR a chain transgenic and littermate T 
cell lines after 15 restimulations. T cell lines were restimulated every 9-11 days with 
peptide (PLP 56-70) and NOD.E splenocytes. At the 15th restimulation RNA was 
extracted from each line and proliferation assays were performed with multiple doses 
of antien. After 48 hours of culture, supernatants were harvested and wells pulsed 
with [ 	thymidine to determine proliferation. Cytokines in the cell culture 
supernatants of the Th2 TCR a chain transgenic line (a) and the littermate line (b) 
were quantitated by ELISA. Relative abundance of GATA3 (c) and Tbet (d) 
transcripts in the Th2 TCR a chain transgenic line (grey bars) compared to the 
littermate line (black bars) were determined by real time PCR. RNA levels in each 
sample were normalised to 18s. For each gene of interest the sample with the lowest 
level of gene expression was assigned a value of 1 and gene expression levels in other 
samples expressed as a value relative to 1. 
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The transgenic T cell line described above was derived from the primed draining 
lymph nodes of Th2 TCR a chain line 20 transgenic animals. Another example of a 
Th2 TCR a chain transgenic T cell line with a rapid TCR (3 chain clonal expansion 
and a Th2 type cytokine phenotype was derived from line 34 transgenic animals. TCR 
(3 chain sequence data in figure 4.10 shows that, over 9 restimulations, a single TCR (3 
chain expanded to comprise the majority of the T cell line, with this TCR already 
making up 50% of the repertoire by the 5th restimulation. The TCR 13 chain expanded 
in this line (TRBV 13-1/TRBJ 2-7) had a long CDR3 (3 of 15 amino acids. This T cell 
line produced no IFN-y (figure 4.11) but made high levels of Th2 cytokines IL-4 and 
IL-5. A switch in cytokine phenotype towards a Th2 type profile between the 1St and 
5th restimulation was also apparent from Tbet and GATA3 real time PCR data with 
Tbet transcripts more abundant at the 1st restimulation and low levels of Tbet 
transcripts but high levels of GATA3 transcripts at the 5th and 9th restimulations. 
Cytokine phenotype data from this line 34 derived T cell line therefore confirmed 
previous findings from the line 20 derived T cell line discussed earlier. 
Although in the line 34 derived transgenic T cell line the kinetics of TCR (3 chain 
expansion are slightly slower, in both examples one TCR ultimately dominates the 
line, which displays a predominantly Th2 type phenotype with low levels of the Thl 
type cytokine IFN-y and high levels of the Th2 type cytokines IL-4 and IL-5. Both 
expanded TCR (3 chains would therefore be good candidates for transgenic expression. 
Transgenic constructs for both Th2 TCR 13 chains were created, but technical 
difficulties verifying the final line 34 derived TRBV 13-1/TRBJ 2-7 construct meant 
that only the line 20 derived TRBV 31/TRBJ 2-3 (3 chain was subsequently used for 
transgenesis. The generation of transgenic animals carrying this Th2 TCR (3 chain are 
described below. 
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TA clone TRBV CDA3p amino acid sequence TRBJ CDR3 length 
1° 34132 
1° 34 B3 
1° 34 135 
I° 34 B7 
16 CASSPDWGETLYF 
CASSLDWGSDYT F 
2-3 
1-2 
1° 34 1316 
1° 34 BI CASSEGKGTNTEVFF I-1 13 
1° 34 BIS CASSLDPAGGYEQY F 2-7 
I ° 34 B21 CASSGDWGDEQYF 11 
1° 34 1317 13-1 CASSGDSTEVFF 1-1 10 
1° 34 BI9 
I ° 34 B4 CASSDAGGTEVF F 11 
I° 34 B6 CASSDAGTGRDTEVFF 14 
I ° 34 BI2 CASSDAGTSANTEVFF 
I ° 34 013 CASTQGPTNERLFF 1-4 12 
I' 34 BI5 CASSQTNNYAEQFF 2-1 
I° 34 B20 CASSDVGRGNAF.TLYF 2-3 14 
1° 34 B8 12-2 CASSLEGWGGAGDTQYF 2-5 15 
I ° 34 1111 19 CASSPPGTTYSGNTLYF 1-3 
Mean CDR3 12.6 
TA clone 
5° 34 132 
5° 34 B3 
5' 34 B4 
r 34 135 
5" 34 06 
r 34 B14 
5° 34 1315 
r 34 B16 
5° 34 1318 
5° 34 1321 
r 34 BI9 
5° 34 B9 
5° 34 B20 
5° 14 B1 
r 34 1310 
5° 34 013 
r 34 BI2 
r 34 Bl7 
5° 34 BI8 
Mean CDR3 
10t restimulation 5th restimulation 	 9th restimulation 
  
     
TRBV CDR33 amino acid sequence TRBJ CDR3 length TA clone TRBV CDR3tI amino acid sequence TRBJ CDR3 length 
13-I CASSDTGGAQSSYEQYF 2-7 15 9°34 131 
9° 34 B2 
9° 34 133 
9° 34 B7 
r 34 I38 
9° 34 119 
9° 34 1310 
r 34 B12 
r 34 BI3 
9° 34 B25 
I3-1 CASSDTGGAQSSYEQYF 2-7 15 
2 CASSQDGLGGLDTQYF 2-5 14 9° 34 B26 
r 34 B27 
CASSQPPTI1NQDTQYF 
9° 34 13213 
r 34 B29 
r 34 B30 
r 34 B31 
16 CASSLDGLVDSNSDYTF 1-2 15 9° 34 B32 
CASSLEW GAEQF F 2-I II 9° 34 1333 ON 
5 CASSRHRADTEVFF I-I 12 r 34 B34 .f:3 
13.5 9° 34 BI4 13-2 CASGDAGGEQDTQY F 2-5 13 i--1 
Mean CDR3 14 
Figure 4.10 Clonal expansion of a TCR over successive restimulations of a Th2 TCR a chain transgenic T cell line. The 
T cell line was established from PLP 56-70 primed draining lymph nodes from line 34 Th2 TCR a chain transgenic animals. 
The line was restimulated with peptide and NOD.E splenocytes every 9-11 days. RNA was extracted at each restimulation and 
TCR beta chain usage determined by PCR. A clonal expansion was apparent at the 5th restimulation of this line and this TCR 
comprises the majority of the TCR beta chain repertoire by the 9th restimulation. 
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Figure 4.11 Cytokine phenotype of a line 34 Th2 TCR a chain transgenic T cell 
line. The T cell line was restimulated with peptide (PLP 56-70) and NOD.E 
splenocytes every 9-11 days. At each restimulation a proliferation assay was 
performed with multiple doses of antigen. After 48 hours of culture, supernatants were 
harvested and plates pulsed with [3H] thymidine to determine proliferation (a). 
Cytokines in cell culture supernatants were quantitated by ELISA (a). Relative 
abundance of GATA3 (b) and Tbet (c) transcripts in cDNA samples from successive 
restimulations were determined by real time PCR. RNA levels in each sample were 
normalised to 18s. For each gene of interest the sample with the lowest level of gene 
expression was assigned a value of 1. Gene expression levels in all other samples are 
expressed as a value relative to 1. 
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4.4. Construction of a Th2 TCR p chain transgene. 
The cassette vector used in the construction of the Thl and Th2 TCR a chain 
transgenes has already been described. The TCR p chain vector (pT(3) was also 
designed by Kouskoff et al. (Kouskoff et al., 1995) and is based upon the same 
principle of using endogenous mouse TCR [3 promoter and enhancer elements to drive 
gene expression. To express a TCR (3 chain transgenically it is necessary to insert into 
the vector the rearranged TCR p V-J coding region of interest. Also described in the 
previous chapter was the importance of using the genomic DNA configuration rather 
than the cDNA configuration of the rearranged TCR chain. However, unlike the 
situation described for the generation of the TCR a chain constructs, genomic DNA 
was available from the T cell line from which the TCR p chain of interest was 
identified. It was therefore possible to obtain the full sequence of the required TCR (3 
chain V-J segment by a single PCR strategy, whereby PCR was used to generate 
restriction sites at either end of the V-J segment which could then be inserted directly 
into the cassette vector (figure 4.12). The nucleotide and amino acid sequence of the 
Th2 TCR p chain used to make the transgene are shown in appendices 21 and 22 
respectively. PCR primers used to clone the V-J segment from cell line genomic DNA 
are listed in appendix 8. 
The PCR product that was cloned into the pT(3 cassette vector and verification of the 
final construct by restriction digest are shown in figure 4.13. The sequence of the 
TCR (3 chain V-J segment in the final construct was also verified by sequencing prior 
to preparation for pronuclear injection. Bacterial sequences were removed from the 
vector prior to pronuclear injection by digestion of the construct with Kpnl and 
purification of the upper 17,700 bp band (figure 4.13). A plasmid map of the complete 
Th2 TCR (3 chain construct is shown in appendix 12. 
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Figure 4.12 A schematic diagram showing the cloning strategy used to create the 
Th2 13 chain construct. (a) Genomic DNA from the Th2 a transgenic cell line was 
used to isolate the required VB31/JB2-3 fragment containing the appropriate intronic 
regions for correct transcript processing. PCR primers (VB31F and VJ2-3R) were 
used to introduce Xho I and Sac II restriction sites to the 5' and 3' ends of the VJ 
fragment respectively. (b) The Th2 p VJ fragment was then inserted into the pTp 
cassette vector by directional cloning using Xho I and Sac II. (c) Bacterial sequences 
were removed from the vector, by digestion with Kpn I, prior to pronuclear injection. 
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Figure 4.13 Cloning of the rearranged Th2 TCR f chain into the TCR 13 
expression cassette. (a) The rearranged configuration of the Th2 TCR p chain was 
cloned from T cell line genomic DNA by PCR. The cloned VJ fragment was 
sequenced and then inserted into the TCR (3 expression cassette using restriction 
enzymes XhoI and SacII. (b) Prior to digestion and purification for pronuclear 
injection, the complete construct was checked by restriction digest to ensure that no 
rearrangement of the plasmid had occurred during cloning. (c) Bacterial sequences 
were removed from the construct before injection by digestion with KpnI and 
purification of the upper 17,000 bp band. 
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4.5. Identification of a Th2 TCR fl chain transgenic founder animal 
The Th2 TCR (3 chain transgene was injected into C57BL/6 oocytes at the MRC 
Clinical Sciences Centre of Imperial College, London. 20 potential founder animals 
were screened for the presence of the Th2 TCR (3 chain transgene. An initial PCR 
screen, using genomic DNA extracted from a tail biopsy, identified 1 founder animal 
(figure 4.14). This founder was subsequently referred to as Th2 TCR [3 line 4 based 
on the number assigned to the animal at the point of tail biopsy. Technical difficulties 
with the technique have meant that, so far, the transgenic status of this animal has not 
been confirmed by Southern blot. 
The founder animal (Th2 TCR [3 line 4) was male. Th2 TCR a chain line 20 
transgenic females were therefore used as breeding partners to obtain the next 
generation of this line, which may be transgenic for both a and p chains of the Th2 
TCR. Normal rates of germline transmission of the Th2 TCR a chain were observed 
in the progeny of this mating. However, transmission of the Th2 TCR p chain 
transgene was very poor. Of 54 progeny screened by PCR for the Th2 TCR a and p 
chain transgenes, 27 animals carried the a chain compared to just 3 carrying the p 
chain. 2 mice carrying both transgenes have now been set up as the next generation 
breeding pair for this transgenic line, but the small number of Th2 TCR (3 chain 
positive animals identified means that experiments to characterise these animals are 
not reported here as they are not within the timecourse of this thesis. 
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Figure 4.14 Identification of the Th2 TCR 13 chain transgenic founder animal. 
The transgenic founder was identified by PCR. The location of primers used for PCR 
screening (20TCR13F1 and 20TCR(3R1) are shown in (a). One transgenic animal was 
identified from an initial PCR screen of 20 potential founders. 
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4.6 Analysis of a PLP (56-70) specific Thl TCR a chain transgenic T cell line. 
To determine whether rapid clonal expansion of a TCR p chain would also occur in T 
cell lines derived from Thl TCR a chain animals, T cell lines were established from 
PLP 56-70 primed draining lymph nodes of these mice. As described for the Th2 TCR 
a chain transgenic lines, T cells were grown in vitro in growth medium containing 
10U/m1 IL-2 by restimulation with peptide and NOD.E splenocytes every 9-11 days. 
Proliferation in response to antigen, and cytokine phenotype, were determined at 
successive restimulations. Figure 4.15 shows that over 6 restimulations the Thl TCR 
a chain transgenic line was highly antigen specific and displayed a predominantly Thl 
type phenotype, producing high levels of IFN-y. Sequence analysis of TCR (3 chain 
usage at the 6th restimulation showed a small clonal expansion, comprising 26% of the 
repertoire. However, sequence analysis of TCR a usage by this line failed to identify 
the transgenic Thl TCR a chain (figure 4.15). A PCR for the rearranged Thl TCR a 
chain in cDNA from the line at the 6th restimulation suggested that the transgenic a 
chain was being expressed by this line. However, sequence data suggests that T cells 
bearing this transgenic a chain are not present at any significant level and are not 
likely to be pairing with the expanding TCR p chain. This finding is consistent with 
the low level of expression of the Thl TCR a chain transgene found in unprimed 
splenocytes of this TCR transgenic line (table 3.6). Further T cell lines derived from 
Thl TCR a chain transgenic animals are currently being characterised. 
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TA clone TRBVCDR313 amino acid sequence TRBJ CDR3  length 
6°Thl 
6°Thl 
1311 
1311 
13-1 CASSDAPGQGAGNTLYF 1-3 15 TA clone TRAY CDR3a amino acid sequence TRAJ CDR3length 
6°Thl B2( 
6°Thl B24 
6thThl Al 3-3 CAVTNTNAYKVIF 30 11 6"Thl 1321 
6thThl Al( 6°Thl B1( CASSDLGTAGNTLYF 13 
6thThl A21 6°Thl 131. 
6thTh1A22 6°Thl B2 CASSEPGTGRSGNTLYF 15 
6thThlA2 4D-3 CAAPSGSFNKLTF 4 6°Thl 134 2 CASSQEGWGAWEQYF 2-7 13 
6thThIA6 6°Thl Blf CASSQDGGGAYEQYF 13 
6thThIA17 6°Thl B3 CASSQVDRPYEQYF 12 
6thThlAl9 CAAMNYNQGKLIF 23 6°Thl B8 CASSQEGTGGYAEQFF 2-I 14 
6thTh1 A20 6°Thl B21 19 CASSILGGHTGQLYF 2-2 13 
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Figure 4.15 Analysis of a Thl TCR a transgenic derived T cell line. A T cell line 
was established from PLP 56-70 primed draining lymph nodes of Thl TCR a 
transgenic animals. The T cell line was restimulated every 9-11 days with peptide 
(PLP 56-70) and NOD.E splenocytes. At each restimulation a proliferation assay was 
performed with multiple doses of antigen and supernatants harvested for cytokine 
analysis by ELISA (a). RNA was also extracted at each restimulation and TCR alpha 
chain (b) and beta chain (c) usage at the 6th restimulation determined by PCR. 
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4.7. Altered cytokine phenotype of an in vivo memory response to antigen in Th2 TCR 
a chain transgenic animals. 
The Th2 TCR a chain transgenic T cell lines described in this chapter were grown in 
vitro in growth medium containing 10 U/ml IL-2. This growth medium should be 
non-polarising (i.e. should not promote a Thl or Th2 phenotype bias). Not all Th2 
TCR a chain transgenic cell lines grown in vitro during the course of this study 
developed a Th2 type phenotype, or indeed demonstrated a rapid TCR clonal 
expansion. However, the expansions and Th2 type phenotype of the 2 lines described 
here, which were derived from different transgenic lines, are quite striking and quite 
surprising given the lack of any exogenous polarising cytokines in the growth 
medium. The implication is that expression of the Th2 TCR a chain can, in the 
context of specificity to antigen (PLP 56-70) predispose to selection of a TCR 1 chain 
pair, which can then bias the T cell response towards a Th2 phenotype. A peptide 
priming experiment was therefore designed to test whether the same bias, observed so 
far in an in vitro system, could also be observed in vivo. Figure 4.16 outlines the 
experimental protocol. Mice were primed with 50 [ig of peptide (PLP 56-70), which 
was administered in the footpad as an emulsion with CFA. Mice were then re-primed 
in the flank with the same dose on day 28. Splenocytes were harvested from groups of 
animals (4 transgenics and 4 littermates) at each time point shown in figure 4.16. At 
each time point, proliferation in response to antigen and cytokine phenotype were 
determined. The proliferative response of splenocytes to peptide (PLP 56-70) at each 
time point was similar between transgenic and littermate groups and demonstrated a 
good memory response to antigen (figure 4.16). At day 10 there was no major 
difference in IFN-y production between transgenics and littermates. However at days 
28 and 32 animals in the transgenic group produced very little, or no IFN-y in response 
to antigen. At day 28 the difference in IFN-y production between the transgenic and 
littermate groups was statistically significant. This was not the case at day 32, but 
animal numbers in groups were small and the difference is still apparent. Neither 
group produced IFN-y in any significant amount at day 38. No splenocytes produced 
IL-4 or IL-5 at any time point of this experiment. From this data it appears that the in 
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vivo memory response to antigen in Th2 TCR a chain transgenic animals is shifted to 
a less Thl type profile than for littermate animals, but that this shift does not extend to 
appearance of a Th2 type profile. 
CDR3 spectratype analysis of TCR l chain usage in splenocyte samples from days 28 
and 32 of this experiment was used to try to determine whether any clonal expansions 
had occurred. Figure 4.17 shows that for a few TRBV genes there was some evidence 
of possible clonal expansions in Th2 TCR a chain transgenic compared to littermate 
samples. These clonal expansions are suggested by the presence of a dominant peak 
in the spectra for these TRBV genes, where the dominant peak comprises greater than 
35% of the total area. However, sequence analysis of TCR 13 chains in these 
splenocytes samples failed to find any evidence of these expansions (figure 4.17). 
Although the spectra for some TRBV genes show the emergence of a dominant peak, 
this does not mean that this expansion within a particular TRBV gene family equates 
to an expansion in the context of all TRBV genes being used in that splenocytes 
sample. To detect these expansions it may be necessary to just sequence TCR 1 
chains using the TRBV gene in question. A further complication is the problem of 
using a whole splenocyte cDNA sample to detect a peptide specific clonal expansion. 
The memory T cells in the spleens of these animals will have many different 
specificities, and although the proliferation and cytokine data can be attributed to PLP 
56-70 specific T cells, the splenocyte sequence and CDR3 spectratype data cannot. 
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Figure 4.16 An in vivo memory response to peptide demonstrates a difference in 
cytokine profile between Th2 TCR a chain transgenic and littermate animals. (a) 
Mice were primed with a peptide (PLP 56-70) / CFA emulsion on day 0 and day 28. 
Splenocytes were harvested at days 10, 28, 32 and 38 and proliferation assays 
performed with multiple doses of antigen. After 48 hours of culture, supernatants 
were harvested and wells pulsed with [3H] thymidine to determine proliferation. (b) 
Proliferation of splenocytes to 50 µg/m1 of peptide from Th2 TCR a chain transgenic 
(grey bars) and littermate (black bars) animals at each time point are shown. Data 
shown are mean values (minus background) for the 4 animals in each group + SE (c) 
Levels of IFN-y in supernatants from cells cultured with 50 µg/m1 of peptide were 
quantitated by ELISA. Data shown are mean values for the 4 animals in each group ± 
SE. The statistical significance of differences between transgenic (grey bars) and 
littermate (black bars) groups were tested using a Mann-Whitney U test. *P <0.05. 
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TA clone TRBV CDR3I3 amino acid sequence TRBJ CDR3 length 
34-196B2 13-2 CASGEQGGTGQLYF 2-2 12 
34-196 B4 
34-196 B5 CASGDTDWGDPNTGQLYF 16 
34-196B13 CASGDATGVYEQYF 2-7 12 
34-196B6 2 CASSQGLDYEQYF 11 
34-196 B8 CASSQELGPSAETLYF 2-3 14 
34-196B10 CASSQERRADTQYF 2-5 12 
34-196B15 CASSPQISNERLFF 1-4 
34-196B21 CASSQVRGRRGNTLYF 2-4 14 
34-196B3 13-1 CASRDSSNERLFF 1-4 11 
34-196B14 CASSDDRTGQLYF 2-2 
34-196B17 CASSPGETLYF 2-3 9 
34-196B19 CASSGNWEQDTQYF 2-5 12 
34-196B11 5 CASSRDWGYAEQFF 2-1 
34-196B18 CASSRRDWGYEQYF 2-7 
34-196 B7 17 CASSPGTGGDTQYF 2-5 
34-196B12 20 CGARDRKNTGQLYF 2-2 
Figure 4.17 TCR analysis of splenocytes from Th2 TCR a transgenic and 
littermate animals at day 32 after priming. (a) Spectratype analysis using 
splenocyte cDNA obtained from animals at day 32 of the in vivo priming protocol 
(figure 4.16) showed some evidence of possible clonal expansions for some TRBV 
genes in Th2 TCR a chain transgenic compared to littermate samples. However, these 
expansions were not apparent when TCR (3 chains were sequenced from these samples 
(b). 
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Discussion 
A previous study demonstrated that CD4+ T cells selected under Th2 polarising 
conditions favoured an elongated CDR3a region and that this longer CDR loop may 
result in less optimal (lower affinity) interactions with the pMHC complex (Boyton et 
al., 2002). This finding led to the hypothesis that, under Th 1 or Th2 polarising 
conditions, different TCR structural motifs are preferred, and that if TCRs bearing 
these motifs were to be expressed transgenically, an inherent Thl or Th2 bias in T cell 
phenotype would be observed. The previous chapter of this thesis described the 
identification of TCR a chains for transgenic expression, and the generation of 
animals expressing these chains on peripheral T cells. Data presented in this chapter 
has described analysis of the TCR p chain repertoire of these animals and experiments 
to try to determine an antigen specific TCR (3 chain partner, as well as any phenotype 
bias that may result from expression of structurally distinct Thl and Th2 derived TCR 
a chains. 
As antigen specific TCR (3 chain partners for the dominant a chains had not been 
identified, TCR transgenic animals, described in chapter 3, were expressing the Thl or 
Th2 TCR a chain only. To exit the thymus as a mature T cell, positive selection 
events dictate that the cell must be expressing an a13 heterodimer at the cell surface 
(Mombaerts et al., 1992b). Cells expressing the transgenic TCR a chain in the 
periphery must, therefore, be pairing with endogenous TCR p chains. To determine 
whether expression of the Th2 TCR a chain during T cell development had any impact 
on the peripheral repertoire of TCR (3 chains, in the absence of peptide specificity, 
sequence analysis and spectratype analysis were employed to look at TCR usage in 
splenocytes. TCR a chain transgenics made by other groups have previously been 
reported to show normal V(3 usage in the periphery (Huang and Kanagawa, 2004) 
implying that these transgenic a chains are capable of pairing with a broad spectrum 
of endogenous 13 chains. In addition, other studies have implied that it is the CDR3a 
region rather than the CDR3(3 region that dictates TCR repertoire diversity in the 
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recognition of foreign antigens and the formation of the preimmune TCR repertoire 
(Yokosuka et al., 2002). In the study by Yokosuka et al, an in vitro transfection 
system was used to analyse hundreds of potential ap heterodimers for their ability to 
recognise foreign antigen. It was found that for a given antigen, very few a chains 
were permissible, but that any one particular a chain could use a wide variety of TCR 
13 chains to achieve peptide specificity. Consistent with these findings, no particular 
bias in VP repertoire, either in terms of the V[3 genes used, or the CDR3f3 region 
lengths observed, were seen in either Th2 TCR a chain transgenic line by sequence 
analysis or by spectratyping. The VP gene families identified by sequencing were 
similar between littermate animals and transgenics and the CDR313 lengths were also 
comparable. No obvious bias in the amino acids used in the CDR3P regions were seen 
and spectra obtained for each VP family showed a normal Gaussian distribution, 
suggesting that no significant expansions of any one sequence were present. This 
analysis suggests that the transgenic Th2 TCR a chain is able to form stable a(3 
heterodimers with a wide variety of different endogenous P chains that bind self-
pMHC with sufficient affinity to be positively selected, although this data does not 
provide evidence that the diverse receptors are able to respond normally to a diverse 
array of foreign antigens. 
The concept of repertoire diversity, however, is not a straightforward one and is highly 
dependent upon the peptide antigen in question. For some peptide antigens, the TCR 
a chain has been seen to be highly restrictive in determining which TCR 13 chains are 
permissible (Turner et al., 1996). Therefore, although in the peripheral T cell 
repertoire of the Th2 TCR a chain transgenic mice a diverse array of TCR 
sequences are observed, this is in the context of many self pMHC having been 
presented in the thymus and the situation may be different in the context of specificity 
to single antigen. The antigen of interest in this study is the proteolipoprotein peptide 
PLP 56-70. The T cells from which the transgenic TCR a chains derive were highly 
specific for this peptide. In order to generate a peptide specific immune response, 
mice were primed with an emulsion of PLP 56-70 and CFA. However, sequence and 
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spectratype analysis of T cells in draining lymph nodes of these animals revealed a 
similar picture to that seen in unprimed mice, where many different TCR (3 chains 
from different gene families were identified and symmetrical spectratype profiles 
revealed no obvious clonal expansions within each V(3 gene family. V(3 gene usage 
and spectratype profiles were comparable between transgenic and littermate animals 
and it is also worth noting that proliferative responses of DLN cells to antigen in vitro 
were also similar between transgenics and non transgenics, indicating that T cells 
bearing the transgenic TCR a chain are able to form PLP peptide specific 
heterodimers with endogenous TCR (3 chains and mount an effective response to this 
antigen. 
Although no obvious TCR 13 chain bias was observed in DLN T cells of primed mice, 
it should be born in mind that in order to provoke an immune response to antigen, 
mice are primed with CFA. The ability of CFA to provoke an immune response is 
mediated by the mycobacterial components it contains and as such, although many T 
cells in the DLN will be specific for the peptide, others are also likely to be specific 
for these bacterial antigens. To look at TCR (3 chain usage in a population of truly 
peptide specific T cells, T cell lines derived from the DLN cells of PLP 56-70 primed 
mice were grown in vitro. This approach also allowed selection and change in the V13 
repertoire to be examined over successive restimulations with antigen. The data from 
two Th2 TCR a chain transgenic T cell lines were presented in this chapter. One line 
was derived from mouse line 20 and the other from mouse line 34. Both T cell lines 
demonstrated a clonal expansion of a dominant TCR (3 chain through successive 
peptide restimulations. The expansion was particularly rapid in the T cells derived 
from mouse line 20 where, by the 6th restimulation, 100% of TCR (3 sequences 
obtained were identical. Both transgenic T cell line expansions were in contrast to the 
absent or very limited expansions observed in a littermate derived T cell line. The 
marked rate of clonal expansion in the TCR a chain transgenic T cell lines could also 
be observed from spectratype profiles of selected V13 families. Small quantities of 
cDNA available from each line at each restimulation meant that a full spectratype 
analysis across all V(3 gene families was not possible. However, using V(3 families 
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known from sequence analysis to be present in the repertoire at very early 
restimulations, spectra reveal that even as early as the 2nd restimulation, the diversity 
of the V13 repertoire in the littermate derived T cell line is far greater than that seen for 
the TCR a chain transgenic line. This data suggests that, in the context of specificity 
to the cognate antigen PLP 56-70, the diversity of the TCR p chain repertoire is 
limited by the expression of the transgenic Th2 TCR a chain. 
The dominant TCR (3 chain sequences selected in the two transgenic lines presented 
here are not the same. They use different V[3 genes, have different CDR3(3 regions 
and indeed have different CDR3 (3 region lengths. Therefore, although influencing 
TCR (3 chain diversity, the transgenic TCR a chain appears not to mediate selection of 
a common, or "public" TCR (3 sequence. A "public" TCR sequence is one that is 
identified as common between different individuals and is probably the least common 
type of TCR bias. One of the most well studied public TCRs is LC13, a human TCR 
specific for an antigen of the Epstein-Barr virus (EBV) (Argaet et al., 1994). In many 
individuals, CD8+ T cells recognising this antigen use the same TRAV26-2/TRBV 7-6 
TCR with identical CDR3 regions. The sequence of this TCR is not the only one able 
to recognise antigen, as individuals expressing the MHC class I molecule HLA-
B*4402 are found to use other receptors different from LC13 (Burrows et al., 1995), 
but structural studies of this TCR have revealed exquisite complimentarity between 
the antigen and peptide binding pockets formed by CDR loops of the TCR (Kjer-
Nielsen et al., 2003). However, aside from complete sequence homology, other forms 
of public TCR bias have also been documented. Some studies document preference of 
particular V(3 genes, for example, the use of V(38 and V(37 genes in murine responses 
to different antigens of the influenza virus (Belz et al., 2000). Others have reported 
the selection of conserved amino acid sequences within CDR3 regions (Trautmann et 
al., 2005). When reviewing the large numbers of TCR (3 sequences obtained during 
the course of this thesis, it is of note that one amino acid motif in the CDR3 region is 
particularly common in the context of antigen specific T cells. Sequences containing 
the amino acid motif, SRDWG, in the CDR3(3 region were observed in both of the 
original Thl and Th2 T cell lines from which the transgenic TCR a chains were 
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cloned. This motif was then also sequenced in peptide specific lines from littermate 
animals and indeed is part of the CDR3I3 region most dominant in this line following 6 
restimulations with peptide. The motif becomes even more common if seen as 
SXDWG although this motif was also isolated from T cells of unprimed mice. The 
SRDWG motif in the CDR3(3 region of a TCR may therefore be predicted to make 
some important contribution towards pMHC recognition to account for this bias, 
although it was not observed in either of the TCR p chains seen to rapidly clonally 
expand in the Th2 TCR a chain transgenic lines. The contributions that the CDR3a 
and CDR3p regions of a TCR make to peptide recognition are known to be dependent 
upon the peptide being recognised and to involve different residues of the peptide. In 
a study by Jorgensen et al. (Jorgensen et al., 1992) mice transgenic for either an a or a 
p chain were immunised to peptide variants in order to determine the relative 
contribution of each chain to the binding of specific residues. This study found that 
the a and p chains contact independent parts of the peptide and so that preferred 
motifs are observed in one chain in conjunction with more heterogeneity in the other is 
not an unexpected finding. 
One of the main aims of this study was to explore the possibility that the transgenic 
expression of structurally distinct Thl and Th2 TCRs results in an inherent Thl or Th2 
bias in T cell phenotype. Transgenic expression of peptide specific Thl and Th2 TCR 
heterodimers has not yet been achieved to permit the ultimate test of this hypothesis, 
but, as discussed in chapter 3, the dominance of the Thl and Th2 TCR a chains in the 
original T cell lines, in the absence concomitant TCR (3 expansion, raises interesting 
questions about the role of the TCR a chain alone. Cytokine production by the 
antigen specific Th2 TCR a chain transgenic and littermate T cell lines was therefore 
determined. As expected, particularly from T cells originally primed using CFA, the 
dominant cytokine produced by the littermate derived T cell line was IFN-y. This was 
in stark contrast to the cytokine profile of both Th2 TCR a chain transgenic lines, 
where high levels of the Th2 cytokines, IL-4 and IL-5 were observed. Production of 
these cytokines was seen to increase through progressive restimulations with cytokine 
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and indeed this phenotype was stable, with the line 20 derived T cells producing 
significant amounts of IL-4 and IL-5, although also a small amount of IFN-y, after 15 
restimulations. At 15 restimulations, the littermate derived T cell line was still 
producing only IFN-y. That T cells expressing the transgenic Th2 TCR a chain had 
spontaneously acquired a Th2 like phenotype was further supported by real time PCR 
data of Tbet and GATA3 transcription factor expression. The enormous number of 
variables involved in CD4+ T cell differentiation can make the relative contribution of 
individual factors hard to assess. However, in this system, transgenic and littermate 
mice were primed identically and T cells restimulated at identical time points using the 
same APCs and the same dose of peptide. Additionally, data presented in chapter 3 
demonstrated that levels of TCR heterodimers on the surface of peripheral T cells were 
similar between transgenic and littermate animals. T cells were cultured in the 
absence of any polarising cytokines, with only a low dose of IL-2 added to the culture 
medium and so as far as possible, the only differences between the T cells present in 
the different lines are the TCR a chains that they express. 
This cytokine and real-time PCR data, while convincing in its demonstration of a Th2 
phenotype, is derived from T cell lines grown over a long period of time in vitro. In 
vitro studies will always be open to criticism surrounding the role of a particular 
variable in normal physiological conditions where interactions and signals are more 
complex. More convincing would be a demonstration of phenotype differences 
between Th2 TCR a chain transgenic and littermate animals in vivo. To begin to 
address this, data presented in this chapter described reduced IFN-y production by 
immediately ex vivo T cells bearing the transgenic TCR a chain, in an experiment 
designed to investigate the consequences of antigen restimulation in vivo. This data 
suggests that, similar to results obtained from in vitro culture, successive restimulation 
of transgenic T cells with antigen results in an altered cytokine phenotype, with 
respect to littermate animals, with a shift away from a Thl phenotype and IFN-y 
production. No Th2 type cytokines were detectable in the immediately ex vivo 
responses of transgenic T cells seen to be making less IFN-y, but given the Th 1 
promoting environment of CFA immunisation, this is perhaps not surprising. It may 
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be that in these animals, spontaneous induction of a Th2 type phenotype will not occur 
in vivo but rather T cell phenotype bias will manifest as a shift away from a polarised 
Thl phenotype as the outcome. If this is the case, it may be of interest to determine 
whether this inherent bias will have any impact in the context of an IFN-y driven 
disease model, such as EAE. In a previously study, Thl T cell responses to the 
antigen PLP 56-70 were associated with susceptibility disease, while deviation away 
from Thl cytokine responses were associated with protection (Takacs et al., 1995). 
Data presented in this chapter appears to support a role for the TCR a chain in 
determining CD4+ T cell phenotype and when put back into context with the original 
study (Boyton et al., 2002), where molecular modelling predicted that elongated 
CDR3a regions of Th2 TCR a chains would make lower affinity interactions with the 
pMHC complex, fits with other data suggesting that lower affinity TCR/pMHC 
interactions favour Th2 type responses (Malherbe et al., 2000) and that interventions 
that impede optimal TCR/pMHC binding, such as the use of APLs, can result in a 
switch in T cell phenotype from Thl to Th2 (Nicholson et al., 1995). Altered 
signalling through the TCR, as explained by the serial triggering hypothesis previously 
discussed, remains the most likely explanation for the link between TCR structure / 
affinity and effector outcome. A model where the elongated CDR3a loops of the 
transgenic Th2 TCR a chain forces a lower affinity interaction with the pMHC 
regardless of the TCR p chain sequence, although where only a limited number of 13 
chains can functionally pair to give good antigen specificity, would suggest that this 
lower affinity interaction then results in suboptimal signalling, and an altered pattern 
of phosphorylation events downstream of the TCR which ultimately result in 
preferential induction of Th2 differentiation pathways. 	Altered patterns of 
phosphorylation signalling molecules, for example ZAP70 and Lck, have been 
observed upon TCR ligation with APLs (Boutin et al., 1997) and more prolonged 
signalling, perhaps via a higher affinity interaction, has been shown to be required for 
full mitogen-activated protein kinase (MAPK) activation and Thl differentiation 
(Badou et al., 2001). More recent data looking at thymic selection, another T cell 
signalling scenario where the affinity of the TCR/pMHC interaction is proposed to 
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play a major role in dictating the outcome of TCR signalling, has shown that the 
signalling proteins Ras and MAPK are segregated into different subcellular regions 
depending on the affinity of the TCR/ligand interaction (Daniels et al., 2006). 
Efforts to identify whether any bias in the TCR [3 chain repertoire had occurred during 
antigen restimulation in vivo were limited and the experimental system not sensitive 
enough to detect this. Although spectratype analysis appeared to show some evidence 
of clonal expansions this was not supported by sequencing data. However, sequencing 
data was obtained from whole splenocytes and so is highly unlikely to reflect the 
antigen specific TCR repertoire. Further experiments are currently underway to try to 
select antigen specific T cells from the spleen following antigen restimulation. The 
ideal way to achieve this would be through the use of pMHC tetramers, although 
selecting T cells activated in response to peptide presentation on the basis of activation 
markers such as CD69, may also be of use. The ultimate test for the role of TCR 
structure in CD4+ T cell phenotype bias will be to look at the T cell responses of Thl 
and Th2 TCR ar3 transgenic animals, which have been crossed onto a RAG"'" 
background and thus do not express any endogenous TCR. The Th2 phenotype of the 
antigen specific transgenic T cell lines described in this chapter and the concomitant 
clonal expansion of TCR p chains observed through successive restimulation makes 
these TCR 13 chains good candidates for transgenic expression. The construction of a 
transgene for one of these chains and identification of a founder animal were described 
in this chapter and a programme of breeding is currently ongoing to generate mice 
carrying both the Th2 TCR a and I chains. 
Chronologically, the two independent lines of Th2 TCR a chain mice were established 
before the Thl TCR a chain transgenic line and as such, much of the data obtained to 
date refers to the Th2 TCR a chain animals. However, expression data presented in 
the previous chapter and towards the end of this chapter highlight potential pitfalls in 
the analysis of the Thl TCR a chain line. Sequence analyses of TCR sequences from 
peripheral T cells of Thl TCR animals were presented in the previous chapter and 
showed that less than 50% of sequences obtained were derived from the transgene. 
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Percentages were also highly variable between animals and in one sample, transgenic 
sequences made up less than 10% of the repertoire. To examine whether the 
transgenic a chain may be more favoured and thus become more dominant in the 
context of antigen specificity, mice were primed with antigen (PLP 56-70) and T cell 
lines derived from the primed draining lymph nodes (DLNs) of these animals grown in 
vitro. This was also with the view to identifying an antigen specific TCR (3 chain 
partner for this Thl TCR a chain. However, following 6 restimulations with antigen, 
TCR sequence analysis revealed a complete lack of transgenic TCR a chains in the 
line. This finding has now been reproduced for 4 separate Thl TCR a chain 
transgenic derived T cell lines and suggests that in the context of antigen specificity, 
the transgenic TCR a chain is highly disfavoured in preference for endogenous chains. 
The reason for this bias is unclear and needs further investigation. From previous 
studies it has been predicted that Th 1 TCRs bind pMHC with high affinity (Malherbe 
et al., 2000). Given that high affinity TCRs show a preference for expansion during 
immune responses (Busch and Pamer, 1999), why would a TCR a chain from a high 
affinity receptor be disfavoured in responses to its cognate antigen? One possibility is 
that the answer may lie in the relationship between the polarising environment and 
costimulation. The T cell line from which the TCR a chain was originally identified 
was a short term T cell line, grown in vitro under highly Thl polarising conditions 
(Boyton et al., 2002) i.e. high levels of the Thl polarising cytokine IL-12, and an anti-
IL-4 monoclonal antibody (mAb) were present in the culture medium. Cytokines 
secreted during the course of an immune response, whether particularly polarising or 
not, will influence expression of costimulatory molecules (Creery et al., 1996) and 
whether through modulating the avidity of the T cell-APC interaction, or through 
signalling, costimulatory molecules can have an enormous impact on the outcome of T 
cell activation (Graf et al., 2007). It may be that under non-polarising conditions, such 
as those used in this study where only a low concentration of IL-2 was added to the 
culture medium, conditions of costimulation are such that high affinity interactions are 
disfavoured e.g. by increasing the dwell time of the TCR/pMHC complex such that 
rates of TCR signalling and T cell activation are suboptimal (Kalergis et al., 2001). 
Under these conditions, T cells bearing TCRs with lower affinity endogenous TCR a 
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chains may proliferate faster and consequently become dominant. To circumvent the 
problem of endogenous TCR a chain expansion, Thl TCR a chain animals could be 
crossed with animals carrying a disrupted TCR a chain locus. These animals would 
not express any endogenous TCR a chains and so questions of selection, 
costimulatory requirements and phenotype bias could more easily be addressed. 
Alternatively, it would be of interest to grow transgenic T cell lines in the same highly 
polarising culture medium used to grow the short term Thl cell line in the first place, 
to determine whether the transgenic TCR a chain is more favoured under these 
conditions. 
With data presented in this chapter serving to confirm the hypothesis that TCR 
structure can influence T cell phenotype, also of interest is whether TCR transgenic 
mice could be used to develop models of Th 1 and Th2 mediated disease. The lung is 
one site at which populations of polarised Thl and Th2 T cells are found associated 
with disease pathology and the following chapter describes the generation of a novel 
model, using lung targeted expression of the antigen PLP 56-70, which could be 
combined with the TCR transgenics discussed in this chapter to create new models of 
Thl and Th2 mediated lung disease. 
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Chapter 5  
Generation of transgenic lines for inducible, lung targeted, antigen  
expression.  
Results 
5.1 Design and construction of transgenes for inducible, lung targeted, expression of 
the antigen PLP56-70. 
The antigen PLP 56-70 is the peptide epitope for which the Thl and Th2 TCRs, 
described in chapter 3, are specific. 	One long-term aim is to use these TCR 
transgenic lines to study inflammatory responses in the lung, by expressing antigen 
(PLP56-70) in a tissue specific and inducible manner. The inducible system chosen 
for this study is the Cre/Lox system (figure 1.5). Figure 5.1 outlines the overall 
expression strategy. 
In an uninduced animal, expression of the peptide is prevented by the presence of a 
stop sequence in the transgene. The stop sequence is flanked by two loxP sites and 
was first described by Lakso et al. (1992) as a way of temporally controlling oncogene 
expression in mice. Transgenic mice were generated that carried a transgene 
containing the simian virus 40 large tumor antigen gene driven by a murine lens 
specific promoter but where the tumor antigen gene was separated from the promoter 
by a floxed stop sequence. These mice showed no sign of tumor development, but 
when crossed with another transgenic line carrying the Cre recombinase protein under 
the control of the same lens specific promoter, Cre mediated deletion of the stop 
sequence resulted in all double transgenic offspring developing lens tumors (Lakso et 
al., 1992). The stop sequence comprises the 550 bp C-terminal sequence of the yeast 
His3 gene, 823 bp of the SV40 polyadenylation signal region and a DNA 
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oligonucleotide that contains a false translational initiation signal. The sequence was 
kindly supplied by Brian Sauer for use in this study. 
Upon administration of the drug tamoxifen the bacteriophage enzyme Cre 
recombinase excises the stop sequence by catalysing recombination between the two 
flanking loxP sites. This allows expression of the peptide, driven by the lung specific 
promoter CC10. The vector used for this strategy means that the peptide will be 
expressed within the protein Hen Egg Lysozyme (HEL). Antigen processing within 
APCs will cleave the HEL protein to yield the peptide PLP 56-70 which can then be 
presented in the context of the MHC class II molecule I-Age. Correct expression of the 
HEL/PLP fusion protein is aided by the presence of rabbit 13 globin intronic and PolyA 
sequence at the 5' and 3' ends of the coding region respectively. This HEL expression 
cassette has been used successfully by Vowles et al. (Vowles et al., 2000) to express a 
peptide of Myelin Basic Protein (MBP 84-105). In that study they showed that the 
HEL/MBP fusion protein could be expressed as a secreted or membrane bound 
protein, depending on whether the membrane domain of the influenza virus A 
hemagglutinin protein (HA) was present at the C terminus of the coding region and 
that, particularly in the case of the membrane bound version of the protein, transgenic 
expression resulted in resistance of these mice to EAE induction using the MBP 
peptide. It is not known whether membrane bound or secreted forms of the HEL/PLP 
protein will result in the PLP peptide being processed and presented most efficiently 
and so both membrane bound and secreted forms of the expression cassette were 
kindly supplied by Helen Bodmer for use in this study. 
Several different promoters have been used to target transgene expression to the lung. 
The three most common are CC10, K18 and SP-C. The promoter of pulmonary 
surfactant protein C (SP-C) drives lung specific expression in mature alveolar type II 
cells (Glasser et al., 2000) with little or no expression observed in more proximal 
bronchiolar structures. Conversely, CC10 and K18 promoters direct transgene 
expression to the trachea and all levels of the bronchial tree with no expression 
observed in alveoli (Stripp et al., 1992 and Chow et al., 1997). As many chronic lung 
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diseases affect larger airway structures, the CC10 promoter was selected for this study. 
It is well characterised and has been more widely used than the K18 promoter, for 
example in targeting expression of the Th2 type cytokines IL-4 and IL-13 to the mouse 
lung in order to study the role of these cytokines in Th2 type lung inflammation 
(Zheng et al., 2000 and Rankin et al., 1996). The DNA sequence of the CC10 
promoter used for this study is derived from rat. This DNA sequence was 
characterised as the genetic element responsible for cell specific regulation of the 
CC10 gene by linking stretches of DNA sequence upstream of the CC10 coding region 
to a reporter gene and transfecting a lung cell line in vitro. Transgenic mice carrying a 
transgene containing this regulatory sequence and the reporter gene were then 
generated and lung specific expression using this promoter was confirmed (Stripp et 
al., 1992). The DNA sequence used in this study was kindly supplied by Jeffrey 
Whitsett. 
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Figure 5.1 The strategy for inducible, lung specific, expression of antigen PLP 
(56-70). Lung specific expression is achieved using the clara cell specific promoter, 
CC10. Clara cells are found only in the bronchi and bronchioles of the lung. The 
peptide PLP (56-70) is expressed within the protein Hen egg lysozyme (HEL), and 
correct mRNA processing is achieved using intronic and poly A sequence from rabbit 
p globin. 2 constructs were created. One construct contains a transmembrane anchor 
sequence and results in the expression of membrane bound HEL/PLP (56-70). In the 
construct not containing this anchor the HEL/PLP protein is secreted. (a) In an 
uninduced animal, expression of HEL and PLP (56-70) is prevented by the presence of 
a translational stop sequence flanked by 2 loxP sites. (b) On administration of 
tamoxifen, Cre recombinase previously sequestered in the cytoplasm (figure 1.5) 
moves to the nucleus and excises the stop sequence by recombination between the two 
loxP sites. Expression of HEL and PLP (56-70) is therefore induced only on 
administration of tamoxifen and only in clara cells of the lung. 
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(b) loxP 
The expression strategy outlined in figure 5.1 depends upon both the Cre recombinase 
and the CC10 promoter being active within the same cell. The strain of MerCreMer 
transgenic mouse available in our laboratory ((3m70) (created by L. Bugeon and M. 
Dallman) expresses the MerCreMer protein under the control of the chicken 13 actin 
promoter. The MerCreMer protein expressed in these animals is known to be 
functional (unpublished data), but expression in the lung is not characterised. In an 
uninduced mouse the MerCreMer protein should be present diffusely in the cell 
cytoplasm. On administration of tamoxifen the Cre protein translocates to the cell 
nucleus where it should be detectable by immunohistochemistry. Inflated lung 
sections from uninduced and tamoxifen induced (3m70 mice were stained with an 
antibody specific for the Cre protein (figure 5.2). No specific staining was observed in 
the uninduced mouse, but widespread nuclear staining can be seen upon induction 
with tamoxifen. Not all cells are positive for nuclear localised Cre protein, but some 
staining was observed in all structures of the lung. An antibody specific for the CC10 
protein was also used (figure 5.2). As expected, staining was only observed in the 
bronchiolar structures of the lung. Staining of the CC10 protein was the same in 
uninduced and induced animals indicating that the activity of the CC10 promoter is 
unaffected by the tamoxifen induction protocol. 
Although, from the biotin based immunohistochemistry shown in figure 5.2, the 
nuclear Cre protein appears to be present in CC10 positive bronchiolar structures of 
the lung, it was important to establish that both proteins were present within exactly 
the same cell. Inflated lung sections from induced animals were therefore stained with 
Cre and CC10 specific antibodies at the same time, and co-localisation of these 
proteins visualised using fluorescently labelled secondary antibodies (figure 5.3). The 
data shows that some, but not all, CC10 positive cells also contained nuclear localised 
Cre protein and that activity of the CC10 promoter was unaffected by the presence of 
the Cre protein within the nucleus. Excision of the stop sequence in the transgene and 
expression of PLP 56-70 in the lung should therefore be possible using the (3m70 
transgenic line. 
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Figure 5.2 	The localisation of Cre and CC10 proteins in uninduced and 
tamoxifen induced lung sections from iii m70 MerCreMer mice. Mice were 
induced with tamoxifen i.p. for 5 days prior to harvesting of the lung. The binding of 
primary antibodies specific for Cre and CC10 proteins was visualised using biotin 
labelled secondary antibodies. (a) CC10 staining is confined to the bronchi and 
bronchiole structures of the lung and expression of the CC10 protein is not affected by 
the tamoxifen induction protocol. (b) No nuclear Cre staining can be seen in the 
uninduced lung, but on induction with tamoxifen, nuclear localised Cre is observed in 
both bronchiolar and alveolar structures of the lung. All photos are at x20 original 
magnification and the main structures of the lung are marked. 
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(a)  x40 magnification x20 magnification 
(b)  
(c)  
bronchi 
Figure 5.3 Co-localisation of Cre and CC10 in the lung of a tamoxifen induced 
13m70 MerCreMer mouse. (a) CC10 was visualised using a FITC labelled 
secondary antibody and is confined to the bronchi and bronchioles of the lung. (b) 
Cre was visualised using a TRITC labelled antibody and nuclear staining is observed 
in both alveolar and bronchiolar structures. (c) Co-localisation of CC10 and Cre 
stains shows that some but not all cells expressing CC10 also contain nuclear 
localised Cre protein. Photos are at x20 or x40 original magnification and main lung 
structures are marked. 
198 
The cloning strategies used to create the membrane bound and secreted versions of the 
inducible, lung targeted, PLP 56-70 constructs are shown in figure 5.4. A synthetic 
oligonucleotide sequence of PLP 56-70 was inserted into both the membrane and 
bound and secreted HEL expression cassettes by directional cloning, replacing the 
MBP peptide used previously in the constructs. PCR was used to confirm correct 
insertion of the PLP 56-70 oligonucleotide into both constructs and presence of the 
HA transmembrane domain in the membrane bound version of the transgene (figure 
5.5). To join the HEL expression cassettes to the floxed stop component it was 
necessary to introduce SfiI sites, by PCR, to the 5' and 3' ends of the rabbit 13 globin 
sequences. The SfiI PCR fragments and restriction digests used to confirm successful 
joining of HEL and stop sequence fragments are shown in figure 5.5. 
The final step in the assembly of each transgene was the joining of the lung specific 
CC1 0 promoter using NotI. The final sequence of each transgene was contained 
within the cloning vector pBluescript II. A PCR using primers specific for the CCI 0 
promoter and rabbit 13 globin sequence, and a XhoI restriction digest, demonstrate that 
the transgenes are complete (figure 5.6). Both transgenes were also verified by 
sequencing. Complete secreted and membrane bound, inducible, lung PLP constructs 
are subsequently referred to as SIPLP and MIPLP respectively. Full nucleotide 
sequences of membrane bound and secreted PLP transgenes are shown in appendices 
23 and 25. Coding nucleotide and amino acid sequences are shown in appendices 24 
and 26. 
Bacterial sequence was removed from the pBluescript II vectors, by digestion with 
BssHII, prior to pronuclear injection. The 6000 bp fragments of each transgene 
purified for injection are shown in figure 5.6. Final plasmid maps of the MIPLP and 
SIPLP constructs are shown in appendices 13 and 14 respectively. 
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Figure 5.4 A schematic diagram of the cloning strategy used to create the 
inducible, lung specific PLP (56-70) transgenes. (a) The peptide PLP (56-70) was 
introduced into the HEL expression cassette (Vowles et al., 2000) using Nan and 
SacII, replacing an MBP peptide used previously. (b) SfiI sites were introduced at 
either end of the HEL construct by PCR and SfiI then used to join this fragment to the 
floxed stop sequence (Lakso et al., 1992) (c). The lung specific promoter of CC10 
(Stripp et al., 1992), was joined using NotI (d). Bacterial sequences were removed 
from the vector by digestion with BssHII prior to pronuclear injection. 
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Figure 5.5 Assembly of the inducible, lung specific, membrane bound and 
secreted PLP (56-70) transgenes. (a) PCRs using primers specific to HEL and PLP 
(56-70) demonstrate successful introduction of this peptide into the HEL expression 
cassette. The presence of the transmembrane anchor is also demonstrated using a 
primer specific to this region. (b) PCR was used to introduce SfiI sites at either end of 
the PLP constructs and products are 1755 bp and 1888 bp for the secreted and 
membrane forms respectively. These products were TA cloned and then joined to the 
floxed stop sequence using SfiI. EcoRI digests demonstrate correct joining of these 
two fragments and also the presence of the transmembrane anchor, as EcoRI sites 
flank the HEL coding sequence (see appendices 13 and 14). HEL fragments are 548 
bp and 681 bp for secreted and membrane forms respectively. 
(b) 
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Figure 5.6 	Complete inducible, lung specific, PLP constructs (membrane 
[MIPLP] and secreted [SIPLP]) (a) A PCR using primers specific to the CC10 
promoter and rabbit 13 globin sequence demonstrates complete assembly of the 
construct. Products are 3239 bp and 3372 bp for the secreted and membrane 
constructs respectively. A XhoI digest also demonstrates that all components are 
present in the correct configuration. Fragments should be (3505 bp, 3006 bp, and 
2175 bp) or (3505 bp, 3006 bp and 2378 bp) for SIPLP and MIPLP respectively (see 
appendices 13 and 14). (b) Prior to pronuclear injection bacterial sequence was 
removed from each vector. This was achieved by digestion with BssHII and 
purification of the upper 6000 bp band. 
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bp 
5.2 Identification of an MIPLP transgenic founder animal. 
The MIPLP construct was injected into FVB/N oocytes at the Nuffield department of 
Medicine in Oxford. 24 potential founder animals were screened for the presence of 
the MIPLP transgene. An initial PCR screen, using genomic DNA extracted from a 
tail biopsy, identified 1 founder animal (figure 5.7). This animal is subsequently 
referred to as MIPLP line 11, based on a number assigned to the animal at the point of 
tail biopsy. Southern blot also confirmed the transgenic status of this animal (figure 
5.7). A single intense band seen on the Southern blot for this transgenic line suggests 
that multiple copies of the transgene have integrated at a single locus. The sequence 
and product sizes of all PCR and Southern primers used for screening of the MIPLP 
transgenic founder animal are shown in appendix 7. 
Prior to generation of the MIPLP transgenic line, Pm70 MerCreMer transgenic 
animals had been backcrossed for at least 3 generations onto a NOD.E genetic 
background. The MHC class II molecule I-Ag7 expressed by the NOD.E strain is 
required for presentation of the peptide PLP 56-70. These NOD.E backcrossed I3m70 
transgenic animals were used for subsequent breeding of MIPLP line 11. 
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Figure 5.7 	Identification of an MIPLP transgenic founder animal. The 
transgenic founder was identified by PCR and by Southern blot. The location of 
primers used for PCR screening (3rdexonF and BetaglobinB) and for generation of 
the Southern probe (CC101500F and CC102100R) are shown in (a). One transgenic 
animal was identified from an initial PCR screen of 24 potential founders (b). The 
transgenic status of this animal (number 11) was then confirmed by Southern blot (c). 
The restriction enzyme used to digest genomic DNA for Southern blotting was 
EcoRV. This enzyme only cuts the integrated construct once, on the 3' side of the 
CC10 promoter region being used as a probe (c), giving information about construct 
integration sites and copy number. 
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5.3 Determination of stop sequence excision and MIPLP transgene expression. 
Lung expression of the antigen PLP 56-70 requires that the stop sequence present in 
the transgene be removed. Cre recombinase is activated to excise the stop sequence 
following administration of the drug tamoxifen. Animals carrying both the MIPLP 
and Cre transgenes were identified. Following administration of tamoxifen, lung 
tissue was harvested, and a PCR strategy used to determine whether stop sequence 
excision had occurred (figure 5.8). A change in size of PCR product in tamoxifen 
induced animals carrying both the MIPLP and Cre transgenes demonstrated that 
removal of the stop sequence had occurred in the lung tissue of these animals and that 
the CC10 promoter and HEL expression cassette were subsequently juxtaposed. No 
stop sequence excision was observed in animals that had not received tamoxifen or in 
induced animals carrying the MIPLP transgene alone. PCR was also used to 
demonstrate expression of the HEL/PLP protein at the level of cDNA in lung tissue 
following tamoxifen induction (figure 5.8). To detect expression of the HEL/PLP 
transgene at the level of protein, immunohistochemistry of inflated lung sections from 
induced and uninduced animals using an anti-HEL antibody was attempted. However, 
no positive staining was observed (data not shown). 
Lung tissue was harvested from transgenic animals at different time points following 
tamoxifen induction. PCR demonstrates that removal of the stop sequence from the 
transgene does start to occur immediately following administration of tamoxifen, but 
takes many days to be removed from all copies in the lung (figure 5.9). 2 days after 
tamoxifen induction, many copies of the transgene still contain the stop sequence. No 
HEL/PLP protein was detectable in lung mRNA from these animals. Removal of the 
stop sequence from the transgene is irreversible. However, following clearance of 
tamoxifen from the circulation, new cells formed as a consequence of normal lung cell 
turnover will carry the full length transgene and will therefore not express the 
HEL/PLP protein. Estimates of the rate of turnover of lung epithelial cells are quite 
varied and probably depend upon many factors such as the age, strain and pathogen 
status of the animal. The most consistent studies have used pulse/chase experiments 
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with tritiated thymidine ([3H]) to calculate airway cell turnover and the consensus is 
that the turnover time of tracheal-bronchial epithelium of adult rodents is more than 
100 days (4 months) (Kauffman, 1980). The PCR data, shown in figure 5.9, show that 
most copies of the stop sequence in the lung are still deleted more than 100 days after 
tamoxifen induction. This suggests a very slow rate of cell turnover. 
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Figure 5.8 Removal of the foxed stop sequence and expression of MIPLP in 
lung tissue following induction with tamoxifen. (a) PCR strategies were used to 
demonstrate removal of the fluxed stop sequence (using primers stopfloxedF and 
stopfloxedR) and expression of PLP (using primers HELA and PLPB) in lung tissue 
from transgenic animals that had been induced with tamoxifen for 5 days. (b) 
Following tamoxifen induction, lung genomic DNA was used as a template to 
demonstrate removal of the floxed stop sequence in animals carrying both the Cre and 
MIPLP transgenes. No change in size of PCR product was observed in animals 
carrying the MIPLP transgene alone. Lung cDNA was then used to demonstrate low 
levels of expression of HEL/PLP. (c) HPRT was used as positive control for 
successful cDNA synthesis and cDNA reactions with (+) and without (-) the reverse 
transcriptase enzyme were used to control for any contaminating genomic DNA in 
lung RNA preparations. PLP expression was observed only in those animals shown to 
have deleted the stop sequence (d). 
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Figure 5.9 Complete removal of the foxed stop sequence occurs over many days 
and persists for many weeks following induction with tamoxifen. (a) Genomic 
DNA from lung tissue harvested 2 days after completion of the tamoxifen induction 
protocol contains copies of the transgene in which the stop sequence has been 
removed, but many copies of the transgene still remain unfloxed. (b) 2 weeks after 
completion of the tamoxifen induction protocol, almost all copies of the stop sequence 
in the lung have been deleted. (c) Copies of the transgene that do not contain the stop 
sequence remain present in the lung at least 100 days after tamoxifen induction. 
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5.4 Re-design of the SIPLP transgene. 
Initial data from the MIPLP line 11 founder animal demonstrates that the lung 
expression constructs designed are functional, i.e. correct deletion of the stop sequence 
is observed and that HEL/PLP 56-70 mRNA transcripts can be detected in the lung. 
However, levels of expression seen are very low (figure 5.8). One possible 
explanation for the low levels of expression observed is that the sequence of the loxP 
site, which remains in the transgene following stop sequence excision, contains an 
ATG triplet and may act as a false translational start site (figure 5.10). The simplest 
solution is to invert the stop cassette such that the loxP sites are still functional but are 
in the reverse orientation. 
No SIPLP transgenic founders were generated from an initial round of pronuclear 
injections. As re-injection of the construct was required, a new SIPLP construct was 
generated containing an inverted stop cassette. The cloning strategy used to create the 
new SIPLP transgene is shown in figure 5.11. The complete nucleotide sequence and 
final plasmid map of the new SIPLP construct are shown in appendices 27 and 15 
respectively. 
Bacterial sequence was removed from the construct prior to pronuclear injection as 
described previously. 
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Figure 5.10 A schematic diagram to demonstrate the potential importance of 
loxP site orientation. (a) Recombination between loxP sites in a forward orientation 
results in the presence of an ATG triplet upstream of the coding region, which has the 
potential to act as a false translational start site. Use of this false start site may affect 
the efficiency of translation from the intended start site and protein expression levels 
may be low. Potential start sites are marked (*). (b) If loxP sites are in the reverse 
orientation, no ATG triplet will remain following recombination and translation of the 
protein of interest should be unaffected by the remaining loxP sequence. 
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Figure 5.11 A schematic diagram of the cloning strategy used to invert the foxed 
stop sequence of the SIPLP construct. (a) A pBluescriptll shuttle vector was 
modified to remove a KpnI restriction site and the Rabbit 13 globin/PLP fragment 
inserted into this vector using HindIII and XbaI (b). The CC10 promoter was joined 
using HindIII (c). The floxed stop sequence was cloned into a modified pBluescriptll 
vector such that it was flanked by KpnI sites which were then used to clone the stop 
sequence into the final vector, with loxP sites in the opposite direction to those in the 
previous inducible PLP constructs (d). Bacterial sequence was removed from the 
vector by digestion with BssHII prior to pronuclear injection. 
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5.5 Identification of SIPLP transgenic founder animals. 
The new SIPLP construct was injected into C57BL/6 oocytes at the MRC Clinical 
Sciences Centre of Imperial College, London. 56 potential founder animals were 
screened for the presence of the SIPLP transgene. An initial PCR screen, using 
genomic DNA extracted from a tail biopsy, identified 4 founder animals (figure 5.12). 
These animals are subsequently referred to as SIPLP line 48, SIPLP line 50, SIPLP 
line 60 and SIPLP line 69, based on numbers assigned at the point of tail biopsy. The 
transgenic status of each of these animals was then confirmed by Southern blot (figure 
5.12). No positive band was seen on the Southern blot of SIPLP line 50. Based on 
this data, SIPLP line 50 was not selected for further breeding. Positive bands on the 
Southern blot for SIPLP line 69 are more intense than those for lines 48 and 60. This 
suggests that the number of copies of the transgene integrated into the genome is the 
greatest in line 69. Two bands are visible on the blot for SIPLP line 48 suggesting 
several sites of integration of the construct in this line. 
All SIPLP transgenic founders were crossed with (3m70 MerCreMer transgenic 
animals that had been backcrossed for at least 6 generations onto a NOD.E genetic 
background. 3 litters derived from SIPLP line 60 were screened by PCR for the 
presence of the SIPLP transgene. From a total of 18 pups, no positive mice were 
identified. The transgenic status of the breeding founder animal was confirmed by 
PCR from a 2nd tail biopsy but, as no germ line transmission of the transgene was 
observed, the line was terminated. 
To date, a single transgene positive animal has been identified from a total of 20 mice 
derived from the breeding of SIPLP line 69. Therefore, no further analysis of this line 
has so far been possible. 
The frequency of germ line transmission of the SIPLP transgene has been the greatest 
for litters derived from the breeding of SIPLP line 48 (19 positive animals from a total 
of 40). Litters derived from SIPLP line 48 were screened by PCR for the presence of 
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the SIPLP and Cre transgenes. To demonstrate expression of the SIPLP construct in 
lung tissue of these animals, mice were induced with tamoxifen and after 14 days, lung 
tissue was harvested and RNA and DNA extracted. As described for the MIPLP 
transgenic line, administration of tamoxifen to animals carrying both the Cre and PLP 
transgenes should result in excision of the foxed stop sequence, which can be detected 
by PCR. Figure 5.13 shows removal of the stop sequence in a tamoxifen induced 
animal carrying both the SIPLP and Cre transgenes. This demonstrates that, despite 
inversion of the stop cassette during the re-design of the SIPLP transgene, the loxP 
sites are still functional. Additionally very low levels of HEL/PLP transcripts were 
detected in lung cDNA from these mice by PCR and as such expression levels 
detected from the MIPLP or SIPLP transgenes appear to be similar regardless of loxP 
site orientation. The SIPLP line from which this data derives (line 48) had the lowest 
number of transgene copies by Southern blot. SIPLP line 69 contains many more 
copies of the transgene in the genome than line 48 and experiments are currently 
ongoing to determine floxing and expression upon tamoxifen induction in these mice. 
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Figure 5.12 Identification of SIPLP transgenic founder animals. The transgenic 
founders were identified by PCR and by Southern blot. The location of primers used 
for PCR screening (3rdexonF and BetaglobinB) and for generation of the Southern 
probe (CC101500F and CC102100R) are shown in (a). Three transgenic animals were 
identified from an initial PCR screen of 56 potential founders (b). The transgenic status 
of these animals (numbers 48, 50, 60 and 69) was then confirmed by Southern blot (c). 
The location of bands on the Southern blot are marked by grey arrows. The restriction 
enzyme used to digest genomic DNA for Southern blotting was EcoRV. This enzyme 
only cuts the integrated construct once, on the 3' side of the CC10 promoter region 
being used as a probe (c), giving information about construct integration sites and copy 
number. Based on the result of Southern analysis, founder animal 50 was not selected 
for further breeding. 
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Figure 5.13 Removal of the floxed stop sequence and expression of SIPLP in 
lung tissue following induction with tamoxifen. (a) PCR strategies were used to 
demonstrate removal of the foxed stop sequence (using primers stopfloxedF and 
stopfloxedR) and expression of PLP (using primers HELA and PLPB) in lung tissue 
from transgenic animals that had been induced with tamoxifen for 5 days. (b) 
Following tamoxifen induction, lung genomic DNA was used as a template to 
demonstrate removal of the foxed stop sequence in animals carrying both the Cre and 
SIPLP transgenes. No change in size of PCR product was observed in animals 
carrying the MIPLP transgene alone. Lung cDNA was then used to demonstrate very 
low levels of expression of HEL/PLP. (c) cDNA reactions with (+) and without (-) the 
reverse transcriptase enzyme were used to control for any contaminating genomic 
DNA in lung RNA preparations. PLP expression was observed only in those animals 
shown to have deleted the stop sequence. 
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Discussion 
Polarised populations of Thl or Th2 CD4+ T cells, and the cytokines that they 
produce, are an important inflammatory component of a number of different lung 
diseases. Thl type cytokines such as IL-12 and IFN-y, and Thl mediated immune 
responses, have been found associated with chronic lung diseases such as sarcoidosis, 
while Th2 type responses, involving cytokines such as IL-4, IL-5 and IL-13, are 
thought to be involved in the pathogenesis of lung diseases such as cryptogenic 
fibrosing alveolitis and asthma. One of the main aims of this thesis was to explore the 
hypothesis that the structure of the TCR could lead to an inherent Thl or Th2 bias in 
CD44- T cell phenotype, and chapters 3 and 4 have described the generation and 
characterisation of TCR transgenic animals to test this hypothesis. An extension of 
this main hypothesis however is an additional question of whether TCR transgenic 
animals, displaying inherent bias towards Thl or Th2 type immune responses, could 
be used to generate new models of Thl and Th2 mediated lung disease. Data 
presented in this chapter has described the generation of inducible transgenic mice 
with lung targeted expression of the Thl and Th2 TCR cognate epitope, PLP 56-70. 
The inducible system selected for this study was the Cre/lox system (figure 1.5) and 
lung targeted expression was achieved using the lung specific CC10 promoter. Two 
versions of the transgene were created. In both versions the PLP peptide is expressed 
as part of the hen egg lysozyme (HEL) protein, but one version contains a membrane 
anchor sequence at the 3' end of the coding region and so results in the antigen being 
membrane bound rather than secreted. Administration of the drug tamoxifen to 
transgenic animals results in nuclear translocation of a ubiquitously expressed Cre 
recombinase, which catalyses the removal of a translational stop sequence situated 5' 
to the start of the coding sequence. Immunohistochemistry was used to demonstrate 
that the Cre recombinase would become nuclear localised in Clara cells of the lung, 
the cell type in which the CC10 promoter is specifically activated, validating the use 
of the pm70 line of Cre mice selected for this study. One important issue of this 
transgenic approach, mentioned previously in discussions of the Cre/lox system, is the 
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issue of Cre toxicity. Cre toxicity has been widely reported in mammalian cells 
(Loonstra et al., 2001) and while in this inducible Cre system toxicity is unlikely to be 
an issue until administration of tamoxifen, the possibility that any lung pathologies 
observed in these mice might be due to the Cre protein itself must be considered. 
Indeed the ubiquitous expression pattern of the Cre protein means that effects in 
tissues other than the lung are also possible. While the issue of Cre toxicity is 
unavoidable in this system and will persist for the lifetime of the drug within the 
mouse, it is straightforward to control for by using animals carrying the Cre transgene 
but not the inducible lung constructs. Any secondary effects of the Cre protein on 
lung tissue and in causing lung pathology will also be observed in these animals. 
Data presented in this chapter have described the cloning of secreted (SIPLP) and 
membrane bound (MIPLP) lung constructs and the identification of transgenic animals 
carrying each of these transgenes. A PCR strategy was used to demonstrate that 
tamoxifen induction resulted in correct excision of the floxed stop sequence in lung 
tissue and low levels of transgene expression were detected in lung cDNA from the 
MIPLP line and SIPLP line 48. Poor germline transmission of the transgene in SIPLP 
line 60 meant that this line was not carried forward for characterisation and 
experiments are currently ongoing to determine transgene floxing and expression 
levels in SIPLP line 69. Yet to be demonstrated in any transgenic line is the presence 
of the HEL/PLP in the lung at the protein level. Attempts to visualise the protein 
intracellularly using immunohistochemistry and an anti-HEL antibody have been 
unsuccessful. One likely explanation for this is that the HEL protein present in the 
lungs of these animals is not the native form. The coding sequence of PLP 56-70 is 
inserted into the centre of the protein and as such is likely to affect the structure of this 
molecule. The antibody used was polyclonal, but if the structural impact of PLP 56-70 
addition to the protein is severe enough, normal antibody binding epitopes may be 
destroyed. Another approach currently ongoing is to try to demonstrate the presence 
of antigen using antigen specific T cell lines. If the HEL/PLP antigen is being 
expressed in the SIPLP lines then protein should be present in the BAL of induced 
animals. However, the presence of the membrane anchor in the MIPLP transgene 
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means that this will not be true for MIPLP transgenic mice and disruption of the lung 
tissue to release intracellular protein would be required. Indeed, membrane bound 
expression of antigen, and data presented in this chapter showing large numbers of 
foxed transgene copies present in the lung more than 100 days following tamoxifen 
induction, raises important questions about how efficiently this protein will be 
presented to T cells in the lung. Presentation of PLP 56-70 in the lungs of induced 
MIPLP animals will rely on natural breakdown of the airway epithelium to release the 
protein. As turnover of the airway epithelium is low (Kaufmann, 1980), the amount of 
antigen presented by lung APCs to resident T cells may be tiny. It may be that in this 
system, infliction of mild lung injury, for example by low dose LPS exposure (Rojas et 
al., 2005), may be required in order to potentiate death of airway epithelial cells, 
release of antigen and initiation of an inflammatory response in the lung. 
From PCR data obtained to date for both MIPLP and SIPLP lines, levels of expression 
appear to be low although, from PCR data of the floxed transgene, expression should 
persist for many days. In previous discussion of different lung diseases, difficulties in 
modelling the chronic nature of many of these diseases, and also the unknown nature 
of the antigens to which the immune system is responding, were mentioned. When the 
SIPLP and MIPLP transgenic lines have been crossed with the TCR transgenic 
animals bearing Thl or Th2 antigen specific TCRs, it may be that the low levels of 
expression of the TCR antigen over an extended period of time that can be induced in 
these animals is an effective model for some of these disease processes, particularly if 
some of the antigens yet to be identified in these diseases derive from endogenous 
lung proteins. Immune responses to weakly expressed endogenous antigens in the 
lung, perhaps following an initial mild insult or injury, would provide an explanation 
for the chronic and progressive nature of many of these lung pathologies. However, 
an alterative outcome of low levels of peptide expression in the lung may turn out to 
be tolerance rather than inflammation. Central tolerance to the PLP 56-70 antigen 
would not be expected as the transgene is inducible and as such, especially given the 
presence of the translational stop sequence 5' to the coding sequence, should not be 
presented as part of the repertoire of self antigens during thymic selection. However, 
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as was noted in the original OVA TCR transgenic mice, subsequent presence of the 
peptide antigen, in the case of the OVA study, by giving peptide intraperitoneally, can 
result in clonal deletion of T cells bearing the OVA specific TCR in the thymus 
(Murphy et al., 1990). Additionally, following tamoxifen induction and removal of 
the floxed stop sequence in all tissue, i.e. not just in the lung, the potential for Aire 
protein mediated tolerance induction in the thymus would exist, and recent evidence 
for the existence of gene microclusters expressed by Aire suggest that this may depend 
on the site of transgene integration in the genome (Derbinski et al., 2005). In the 
periphery, it is well established that TCR ligation in the absence of APC-derived 
costimulatory signals, such as those of the CD28 or CD4OL pathways, leads to 
functional inactivation and anergy (Howland et al., 2000). This idea has been 
explored in the field of allergen immunotherapy, where administration of therapeutic 
doses of protein or peptide can lead to tolerance and attenuation of the normal immune 
response to allergen. Peptide studies have administered antigens subcutaneously 
(Norman et al., 1996), intradermally (Alexander et al., 2005) orally (Takagi et al., 
2005) and intranasally (Hall et al., 2003) and have all demonstrated improvements in 
outcome measures of allergic airways disease, suggesting that the peptides have 
indeed induced tolerance to the allergen. However, although many of these studies 
have described using low doses of peptide, in the study of peptide tolerance by 
intranasal peptide administration, therapeutic doses of peptide were quite high (100 
!Ag), and such levels are unlikely to be reached in this inducible system, especially 
given the low levels of transcription observed from PCR data. However, as there are 
currently no reports in the literature of inducible peptide antigens in the lung, the 
outcome of either low or high levels of expression on potential tolerance induction is 
unknown. Peptide expression levels are likely to be a key determinant of which 
immune mechanisms are initiated in these mice and the time course of any response 
will also be of interest. In mouse models of lung inflammation, chronic exposure to 
antigen actually decreases inflammatory responses and a suppressed, or more tolerant, 
immune response is observed (Yiamouyiannis et al., 1999). Again, antigen dose is 
probably a key issue and in mouse models of asthma, doses used to initiate disease are 
very high. It would be interesting to observe whether the chronic stages of any 
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inflammation induced by peptide expression in the lung in this model are different and 
perhaps better reflect the ongoing chronic inflammation observed in many human 
diseases. 
The nature of the inflammation induced using this model, in combination with the Thl 
and Th2 TCR transgenic models, will depend very much on the phenotype of the TCR 
transgenic T cells that traffic to the site of antigen expression. Whether prior priming 
of TCR transgenic T cells with antigen and adjuvant, or as previously mentioned, the 
generation of some form of mild inflammation in the lung, before T cells will traffic 
there, remains to be seen. Ideally no adjuvant or other inflammatory stimulus would 
be required as this will inevitably bias the Thl/Th2 nature of the subsequent 
inflammatory reaction. If the TCR structural hypothesis holds true then Thl and Th2 
TCR transgenic T cells in vivo will have an inherent phenotype bias. If phenotypes 
observed in vitro are similar to those subsequently seen in vivo, then you would expect 
T cells from the Th2 TCR transgenic line, chains for which have now both been 
expressed transgenically and mice lines of which are currently being crossed together, 
to express predominantly IL-5, with some IL-4 and low levels of IFN-y. In the context 
of lung inflammation, one major action of the cytokine IL-5 is in the recruitment of 
eosinophils. Eosinophilic inflammation may therefore be a predicted outcome in these 
mice, as might several other Th2 immune pathologies, as mice constitutively 
expressing high levels of IL-5 in the lung have evidence of goblet cell hyperplasia, 
collagen deposition, eosinophil infiltration and airway hyperresponsiveness (Lee et al., 
1997). 
As cytokine signalling pathways both antagonise and synergise in the context of 
immune responses in the lung, exactly what pathologies may arise in the transgenic 
mice and models of this study are unknown. However, that polarised CD4+ T cell 
responses may be generated without having to artificially manipulate one cytokine, 
e.g. IL-5 (Lee et al., 1997) or component of T cell differentiation, e.g. Tbet (Finotto et 
al., 2002) in the context of continuous antigen presentation in the lung without having 
to administer a biasing adjuvant or exceptionally high dose of antigen, means that the 
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transgenics described in this chapter and in chapters 3 and 4 of this thesis may lead to 
valuable new models of Thl and Th2 mediated pulmonary pathology, particularly in 
the context of chronic lung disease. 
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Chapter 6  
Generation and initial characterisation of transgenic lines with lung 
targeted expression of human interleukin 8.  
Results 
6.1 Design and construction of a transgene for lung targeted expression of human 
interleukin 8. 
A schematic diagram of the cloning strategy used to construct a transgene for lung 
targeted expression of human interleukin 8 (hIL-8) is shown in figure 6.1. The lung 
specific promoter of CC10, and the rabbit beta globin expression cassette, are the same 
as those used for the inducible lung targeted antigen transgenes discussed in chapter 5. 
Use of the CC10 promoter means that the human IL-8 protein will only be expressed 
within bronchial epithelial cells. In human cells, the IL-8 protein is expressed as a 99 
amino acid precursor (Matsushima et al., 1988). Following removal of a 20 amino 
acid signal peptide, this precursor is secreted, and then cleaved extracellularly at the 
N-terminus into several possible biologically active forms of the protein (Padrines et 
al., 1994). To ensure secretion and correct subsequent processing of the hIL-8 protein 
it was therefore necessary to use the coding sequence for the entire 99 amino acid 
precursor protein in this transgene. Low levels of hIL-8 cDNA transcripts are found in 
normal human peripheral blood mononuclear cells (PMBCs) (Matsushima et al., 
1988). RNA was therefore isolated from a human PBMC sample and, following 
cDNA synthesis, PCR was used to clone the coding sequence of hIL-8 (figure 6.2). 
The cloned PCR product was verified by sequencing prior to proceeding with the 
cloning strategy. The nucleotide and amino acid sequence of hIL-8 used in this 
construct is shown in appendix 29. The hIL-8 coding sequence was inserted into an 
expression cassette that uses rabbit beta globin derived intronic and polyA sequences, 
at the 5' and 3' ends of the cassette respectively, to aid correct processing and mRNA 
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stability of the gene of interest. The hIL-8 sequence replaced the coding sequence of 
Hen Egg Lysoszyme (HEL) and the antigen PLP 56-70, used in a previous construct 
(chapter 5). Removal of the HEL/PLP sequence and insertion of hIL-8 required the 
use of the restriction enzyme EcoRl. An endogenous EcoR1 restriction site is present 
at the 3' end of the hIL-8 sequence and so a single base pair mutation (T-->C) was 
introduced by PCR at the time of cloning from cDNA such that there was no change in 
amino acid sequence of the protein but that the EcoRl site was destroyed. 
Joining of the lung specific CC10 promoter to the hIL-8 expression cassette was by 
directional cloning using BamHI and XbaI restriction enzymes. The final construct 
was checked by restriction digest (figure 6.2) and also by sequencing. The complete 
sequence of the lung targeted hIL-8 transgene is shown in appendix 28. A plasmid 
map of the construct is shown in appendix 16. 
Bacterial sequences were removed from the construct, prior to pronuclear injection, by 
digestion of the construct with Xho I and purification of the upper 3930 bp band. This 
injection fragment is shown in figure 6.2. 
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Figure 6.1 A schematic diagram of the cloning strategy used to create the lung 
targeted hIL-8 transgene. (a) Human IL-8 cDNA was cloned from human PBMC 
cDNA using PCR primers specific for IL-8 (IL-8F and IL-8R) modified to contain 
EcoR1 sites at each end of the transcript and to destroy an endogenous EcoRl site. 
The point mutation (T—>C) did not alter the amino acid sequence of the protein. (b) 
hIL-8 cDNA was inserted into a rabbit beta globin expression cassette using EcoRl. 
(c) The rabbit beta globin expression cassette containing hIL-8 cDNA was joined to 
the lung specific promoter of CC10, contained in the shuttle vector pBluescriptII, 
using BamHl and Xbal. Bacterial sequences were removed from the vector, by 
digestion with Xhol, prior to pronuclear injection. 
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Figure 6.2 Cloning of human IL-8 cDNA into a lung targeted expression 
construct (a) The coding sequence of human IL-8 was cloned by PCR from human 
PBMC cDNA. The cloned PCR product inserted into a lung expression construct 
containing the rat lung specific promoter, CC10, and intronic sequence from rabbit 
beta globin. (b) The final construct was verified by restriction digest. A BamHI/XbaI 
digest gives expected restriction fragments of 5516 bp and 1500 bp. A XhoI digest 
gives expected restriction fragments of 3930 bp and 3086 bp. (c) Bacterial sequences 
were removed from the construct prior to pronuclear injection by digestion of the 
construct with XhoI and purification of the upper 3930 bp band. 
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6.2 Identification of lung targeted hIL-8 transgenic founder animals. 
The lung targeted hIL-8 construct was injected into FVB/N oocytes at the Nuffield 
department of Medicine in Oxford. 36 potential founder animals were screened for the 
presence of the hIL-8 transgene. An initial PCR screen, using gDNA extracted from 
tail biopsy, identified 2 founder animals (figure 6.3). These animals are subsequently 
referred to as hIL-8 line 19 and line 33 based on numbers assigned to each animal at 
the point of tail biopsy. Following the PCR screen, the transgenic status of animals 19 
and 33 was confirmed by Southern blotting (figure 6.3). EcoRV was the restriction 
enzyme selected to cut genomic DNA used for Southern blotting, as this enzyme 
cleaves the transgene only once. The Southern blot for hIL-8 lines 19 and 33 show 
that in both lines the transgene has integrated at more than one locus. These 
integration sites are represented by bands that are differential between the two 
transgenic lines. The EcoRV restriction site is located 2473 bp from the 5' end of the 
transgene. The intense band present in both lanes represents multiple copies of the 
transgene that have inserted as head to tail concatamers at one or more of the 
integration loci. The sequence and product sizes of all PCR and Southern primers used 
for screening of lung targeted hIL-8 transgenic founder animals are shown in appendix 
8. 
Both transgenic founders were subsequently bred with C57BL/6 animals to obtain 
lung targeted hIL-8 transgenics for further analysis. 
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Figure 6.3 Identification of lung targeted hIL-8 transgenic founder animals. 
Transgenic founders were identified by PCR and by Southern blot. The location of 
primers used for PCR screening (IL-8F and IL-8R) and for generation of the Southern 
probe (CC101500F and CC102100R) are shown in (a). Two transgenic animals were 
identified from an initial PCR screen of 36 potential founders (b). The transgenic 
status of these animals (numbers 19 and 33) was then confirmed by Southern blot (c), 
using rat genomic DNA as a positive control for the CC10 sequence. The restriction 
enzyme used to digest genomic DNA for Southern blotting was EcoRV. This enzyme 
only cuts the integrated construct once, on the 3' side of the CC10 promoter region 
being used as a probe (c), giving information about construct integration sites and 
copy number. 
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6.3 Determination of lung specific hIL-8 transgene expression. 
The lung specific promoter used in the transgene is derived from the rat CC10 gene 
and should direct expression of the gene of interest (hIL-8) in epithelial cells lining the 
trachea, bronchi and bronchioles of the murine lung (Stripp et al., 1992). PCR was 
used to determine the presence of hIL-8 cDNA transcripts in lung tissue from both 
hIL-8 transgenic lines (figure 6.4). No hIL-8 cDNA transcripts were detected in lung 
tissue from littermate control animals. In line 33 animals, hIL-8 cDNA transcripts 
were only detected in the lung. In line 19, very low levels of hIL-8 transcripts were 
also detected in brain tissue. The CC 10 sequence used in this transgene is well 
characterised as a promoter for lung specific expression of a target gene. Expression 
of hIL-8 cDNA transcripts in brain tissue is therefore unlikely to be driven by this 
promoter. The observation of hIL-8 transcripts in brain tissue from line 19 but not line 
33 suggests that in line 19, one or more copies of the transgene has integrated close to 
a strong promoter that is active in the brain. The data shown in figure 6.4 
demonstrates that hIL-8 cDNA transcripts are present in lung tissue of both hIL-8 
transgenic lines. Real-time PCR was then used to investigate whether there was a 
difference in relative levels of transcripts between line 19 and line 33 (figure 6.5). The 
data shows that line 19 animals have a greater number of hIL-8 cDNA transcripts in 
the lung compared to line 33 animals (P = 0.0005). A difference in level of hIL-8 
expression between the two lines was also observed at the level of protein. hIL-8 
levels in bronchoalveolar lavage (BAL) fluid (P = 0.0005) and in lung homogenate (P 
= 0.0098) were higher in line 19 than in line 33. The BAL data also confirms that the 
hIL-8 protein is being secreted by the lung cells expressing the transgene, and failure 
to detect any hIL-8 protein in serum samples from these animals suggested that the 
secreted hIL-8 protein remained in the local lung environment and was not present in 
the peripheral circulation. Activity of the rat CC10 promoter has been shown to be 
localised to bronchial epithelial cells of the lung rather than lung alveoli. This pattern 
of expression for the transgenic hIL-8 protein was confirmed for both lines of mice 
using immunohistochemistry (figure 6.6). In keeping with the cDNA transcript and 
protein data shown in figure 6.5, more IL-8 staining was observed in lung sections 
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from line 19 animals. However, for both lines, IL-8 staining was patchy suggesting 
that, at any one time, the transgene is not being expressed by all bronchial epithelial 
cells in the lung. 
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Figure 6.4 Tissue specific expression of hIL-8 in both transgenic lines. (a) and 
(b) RNA was isolated from a range of different tissues, and primers specific for hIL-8 
cDNA (IL-8F and IL-8R) were used to demonstrate lung specific expression of the 
transgene in both transgenic lines. cDNA reactions where no reverse transcriptase 
(RT) enzyme had been included were used as negative controls to ensure that any PCR 
product seen was not due to genomic DNA carried over during the RNA isolation 
procedure. (c) No hIL-8 transcripts were detectable in littermate control samples. 
Primers specific for 18s RNA (Ambion-1716) were used as an internal control for 
each sample. (a) Low levels of hIL-8 expression were also detected in brain tissue 
from line 19. Gels shown are representative of 3 animals per group. 
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Figure 6.5 Levels of hIL-8 cDNA transcripts and hIL-8 protein in the lung of 
both lines of hIL-8 transgenic mice. (a) Real-time PCR was used to compare levels 
of hIL-8 cDNA transcripts in lung tissue from hIL-8 line 19 and line 33 transgenic 
animals. Levels of IL-8 protein in BAL fluid (b) and lung homogenate (c) were 
determined by ELISA. hIL-8 cDNA transcripts and protein were both shown to be 
more abundant in lung tissue from line 19 animals. Data shown represent means + SE 
for each group. n = 9 for line 19, n = 11 for line 33, n = 8 for littermate controls. 
Statistical significance of differences between line 19 and line 33 were tested using a 
Mann-Whitney U test. ** P < 0.01, *** P < 0.001. 
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Figure 6.6 hIL-8 expression is confined to bronchial epithelial cells of the lung in 
both lines of transgenic mice. Inflated lung sections from line 19, line 33 and 
littermate control mice were stained using primary antibodies specific for the CC10 
protein and hIL-8. 	Staining was visualised using a peroxidase based 
immunohistochemistry protocol. CC10 staining was observed in bronchiolar 
epithelial cells of all mice. 	hIL-8 staining was observed in some bronchiolar 
epithelial cells of lungs from both lines of transgenic animals while no staining was 
observed in littermate control samples. More staining was observed in samples from 
line 19 animals than from line 33. Images shown are representative of staining 
observed for more than 5 animals per group and are x20 normal magnification. The 
main structures of the lung are marked. 
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6.4 	Lung function and lung cell infiltrate in lung targeted hIL-8 transgenics. 
Having established lung specific expression of hIL-8 in both lines of transgenic mice, 
the impact of constitutive expression of hIL-8 in the murine lung on lung function and 
lung cell infiltrate was investigated. hIL-8 is a neutrophil chemoattractant and the 
ability of hIL-8 to be chemotactic for the neutrophils of other species, including 
mouse, has previously been demonstrated (Rot, 1991). Analysis of the numbers and 
types of cells infiltrating both the BAL and lung of hIL-8 transgenic and littermate 
animals revealed that while the total number of cells in the lung was not elevated in 
the presence of hIL-8, the percentage of infiltrating cells that were neutrophils was 
significantly increased (figure 6.7). The observed increase in the percentage of 
neutrophils infiltrating the lung was greatest in line 19 animals (P = 0.0002), the line 
previously shown to be expressing the highest levels of the hIL-8 protein, although a 
significant difference was also seen in the lavage of line 33 animals (P = 0.0345). The 
percentage increase in neutrophils was most apparent in the BAL, as in normal healthy 
animals most cells recovered from BAL are macrophages and the percentage of cells 
that are neutrophils is very low. However, in the lung, where normally at least 50 % 
of cells are neutrophils, the percentage increase in neutrophils in the lungs of hIL-8 
line 19 transgenic animals was still significant (P = 0.0091). Staining of inflated lung 
sections with an antibody against myeloperoxidase (MPO), an enzyme that serves as a 
specific marker for neutrophils (Schmekel et al., 1990), confirmed increased numbers 
in line 19 animals, but also showed the location of neutrophils in the lung tissue of 
these animals to be clustered around bronchi and blood vessels compared to a more 
diffuse pattern of staining seen for line 33 and littermates (figure 6.8). When 
consecutive lung sections from line 19 animals were stained with antibodies against 
hIL-8 and myeloperoxidase, areas of neutrophil clustering next to bronchi were seen to 
be associated with areas of intense hIL-8 staining (figure 6.8). The clustering of cells 
around some airways and blood vessels in the lungs of line 19 animals was also 
evident from the staining of lung sections with Haemotoxylin and Eosin (H+E). This 
stain does not allow the different types of cells infiltrating the lung to be distinguished, 
but when a general inflammatory scoring system was used, mild inflammation was 
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evident around some bronchi and vessels in the lungs of line 19 animals, compared to 
very little or no inflammation in the lungs of line 33 or littermate mice (figure 6.9). 
Mice used to examine cell infiltrates and lung pathology in hIL-8 transgenics 
compared to littermates were 20 to 30 weeks in age and despite some evidence of mild 
inflammation around bronchi and blood vessels of the transgenic line expressing the 
highest levels of hIL-8, lung histology by H+E staining showed no evidence of other 
lung pathology. 
Lung diseases associated with high levels of IL-8 such as asthma and chronic 
obstructive pulmonary disesase (COPD) (Nocker et al., 1996) are also invariably 
associated with altered lung function (Cherniack, 1956). 	The three main 
measurements of lung function used routinely in other mouse models of lung disease, 
bronchial hyperreactivity (Penh), resistance and compliance were measured in the hIL-
8 transgenic lines and littermate animals. Neither hIL-8 transgenic line showed any 
difference, compared to littermates, in bronchial hyperreactivity or airway resistance 
in response to the muscarinic receptor agonist methacholine (figure 6.10). However, 
line 19 animals and to a lesser extent, line 33 animals showed decreased airway 
compliance compared to littermates although the difference was not statistically 
significant. 
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Figure 6.7 Baseline cell infiltrates in the lungs of IL-8 transgenics and littermate 
animals. (a) The total number of cells recovered from the bronchoalveolar lavage 
(BAL) and whole lung lobe of IL-8 transgenic and littermate mice were determined by 
cell counting. (b) Differential cell counts of cytospins from BAL and lung were used 
to determine the percentage neutrophils in each sample. Mice used were 20-30 weeks 
of age and the data shown represents the mean values for 9 animals for line 19, 11 
animals for line 33 and 8 littermate animals + SE. The statistical significance of 
differences between line 19, line 33 and littermate groups were tested using a Mann-
Whitney U test. * P <0.05, ** P < 0.01, *** P < 0.0005 
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Figure 6.8 Neutrophil staining by immunohistochemistry of lung sections from 
IL-8 transgenic and littermate animals. Inflated frozen lung sections from IL-8 
transgenic and littermate control animals aged 20 -30 weeks were stained using a 
primary antibody specific for the neutrophil marker myeloperoxidase. Staining was 
visualised using a peroxidase based immunohistochemistry protocol. (a) The number 
of neutrophils surrounding bronchi and blood vessels in each section were assessed 
using an inflammatory score system (appendix 30). The data is presented as a mean 
value + SE for each group and represents 9 line 19, 9 line 33 and 3 littermate animals. 
The statistical significance of differences between transgenic and littermate groups was 
tested using a Mann-Whitney U test. *P <0.05, **P <0.005. (b) Line 19 animals were 
found to have a greater number of neutrophils around both bronchi and blood vessels 
compared to line 33 and littermate animals. (c) Staining of consecutively cut sections 
with myeloperoxidase and IL-8 antibodies showed a relationship between clustering of 
neutrophils around bronchi and secretion of IL-8 by bronchial epithelial cells in line 19 
animals. All photos are x20 normal magnification. 
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Figure 6.9 Mild inflammation in line 19 transgenics compared to line 33 and 
littermate animals. Inflated frozen lung sections from IL-8 transgenic and littermate 
animals aged 20-30 weeks were stained with Haematoxylin and Eosin (H+E). (a) 
Cell infiltrates around bronchi and blood vessels were assessed using an inflammatory 
score system. Data is presented as mean values per group + SE and represents 9 line 
19, 9 line 33 and 3 littermate animals. The statistical significance of differences 
between groups was tested using a Mann-Whitney U test. ** P < 0.01. (b) Lung 
sections from line 19 animals showed evidence of mild cell infiltrates around some 
bronchi and vessels. Very few or no cell infiltrates were present in the lung sections 
from line 33 and littermate animals. All photos are x20 normal magnification. 
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Figure 6.10 Lung function of IL-8 transgenic and littermate animals. Mice aged 
20-30 weeks were used to obtain Penh (a), resistance (b) and compliance (c) lung 
function measurements for IL-8 transgenic and littermate animals. Penh data shown is 
shown as mean values for 14 line 19 (0), 16 line 33 (A) and 8 littermate animals (0) + 
SE and is representative of three independent experiments. Resistance and compliance 
data is shown as mean values for 4 line 19, 5 line 33 and 3 littermate animals + SE and 
is representative of a single experiment. 
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6.5 	Investigation of the impact of hIL-8 expression in the murine lung during 
ovalbumin induced lung inflammation. 
Lung data obtained for the hIL-8 transgenic lines thus far was obtained in the absence 
of any external inflammatory stimulus. To examine the effect of hIL-8 expression in 
the lung, in the context of an inflammatory response, an ovalbumin (OVA) model of 
lung inflammation was used. Mice used for this experiment were 20-30 weeks in age 
and were sensitised to OVA antigens by intra-peritoneal (i.p) injection of OVA, using 
alum as an adjuvant. Control mice received PBS and alum. All mice were then 
exposed to aerosolised OVA for 5 consecutive days before analysis of lung function 
and lung tissue. 	Lung function measurements showed greater bronchial 
hyperreactvity, greater resistance and reduced compliance in OVA sensitised mice 
compared to controls, but differences were small and not statistically significant 
(figure 6.11). In the OVA sensitised groups no significant differences were observed 
between transgenic and littermate control animals for Penh, resistance or compliance 
measurements. Line 33 OVA sensitised animals appeared to show increased 
resistance compared to line 19 and littermate controls but this difference did not reach 
statistical significance. However, of note was an apparent difference in bronchial 
hyperreactivity between hIL-8 transgenic and littermate animals that had received just 
alum as part of the sensitisation protocol. hIL-8 transgenic animals showed increased 
bronchial hyperreactivity compared to littermate controls with the difference reaching 
statistical significance in the case of line 33 animals (P=0.0159) (figure 6.11). 
Despite the lack of significant changes in lung function between OVA sensitised and 
alum control groups upon antigen challenge, there were differences in lung cell 
infiltrates and pathology. Figure 6.12 shows differential cell counts for BAL and lung 
in all groups. In the BAL of control mice, dominant cell types were macrophages and 
lymphocytes although some neutrophils and eosinophils were also present. The 
percentage of neutrophils in the BAL of these animals followed the same pattern as 
seen previously in the absence of any antigen challenge, with the greatest percentage 
in the line 19 hIL-8 transgenic group. This was also true in the BAL of mice 
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sensitised to OVA, although in all groups of OVA sensitised mice, the dominant cell 
type was the eosinophil and actual neutrophil numbers found in the lung were not 
greatly increased. In the lung tissue of control mice the most dominant cell type was 
the neutrophil. Again, the greatest percentage was in the line 19 hIL-8 transgenic 
group, although this was not the case in lung tissue of mice sensitised to OVA. In all 
OVA sensitised groups, the dominant cell type was the eosinophil, numbers of which 
were greatly increased compared to controls. The number of neutrophils in the lungs 
of these mice remained largely unchanged even in hIL-8 transgenic lines. 
Inflammation scores for H+E and myeloperoxidase (MPO) (figure 6.13) stained lung 
sections from all groups of mice revealed significant differences in severity of 
inflammation and pathology between control and OVA sensitised groups, but very 
little difference between hIL-8 transgenic groups and littermates. The biggest, 
although not statistically significant difference, was in the H+E inflammation scores of 
bronchi and vessels for the hIL-8 line 33 transgenic control group which appeared to 
show a greater degree of mild inflammation. However, the same trend was not 
observed in the MPO inflammation score and so any differential inflammation that 
may be present in this group is not due to neutrophils. Equivalent inflammation by 
H+E and MPO staining was seen around the bronchi and blood vessels in all groups of 
OVA sensitised animals. 
Periodic Acid Schiff (PAS) staining was also performed. PAS is used to identify cells 
containing high levels of glycoproteins. Glycoproteins known as mucins are the major 
component of mucus which is secreted by airway epithelial goblet cells (Rogers 1994). 
Unlike in humans, goblet cells are not found in murine airways in the absence of an 
inflammatory stimulus (Pack et al., 1981), however, goblet cell mucus hypersecretion 
is a common characteristic of airway inflammation in both species. PAS staining of 
lung tissue from hIL-8 transgenic and littermate animals following OVA challenge 
showed increased numbers of mucus secreting globlet cells in the airways of hIL-8 
transgenic animals in both control and OVA sensitised groups compared to littermates 
(figure 6.14). No mucus secreting cells at all were found in the airways of littermate 
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control animals and while OVA sensitisation and challenge did induce globlet cell 
mucus secretion in some airways of littermate animals, the number of airways 
secreting mucus and the average number of globlet cells in each airway was greater in 
hIL-8 transgenic animals. Statistical significance was not reached with this data 
however, and so further experiments are necessary. 
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Figure 6.11 Lung function measurements in IL-8 transgenic and littermate 
animals following ovalbumin sensitisation and challenge. Mice were sensitised to 
ovalbumin by i.p injection of ovalbumin and alum on days 0 and 12. Control mice 
received PBS and alum. All mice received an ovalbumin aerosol on days 19, 20, 21, 
22 and 23. (a) Penh lung function measurements were obtained on day 24. Resistance 
(b) and compliance (c) measurements were obtained on day 25. Data shown 
represents mean values for a minimum of 3 animals per group + SE. 
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Figure 6.12 Differential BAL and lung cell counts from IL-8 transgenic and littermate animals following ovalbumin 
sensitisation and challenge. Cytospins of BAL and lung cells were stained with Wright Geimsa and numbers of neutrophils, 
eosinsophils, macrophages and lymphocytes counted in each sample. The percentage of each cell type (a) was calculated and 
converted to a total number of cells in BAL or lung (b) by multiplying the cell percentage by the total number of cells isolated for 
each sample. Data shown represents a minimum of 3 animals per group and is presented as a mean value for the group ± SE. 
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Figure 6.13 Lung inflammation in OVA sensitised and challenged IL-8 
transgenic and littermate animals. IL-8 transgenic and littermate animals were 
sensitised by i.p injection of OVA and alum on days 0 and 12. Control mice received 
PBS and alum. All mice were challenged with aerosolised OVA on days 19 to 23. 
Lung tissue was harvested on day 25 and frozen lung sections stained with H+E (a) or 
an antibody specific for the neutrophil marker myeloperoxidase (b). Cell infiltrates 
around bronchi and blood vessels were assessed using an inflammatory score system 
(appendix 30). Data is presented as mean values per group ± SE and represents a 
minimum of 3 animals per group. The statistical significance of differences between 
groups was tested using a Mann-Whitney U test. (c) H+E stained lung sections from 
line 33 PBS control animals showed evidence of mild cell infiltrates around some 
bronchi and vessels but equivalent inflammation was seen in lung sections from all 
groups of OVA sensitised animals. 
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Figure 6.14 Prevalence of mucus secreting goblet cells in inflated lung sections 
from OVA sensitised and challenged IL-8 transgenic and littermate animals. IL-
8 transgenic and littermate animals were sensitised by i.p injection of OVA and alum 
on days 0 and 12. Control mice received PBS and alum. All mice were challenged 
with aerosolised OVA on days 19 to 23. Lung tissue was harvested on day 25 and 
frozen lung sections stained with PAS to identify mucus secreting goblet cells (bright 
purple staining). (a) A score system based on the percentage of each airway containing 
goblet cells was used to assess the prevalence of goblet cells in each sample. Data is 
presented as mean values per group + SE and represents a minimum of 3 animals per 
group. The statistical significance of differences between groups was tested using a 
Mann-Whitney U test. (b) Small numbers of goblet cells were found in the airways of 
PBS control IL-8 transgenic animals. In animals that had been sensitised to OVA, 
goblet cells were most prevalent in the airways of line 19 animals and the least 
prevalent in the airways of littermate animals. 
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Discussion 
IL-8 is a CXC chemokine with potent chemoattractant properties. It is secreted by 
many different cell types including T cells, neutrophils and NK cells, as well as by 
somatic cells such as endothelial cells, fibroblasts and epithelial cells. It acts 
predominantly to recruit and activate neutrophils at sites of infection or injury and 
high levels of IL-8 have been detected in a variety of disease states including lung 
diseases such as cystic fibrosis, bronchiecstasis, COPD and asthma. There are 
currently no reports in the literature of human IL-8 having been overexpressed in the 
mouse lung, but the reported associations between high levels of this protein and 
disease and increasing evidence for neutrophil independent roles of this cytokine in 
disease processes make IL-8 an attractive target for transgenesis. Data presented in 
this chapter has described the generation of two mouse lines with lung targeted 
expression of human IL-8 and initial basic characterisation of their phenotype. 
The IL-8 transgene created for this study contained the human IL-8 (hIL-8) cDNA 
sequence, intronic and polyA sequences from the rabbit beta globin protein and the rat 
lung specific CC10 promoter. Two founder animals carrying this transgene were 
identified by PCR and southern blot, which revealed both lines to be carrying multiple 
copies of the transgene at multiple integration loci. Transgene expression levels in 
each line were assessed by PCR, ELISA and antibody staining. Each revealed line 19 
animals to be expressing higher levels of hIL-8 than those of line 33 and in both lines 
expression was restricted to lung tissue, although in line 19 low levels of expression 
were also detected in the brain. The CC10 promoter has been used extensively in lung 
targeted transgenesis and is well characterised as a lung specific promoter whose 
activity is restricted to Clara cells of the airway epithelium (Hagen et al., 1990). The 
promoter regions surrounding the CC10 gene that confer lung specific expression have 
been characterised (Stripp et al., 1992) and while exactly how this tissue specific 
expression is achieved is not yet completely understood, negative regulators thought to 
repress CC10 expression in non-Clara cells have been identified (Navab et al., 2002). 
There are no reports in the literature of the CC10 protein being expressed, or the CC10 
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promoter being active, in brain tissue and so the low levels of expression found in the 
brain tissue of line 19 animals are most likely to be due to position effects at the site of 
transgene integration in this line. Brain expression of IL-8 in line 19 animals was not 
explored further in this study, but it may be worthwhile to do so in the future. IL-8 is 
known to be expressed by neural cells, such as microglia, and upregulation has been 
associated with some inflammatory pathologies in the brain, such as that mediated by 
the amyloid beta peptide in Alzheimer's disease (Walker et al., 2006). Whether 
constitutive hIL-8 expression in brain tissue of these mice causes any kind of 
inflammatory cell recruitment or other pathology to be observed may therefore be of 
interest. Different integration loci between the two lines are also the most likely 
explanation for the higher levels of expression seen in line 19 compared to line 33 and 
that transgene expression can be affected by the flanking 5' and 3' chromosomal 
regions at an integration locus has been well documented (Cranston et al., 2001). 
Although immunohistochemical staining of inflated lung sections demonstrated that 
lung expression in both lines was restricted to the bronchial epithelium, expression 
patterns in both lines were patchy. This may reflect the impact of 5' and 3' 
chromosomal regions on the activity of the transgenic CC10 promoter or perhaps 
suggests that some elements that control endogenous CC10 gene expression are 
missing from the sequence used in the transgene. The CC10 protein, also known as 
the Clara cell secretory protein (CCSP) is the predominant protein product of Clara 
cells (Patton et al., 1986) and has been proposed to function as a downregulator of 
airway inflammation. Indeed, altered levels of this protein have been associated with 
some lung diseases, such as sarcoidosis, where lower levels of the CC10 protein in 
serum and in BAL were found in patients with progressive compared to regressive 
disease (Shijubo et al., 2000). However, inflammatory cytokines are also major 
secretory products of the bronchial epithelium with lung insults or infection being 
potent inducers of production. For example, exposure to cigarette smoke, the main 
known cause of COPD, is known to induce high levels of IL-8 production by human 
bronchial epithelial cells (Mio et al., 1997) and recently the bacterial compound LPS 
was found to induce production of the murine IL-8 homologue KC in Clara cells 
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(Elizur et al., 2007). IL-8 expression therefore constitutes a normal function of the 
airway epithelium. 
As discussed previously, the major function of IL-8 is in mediating chemoattraction 
and activation of leukocytes, particularly neutrophils. That hIL-8 is able to mediate 
chemotaxis of mouse neutrophils has been described (Rot, 1991) and although mice do 
not possess an IL-8 gene, murine proteins with potent neutrophil chemoattractant 
properties which bind the murine CXCR2 receptor have been identified (Bozic et al., 
1994). The murine CXC chemokine KC has been overexpressed in the murine lung 
under the control of the CC10 promoter and has been reported to result in enhanced 
neutrophil migration within the lungs of transgenic animals, although the neutrophils 
were not activated and no tissue damage was apparent (Lira, 1996). Given that mouse 
neutrophils can respond to hIL-8 and the similarities in function between KC and IL-8, 
it might be predicted that overexpression of hIL-8 in the lungs of the two mouse lines 
described in this study would also result in elevated numbers of neutrophils in the 
lungs of these animals. Differential cell counts from BAL and lung tissue of IL-8 
transgenic and littermate animals showed that IL-8 expression in the mouse lung did 
result in an increased percentage of neutrophils in the lungs of transgenic animals and 
this increase was observed to be the greatest in line 19 animals, the line also reported 
to have the highest levels of IL-8 protein expression. However, perhaps unexpectedly, 
no real differences were observed in terms of absolute cell numbers, although scoring 
of transgenic and littermate inflated lung sections did suggest that some bronchi and 
vessels showed signs of inflammation with the degree of inflammation being the 
greatest in the lungs of line 19 animals. Although no large infiltrates of neutrophils 
were observed in either line, the increased percentage of neutrophils in both BAL and 
lung tissue suggests that the hIL-8 expressed by the lung epithelial cells in this model 
is biologically active. This was also implied by immunohistochemistry staining for 
neutrophils in inflated lung sections where areas of neutrophil clustering in the lungs 
of transgenic mice were found to be associated with areas of greatest IL-8 protein 
expression. This suggests that hIL-8 can indeed bind to and activate the CXCR2 
receptor expressed by murine neutrophils and as expression is limited to bronchial 
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epithelial cells, the IL-8 protein secreted into airways of these mice is likely to be 
capable of endothelial transcytosis in order to mediate neutrophil recruitment from 
vessels into the lung tissue and BAL fluid. This is also supported by studies in which 
recombinant hIL-8 has been administered directly into an organ and neutrophil 
infiltration reported (Singer and Sansonetti 2004). However, this study by Singer and 
Sansonetti, which reports colitis type pathology in mice given intracolonic rhIL-8 
concomitantly with bacterial infection, also reports a lack of pathology or infiltrate 
when rhIL-8 was administered alone. The authors speculate that lack of neutrophilic 
infiltrates in mice given rhIL-8 alone may be due to the short half life of the protein in 
the gut or due to a low affinity for murine CXCR2 compared to the murine 
homologues, KC and MIP-2. In relation to the data presented in this chapter, where 
expression of hIL-8 in the lung results in only mild inflammatory cell infiltrates, short 
half-life of the protein is an unlikely explanation as IL-8 expression is constitutive. 
However, it is possible that low affinity binding of hIL-8 to the mouse CXCR2 
receptor means that much higher levels than those reported in lines 19 and line 33 of 
this study would be required to mediate infiltration of large numbers of neutrophils 
into the lung. This hypothesis is supported by the increased percentage of neutrophils 
found in BAL and lung of line 19 animals compared to the lower expressing line 33 
and the increased numbers of neutrophils and greater levels of lung inflammation 
found in BAL and lung of some, although not all, line 19 animals. However, an 
alternative explanation, which also has some support in the literature, is that 
constitutive expression of the IL-8 protein results in downregulation of trafficking, 
perhaps though altered adhesion molecule expression or reduced expression of the 
chemokine receptor itself on the surface of circulating leukocytes. In support of 
reduced neutrophil chemotaxis, a recent study of neutrophils from COPD patients who 
also display high levels of IL-8 protein in the lung over long periods of time, found 
COPD patient neutrophils to have reduced chemotactic responsiveness compared to 
cells from healthy controls (Yoshikawa et al., 2007). Although there are no previous 
reports of hIL-8 overexpression in the mouse lung, hIL-8 has been targeted to other 
organs. The first report of a hIL-8 transgenic mouse described hIL-8 under the control 
of a liver specific promoter (Simonet et al., 1994). In this study by Simonet et al. high 
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levels of circulating neutrophils in the peripheral blood were observed, but neutrophil 
migration in response to localised administration of rhIL-8 was impaired. It is of note 
that concentrations of rhIL-8 used in this study to induce local neutrophil trafficking 
when given intraperitoneally are similar and often lower than those used by Singer and 
Sansonetti, (2004) intracolonically, where no infiltrates were reported, suggesting that 
mechanisms dictating levels of neutrophil trafficking may be different depending on 
the site of IL-8 administration. In the transgenic study by Simonet et al. where 
impaired neutrophil migration was reported, peripheral blood neutrophils were found 
to have reduced levels of the adhesion molecule L-selectin. L-selectin is an important 
mediator of neutrophil recruitment as it supports rolling of leukocytes along the 
vascular endothelium. Downregulation of this molecule was proposed to be mediated 
by the long term elevation of hIL-8 in the serum of these transgenic mice. With 
constitutive expression of hIL-8 in the lungs of the two IL-8 transgenic lines described 
in this chapter, that some IL-8 protein may reach the peripheral circulation is not 
implausible and may have meant that a similar mechanism of adhesion molecule 
downregulation was occurring. However, there were no detectable levels of hIL-8 
protein in serum from either transgenic line described in this study. Other studies have 
described receptor desensitisation as a mechanism of reducing neutrophil migration 
(Wiekowski et al., 2001b). In this study by Wiekowski et al. inducible expression of 
KC was targeted to many different tissues using the chicken beta actin promoter. No 
inflammatory cell infiltrates were observed in any organ expressing KC and CXCR2 
mediated signals were found to be attenuated in peripheral blood neutrophils 
compared to cells from non transgenic animals. In keeping with the study by Simonet 
et al. high levels of KC were detectable in serum, a finding not consistent with data 
obtained from the lung targeted hIL-8 mice described in this study. However IL-8 is 
known to regulate receptor expression on the cell surface (Samanta et al., 1990) and 
the observation of downmodulation of CXCR1 and CXCR2 on peripheral blood and 
also sputum neutrophils from COPD and asthmatic patients suggests that high levels 
of local as well as systemic IL-8 protein may be able to mediate this mechanism of 
regulation (Pignatti et al., 2005). 	To determine the reason for the lack of 
inflammatory cell infiltrates in the mice described in this chapter several different 
250 
approaches are possible. If concentration of hIL-8 is the issue then intranasal 
administration of rhIL-8 should induce neutrophil trafficking into the lungs of these 
mice. However, additional evidence against this hypothesis includes a report into the 
effects of rhIL-8 in guinea pigs where intranasal administration of this protein induced 
bronchoconstriction but with no evidence of leukocyte accumulation (Fujimura et al., 
1999). Additionally, peripheral blood neutrophils and indeed neutrophils from the 
lungs of these animals should migrate normally to rhIL-8 in in vitro chemotaxis 
assays. If neutrophil migration has in some way become impaired, through the 
constitutive expression of IL-8 over a long period of time, then in vitro neutrophil 
chemotaxis should also be impaired. In addition you would expect neutrophils 
transferred from a non transgenic animal to traffic normally to the lung in response to 
IL-8 expression there. Analysis of the cell surface expression levels of adhesion 
molecules such as L-selectin, CD11 b and CD11c and the CXCR2 receptor on 
neutrophils from these transgenic animals would also be of interest as would intranasal 
administration of KC or MIP-2 to determine whether impaired migration is also in 
response to endogenous CXC chemokines. 
Although at a baseline level, neutrophil accumulation in the lungs of both line 19 and 
line 33 transgenic animals is not induced or is impaired, other studies have reported 
that even when neutrophils are recruited in response to overexpression of CXC 
chemokines, they do not appear to be activated (Lira, 1996 and Kucharzik et al., 
2005). Further experiments presented in this chapter attempted to determine whether 
patterns of neutrophil recruitment would be different between transgenic and littermate 
animals in the context of an inflammatory response. The well characterised 
ovalbumin model of allergic airway inflammation was used in this study as it is a 
potent inducer of inflammation in the lung and although neutrophilic infiltrates and 
elevated IL-8 levels are a common feature of chronic asthma, the inflammation 
observed in the ovalbumin model is predominantly eosinophilic. Any subtle changes 
in neutrophil infiltration into the lungs of the IL-8 transgenic mice of this study should 
therefore be more apparent, but the effect of hIL-8 on the other disease outcome 
measures of this model of asthma could also be measured. However, despite seeing 
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the same increased percentage of neutrophils in the BAL of transgenic animals 
compared to littermates as was reported previously in the baseline data, no significant 
increase in neutrophil numbers was observed in any group following sensitisation and 
exposure to ovalbumin. In both transgenic and littermate groups the lung infiltrate 
was predominantly and equally eosinophilic and no major differences in general 
inflammation scores or neutrophilic inflammation scores were found. From this data, 
any impairments in neutrophil accumulation in the lung targeted hIL-8 transgenic mice 
cannot be overcome by inflammatory signals in the ovalbumin lung disease model and 
the migration of eosinophils to the lung is not impaired or indeed augmented by the 
presence of the IL-8 protein. However, impaired neutrophil migration is difficult to 
assess here as no significant neutrophilic infiltrate is expected in normal non-
transgenic animals. It would be of interest to determine whether migration in response 
to a well characterised neutrophil activating stimulus, such as LPS, is perturbed. 
However, a study by Remick et al. showing normal recruitment of neutrophils in 
response to acid induced lung injury in transgenic mice with high levels of serum IL-8, 
previously described as having impaired neutrophil migration, suggests that it might 
not be (Remick et al., 2001). In that study, neutrophil migration was found to be 
mediated normally by the endogenous murine chemokines KC and MIP-2. 
If neutrophil migration is indeed impaired in the lung targeted hIL-8 transgenic mice 
described in this chapter, then this effect could be circumvented with the use of 
conditional transgenic mice. There are now several reports in the literature of 
conditional IL-8 expression. In one study an adenoviral vector was used to 
overexpress hIL-8 in the cornea (Oka et aL, 2006) and in another the tetracycline 
system was used to induce hIL-8 expression in the intestine (Kucharzik et al., 2005). 
In both cases, significant infiltration of neutrophils to the site of hIL-8 expression was 
induced. However, it may be of interest to study the impact of hIL-8 in the lung in the 
absence of large numbers of neutrophils and neutrophil driven inflammation and 
damage as there is increasing evidence for potential neutrophil independent roles for 
IL-8 in human lung pathology. One important study recently published concerned a 
potential role for IL-8 in impaired lung function and lung remodelling with evidence 
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that IL-8 could induce Ca2+ release in human airway smooth muscle cells as well as 
causing cell contraction and inducing cell migration (Govindaraju et al., 2006). Lung 
responses to methacholine, measured as Perth, resistance and compliance are the most 
commonly used markers of lung function in the mouse and so these parameters were 
determined in the two lung targeted hIL-8 transgenic lines and compared to littermate 
animals. No differences in lung function by any of these measures were observed 
however, except perhaps for lower compliance measurements particularly in line 19 
compared to littermates, although differences were not significant. From this data it 
appears that constitutively high levels of IL-8 in the mouse lung do not affect lung 
responses to methacholine, i.e. there is no apparent increase in bronchial 
hyperreactivity, as might have been suggested from studies with guinea pigs (Fujimura 
et al., 1999). However, in the study by Fujimura et al. IL-8 was not expressed by the 
lung but delivered as a single dose at a single time point and the constitutive nature of 
IL-8 expression in this study may have a major impact, for example by decreasing 
CXCR2 expression levels on the surface of murine airway smooth muscle. Of interest 
however were the findings of differences in bronchial hyperreactivity between hIL-8 
transgenic mice and littermate controls that had been sensitised with alum alone but 
then exposed to aerosolised OVA. Reasons for increased bronchial hyperreactivity in 
transgenic animals compared to littermate controls in this situation, but not in the 
absence of antigen challenge, are not clear but it may be that chronic exposure to hIL-
8 over long periods of time in these mice somehow predisposes to impaired lung 
function upon challenge with antigen in a way that is independent of a T cell mediated 
immune response e.g. by directly impacting on the lung tissue itself in terms of airway 
remodelling or smooth muscle reactivity, the consequences of which are more 
pronounced in the context of aerosolised exposure to a foreign protein 
Despite this small difference in lung function between alum treated transgenic and 
littermate control groups, differences in lung function measurements between 
transgenic and littermate control disease groups were not observed. Also importantly, 
although in all transgenic and littermate groups sensitisation and exposure to 
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ovalbumin was associated with slightly worse lung function measurements, 
differences between disease and alum only control groups were very slight. As other 
parameters, such as eosinophilic lung inflammation and goblet cell scoring suggested 
that disease had indeed been successfully induced, the lack of large changes in lung 
function is most likely due to the genetic background of mice used in this study. 
Ovalbumin protocols involving lung function measurements most commonly use 
BALB/c mice as they show good susceptibility and marked outcomes of disease 
compared to other strains. Strain dependent variations in lung function measurements 
are well reported (Reinhard et al., 2002) and it is likely that larger differences between 
disease and control groups, and perhaps even at a baseline as a consequence of IL-8 
expression, may be more evident on a different genetic background. 
Despite no observed differences between IL-8 transgenic and littermate disease groups 
with respect to cell infiltrates and lung function, one disease parameter was found to 
be altered. The disease groups of both lines of lung targeted hIL-8 transgenic animals 
showed an increased prevalence of mucus secreting goblet cells in the airways of the 
lung when compared to littermate control animals. Goblet cell mucus hypersecretion 
and goblet cell metaplasia is a common characteristic of allergic airway inflammation 
in both humans and mice and is associated with airway remodelling. Metaplasia is the 
process by which goblet cells arise from normal airway epithelial cells, such as Clara 
cells, and once formed, produce mucins in response to many factors including Th2 
type cytokines IL-13 and IL-4 (Kuperman et al., 2005). Mucus hypersecretion is not 
just a feature of asthma, but is found in association with many other lung diseases such 
as cystic fibrosis, chronic bronchitis, bronchiectasis and COPD, and excessive mucus 
plays a major part in the pathology of these diseases by plugging airways and causing 
recurrent infections. Neutrophils have been implicated in pathways leading to goblet 
cell hyperplasia (Shao and Nadel, 2005) but aside from their role in neutrophil 
recruitment, there have been no reports directly implicating CXC chemokines in this 
process. Data presented in this chapter suggests that there is no difference in the 
number of goblet cells or mucus secretion in the lungs of transgenic compared to 
control mice in the absence of disease induction. This argues against a hypothesis 
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where IL-8 is acting directly on the airway epithelium in the absence of other 
inflammatory stimuli to mediate hyperplasia. The lack of a neutrophil infiltrate in 
these animals also argues against a neutrophil mediated mechanism and so perhaps 
one more likely hypothesis is that IL-8 may be affecting the IL-4 and IL-13 mediated 
pathways of goblet cell production and activation. Mice that overexpress IL-4 or IL-
13 show evidence of increased goblet cell hyperplasia and mucus production (Temann 
et al., 1997 and Zhu et al., 1999). It would therefore be of great interest to look at 
levels of IL-4 and IL-13 in the BAL and lung of all disease groups in the ovalbumin 
experiment described in this study to try to determine whether presence of the hIL-8 
protein in the lung has affected endogenous cytokine production in the context of this 
disease model. If no differences in IL-4 or IL-13 levels are observed then possible 
novel mechanisms involving IL-8, probably in conjunction with another inflammatory 
mediator(s) should start to be explored and, as Clara cells themselves can both become 
goblet cells and are constitutively expressing the IL-8 protein, the possibility that any 
mechanism could be mediated by IL-8 protein inside the cell should also be borne in 
mind. As goblet cell hyperplasia and mucus secretion is one measure of airway 
remodelling, other markers of this process, such as collagen deposition and fibrosis 
should also be considered. Angiogenesis is one part of the fibrotic process in which 
CXC chemokines are heavily implicated (Strieter et al., 1995) and in a broader picture 
of fibrosis, neutralisation of the murine IL-8 homologue, MIP-2, was found to be 
protective in a mouse model of fibrotic lung disease (Keane et al., 1999). Of interest 
would be assessment of fibrosis in lung tissue from the ovalbumin disease experiment 
described in this chapter, but also important would be characterisation of any fibrotic 
pathologies in lungs of these transgenic animals prior to disease induction. Indeed 
subtle changes in airway structure may be able to account for the small changes 
observed in baseline airway compliance and increased bronchial hyperreactivity upon 
aerosol exposure to OVA of these lines. 
255 
Overview 
Transgenesis, CD4+ T cells and lung inflammation have been the main themes of this 
thesis, but while much has been achieved, much work still remains in characterising 
the new transgenic lines that have been created, answering questions surrounding 
observed phenotypes and in creating new models to try to answer key questions about 
disease pathogenesis and basic T cell biology. 
One of the main aims at the start of this thesis was to address a possible role for the T 
cell receptor in determining CD4+ T cell effector phenotype. Evidence from previous 
studies suggested that preferred structural motifs may expand during the course of Thl 
or Th2 type immune response and that these motifs may convey TCR/pMHC binding 
characteristics that inherently skew the process of differentiation and Thl or Th2 T 
cell development. This thesis described identification of Th 1 and Th2 derived TCR a 
chains that were successfully expressed transgenically, although levels of Thl TCR a 
chain expression were much lower than those seen in the Th2 TCR a transgenic lines. 
Ongoing work is needed to establish the cause of this apparent low transgene 
expression level in the Thl TCR a chain transgenic mice as this low level of 
expression and lack of expansion of the transgenic TCR sequence in the context of 
peptide specificity in in vitro culture is precluding the use of this line to determine 
inherent T cell phenotype and p chain pairing. It may be necessary to cross this mouse 
line with mice carrying a disrupted TCR a locus in order to achieve these aims. High 
levels of expression in the Th2 TCR a chain transgenic lines meant that experiments 
to determine 1 chain pairing and inherent effector cell phenotype were possible. It 
was found that transgenic expression of this Th2 TCR a chain, with an elongated 
CDR3a region, did not bias the naïve TCR [3 chain repertoire of these mice, but that in 
the context of peptide specificity a [3 chain pair could quickly be established. A 
dominant a13 TCR in peptide specific T cell lines derived from these animals was also 
associated with a Th2 type cytokine and transcription factor profile suggesting that 
expression of the elongated Th2 derived TCR a chain is sufficient to bias TCR p chain 
selection and pMHC binding such that development of a Th2 phenotype is favoured. 
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In vivo data supported this argument by demonstrating that during a memory response 
to peptide, T cells bearing the elongated transgenic TCR a chain produced less IFNI. 
Experiments are currently ongoing to determine whether these cells that make less 
IFN-y are associated with a dominant TCR 13 chain, and further work to establish an 
inherent Thl or Th2 bias in vivo could include a disease model such as EAE, to 
demonstrate increased resistance or susceptibility to disease as a consequence of 
inherent T cell phenotype. It will also be of interest to look at Th17 and regulatory T 
cell phenotypes in these animals. The question of inherent phenotype bias will 
nevertheless be most easily and most conclusively answered in mice expressing a 
transgenic TCR a and 13 chain that have been subsequently crossed onto a RAG 
knockout background and thus do not express any endogenous TCR at all. One TCR 
[3 chain pair identified from in vitro studies has now been expressed transgenically and 
breeding of these animals with Th2 TCR a chain animals is now currently underway. 
Basic characterisation of these animals in terms of normal proliferative and cytokine 
responses to peptide stimulation will be required both in vitro and in vivo, leading to 
the ultimate test of the original hypothesis using a RAG knockout background and 
comparing these animals to those with a Thl TCR a and 13 chain pair. At this point, 
comparisons of TCR binding affinity for pMHC can be achieved using MHC class II 
tetramers and signalling experiments to determine differential downstream 
consequences of TCR/pMHC ligation will also be possible. The predicted outcome 
from these studies would be that the Th2 TCR makes lower affinity interactions with 
the pMHC ligand and consequently has an altered pattern of phosphorylation and 
downstream signalling events that lead to a Th2 rather than Thl profile of gene 
expression. 
A second hypothesis leading from these studies concerned Thl and Th2 responses in 
the context of lung inflammation. If transgenic expression of Thl and Th2 derived 
TCRs can lead to inherent T cell phenotype bias then these transgenic animals could 
be used to generate Thl and Th2 type models of lung inflammation. As a starting 
point for this question this thesis has described the generation of an inducible 
transgene that confers lung specific, but inducible expression of the TCR cognate 
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peptide, PLP 56-70, in the mouse lung. Results obtained to date have shown the 
inducible mechanism of this approach to be functioning correctly and low levels of 
transgene expression have been detected using both membrane bound and secreted 
versions of the construct. Trafficking of T cells to the lung in response to this peptide 
expression has yet to be demonstrated and should become the immediate focus of 
work with these lines. In the absence of a complete TCR transgenic animal, 
experiments to try to prime and induce T cell trafficking in mice transgenic for the 
lung construct and the Cre protein have been started. Priming with peptide followed 
by induction of lung expression has been the first approach, but it may be that due to 
peptide induced tolerance mechanisms priming with whole PLP protein will be 
required. Whether any priming at all will be required and whether Thl or Th2 biased 
T cells will successfully traffic to the lung upon transgene induction awaits the 
existence of complete Thl and Th2 TCR transgenic animals and so at present this 
second hypothesis remains far from being properly addressed. However, if transgenic 
T cells do successfully traffic in this model, there is great potential for modelling some 
of the chronic inflammatory processes in the lung that have so far eluded many others. 
An alternative approach to lung inflammation and the last section of this thesis 
described overexpression of the human interleukin 8 cytokine in the bronchial 
epithelial cells of the mouse lung. High levels of IL-8 protein and concomitant 
neutrophilia in the lung are found in association with a number of different lung 
diseases but, despite much evidence that the human protein is biologically active in the 
mouse, there are as yet no reports in the literature of this protein having been 
overexpressed in the lung. This thesis has described the generation of two lines of IL-
8 expressing mice and lung specific expression has been demonstrated in both. 
Despite well known functions of IL-8 as a chemoattractant for leukocytes, especially 
neutrophils, no significant inflammatory cell infiltrates were observed in these animals 
in response to the constitutive IL-8 expression, although that the protein was 
biologically active was suggested by altered neutrophil percentages and distribution in 
the lung. Levels of IL-8 protein, as well as mechanisms of impaired recruitment such 
as receptor desensitisation have been suggested to explain these findings and further 
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work is required to establish the reason for the lack of neutrophil trafficking into the 
lungs of these mice. Lack of neutrophilic infiltrates in these animals could aid the 
analysis of neutrophil independent IL-8 mediated disease mechanisms in the lung. 
The finding of increased goblet cell numbers and mucus production in the lungs of 
transgenic animals compared to littermate controls, in the context of ovalbumin 
induced lung inflammation, is of particular interest and leads to further questions 
about potential roles for IL-8 in lung remodelling and fibrosis. Further work to 
establish whether there are any changes in lung structure as a consequence of IL-8 
overexpression, in the absence of lung inflammation, is required as well as 
experiments to try to determine the mechanism of increased mucus production in the 
context of disease. To establish a model of lung neutrophilia and the pathologies 
associated with these infiltrates it may be necessary to generate mice carrying an 
inducible version of this hIL-8 transgene, but despite the absence of these cells in the 
lungs of mice described here, this model still holds much potential for dissecting 
mechanisms of IL-8 mediated pathology in the lung. 
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Appendices  
Appendix 1. Stock solutions and Buffers 
TE 
■ 10 mM Tris (pH 8.0) (Sigma-T1503) 
■ 1 mM EDTA (pH 8.0) (Sigma-E4884) 
TAE 
■ 40 mM Tris-acetate 
■ 1 mM EDTA (pH 8.0) 
Tissue digestion buffer for genomic DNA extraction 
■ 100 mM Tris (pH 8.0) 
■ 5 mM EDTA 
■ 200 mM NaC1 (Sigma-S7653) 
■ 0.2 % w/v SDS (Calbiochem-428015) 
Competent cell preparation solution A 
■ 10 mM MgC12 (Sigma-M2670) 
■ 0.2 mM MES (Sigma-M5287) 
■ 0.05 mM CaC12 (Sigma-C7902) 
Competent cell preparation solution B 
■ 15 % glycerol (BDH-101186M) 
■ 50 mM CaC12 
■ 10 mM MgC12 
■ 2 mM MES 
Southern blot depurination solution 
■ 11 mM HC1 (BDH-101254M) 
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Southern blot denaturing buffer 
■ 1.5 M NaC1 
■ 0.5 M NaOH (BDH-102524X) 
Southern blot neutralisation buffer 
■ 1.5 M NaC1 
■ 0.5 M Tris (pH 7.5) 
1 x SSC 
■ 0.015 M Tri-sodium citrate (Sigma-S4641) 
■ 0.15 M NaC1 
Maleic acid wash buffer 
■ 0.1 M Maleic acid (Sigma-M0375) 
■ 0.15 M NaC1 
adjust to pH 7.5 with concentrated NaOH 
■ 0.3 % v/v Tween 20 (Sigma-P7949) 
DIG detection buffer 
■ 0.1 M Tris 
■ 0.1 M NaC1 
adjust to pH 9.5 
Immunohistochemistry block solution 
Solution should be made up with PBS 
■ 1 % BSA (Sigma-A9647) 
■ 0.2 % TritonX100 (Sigma-X100) 
■ 0.1 % NaN3 (BDH-10369) 
■ 10 % Normal mouse serum (Sigma-M5905) 
■ 10 % goat serum (Sigma-G9023) or 10 % donkey serum (Sigma-D9663) depending 
on species origin of secondary antibody 
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ELISA block solution 
Solution should be made up with PBS 
■ 1% BSA 
■ 5% sucrose (Sigma-S7903) 
■ 0.05% NaN3  
ELISA wash buffer 
■ 0.05% Tween 20 in PBS 
Turks stain 
■ 0.01% crystal violet 
■ 1% acetic acid (BDH-10001) 
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Appendix 2. Antibodies and recombinant proteins 
Antibody  
ELISA capture antibodies 
Anti human IL-8 
Anti-mouse IFN-y 
Anti-mouse IL-4 
Anti-mouse IL-5 
 
Product details Concentration used 
 
R&Dsystems-MAB208 
R&Dsystems-MAB785 
R&Dsystems-MAB404 
R&Dsystems-MAB405 
0.5 µg/m1 
4 vg/m1 
2 vg/m1 
1 µg/m1 
ELISA detection antibodies 
Biotinylated anti human IL-8 
Biotinylated anti-mouse IFN-y 
Biotinylated anti-mouse IL-4 
Biotinylated anti-mouse IL-5 
R&Dsystems-BAF208 
R&Dsystems-BAF485 
R&Dsystems-BAF404 
R&Dsystems-BAM705 
20 ng/ml 
400 ng/ml 
100 ng/ml 
50 ng/m1 
Immunohistochemistry primary antibodies 
Rabbit anti-Cre 
Goat anti-mouse CC10 
Rabbit anti-human IL-8 
Rabbit anti-human myeloperoxidase 
Rabbit anti Hen Lysozyme 
Covance-PRB-106C 
SantaCruz-SC9773 
Serotec-AHP781 
DakoCytomation-A0398 
Abcam-ab391-100 
1/2500 
1/1000 
1/500 
1/500 
1/200— 1/1000 
Immunohistochemistry secondary antibodies 
Biotinylated goat anti-rabbit 	 Jackson-111-066-047 
	
1/500 
Biotinylated donkey anti-goat Jackson-705-065-003 1/500 
  
Recombinant protein 
	
Product details 
 
  
Human IL-8 	 eBioscience-14-8089 
Mouse IFN-y R&Dsystems-485-MI 
Mouse IL-4 
	
R&Dsystems-404-ML 
Mouse IL-5 R&Dsystems-405-ML-005 
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Appendix 3. Restriction enzymes and buffers 
Enzyme 
BamHI 
BssHII 
EcoR1 
EcoRV 
HindIII 
KpnI 
Nan 
NcoI 
NotI 
Sad 
SacII 
Sall 
SfiI 
XbaI 
XhoI 
XmaI  
Product details 
Promega-R6021 
Promega-R6831 
Promega-R6011 
Promega-R6351 
Promega-R6041 
Promega-R6341 
Promega-R6861 
Promega-R6513 
Promega-R6431 
Promega-R6061 
Promega-R6221 
Roche-348-783 
Promega-R6391 
Promega-R6 181 
Promega-R6161 
Promega-R6491 
Cleavage site (A) (5'-3') 
G A GATCC 
G A CGCGC 
G A AATTC 
GAT A ATC 
A A AGCTT 
GGTAC A C 
GG A CGCC 
C A CATGG 
GC A GGCCGC 
GAGCT A C 
CCGC A GG 
G A TCGAC 
GGCCNNNN A NGGCC 
T A CTAGA 
C A TCGAG 
C A CCGGG 
Optimal 
buffer 
E 
H 
H 
D 
E 
J 
G 
D 
D 
J 
C 
suRE/cut H 
B 
D 
D 
B 
Temperature 
(°C)  
37.0 
50.0 
37.0 
37.0 
37.0 
37.0 
37.0 
37.0 
37.0 
37.0 
37.0 
37.0 
50.0 
37.0 
37.0 
37.0 
Buffer (1x) 
B 
C 
D 
E 
G 
H 
J 
suRE/cut H  
Tris (mM) MgC12 (mM) NaC1 (mM) KC1 (mM) DTT (mM) 
6 	6 	50 	 1 
10 10 50 1 
150 	 1 
100 1 
50 
50 	1 
150 
pH 
7.5 
7.9 
7.9 
7.5 
8.2 
7.5 
7.5 
7.6 
6 
6 
50 
90 
10 
100 
6 
6 
5 
10 
7 
10 
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Appendix 4. PCR primers for analysis of TCR a and 13 gene usage 
Primer 	 Sequence (5' - 3') 
TCR a V region primers 
NW36 	 (F) GTCCTGACCTCGCATGCTHCMMBWMYYTCYYSTGGTAY 
NW37 (F) GTCCTGACCTCGCATGCTTCDWYTRYHTCYTYTGGTAY 
NW38 	 (F) GTCCTGACCTCGCATGCRYSASRRYYGTSCWGTGGTTY 
TCR a C region primers 
NJ108 	 (R) GGCCCCATTGCTCTTGGAATC 
NJ109 (R) CGGCACATTGATTTGGGAGTC 
NJ110 	 (R) TCTCGAATTCAGGCAGAGGGTGCTGTCC 
TCR f3 V region primers 
NK121 	 (F) GTCCTGACCTCGCATGCCAYMAYDMYRTKKAYTGGTAY 
NK122 (F) GTCCTGACCTCGCATGCCAYCMADMWRTKTWYTGGTAY 
NK123 	 (F) GTCCTGACCTCGCATGCMCYWMSRTMRMYTGGTAY 
TCR p C region primers 
MQ284 
	
(R) AGCACACGAGGGTAGCCTT 
MS175 (R) GACAGAACTTTGAATTCCTCTGCTTTTGATGG 
M13 (sequencing primer) 	(F) CTGGCCGTCGTTTTAC 
B=CorGorT 	 R=AorG 
D=AorGorT 	 S=CorG 
H=AorCorT 	 W=AorT 
K=GorT 	 Y=CorT 
M=AorC 
(F)= forward primer 
(R) = reverse primer 
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Appendix 5. TCR CDR3I3 spectratyping primers 
primer 	 Sequence (5' - 3') 
TCR V ri (TRBV) primer 
V(3 1 	TRBV 5 
vp 2 	TRBV I 
Vi3 3.1 	TRBV26 
VI3 4 	TRBV 2 
Vi3 5.1 	TRBV 12-2 
V(3 5.2 	TRBV 12-1 
V13 5.3 	TRBV 12-3 
Vi3 6 	TRBV 19 
VP 7 	TRBV 29 
VI3 8.1 	TRBV 13-3 
V(3 8.2 	TRBV 13-2 
V(3 8.3 	TRBV 13-1 
V(3 9 	TRBV 17 
V13 10 	TRBV 4 
V(3 11 	TRBV 16 
V(3 12 	TRBV 15 
V(3 13 	TRBV 14 
vp 14 	TRBV 31 
VI3 15 	TRBV 20 
V13 16 	TRBV 3 
V13 17 	TRBV 24 
VI3 18 	TRBV 30 
V13 19 	TRBV 21 
Vi3 20 	TRBV 23  
(F) CTGAATGCCCAGACAGCTCCAAGC 
(F) TCACTGATACGGAGCTGAGGC 
(F) CCTTGCAGCCTAGAAATTCAGT 
(F) GCCTCAAGTCGCTTCCAACCTC 
(F) CATTATGATAAAATGGAGAGAGAT 
(F) AAGGTGGAGAGAGACAAAGGATTC 
(F) AGAAAGGAAACCTGCCTGGTT 
(F) CTCTCACTGTGACATCTGCCC 
(F) TACAGGGTCTCACGGAAGAAGC 
(F) CATTACTCATATGTCGCTGAC 
(F) CATTATTCATATGGTGCTGGC 
(F) TGCTGGCAACCTTCGAATAGGA 
(F) TCTCTCTACATTGGCTCTGCAGGC 
(F) ATCAAGTCTGTAGAGCCGGAGGA 
(F) GCACTCAACTCTGAAGATCCAGAGC 
(F) GATGGTGGGGCTTTCAAGGATC 
(F) AGGCCTAAAGGAACTAACTCCCAC 
(F) ACGACCAATTCATCCTAAGCAC 
(F) CCCATCAGTCATCCCAACTTATCC 
(F) CACTCTGAAAATCCAACCCAC 
(F) AGTGTTCCTCGAACTCACAG 
(F) CAGCCGGCCAAACCTAACATTCTC 
(F) CTGCTAAGAAACCATGTACCA 
(F) TCTGCAGCCTGGGAATCAGAA 
Constant 3 region primer 
C(3 - FAM labelled 	 (R) 6FAM-CTTGGGTGGAGTCACATTTCTC 
6FAM = 6-carboxyflurorescein-amino-hexy fluorescent dye 
(F) = forward primer 
(R) = reverse primer 
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Appendix 6. Thl and Th2 TCR a chain primers 
Primer 	 Sequence (5' — 3') 
Annealing 	Product 
temp 	[MgC12] 	size 
Thl a construct 
ThlIntronF 	(F) CAGGAAGAATGATGAAGACATC 
ThlHindIIIR 	(R) CAAATGAAAGCTTAGACCCAG 
TRAV 10 	(F) GTCCCGGGTCCCAGGCAGGAAGAATGATG 
Th1 LP1/2IntronR (R) CATTTGAACGAATGTCTATCAC 
HindIIITh I F 	(F) CTGGGTCTAAGCTTTCATTTG 
TRAVJ58 	(R) GCCGCGGCCGCGAAGCCACATGCCCATCAGTTGGTG 
Thl CDR3 motif (F) TGCAGCAAGCAGGGAAGGCACTGGGTCTAAGC 
NJ108 	 (R) GGCCCCATTGCTCTTGGAATC 
TRAVIO 	See above 
TRAVJ58 	See above 
55 °C 
52 °C 
52 °C 
56 °C 
55 °C 
1.5 mM 
2.5 mM 
3.0 mM 
1.5 mM 
1.5 mM 
538 / 384 
bp 
403 by 
148 bp 
250 by 
661 by 
Th2 a construct 
Th2lntronF 	(F) CTGCCTAGCCATGTTCCTAGTG 
Th2HindIIIR 	(R) CTGCCCAAACACAAGCTTGC 
TRAV17 	(F) GTCCCGGGCTTCTCACTGCCTAGCCATG 
Th2LP1/2IntronR (R) GGCTCTGGCCAGGATACTGC 
Th2HindIIIF 	(F) GCAAGCTTGTGTTTGGGCAG 
TRAJ50 	(R) GCCGCGGCCGCTTAAAGGACCCTAGTAGTAGCAAGG 
Th2 CDR3 motif (F) GCTGTGAGCTGGGATAACTATGCCCAGGGATTAAC 
NJ108 	 (R) GGCCCCATTGCTCTTGGAATC 
TRAV17 	See above 
TRAVJ58 	See above 
55°C 
52 °C 
52 °C 
56 °C 
55 °C 
1.5 mM 
2.5 mM 
2.5 mM 
1.5 mM 
1.5 mM 
527 / 391 
 bp 
348 by 
119 bp 
250 by 
622 by 
(F) = forward primer 
(R) = reverse primer 
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Appendix 7. MIPLP and SIPLP trans2ene primers and oli2onucleotides 
Primer Sequence (5' — 3') 
Annealing 	Product size 
temp 	[MgCl2] Sec./Memb. 
PLP constructs 
HELA 
PLPB 
HELA 
TM/CYTOB 
SfilBamHlBodF 
BodXho I Sfi1R 
CC102000F 
BetaglobinB 
3rdexonF 
BetaglobinB 
CC101500F 
CC10210OR 
StopfloxedF 
StopfloxedR 
SIPLPStopfloxedR 
(F) CTGCTCTGGGGAAAGTCTTT 
(R) GTTCCATAGATGACATACTG 
(F) CTGCTCTGGGGAAAGTCTTT 
(R) TATTCTGCACTGCAAAGATC 
(F) GGCCATTGCGGCCGGATCCTGAGAACTTCA 
(R) GGCCGCAATGGCCCTCGAGGGATCTCCATA 
(F) GCCTCTGGTTCTCCAGGGTT 
(R) TGATAGGCAGCCTGCACCTG 
(F) CTGGGCAACGTGCTGGTTAT 
See above 
(F) ATAAAAGCACTGGAGAAGTA 
(R) CAGAGGTCGTGGAACTGTAG 
(F) CATCAGCCCACATCTACAGAC 
(R) CAATGGCCAGTACTAGTGAAC 
(R) CCTGAAGTTCTCAGGATCCG 
53 °C 
53 °C 
68 °C 
53 °C 
55 °C 
53 °C 
60 °C 
1.5 mM 
1.5 mM 
1.5 mM 
1.5 mM 
1.5 mM 
1.5 mM 
2.5/1.5 
mM 
214 bp 
611 bp 
1755 / 1888 by 
3239 / 3372 by 
625 / 758 by 
629 bp 
1736/1647 bp 
Oligonucleotide 	 Sequence (5' — 3') 
PLP 56-70 top 
PLP 56-70 bottom 
Kpnl linker top 
Kpnl linker bottom  
(T) CGCCAAAAACTACCAGGACTATGAGTATCTCATTAATGTGATTCATGCTTTCC 
AGTATGTCATCTATGGAACCCGC 
(B) GGGTTCCATAGATGACATACTGGAAAGCATGAATCACATTAATGAGATA 
CTCATA GTCCTGGTAGTTTTTGG 
(T) GGAGAGGTACCAACTTGAACGCTATGGGCATCCAATGCATCCATGGAGCT 
(B) CCATGGATGCATTGGATGCCCATAGCGTTCAAGTTGGTACCTCTCCGC 
(F) = forward primer 
(R) = reverse primer 
(T) = top strand 
(B) = bottom strand 
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Appendix 8. PCR primers 
Primer Sequence (5' — 3') 
Annealing 
temp 	[MgCl2] Product size 
Th2 13 construct 
VP3 1 F 
J(32-3R 
20TCRI3F1 
20TCROR1 
(F) GACTCGAGCCTAGACAAAGACCATCTTGAAC 
(R) CTCCGCGGTCACAGCCTCTTGGTACAGGAC 
(F) CATCTTGAACTATGCTGTACTCTC 
(R) CCAACTTACCGAGAACAGTCAG 
55 °C 
55 °C 
2.0 mM 
1.5 mM 
850 by 
755 by 
hIL-8 construct 
IL-8F 
IL-8R 
CC101500F 
CC10210OR 
(F) AGGAATTCTGTAAACATGACTTCCAAGC 
(R) GCGAATTCTTATGAGTTCTCAGCCCTCTTC 
(F) ATAAAAGCACTGGAGAAGTA 
(R) CAGAGGTCGTGGAACTGTAG 
55 °C 
53 °C 
1.5 mM 
1.5 mM 
319 by 
629 by 
Bm70 MerCreMer 
Cre 1 
Cre 2 
(F) CGCAGAACCTGAAGATGTTCGCGA 
(R) GGATCATCAGCTACACCAGAGACG 
60 °C 2.0 mM 500 by 
HPRTF 
HPRTR 
(F) TCGTGATTAGCGATGATGAACC 
(R) CTGGCAACATCAACAGGACTCC 
60 °C 1.5 mM 650 by 
(F) = forward primer 
(R) = reverse primer 
Real- time PCR 
18s 
Human IL-8 
Mouse Tbet 
Mouse Gata3 
Applied Biosystems — Hs-99999901_sl 
Applied Biosystems — Hs-00174103_ml 
Applied Biosystems— Mm00450960_m1 
Applied Biosystems — Mm00484683_ml 
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Appendix 9. Wright-Giemsa stain — cell morphology 
A = Macrophage 
B = Lymphocyte 
C = Eosinophil 
D = Neutrophil 
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Cla 118941 	Sal 119941 
Not I, Sac 112841 
BamH112441 
Appendix 10. Thl TCR a chain construct - plasmid map 
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Appendix 11. Th2 TCR a chain construct - plasmid map 
BamHI 0 
Sal 11990 
Cla 1 18956 
/mai 2180 
pEMBL18 	
Th2 V17/J50 
	of I, Sac II 2802 
JA2 
Sal 1 1510 
Th2 pTA cassette 
19902 bp 
	 BamH1 4947 
Bam1-11 1445 
constant  region 
BamH 112456 
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Appendix 12. Th2 TCR 13 chain construct - plasmid map 
Kpn 1 20670 
BamHI 860 
coR1 2190 
Kpn 117740 
BamHI 17740 
EcoRI 17590 
_____X ho 14470 
Th2 pTB cassette 
Th2 VB31/JB2-3 
20670 bp 
--Sac II 5320 
J62.6 
amHI 6490 
coRl 6690 
BamHI 1259 
 
constant region 
\coRI 7590 
    
320 
PTZ 18 
BssH II 601 S 
Sac 115971 
Not 1595 • 
Sfi 15958 
Xho 15945 
EcoR 15410 
Rabbit beta globin 
TM region 
HEL 
PLP (56-70) 
HEL 
ind III 2465 
EcoR 12477 
amH 12495 
of 1 2514 
EcoR 1 2595 
ind III 2605 
amH 1 2612 
ind III 2686 
LoxP 
Floxed STOP 
LoxP 
Xho 13557 
Appendix 13. MIPLP construct — plasmid map 
ssH111 
hoI53 
Hind III 74 
amH 18D 
EcoR 1340 
EcoR 1744 
CC10 promoter 
MIPLP 
8793 bp 
Sac II 500 
Nar 14926 
EcoR I 4729 
   
   
  
amH 13995 
fi 1 4083 
amH 14089 
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Appendix 14. SIPLP construct - plasmid map 
-=--1"-Flind III 2465 
EcoR 1 2477 
BamH 1 2495 
Not 1 2514 
EcoR 1 2595 
ind 111 2605 
amH 1 2612 
Hind III 2686 
BssH II 5877 
Sac II 5838 
Not 1 5826 
Sfi 1 5825 
Xho 1 581 
amH 1 3995 
fi 1 4083 
amH 1 4089 
EcoR 1 5277 
Sac II 5002 
Nar 1 492 
ssH 111 
ho 153 
indlIl 74 
amH 180 
EcoR 1 340 
322 
ind1112461 
pnl 2471 
Notl 2485 
SacI12479 
BamH1 2574 LoxP 
SIPLP (LSL rev) 
8733 bp 
CC10 promoter 
BssH 115948 
Sacll 5906 
Notl 5894 
Xbal 5887 
Xhol 5875 
Rabbit beta globin 
HEL 
PLP (56-70) 
HEL 
Floxed STOP 
Lox P 
EcoR15340/  
Xhol 3012 
Sacll 5065-j  
Nan 4989 
EcoRl 479 
hol 4125 
pnl 4144 
amHI 4152 
'nal 3883 
	BamHI 3957 
ind1113964 
otl 4055 EcoR1 3974 
Xbal 4062 
amH14074 
coR1 4092 
Hind111 4104 
Appendix 15. Inverted stop sequence SIPLP construct — plasmid map 
BssH111 
Xhol 49 
ind11170 
EcoRl 332 
EcoR1 739 
323 
BasH11405 
Not1 4002 
Xbal 3995 
Xhol 398 
\----EcoR1 3135 
indlIl 3352 
coR1 3448 
BssH11 1 
Kpnl 42 
hol 53 
indlIl 74 
HindlIl 2465 
NN  .-,--NE,  csoRV 2473 
---EcoR1 2477 
amHi 2495 
Appendix 16. Lung targeted hIL-8 construct — plasmid map 
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Appendix 17. Thl TCR a complete V-J insert nucleotide sequence 
1 
TCCCAGGCAG GAAGAATGAT GAAGACATCC CTTCACACTG TATTCCTATT 
51 
CTTGTGGCTG TGGATGGACT GTGAGTTGGA AGATTTGGGT CAAGAGAAAA 
101 
AAATGGTGGA TGTTAGACAT CTATGGGCAA TCTATTTTAT ACAGTTCCTT 
151 
CTAGTTGTGG ACAAAGAGAT TTAGCAGAGT ACTGCCTGAC TGCTCCTCTC 
201 
CTTTCTGTTT TTCTTTCTGT GTAGGGGAAA GCCATGGAGA GAAGGTCGAG 
251 
CAACACCAGT CTACACTGAG TGTTCGAGAG GGAGACAGCG CTGTCATCAA 
301 
CTGCACTTAC ACAGATACTG CCTCATCATA CTTCCCTTGG TACAAGCAAG 
351 
AAGCTGGAAA GAGTCTCCAC TTTGTGATAG ACATTCGTTC AAATGTGGAC 
401 
AGAAAACAGA GCCAAAGACT TACAGTTTTA TTGGATAAGA AAGCCAAACG 
451 
ATTCTCCCTG CACATCACAG CCACACAGCC TGAAGATTCA GCCATCTACT 
501 
TCTGTGCAGC AAGCAGGGAA GGCACTGGGT CTAAGCTTTC ATTTGGGAAG 
551 
GGGGCAAAGC TCACAGTGAG TCCAGGTAAG TGTGAGGCTA TCTAACCATC 
601 
TTTCTAAATG CGATTTGAGA ATTTTTTTTT CTTTCACACC AACTGATGGG 
651 
CATGTGGCTT C 
Black = intronic sequence. 
Blue = coding sequence 
Red = mutated base pair (G—>T) 
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Appendix 18. Thl TCR a rearranged V-J insert nucleotide/protein  
sequence  
1 - ATG AAG ACA TCC CTT CAC ACT GTA TTC CTA TTC TTG TGG CTG GAA 
1-M K T S L H T VF L F LW L E 
46 - AGC CAT GGA GAG AAG GTC GAG CAA CAC CAG TCT ACA CTG AGT GTT 
16-S HGE KVEQHQST L S V 
91 - CGA GAG GGA GAC AGC GCT GTC ATC AAC TGC ACT TAC ACA GAT ACT 
31-R E G D S A V I N C T YT D T 
136 - GCC TCA TCA TAC TTC CCT TGG TAC AAG CAA GAA GCT GGA AAG AGT 
46-A S S YFPWYKQE AGK S 
181 - CTC CAC TTT GTG ATA GAC ATT CGT TCA AAT GTG GAC AGA AAA CAG 
61-L H F V ID I R S N V D R K Q 
226 - AGC CAA AGA CTT ACA GTT TTA TTG GAT AAG AAA GCC AAA CGA TTC 
76-S Q R LT V L L D K K A K R F 
271 - TCC CTG CAC ATC ACA GCC ACA CAG CCT GAA GAT TCA GCC ATC TAC 
91-S L H IT A T Q P E D S A I Y 
316 - TTC TGT GCA GCA AGC AGG GAA GGC ACT GGG TCT AAG CTT TCA TTT 
106-F CAA SR E G T G S K L S F 
361 - GGG AAG GGG GCA AAG CTC ACA GTGAGT CCA 
121-G K GA K LT VSP 
Light blue = Leader sequence of TRAV10 
Dark blue = TRAV10 
Red = CDR3a region 
Green = TRAJ58 
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Appendix 19. Th2 TCR a complete V-J insert nucleotide sequence 
1 
CTTCTCACTG CCTAGCCATG TTCCTAGTGA CCATTCTGCT GCTCAGCGCG 
51 
TTCTTCTCAC TGAGTAAGTA TTATTTCAGT CCTTGCTTGC TTTTGTTTCC 
1 01 
ACAGACAGAA CATGTTCCTA GTCAGAATCT ACACAAGGGA CATAGTATCA 
151 
TTACAGGTAG GTCTATTCTG GTCTCACTGC TGCTACGTTG GTATTACAGG 
201 
AGGAAACAGT GCCCAGTCCG TGGACCAGCC TGATGCTCAC GTCACGCTCT 
251 
ATGAAGGAGC CTCCCTGGAG CTCAGATGCA GTTATTCATA CAGTGCAGCA 
301 
CCTTACCTCT TCTGGTACGT GCAGTATCCT GGCCAGAGCC TCCAGTTTCT 
351 
CCTCAAATAC ATCACAGGAG ACGCCGTTGT TAAAGGCACC AAGGGCTTTG 
401 
AGGCCGAGTT TAGGAAGAGT AACTCCTCTT TCAACCTGAA GAAATCCCCA 
451 
GCCCATTGGA GCGACTCAGC CAAGTACTTC TGTGCACTGG AGGGTATAGC 
501 
ATCCTCCTCC TTCAGCAAGC TTGTGTTTGG GCAGGGGACA TCCTTATCAG 
551 
TCGTTCCAAG TAAGTTTGCA GGCTGCCTGT GGGGCAATGG TTCTCAACCT 
601 
TGCTACTACT AGGGTCCTTT AA 
Black = intronic sequence. 
Blue = coding sequence 
Red = mutated base pair (G—T) 
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Appendix 20. Th2 TCR a rearranged V-J insert nucleotide/protein  
sequence 
1 - ATG TTC CTA GTG ACC ATT CTG CTG CTC AGC GCG TTC TTC TCA CTG 
1-M F L V T I L LL S AF FS L 
46 - AGA GGA AAC AGT GCC CAG TCC GTG GAC CAG CCT GAT GCT CAC GTC 
16-R G N S A QS V D Q P D A II V 
91 - ACG CTC TAT GAA GGA GCC TCC CTG GAG CTC AGA TGC AGT TAT TCA 
31-T LYE G A SL E L R CS YS 
136 - TAC AGT GCA GCA CCT TAC CTC TTC TGG TAC GTG CAG TAT CCT GGC 
46-YS A A P Y L F W Y V Q Y P G 
181 - CAG AGC CTC CAG TTT CTC CTC AAA TAC ATC ACA GGA GAC GCC GTT 
61-Q SLQFLL KYI T G D A V 
226 - GTT AAA GGC ACC AAG GGC TTT GAG GCC GAG TTT AGG AAG AGT AAC 
76-V K G T K G F E AEFR K S N 
271 - TCC TCT TTC AAC CTG AAG AAA TCC CCA GCC CAT TGG AGC GAC TCA 
91-SS F N L K K SPA H W S D S 
316 - GCC AAG TAC TTC TGT GCA CTG GAG GUT ATA GCA TCC TCC TCC TTC 
106-A K YFCAL E GI A SS SF 
361 - AGC AAG CTT GTG TTT GGG CAG GGG ACA TCC TTA TCA GTC GTT CCA 
121-S K L V F G Q G T SL S V V P 
Light blue = Leader sequence of TRAV17 
Dark blue = TRAV17 
Red = CDR3a region 
Green = TRAJ50 
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Appendix 21. Th2 TCR 13 complete V-J insert nucleotide sequence 
CCTAGACAAA GACCATCTTG AACTATGCTG TACTCTCTCC TTGCCTTTCT 
51 
CCTGGGCATG TTCTTGGGTG GGTGCATTCC CCTGTTGAAA ACCTACTTTC 
101 
AAATTGTTGC TTCCATCTCT CCACCTGTTA AAGGTGTAGA TTCTTTGGTA 
151 
CTGGCTTGCC TCTCTTGACC ACAGTCCTCC AATTACTGAG ATATGGGCAT 
201 
TTCACACTCT TTCAGTATTG ACTCTCAGTT TTGTATCTTT TAGAAAGGAT 
251 
TTGTCTCCCC TTGCCCTGTA ACATTTTTCA TCCCTGGCTC TTCTAGTATA 
301 
CTCCCTGAGA CTGATTACAT GTAACCCCTT CAGAGGGAAG GCAAGCAAGC 
351 
TGGTGTGTGT GTATGTGTAG AGGTGTGTGT TTCTACTCTA AATGACTCTA 
401 
TTTCTTTACA GGTGTTAGTG CTCAGACTAT CCATCAATGG CCAGTTGCCG 
451 
AGATCAAGGC TGTGGGCAGC CCACTGTCTC TGGGGTGTAC CATAAAGGGG 
501 
AAATCAAGCC CTAACCTCTA CTGGTACTGG CAGGCCACAG GAGGCACCCT 
551 
CCAGCAACTC TTCTACTCTA TTACTGTTGG CCAGGTAGAG TCGGTGGTGC 
601 
AACTGAACCT CTCAGCTTCC AGGCCGAAGG ACGACCAATT CATCCTAAGC 
651 
ACGGAGAAGC TGCTTCTCAG CCACTCTGGC TTCTACCTCT GTGCCTGGAG 
701 
TCTGGGGGGA GGTGCAGAAA CGCTGTATTT TGGCTCAGGA ACCAGACTGA 
751 
CTGTTCTCGG TAAGTTGGGA GCTAGTAATG AAGGGGAGGG AGCATTTCCC 
801 
AGGCTAAGGA TAGCCAGAGC CAGTTTTTGT CCTGTACCAA GAGGCTGTGA 
Black = intronic sequence 
Blue = coding sequence 
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Appendix 22. Th2 TCR 13 rearranged V-J insert nucleotide/protein 
sequence 
1 - ATG CTG TAC TCT CTC CTT GCC TTT CTC CTG GGC ATG TTC TTG GGT 
1-ML YS LL A FLLG M F L G 
46 - GTT AGT GCT CAG ACT ATC CAT CAA TGG CCA GTT GCC GAG ATC AAG 
16-VS A Q T I H Q W P V A E I K 
91- GCT GTG GGC AGC CCA CTG TCT CTG GGG TGT ACC ATA AAG GGG AAA 
31-AVG S P L S L GCTIK GK 
136- TCA AGC CCT AAC CTC TAC TGG TAC TGG CAG GCC ACA GGA GGC ACC 
46-S SP N L Y W Y W Q A T G G T 
181- CTC CAG CAA CTC TTC TAC TCT ATT ACT GTT GGC CAG GTA GAG TCG 
61-LQQLFYSI T VGQVES 
226- GTG GTG CAA CTG AAC CTC TCA GCT TCC AGG CCG AAG GAC GAC CAA 
76-VV Q L N L S A SR P K D D Q 
271- TTC ATC CTA AGC ACG GAG AAG CTG CTT CTC AGC CAC TCT GGC TTC 
91-F IL S T E K L L L S HS G F 
316- TAC CTC TGT GCC TGG AGT CTG GGG GGA GGT GCA GAA ACG CTG TAT 
106-YLCAWSLGGGA E 	L Y 
361- ITT GGC TCA GGA ACC AGA CTG ACT GTT CTC 
121-FGS GTR L T V L 
Light blue = Leader sequence of TRBV31 
Dark blue = TRBV31 
Red = CDR313 region 
Green = TRBJ2-3 
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Appendix 23. MIPLP construct — complete nucleotide sequence 
1 
GCGCGCAATT AACCCTCACT AAAGGGAACA AAAGCTGGGT ACCGGGCCCC 
51 
CCCTCGAGGT CGACGGTATC GATAAGCTTA TCGATTTCGA ACCCTGTAGC 
101 
AGGGCCTCTG TGCAGCAGAG GGTGCACACT ACAGGTTGTG CACACGCGTG 
151 
TGCGTGCATG CATGCAAGGG TGCACATGCA CAGGGTGGAG GTCAGAGGTC 
201 
AACGTCAGGT GTCTTCGTCT GTCACCCACA GTCTTGTTTT TCAGACAGGA 
251 
CTTCTCACTG AATCTGAATC CTGCCCATTT GATGGGCTCA TCAGTCAGTT 
301 
TCCAGGTTTC CCTGGTCCCC ACCTCCCCAG GGCTGGAATT CAAGGCATAT 
351 
CTAGCTTTTT TGCATGAATG TTTGAGAGCC AAATTCAGTT CCTCATACTT 
401 
GCCCAATAGG CATAGTATAT CCACTGAGCC ATGTCCCCAA CTCATTATGT 
451 
TCACCTCATT CATTCATTCA TCCATCCATC CATCCATCCA TCCATTCATT 
501 
CATTCAGGTT TGGTTTGGTT TGGTTTTAGT GTTTTGGGTT TTTTTTCAAG 
551 
ACAGGGTTTC TCTGTGTAGC CCTGGCTGCC CTGAAACTAA CTTTCTTACT 
601 
TACTTTCTTT CTTTCTTCCT TCCTTCCTTT CTTTCTTTAA GTTGGTTTGG 
651 
GTTTTTTGGG GGGGGGAGGG TTTGGGTTTT TTTGTTTGTT TGTATTTTAT 
701 
TCAAGGAAAG GCTCCTCTGG GTTGCCCTGG CTGCCCTGGA AGGAATTCTA 
751 
TAGCCAGGCT GACCATGAAC TCAGAAATCT ACCTGCCTCT CCCTCTGCCT 
801 
CCCAAGTGCT AGGATTAAAG GTGTGTGACA CACACACAAC TGGCTCTACA 
851 
TTTGACACTC ACAGTATTCT GCACACAGCC ACAGGGCTGT ATCGCTAAGA 
901 
GGCCATGTCA CAGGTCCAGG AAGGCTTCAC TGTTTAATAA CTGGTTTGGA 
951 
ATTTGGAAGT GGGAAAGTAT GTAGAGACAA TCTCACTCTA GGACTCAAAG 
1001 
ACAGAGATAA AATGCTCTTT AGAAACCTAT TCTGTGGGGG AACAGAATCA 
1051 
GAACTCTATG TCAGCCTCTG TGCTAGCTGG GGTCAGGCCA GAGACACAGA 
331 
1101 
AATGAGCTAA GCCTACAGTG AGAACTGATA CGCAGGACAG TTGAGAACAA 
1151 
TGGGAAAGTG CATCTGAAGG GCCCAAGGCC ACTAGGAAAA AGGCAACCCA 
1201 
AAATGCCCAC AACTTTAAAT CCCCTTCCTG ATGTGTCATT AGATGCAAAC 
1251 
GGCCCTGGGG AGGATGTGAC GTTAAACAAG GCAGTGTTCT GTACAGGGGC 
1301 
AGATCCTGCA GTTACTGGAA GCTGAAGGCT CCAGGCTGAC CACACTAGGT 
1351 
AGGAAGTTCA TGAAATGAGC TCTCGAAGCG CCTCTTCAGG TCTTCCCCGA 
1401 
TGTCCAGCCC CACCAGCACC GTAGCAGGTA CTGGGCATCT ATTGATTGGG 
1451 
TGGGTAGGTG AACATTTGAG ACAACCTGGA AGTTTAAATG GGATTTGTGG 
1501 
AAATAGAGAG GGTGTTGGTT CCAGCCAAGC CAGGTTCCAT GCTAAGACAT 
1551 
AAAAGCACTG GAGAAGTAAA AGAGTTAACG CTGAACATGG CCGTGGGAAG 
1601 
CGAGGAGACC AAGGTAAAGC CTGGGAATGG CTAACACTTG AGAACTGTCA 
1651 
ACATCATGAA AGGATAAGAA AGAATGGCCA AGGAAAGAAA ACAGGAAAGA 
1701 
GCTGAGTGTG GGAGAGGCCT GGAGAGAATG GGGCAAGAAG TGGGAGGCTA 
1751 
AAGGGTAAGG GCAAGGGAGG GTCAAGTCAG ATGAGGACTG AAGGTGCTTT 
1801 
CAACTGGTAG GACTTGAGGG CTGCTCTGGG TAGGAGCCAG CCCGGTCTGG 
1851 
GCCCTGGGTC TCTCATGTGT TCTATGGAGA AGTCTTTATA TTTGTTCATG 
1901 
TGTATTGTAT GTGGGCTCTA ACCTGGCCAA CAATGCCCAA GAATCAAGTG 
1951 
ATTTTTGTGG CTTGAAGTCT AGCCACCTTC CTTGGAGGGA GGCAATAGAA 
2001 
GGAGCCTAGT GACATCTCGG ACGGAGTCTG GGGTCTTTGT CCTTCCCCTT 
2051 
GATCCCTGAA GGGTCTCCAG CCTCTGGTTC TCCAGGGTTG GCAAGTCTAC 
2101 
AATTGCTTCC CGGAACCTGG AGTGCTCAGT GCTTGACTTT AAAGAGGACA 
2151 
CAGGTGCCTA CAGTTCCACG ACCTCTGGGT TCCCCGACGC CCCCCCCCCC 
2201 
GCACTGCCCA TTGCCCAAAC ACCCCACAAG TGGCCTATTG TGTGAGCTCA 
332 
2251 
GTTTCAATGG GAAAAGAAAC TGGGTTTATG AAAAGAGATT ATTTGCTTAT 
2301 
TGCATGGAGA TGACTAAGTA AATAGTGCAA TTTCTTGAGT GGAGCACAAT 
2351 
CCCTGCCCCT ACCTCTTGTG GGCTGCCAGG AACATATAAA AAGCCACACG 
2401 
CATACCCACA CATACCCACA CATACCCTCA CATTACAACA TCAGCCCACA 
2451 
TCTACAGACA GCCCAAGCTT GATATCGAAT TCCTGCAGCC CGGGGGATCC 
2501 
ACTAGTTCTA GAGCGGCCGC ACGTCTAAGA AACCATTATT ATCATGACAT 
2551 
TAACCTATAA AAATAGGCGT ATCACGAGGC CCTTTCGTCT TCAAGAATTC 
2601 
CATCAAGCTT AGGATCCGGA ACCCTTAATA TAACTTCGTA TAATGTATGC  loxP 
2651 	 f site 
TATACGAAGT TAT TAGGTCC CTCGACCTGC AGCCCAAGCT TACTTACCATJ  
2701 
GTCAGATCCA GACATGATAA GATACATTGA TGAGTTTGGA CAAACCACAA 
2751 
CTAGAATGCA GTGAAAAAAA TGCTTTATTT GTGAAATTTG TGATGCTATT 
2801 
GCTTTATTTG TAACCATTAT AAGCTGCAAT AAACAAGTTA ACAACAACAA 
2851 
TTGCATTCAT TTTATGTTTC AGGTTCAGGG GGAGGTGTGG GAGGTTTTTT 
2901 
AAAGCAAGTA AAACCTCTAC AAATGTGGTA TGGCTGATTA TGATCTCTAG 
2951 
TCAAGGCACT ATACATCAAA TATTCCTTAT TAACCCCTTT ACAAATTAAA 
3001 
AAGCTAAAGG TACACAATTT TTGAGCATAG TTATTAATAG CAGACACTCT 
3051 
ATGCCTGTGT GGAGTAAGAA AAAACAGTAT GTTATGATTA TAACTGTTAT 
3101 
GCCTACTTAT AAAGGTTACA GAATATTTTT CCATAATTTT CTTGTATAGC 
3151 
AGTGCAGCTT TTTCCTTTGT GGTGTAAATA GCAAAGCAAG CAAGAGTTCT 
3201 
ATTACTAAAC ACAGCATGAC TCAAAAAACT TAGCAATTCT GAAGGAAAGT 
3251 
CCTTGGGGTC TTCTACCTTT CTCTTCTTTT TTGGAGGAGT AGAATGTTGA 
3301 
GAGTCAGCAG TAGCCTCATC ATCACTAGAT GGCATTTCTT CTGAGCAAAA 
3351 
CAGGTTTTCC TCATTAAAGG CATTCCACCA CTGCTCCCAT TCATCAGTTC 
333 
3401 
CATAGGTTGG AATCTAAAAT ACACAAACAA TTAGAATCAG TAGTTTAACA 
3451 
CATTATACAC TTAAAAATTT TATATTTACC TTAGAGCTTT AAATCTCTGT 
3501 
AGGTAGTTTG TCCAATTATG TCACACCACA GAAGTAAGGT TCCTTCACAA 
3551 
AGATCCCTCG AGAAAAAAAA TATAAAAGAG ATGGAGGAAC GGGAAAAAGT 
3601 
TAGTTGTGGT GATAGGTGGC AAGTGGTATT CCGTAAGAAC AACAAGAAAA 
3651 
GCATTTCATA TTATGGCTGA ACTGAGCGAA CAAGTGCAAA ATTTAAGCAT 
3701 
CAACGACAAC AACGAGAATG GTTATGTTCC TCCTCACTTA AGAGGAAAAC 
3751 
CAAGAAGTGC CAGAAATAAC AGTAGCAACT ACAATAACAA CAACGGCGGC 
3801 
TACAACGGTG GCCGTGGCGG TGGCAGCTTC TTTAGCAACA ACCGTCGTGG 
3851 
TGGTTACGGC AACGGTGGTT TCTTCGGTGG AAACAACGGT GGCAGCAGAT 
3901 
CTAACGGCCG TTCTGGTGGT AGATGGATCG ATGGCAAACA TGTCCCAGCT 
3951 
CCAAGAAACG AAAAGGCCGA GATCGCCATA TTTGGTGTCC CCGAGGATCC 
4001 
GGAACCCTTA ATIATAACTTC GTATAATGTA TGCTATACGA AGTTATTAGG  loxP 
4051 	 site 
TCCCTCGAAG AGGTTCACTA GTACTGGCCA TTGCGGCCGG ATCCTGAGAA 
4101 
CTTCAGGGTG AGTTTGGGGA CCCTTGATTG TTCTTTCTTT TTCGCTATTG 
4151 
TAAAATTCAT GTTATATGGA GGGGGCAAAG TTTTCAGGGT GTTGTTTAGA 
4201 
ATGGGAAGAT GTCCCTTGTA TCACCATGGA CCCCCATGAT AATTTTGTTT 
4251 
CTTTCACTTT CTACTCTGTT GACAACCATT GTCTCCTCTT ATTTTCTTTT 
4301 
CATTTTCTGT AACTTTTTCG TTAAACTTTA GCTTGCATTT GTAACGAATT 
4351 
TTTAAATTCA CTTTTGTTTA TTTGTCAGAT TGTAAGTACT TTCTCTAATC 
4401 
ACTTTTTTTT CAAGGCAATC AGGGTATATT ATATTGTACT TCAGCACAGT 
4451 
TTTAGAGAAC AATTGTTATA ATTAAATGAT AAGGTAGAAT ATTTCTGCAT 
4501 
ATAAATTCTG GCTGGCGTGG AAATATTCTT ATTGGTAGAA ACAACTACAC 
334 
4551 
CCTGGTCATC ATCCTGCCTT TCTCTTTATG GTTACAATGA TATACACTGT 
4601 
TTGAGATGAG GATAAAATAC TCTGAGTCCA AACCGGGCCC CTCTGCTAAC 
4651 
CATGTTCATG CCTTCTTCTC TTTCCTACAG CTCCTGGGCA ACGTGCTGGT 
4701 
TGTTGTGCTG TCTCATCATT TTGGCAAAGA ATTCTGGCAA CATGAGGTCT 
4751 
TTGCTAATCT TGGTGCTTTG CTTCCTGCCC CTGGCTGCTC TGGGGAAAGT 
4801 
CTTTGGACGA TGTGAGCTGG CAGCGGCTAT GAAGCGTCAC GGACTTGATA 
4851 
ACTATCGGGG ATACAGCCTG GGAAACTGGG TGTGTGCCGC AAAATTCGAG 
4901 
AGTAACTTCA ACACCCAGGC TACAGGCGCC AAAAACTACC ACIGACTATGA  
4951 
GTATCTCATT AATGTGATTC ATGCTTTCCA GTATGTC ATC TATGGAACCC 
5001 
GCGGAAACCG TAACACCGAT GGGAGTACCG ACTACGGAAT CCTACAGATC 
5051 
AACAGCCGCT GGTGGTGCAA CGATGGCAGG ACCCCAGGCT CCAGGAACCT 
5101 
GTGCAACATC CCGTGCTCAG CCCTGCTGAG CTCAGACATA ACAGCGAGCG 
5151 
TGAACTGCGC GAAGAAGATC GTCAGCGATG GAAACGGCAT GAACGCGTGG 
5201 
GTCGCCTGGC GCAACCGCTG CAAGGGCACC GACGTCCAGG CGTGGATCAG 
5251 
AGGCTGCCGG CTGGGCTCGT CCAGCTCAGG GATCTATCAG ATTCTGGCGA 
5301 
TCTACTCAAC TGTCGCCAGT TCACTGGTGC TTTTGGTCTC CCTGGGGGCA 
5351 
ATCAGTTTCT GGATGTGTTC TAATGGATCT TTGCAGTGCA GAATATGCAT 
5401 
CTGAGATTAG AATTCACTCC TCAGGTGCAG GCTGCCTATC AGAAGGTGGT 
5451 
GGCTGGTGTG GCCAATGCCC TGGCTCACAA ATACCACTGA GATCGATCTT 
5501 
TTTCCCTCTG CCAAAAATTA TGGGGACATC ATGAAGCCCC TTGAGCATCT 
5551 
GACTTCTGGC TAATAAAGGA AATTTATTTT CATTGCAATA GTGTGTTGGA 
5601 
ATTTTTTGTG TCTCTCACTC GGAAGGACAT ATGGGAGGGC AAATCATTTA 
5651 
AAACATCAGA ATGAGTATTT GGTTTAGAGT TTGGCAACAT ATGCCCATAT 
PLP(: 
-70) 
335 
5701 
GCTGGCTGCC ATGAACAAAG GTTGGCTATA AAGAGGTCAT CAGTATATGA 
5751 
AACAGCCCCC TGCTGTCCAT TCCTTATTCC ATAGAAAAGC CTTGACTTGA 
5801 
GGTTAGATTT TTTTTATATT TTGTTTTGTG TTATTTTTTT CTTTAACATC 
5851 
CCTAAAATTT TCCTTACATG TTTTACTAGC CAGATTTTTC CTCCTCTCCT 
5901 
GACTACTCCC AGTCATAGCT GTCCCTCTTC TCTTATGGAG ATCCCTCGAG 
5951 
GGCCATTGCG GCCGCCACCG CGGTGGAGCT CCAGCTTTTG TTCCCTTTAG 
6001 
TGAGGGTTAA TTGCGCGC 
Black = pBluescript II vector sequence 
Brown = CC10 promoter 
Blue = Floxed STOP sequence 
Green = Rabbit beta globin intronic and PolyA sequence 
Red = HEL/PLP (56-70) coding region 
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Appendix 24. Transmembrane HEL/PLP(56-70) nucleotide/protein 
sequence  
1- ATG AGG TCT TTG CTA ATC TTG GTG CTT TGC TTC CTG CCC CTG GCT 
1-MR S L L I LV LCF L P L A 
46- GCT CTG GGG AAA GTC TTT GGA CGA TGT GAG TTG GCA GCG GCT ATG 
16-ALGK V F G R CE LAAA M 
91- AAG CGT CAC GGA CTT GAT AAC TAT CGG GGA TAC AGC CTG GGA AAC 
31-K R H G L D N Y R G YS L G N 
136-TGG GTG TGT GCC GCA AAA TTC GAG AGT AAC TTC AAC ACC CAG GCT 
46-WV CA AK FE S N F N T QA 
181-ACA GGC GCC AAA AAC TAC CAG GAC TAT GAG TAT CTC ATT AAT GTG 
61-T G AKNYQDYE YLINV 
226-ATT CAT GCT TTC CAG TAT GTC ATC TAT GGA ACC CGC GGA AAC CGT 
76-IHA F Q YV I Y G T R G N R 
271-AAC ACC GAT GGG AGT ACC GAC TAC GGA ATC CTA CAG ATC AAC AGC 
91-N TDGS T D Y G I L Q I N S 
316-CGC TGG TGG TGC AAC GAT GGC AGG ACC CCA GGC TCC AGG AAC CTG 
106-R WWCND GRIP GSRNL 
361-TGC AAC ATC CCG TGC TCA GCC CTG CTG AGC TCA GAC ATA ACA GCG 
121-C N I P C S A L L S SDI TA 
406-AGC GTG AAC TGC GCG AAG AAG ATC GTC AGC GAT GGA AAC GGC ATG 
136-S V N C A K K IV SD G N GM 
451-AAC GCG TGG GTC GCC TGG CGC AAC CGC TGC AAG GGC ACC GAC GTC 
151-N A W VA 	 NW R R C K G T D V 
496-CAG GCG TGG ATC AGA GGC TGC CGG CTG GGC TCG TCC AGC TCA GGG 
166-Q A W I R G C R L G S SS SG 
541-ATC TAT CAG ATT CTG GCG ATC TAC TCA ACT GTC GCC AGT TCA CTG 
181-IYQILA I Y S T VAS S L 
586-GTG CTT TTG GTC TCC CTG GGG GCA ATC AGT TTC TGG ATG TGT TCT 
196-V L L V S L G A I S F W M C S 
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631-AAT GGA TCT TTG CAG TGC AGA ATA TGC ATC 
211-N G S L Q C R I CI 
Black = HEL 
Red = PLP (56-70) 
Green = joining sequence 
Blue = Transmembrane anchor region 
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Appendix 25. SIPLP construct - complete nucleotide sequence 
1 
GCGCGCAATT AACCCTCACT AAAGGGAACA AAAGCTGGGT ACCGGGCCCC 
51 
CCCTCGAGGT CGACGGTATC GATAAGCTTA TCGATTTCGA ACCCTGTAGC 
101 
AGGGCCTCTG TGCAGCAGAG GGTGCACACT ACAGGTTGTG CACACGCGTG 
151 
TGCGTGCATG CATGCAAGGG TGCACATGCA CAGGGTGGAG GTCAGAGGTC 
201 
AACGTCAGGT GTCTTCGTCT GTCACCCACA GTCTTGTTTT TCAGACAGGA 
251 
CTTCTCACTG AATCTGAATC CTGCCCATTT GATGGGCTCA TCAGTCAGTT 
301 
TCCAGGTTTC CCTGGTCCCC ACCTCCCCAG GGCTGGAATT CAAGGCATAT 
351 
CTAGCTTTTT TGCATGAATG TTTGAGAGCC AAATTCAGTT CCTCATACTT 
401 
GCCCAATAGG CATAGTATAT CCACTGAGCC ATGTCCCCAA CTCATTATGT 
451 
TCACCTCATT CATTCATTCA TCCATCCATC CATCCATCCA TCCATTCATT 
501 
CATTCAGGTT TGGTTTGGTT TGGTTTTAGT GTTTTGGGTT TTTTTTCAAG 
551 
ACAGGGTTTC TCTGTGTAGC CCTGGCTGCC CTGAAACTAA CTTTCTTACT 
601 
TACTTTCTTT CTTTCTTCCT TCCTTCCTTT CTTTCTTTAA GTTGGTTTGG 
651 
GTTTTTTGGG GGGGGGAGGG TTTGGGTTTT TTTGTTTGTT TGTATTTTAT 
701 
TCAAGGAAAG GCTCCTCTGG GTTGCCCTGG CTGCCCTGGA AGGAATTCTA 
751 
TAGCCAGGCT GACCATGAAC TCAGAAATCT ACCTGCCTCT CCCTCTGCCT 
801 
CCCAAGTGCT AGGATTAAAG GTGTGTGACA CACACACAAC TGGCTCTACA 
851 
TTTGACACTC ACAGTATTCT GCACACAGCC ACAGGGCTGT ATCGCTAAGA 
901 
GGCCATGTCA CAGGTCCAGG AAGGCTTCAC TGTTTAATAA CTGGTTTGGA 
951 
ATTTGGAAGT GGGAAAGTAT GTAGAGACAA TCTCACTCTA GGACTCAAAG 
1001 
ACAGAGATAA AATGCTCTTT AGAAACCTAT TCTGTGGGGG AACAGAATCA 
1051 
GAACTCTATG TCAGCCTCTG TGCTAGCTGG GGTCAGGCCA GAGACACAGA 
339 
1101 
AATGAGCTAA GCCTACAGTG AGAACTGATA CGCAGGACAG TTGAGAACAA 
1151 
TGGGAAAGTG CATCTGAAGG GCCCAAGGCC ACTAGGAAAA AGGCAACCCA 
1201 
AAATGCCCAC AACTTTAAAT CCCCTTCCTG ATGTGTCATT AGATGCAAAC 
1251 
GGCCCTGGGG AGGATGTGAC GTTAAACAAG GCAGTGTTCT GTACAGGGGC 
1301 
AGATCCTGCA GTTACTGGAA GCTGAAGGCT CCAGGCTGAC CACACTAGGT 
1351 
AGGAAGTTCA TGAAATGAGC TCTCGAAGCG CCTCTTCAGG TCTTCCCCGA 
1401 
TGTCCAGCCC CACCAGCACC GTAGCAGGTA CTGGGCATCT ATTGATTGGG 
1451 
TGGGTAGGTG AACATTTGAG ACAACCTGGA AGTTTAAATG GGATTTGTGG 
1501 
AAATAGAGAG GGTGTTGGTT CCAGCCAAGC CAGGTTCCAT GCTAAGACAT 
1551 
AAAAGCACTG GAGAAGTAAA AGAGTTAACG CTGAACATGG CCGTGGGAAG 
1601 
CGAGGAGACC AAGGTAAAGC CTGGGAATGG CTAACACTTG AGAACTGTCA 
1651 
ACATCATGAA AGGATAAGAA AGAATGGCCA AGGAAAGAAA ACAGGAAAGA 
1701 
GCTGAGTGTG GGAGAGGCCT GGAGAGAATG GGGCAAGAAG TGGGAGGCTA 
1751 
AAGGGTAAGG GCAAGGGAGG GTCAAGTCAG ATGAGGACTG AAGGTGCTTT 
1801 
CAACTGGTAG GACTTGAGGG CTGCTCTGGG TAGGAGCCAG CCCGGTCTGG 
1851 
GCCCTGGGTC TCTCATGTGT TCTATGGAGA AGTCTTTATA TTTGTTCATG 
1901 
TGTATTGTAT GTGGGCTCTA ACCTGGCCAA CAATGCCCAA GAATCAAGTG 
1951 
ATTTTTGTGG CTTGAAGTCT AGCCACCTTC CTTGGAGGGA GGCAATAGAA 
2001 
GGAGCCTAGT GACATCTCGG ACGGAGTCTG GGGTCTTTGT CCTTCCCCTT 
2051 
GATCCCTGAA GGGTCTCCAG CCTCTGGTTC TCCAGGGTTG GCAAGTCTAC 
2101 
AATTGCTTCC CGGAACCTGG AGTGCTCAGT GCTTGACTTT AAAGAGGACA 
2151 
CAGGTGCCTA CAGTTCCACG ACCTCTGGGT TCCCCGACGC CCCCCCCCCC 
2201 
GCACTGCCCA TTGCCCAAAC ACCCCACAAG TGGCCTATTG TGTGAGCTCA 
340 
2251 
GTTTCAATGG GAAAAGAAAC TGGGTTTATG AAAAGAGATT ATTTGCTTAT 
2301 
TGCATGGAGA TGACTAAGTA AATAGTGCAA TTTCTTGAGT GGAGCACAAT 
2351 
CCCTGCCCCT ACCTCTTGTG GGCTGCCAGG AACATATAAA AAGCCACACG 
2401 
CATACCCACA CATACCCACA CATACCCTCA CATTACAACA TCAGCCCACA 
2451 
TCTACAGACA GCCCAAGCTT GATATCGAAT TCCTGCAGCC CGGGGGATCC 
2501 
ACTAGTTCTA GAGCGGCCGC ACGTCTAAGA AACCATTATT ATCATGACAT 
2551 
TAACCTATAA AAATAGGCGT ATCACGAGGC CCTTTCGTCT TCAAGAATTC 
2601 
CATCAAGCTT AGGATCCGGA ACCCTTAAT A TAACTTCGTA TAATGTATGC 
/651  
TATACGAAGT TATTAGGTCC CTCGACCTGC AGCCCAAGCT TACTTACCAT 
2701 
GTCAGATCCA GACATGATAA GATACATTGA TGAGTTTGGA CAAACCACAA 
2751 
CTAGAATGCA GTGAAAAAAA TGCTTTATTT GTGAAATTTG TGATGCTATT 
2801 
GCTTTATTTG TAACCATTAT AAGCTGCAAT AAACAAGTTA ACAACAACAA 
2851 
TTGCATTCAT TTTATGTTTC AGGTTCAGGG GGAGGTGTGG GAGGTTTTTT 
2901 
AAAGCAAGTA AAACCTCTAC AAATGTGGTA TGGCTGATTA TGATCTCTAG 
2951 
TCAAGGCACT ATACATCAAA TATTCCTTAT TAACCCCTTT ACAAATTAAA 
3001 
AAGCTAAAGG TACACAATTT TTGAGCATAG TTATTAATAG CAGACACTCT 
3051 
ATGCCTGTGT GGAGTAAGAA AAAACAGTAT GTTATGATTA TAACTGTTAT 
3101 
GCCTACTTAT AAAGGTTACA GAATATTTTT CCATAATTTT CTTGTATAGC 
3151 
AGTGCAGCTT TTTCCTTTGT GGTGTAAATA GCAAAGCAAG CAAGAGTTCT 
3201 
ATTACTAAAC ACAGCATGAC TCAAAAAACT TAGCAATTCT GAAGGAAAGT 
3251 
CCTTGGGGTC TTCTACCTTT CTCTTCTTTT TTGGAGGAGT AGAATGTTGA 
3301 
GAGTCAGCAG TAGCCTCATC ATCACTAGAT GGCATTTCTT CTGAGCAAAA 
3351 
CAGGTTTTCC TCATTAAAGG CATTCCACCA CTGCTCCCAT TCATCAGTTC 
loxP 
site 
341 
3401 
CATAGGTTGG AATCTAAAAT ACACAAACAA TTAGAATCAG TAGTTTAACA 
3451 
CATTATACAC TTAAAAATTT TATATTTACC TTAGAGCTTT AAATCTCTGT 
3501 
AGGTAGTTTG TCCAATTATG TCACACCACA GAAGTAAGGT TCCTTCACAA 
3551 
AGATCCCTCG AGAAAAAAAA TATAAAAGAG ATGGAGGAAC GGGAAAAAGT 
3601 
TAGTTGTGGT GATAGGTGGC AAGTGGTATT CCGTAAGAAC AACAAGAAAA 
3651 
GCATTTCATA TTATGGCTGA ACTGAGCGAA CAAGTGCAAA ATTTAAGCAT 
3701 
CAACGACAAC AACGAGAATG GTTATGTTCC TCCTCACTTA AGAGGAAAAC 
3751 
CAAGAAGTGC CAGAAATAAC AGTAGCAACT ACAATAACAA CAACGGCGGC 
3801 
TACAACGGTG GCCGTGGCGG TGGCAGCTTC TTTAGCAACA ACCGTCGTGG 
3851 
TGGTTACGGC AACGGTGGTT TCTTCGGTGG AAACAACGGT GGCAGCAGAT 
3901 
CTAACGGCCG TTCTGGTGGT AGATGGATCG ATGGCAAACA TGTCCCAGCT 
3951 
CCAAGAAACG AAAAGGCCGA GATCGCCATA TTTGGTGTCC CCGAGGATCC 
4001 
GGAACCCTTA ATATAACTTC GTATAATGTA TGCTATACGA AGTTATTAGG}  loxP 
4051 	 site 
TCCCTCGAAG AGGTTCACTA GTACTGGCCA TTGCGGCCGG ATCCTGAGAA 
4101 
CTTCAGGGTG AGTTTGGGGA CCCTTGATTG TTCTTTCTTT TTCGCTATTG 
4151 
TAAAATTCAT GTTATATGGA GGGGGCAAAG TTTTCAGGGT GTTGTTTAGA 
4201 
ATGGGAAGAT GTCCCTTGTA TCACCATGGA CCCCCATGAT AATTTTGTTT 
4251 
CTTTCACTTT CTACTCTGTT GACAACCATT GTCTCCTCTT ATTTTCTTTT 
4301 
CATTTTCTGT AACTTTTTCG TTAAACTTTA GCTTGCATTT GTAACGAATT 
4351 
TTTAAATTCA CTTTTGTTTA TTTGTCAGAT TGTAAGTACT TTCTCTAATC 
4401 
ACTTTTTTTT CAAGGCAATC AGGGTATATT ATATTGTACT TCAGCACAGT 
4451 
TTTAGAGAAC AATTGTTATA ATTAAATGAT AAGGTAGAAT ATTTCTGCAT 
4501 
ATAAATTCTG GCTGGCGTGG AAATATTCTT ATTGGTAGAA ACAACTACAC 
342 
4551 
CCTGGTCATC ATCCTGCCTT TCTCTTTATG GTTACAATGA TATACACTGT 
4601 
TTGAGATGAG GATAAAATAC TCTGAGTCCA AACCGGGCCC CTCTGCTAAC 
4651 
CATGTTCATG CCTTCTTCTC TTTCCTACAG CTCCTGGGCA ACGTGCTGGT 
4701 
TGTTGTGCTG TCTCATCATT TTGGCAAAGA ATTCTGGCAA CATGAGGTCT 
4751 
TTGCTAATCT TGGTGCTTTG CTTCCTGCCC CTGGCTGCTC TGGGGAAAGT 
4801 
CTTTGGACGA TGTGAGCTGG CAGCGGCTAT GAAGCGTCAC GGACTTGATA 
4851 
ACTATCGGGG ATACAGCCTG GGAAACTGGG TGTGTGCCGC AAAATTCGAG 
4901 
AGTAACTTC A ACACCCAGGC TACAGGCGCC AAAAACTACC AG  ACTATGA  
4951 	 PLP(5 
GTATCTCATT AATGTGATTC ATGCTTTCCA GTATGTC ATC TATGGAACCC  701 
5001 
GCGGAAACCG TAACACCGAT GGGAGTACCG ACTACGGAAT CCTACAGATC 
5051 
AACAGCCGCT GGTGGTGCAA CGATGGCAGG ACCCCAGGCT CCAGGAACCT 
5101 
GTGCAACATC CCGTGCTCAG CCCTGCTGAG CTCAGACATA ACAGCGAGCG 
5151 
TGAACTGCGC GAAGAAGATC GTCAGCGATG GAAACGGCAT GAACGCGTGG 
5201 
GTCGCCTGGC GCAACCGCTG CAAGGGCACC GACGTCCAGG CGTGGATCAG 
5251 
AGGCTGCCGG CTGTGAGGAG CTGCCGGAAT TCTCTATCAG ATTCACTCCT 
5301 
CAGGTGCAGG CTGCCTATCA GAAGGTGGTG GCTGGTGTGG CCAATGCCCT 
5351 
GGCTCACAAA TACCACTGAG ATCGATCTTT TTCCCTCTGC CAAAAATTAT 
5401 
GGGGACATCA TGAAGCCCCT TGAGCATCTG ACTTCTGGCT AATAAAGGAA 
5451 
ATTTATTTTC ATTGCAATAG TGTGTTGGAA TTTTTTGTGT CTCTCACTCG 
5501 
GAAGGACATA TGGGAGGGCA AATCATTTAA AACATCAGAA TGAGTATTTG 
5551 
GTTTAGAGTT TGGCAACATA TGCCCATATG CTGGCTGCCA TGAACAAAGG 
5601 
TTGGCTATAA AGAGGTCATC AGTATATGAA ACAGCCCCCT GCTGTCCATT 
5651 
CCTTATTCCA TAGAAAAGCC TTGACTTGAG GTTAGATTTT TTTTATATTT 
343 
5701 
TGTTTTGTGT TATTTTTTTC TTTAACATCC CCTAAAATTTT CCTTACATGT 
5751 
TTTACTAGCC AGATTTTTCC TCCTCTCCTG ACTACTCCCA GTCATAGCTG 
5801 
TCCCTCTTCT CTTATGGAGA TCCCTCGAGG GCCATTGCGG CCGCCACCGC 
5851 
GGTGGAGCTC CAGCTrITGT TCCCTTTAGT GAGGGTTAAT TGCGCGC 
Black = pBluescript II vector sequence 
Brown = CC10 promoter 
Blue = Floxed STOP sequence 
Green = Rabbit beta globin intronic and PolyA sequence 
Red = HEL/PLP (56-70) coding region 
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Appendix 26. Secreted HEL/PLP(56-70) nucleotide/protein sequence 
1- ATG AGG TCT TTG CTA ATC TTG GTG CTT TGC TTC CTG CCC CTG GCT 
1-MR S L L I LV LCF L P L A 
46- GCT CTG GGG AAA GTC TTT GGA CGA TGT GAG TTG GCA GCG GCT ATG 
16-A L G K V F G R CE L A A A M 
91- AAG CGT CAC GGA CTT GAT AAC TAT CGG GGA TAC AGC CTG GGA AAC 
31-K RHGLDNYR G YS L G N 
136-TGG GTG TGT GCC GCA AAA TTC GAG AGT AAC TTC AAC ACC CAG GCT 
46-WV CA AK FE S N F N T QA 
181-ACA GGC GCC AAA AAC TAC CAG GAC TAT GAG TAT CTC ATT AAT GTG 
61-T G A K N YQDYE YLINV 
226-ATT CAT GCT TTC CAG TAT GTC ATC TAT GGA ACC CGC GGA AAC CGT 
76-IHA F Q YV I Y G T R G N R 
271-AAC ACC GAT GGG AGT ACC GAC TAC GGA ATC CTA CAG ATC AAC AGC 
91-N T D G S T D Y G I L Q I N S 
316-CGC TGG TGG TGC AAC GAT GGC AGG ACC CCA GGC TCC AGG AAC CTG 
106-R WWCND G R T P G SRNL 
361-TGC AAC ATC CCG TGC TCA GCC CTG CTG AGC TCA GAC ATA ACA GCG 
121-C N I P C S A L L S SDI TA 
406-AGC GTG AAC TGC GCG AAG AAG ATC GTC AGC GAT GGA AAC GGC ATG 
136-S V N C A K K IV SD GNGM 
451-AAC GCG TGG GTC GCC TGG CGC AAC CGC TGC AAG GGC ACC GAC GTC 
151-N A W YAW N   RNR C K G TD V 
496-CAG GCG TGG ATC AGA GGC TGC CGG CTG 
166-Q A W I R G C R L 
Black = HEL 
Red = PLP (56-70) 
Green = joining sequence 
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Appendix 27. Inverted stop sequence SIPLP construct - complete 
nucleotide sequence  
1 
GCGCGCAATT AACCCTCACT AAAGGGAACA AAAGCTGGCG GGCCCCCCCT 
51 
CGAGGTCGAC GGTATCGATA AGCTTATCGA TTTCGAACCC TGTAGCAGGG 
101 
CCTCTGTGCA GCAGAGGGTG CACACTACAG GTTGTGCACA CGCGTGTGCG 
151 
TGCATGCATG CAAGGGTGCA CATGCACAGG GTGGAGGTCA GAGGTCAACG 
201 
TCAGGTGTCT TCGTCTGTCA CCCACAGTCT TGTTTTTCAG ACAGGACTTC 
251 
TCACTGAATC TGAATCCTGC CCATTTGATG GGCTCATCAG TCAGTTTCCA 
301 
GGTTTCCCTG GTCCCCACCT CCCCAGGGCT GGAATTCAAG GCATATCTAG 
351 
CTTTTTTGCA TGAATGTTTG AGAGCCAAAT TCAGTTCCTC ATACTTGCCC 
401 
AATAGGCATA GTATATCCAC TGAGCCATGT CCCCAACTCA TTATGTTCAC 
451 
CTCATTCATT CATTCATCCA TCCATCCATC CATCCATCCA TTCATTCATT 
501 
CAGGTTTGGT TTGGTTTGGT TTTAGTGTTT TGGGTTTTTT TTCAAGACAG 
551 
GGTTTCTCTG TGTAGCCCTG GCTGCCCTGA AACTAACTTT CTTACTTACT 
601 
TTCTTTCTTT CTTCCTTCCT TCCTTTCTTT CTTTAAGTTG GTTTGGGTTT 
651 
TTTGGGGGGG GGAGGGTTTG GGTTTTTTTG TTTGTTTGTA TTTTATTCAA 
701 
GGAAAGGCTC CTCTGGGTTG CCCTGGCTGC CCTGGAAGGA ATTCTATAGC 
751 
CAGGCTGACC ATGAACTCAG AAATCTACCT GCCTCTCCCT CTGCCTCCCA 
801 
AGTGCTAGGA TTAAAGGTGT GTGACACACA CACAACTGGC TCTACATTTG 
851 
ACACTCACAG TATTCTGCAC ACAGCCACAG GGCTGTATCG CTAAGAGGCC 
901 
ATGTCACAGG TCCAGGAAGG CTTCACTGTT TAATAACTGG TTTGGAATTT 
951 
GGAAGTGGGA AAGTATGTAG AGACAATCTC ACTCTAGGAC TCAAAGACAG 
1001 
AGATAAAATG CTCTTTAGAA ACCTATTCTG TGGGGGAACA GAATCAGAAC 
346 
1051 
TCTATGTCAG CCTCTGTGCT AGCTGGGGTC AGGCCAGAGA CACAGAAATG 
1101 
AGCTAAGCCT ACAGTGAGAA CTGATACGCA GGACAGTTGA GAACAATGGG 
1151 
AAAGTGCATC TGAAGGGCCC AAGGCCACTA GGAAAAAGGC AACCCAAAAT 
1201 
GCCCACAACT TTAAATCCCC TTCCTGATGT GTCATTAGAT GCAAACGGCC 
1251 
CTGGGGAGGA TGTGACGTTA AACAAGGCAG TGTTCTGTAC AGGGGCAGAT 
1301 
CCTGCAGTTA CTGGAAGCTG AAGGCTCCAG GCTGACCACA CTAGGTAGGA 
1351 
AGTTCATGAA ATGAGCTCTC GAAGCGCCTC TTCAGGTCTT CCCCGATGTC 
1401 
CAGCCCCACC AGCACCGTAG CAGGTACTGG GCATCTATTG ATTGGGTGGG 
1451 
TAGGTGAACA TTTGAGACAA CCTGGAAGTT TAAATGGGAT TTGTGGAAAT 
1501 
AGAGAGGGTG TTGGTTCCAG CCAAGCCAGG TTCCATGCTA AGACATAAAA 
1551 
GCACTGGAGA AGTAAAAGAG TTAACGCTGA ACATGGCCGT GGGAAGCGAG 
1601 
GAGACCAAGG TAAAGCCTGG GAATGGCTAA CACTTGAGAA CTGTCAACAT 
1651 
CATGAAAGGA TAAGAAAGAA TGGCCAAGGA AAGAAAACAG GAAAGAGCTG 
1701 
AGTGTGGGAG AGGCCTGGAG AGAATGGGGC AAGAAGTGGG AGGCTAAAGG 
1751 
GTAAGGGCAA GGGAGGGTCA AGTCAGATGA GGACTGAAGG TGCTTTCAAC 
1801 
TGGTAGGACT TGAGGGCTGC TCTGGGTAGG AGCCAGCCCG GTCTGGGCCC 
1851 
TGGGTCTCTC ATGTGTTCTA TGGAGAAGTC TTTATATTTG TTCATGTGTA 
1901 
TTGTATGTGG GCTCTAACCT GGCCAACAAT GCCCAAGAAT CAAGTGATTT 
1951 
TTGTGGCTTG AAGTCTAGCC ACCTTCCTTG GAGGGAGGCA ATAGAAGGAG 
2001 
CCTAGTGACA TCTCGGACGG AGTCTGGGGT CTTTGTCCTT CCCCTTGATC 
2051 
CCTGAAGGGT CTCCAGCCTC TGGTTCTCCA GGGTTGGCAA GTCTACAATT 
2101 
GCTTCCCGGA ACCTGGAGTG CTCAGTGCTT GACTTTAAAG AGGACACAGG 
2151 
TGCCTACAGT TCCACGACCT CTGGGTTCCC CGACGCCCCC CCCCCCGCAC 
347 
2201 
TGCCCATTGC CCAAACACCC CACAAGTGGC CTATTGTGTG AGCTCAGTTT 
2251 
CAATGGGAAA AGAAACTGGG TTTATGAAAA GAGATTATTT GCTTATTGCA 
2301 
TGGAGATGAC TAAGTAAATA GTGCAATTTC TTGAGTGGAG CACAATCCCT 
2351 
GCCCCTACCT CTTGTGGGCT GCCAGGAACA TATAAAAAGC CACACGCATA 
2401 
CCCACACATA CCCACACATA CCCTCACATT ACAACATCAG CCCACATCTA 
2451 
CAGACAGCCC AAGCTTGGTA CCTCTCCGCG GTGGCGGCCG CAATGGCCAG 
2501 
f 51   TACGAAGTTA TATTAAGGGT TCCGGATCCT CGGGGACACC AAATATGGCG} 
 loxP 
site 
2601 
ATCTCGGCCT TTTCGTTTCT TGGAGCTGGG ACATGTTTGC CATCGATCCA 
2651 
TCTACCACCA GAACGGCCGT TAGATCTGCT GCCACCGTTG TTTCCACCGA 
2701 
AGAAACCACC GTTGCCGTAA CCACCACGAC GGTTGTTGCT AAAGAAGCTG 
2751 
CCACCGCCAC GGCCACCGTT GTAGCCGCCG TTGTTGTTAT TGTAGTTGCT 
2801 
ACTGTTATTT CTGGCACTTC TTGGTTTTCC TCTTAAGTGA GGAGGAACAT 
2851 
AACCATTCTC GTTGTTGTCG TTGATGCTTA AATTTTGCAC TTGTTCGCTC 
2901 
AGTTCAGCCA TAATATGAAA TGCTTTTCTT GTTGTTCTTA CGGAATACCA 
2951 
CTTGCCACCT ATCACCACAA CTAACTTTTT CCCGTTCCTC CATCTCTTTT 
3001 
ATATTTTTTT TCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG 
3051 
TGACATAATT GGACAAACTA CCTACAGAGA TTTAAAGCTC TAAGGTAAAT 
3101 
ATAAAATTTT TAAGTGTATA ATGTGTTAAA CTACTGATTC TAATTGTTTG 
3151 
TGTATTTTAG ATTCCAACCT ATGGAACTGA TGAATGGGAG CAGTGGTGGA 
3201 
ATGCCTTTAA TGAGGAAAAC CTGTTTTGCT CAGAAGAAAT GCCATCTAGT 
3251 
GATGATGAGG CTACTGCTGA CTCTCAACAT TCTACTCCTC CAAAAAAGAA 
3301 
GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT 
TACTAGTGAA CCTCTTCGAG GGACCTAATA ACTTCGTATA GCATACATTA 
348 
3351 
TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTTAC 
3401 
ACCACAAAGG AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA 
3451 
TTCTGTAACC TTTATAAGTA GGCATAACAG TTATAATCAT AACATACTGT 
3501 
TTTTTCTTAC TCCACACAGG CATAGAGTGT CTGCTATTAA TAACTATGCT 
3551 
CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAAGGGG TTAATAAGGA 
3601 
ATATTTGATG TATAGTGCCT TGACTAGAGA TCATAATCAG CCATACCACA 
3651 
TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCCACACC TCCCCCTGAA 
3701 
CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG 
3751 
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA 
3801 
GCATTTTTTT CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT 
3851 
ATCTTATCAT GTCTGGATCT GACATGGTAA GTAAGCTTGG GCTGCAGGTC 
3901 
GAGGGACCTA ATAACTTCGT ATAGCATACA TTATACGAAG TTATATTAAG}  loxP 
3951 	 site 
GGTTCCGGAT CCTAAGCTTG ATGGAATTCT TGAAGACGAA AGGGCCTCGT 
4001 
GATACGCCTA TTTTTATAGG TTAATGTCAT GATAATAATG GTTTCTTAGA 
4051 
CGTGCGGCCG CTCTAGAACT AGTGGATCCC CCGGGCTGCA GGAATTCGAT 
4101 
ATCAAGCTTA TCGATACCGT CGACCTCGAG GGGGGGCCCG GTACCGAGCT 
4151 
CGGATCCTGA GAACTTCAGG GTGAGTTTGG GGACCCTTGA TTGTTCTTTC 
4201 
TTTTTCGCTA TTGTAAAATT CATGTTATAT GGAGGGGGCA AAGTTTTCAG 
4251 
GGTGTTGTTT AGAATGGGAA GATGTCCCTT GTATCACCAT GGACCCTCAT 
4301 
GATAATTTTG TTTCTTTCAC TTTCTACTCT GTTGACAACC ATTGTCTCCT 
4351 
CTTATTTTCT TTTCATTTTC TGTAACTTTT TCGTTAAACT TTAGCTTGCA 
4401 
TTTGTAACGA ATTTTTAAAT TCACTTTTGT TTATTTGTCA GATTGTAAGT 
4451 
ACTTTCTCTA ATCACTTTTT TTTCAAGGCA ATCAGGGTAT ATTATATTGT 
349 
4501 
ACTTCAGCAC AGTTTTAGAG AACAATTGTT ATAATTAAAT GATAAGGTAG 
4551 
AATATTTCTC CATATAAATT CTGGCTGGCG TGGAAATATT CTTATTGGTA 
4601 
GAAACAACTA CACCCTGGTC ATCATCCTGC CTTTCTCTTT ATGGTTACAA 
4651 
TGATATACAC TGTTTGAGAT GAGGATAAAA TACTCTGAGT CCAAACCGGG 
4701 
CCCCTCTGCT AACCATGTTC ATGCCTTCTT CTCTTTCCTA CAGCTCCTGG 
4751 
GCAACGTGCT GGTTGTTGTG CTGTCTCATC ATTTTGGCAA AGAATTCTGG 
4801 
CAACATGAGG TCTTTGCTAA TCTTGGTGCT TTGCTTCCTG CCCCTGGCTG 
4851 
CTCTGGGGAA AGTCTTTGGA CGATGTGAGT TGGCAGCGGC TATGAAGCGT 
4901 
CACGGACTTG ATAACTATCG GGGATACAGC CTGGGAAACT GGGTGTGTGC 
4951 
CGCAAAATTC GAGAGTAACT TCAACACCCA GGCTACAGGC GCCAAAAACT 
5001 
ACCAGIGACTA TGAGTATCTC ATTAATGTGA TTCATGCTTT CCAGTATGTC11  PLP(56- 
5051 	 701 
ATCTATGGAA CCCGCGGAAA CCGTAACACC GATGGGAGTA CCGACTACGG 
5101 
AATCCTACAG ATCAACAGCC GCTGGTGGTG CAACGATGGC AGGACCCCAG 
5151 
GCTCCAGGAA CCTGTGCAAC ATCCCGTGCT CAGCCCTGCT GAGCTCAGAC 
5201 
ATAACAGCGA GCGTGAACTG CGCGAAGAAG ATCGTCAGCG ATGGAAACGG 
5251 
CATGAACGCG TGGGTCGCCT GGCGCAACCG CTGCAAGGGC ACCGACGTCC 
5301 
AGGCGTGGAT CAGAGGCTGC CGGCTGTGAG GAGCTGCCGG AATTCACTCC 
5351 
TCAGGTGCAG GCTGCCTATC AGAAGGTGGT GGCTGGTGTG GCCAATGCCC 
5401 
TGGCTCACAA ATACCACTGA GATCGATCTT TTTCCCTCTG CCAAAAATTA 
5451 
TGGGGACATC ATGAAGCCCC TTGAGCATCT GACTTCTGGC TAATAAAGGA 
5501 
AATTTATTTT CATTGCAATA GTGTGTTGGA ATTTTTTGTG TCTCTCACTC 
5551 
GGAAGGACAT ATGGGAGGGC AAATCATTTA AAACATCAGA ATGAGTATTT 
5601 
GGTTTAGAGT TTGGCAACAT ATGCCCATAT GCTGGCTGCC ATGAACAAAG 
350 
5651 
GTTGGCTATA AAGAGGTCAT CAGTATATGA AACAGCCCCC TGCTGTCCAT 
5701 
TCCTTATTCC ATAGAAAAGC CTTGACTTGA GGTTAGATTT TTTTTATATT 
5751 
TTGTTTTGTG TTATTTTTTT CTTTAACATC CCTAAAATTT TCCTTACATG 
5801 
TTTTACTAGC CAGATTTTTC CTCCTCTCCT GACTACTCCC AGTCATAGCT 
5851 
GTCCCTCTTC TCTTATGGAG ATCCCTCGAG CATGCATCTA GAGCGGCCGC 
5901 
CACCGCGGTG GAGCTCCAGC TTTTGTTCCC TTTAGTGAGG GTTAATTGCG 
5951 
CGC 
Black = pBluescript II vector sequence 
Brown = CC10 promoter 
Blue = Floxed STOP sequence 
Green = Rabbit beta globin intronic and PolyA sequence 
Red = HEL/PLP (56-70) coding region 
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Appendix 28. Lung targeted h1L-8 construct - complete nucleotide 
sequence  
1 
GCGCGCAATT AACCCTCACT AAAGGGAACA AAAGCTGGG ACCGGGCCCC 
51 
CCCTCGAGGT CGACGGTATC GATAAGCTTA TCGATTTCGA ACCCTGTAGC 
101 
AGGGCCTCTG TGCAGCAGAG GGTGCACACT ACAGGTTGTG CACACGCGTG 
151 
TGCGTGCATG CATGCAAGGG TGCACATGCA CAGGGTGGAG GTCAGAGGTC 
201 
AACGTCAGGT GTCTTCGTCT GTCACCCACA GTCTTGTTTT TCAGACAGGA 
251 
CTTCTCACTG AATCTGAATC CTGCCCATTT GATGGGCTCA TCAGTCAGTT 
301 
TCCAGGTTTC CCTGGTCCCC ACCTCCCCAG GGCTGGAATT CAAGGCATAT 
351 
CTAGCTTTTT TGCATGAATG TTTGAGAGCC AAATTCAGTT CCTCATACTT 
401 
GCCCAATAGG CATAGTATAT CCACTGAGCC ATGTCCCCAA CTCATTATGT 
451 
TCACCTCATT CATTCATTCA TCCATCCATC CATCCATCCA TCCATTCATT 
501 
CATTCAGGTT TGGTTTGGTT TGGTTTTAGT GTTTTGGGTT TTTTTTCAAG 
551 
ACAGGGTTTC TCTGTGTAGC CCTGGCTGCC CTGAAACTAA CTTTCTTACT 
601 
TACTTTCTTT CTTTCTTCCT TCCTTCCTTT CTTTCTTTAA GTTGGTTTGG 
651 
GTTTTTTGGG GGGGGGAGGG TTTGGGTTTT TTTGTTTGTT TGTATTTTAT 
701 
TCAAGGAAAG GCTCCTCTGG GTTGCCCTGG CTGCCCTGGA AGGAATTCTA 
751 
TAGCCAGGCT GACCATGAAC TCAGAAATCT ACCTGCCTCT CCCTCTGCCT 
801 
CCCAAGTGCT AGGATTAAAG GTGTGTGACA CACACACAAC TGGCTCTACA 
851 
TTTGACACTC ACAGTATTCT GCACACAGCC ACAGGGCTGT ATCGCTAAGA 
901 
GGCCATGTCA CAGGTCCAGG AAGGCTTCAC TGTTTAATAA CTGGTTTGGA 
951 
ATTTGGAAGT GGGAAAGTAT GTAGAGACAA TCTCACTCTA GGACTCAAAG 
1001 
ACAGAGATAA AATGCTCTTT AGAAACCTAT TCTGTGGGGG AACAGAATCA 
352 
1051 
GAACTCTATG TCAGCCTCTG TGCTAGCTGG GGTCAGGCCA GAGACACAGA 
1101 
AATGAGCTAA GCCTACAGTG AGAACTGATA CGCAGGACAG TTGAGAACAA 
1151 
TGGGAAAGTG CATCTGAAGG GCCCAAGGCC ACTAGGAAAA AGGCAACCCA 
1201 
AAATGCCCAC AACTTTAAAT CCCCTTCCTG ATGTGTCATT AGATGCAAAC 
1251 
GGCCCTGGGG AGGATGTGAC GTTAAACAAG GCAGTGTTCT GTACAGGGGC 
1301 
AGATCCTGCA GTTACTGGAA GCTGAAGGCT CCAGGCTGAC CACACTAGGT 
1351 
AGGAAGTTCA TGAAATGAGC TCTCGAAGCG CCTCTTCAGG TCTTCCCCGA 
1401 
TGTCCAGCCC CACCAGCACC GTAGCAGGTA CTGGGCATCT ATTGATTGGG 
1451 
TGGGTAGGTG AACATTTGAG ACAACCTGGA AGTTTAAATG GGATTTGTGG 
1501 
AAATAGAGAG GGTGTTGGTT CCAGCCAAGC CAGGTTCCAT GCTAAGACAT 
1 551 
AAAAGCACTG GAGAAGTAAA AGAGTTAACG CTGAACATGG CCGTGGGAAG 
1601 
CGAGGAGACC AAGGTAAAGC CTGGGAATGG CTAACACTTG AGAACTGTCA 
1651 
ACATCATGAA AGGATAAGAA AGAATGGCCA AGGAAAGAAA ACAGGAAAGA 
1701 
GCTGAGTGTG GGAGAGGCCT GGAGAGAATG GGGCAAGAAG TGGGAGGCTA 
1751 
AAGGGTAAGG GCAAGGGAGG GTCAAGTCAG ATGAGGACTG AAGGTGCTTT 
1801 
CAACTGGTAG GACTTGAGGG CTGCTCTGGG TAGGAGCCAG CCCGGTCTGG 
1851 
GCCCTGGGTC TCTCATGTGT TCTATGGAGA AGTCTTTATA TTTGTTCATG 
1901 
TGTATTGTAT GTGGGCTCTA ACCTGGCCAA CAATGCCCAA GAATCAAGTG 
1951 
ATTTTTGTGG CTTGAAGTCT AGCCACCTTC CTTGGAGGGA GGCAATAGAA 
2001 
GGAGCCTAGT GACATCTCGG ACGGAGTCTG GGGTCTTTGT CCTTCCCCTT 
2051 
GATCCCTGAA GGGTCTCCAG CCTCTGGTTC TCCAGGGTTG GCAAGTCTAC 
2101 
AATTGCTTCC CGGAACCTGG AGTGCTCAGT GCTTGACTTT AAAGAGGACA 
2151 
CAGGTGCCTA CAGTTCCACG ACCTCTGGGT TCCCCGACGC CCCCCCCCCC 
353 
2201 
GCACTGCCCA TTGCCCAAAC ACCCCACAAG TGGCCTATTG TGTGAGCTCA 
2251 
GTTTCAATGG GAAAAGAAAC TGGGTTTATG AAAAGAGATT ATTTGCTTAT 
2301 
TGCATGGAGA TGACTAAGTA AATAGTGCAA TTTCTTGAGT GGAGCACAAT 
2351 
CCCTGCCCCT ACCTCTTGTG GGCTGCCAGG AACATATAAA AAGCCACACG 
2401 
CATACCCACA CATACCCACA CATACCCTCA CATTACAACA TCAGCCCACA 
2451 
TCTACAGACA GCCCAAGCTT GATATCGAAT TCCTGCAGCC CGGGGGATCC 
2501 
TGAGAACTTC AGGGTGAGTT TGGGGACCCT TGATTGTTCT TTCTTTTTCG 
2551 
CTATTGTAAA ATTCATGTTA TATGGAGGGG GCAAAGTTTT CAGGGTGTTG 
2601 
TTTAGAATGG GAAGATGTCC CTTGTATCAC CATGGACCCC CATGATAATT 
2651 
TTGTTTCTTT CACTTTCTAC TCTGTTGACA ACCATTGTCT CCTCTTATTT 
2701 
TCTTTTCATT TTCTGTAACT TTTTCGTTAA ACTTTAGCTT GCATTTGTAA 
2751 
CGAATTTTTA AATTCACTTT TGTTTATTTG TCAGATTGTA AGTACTTTCT 
2801 
CTAATCACTT TTTTTTCAAG GCAATCAGGG TATATTATAT TGTACTTCAG 
2851 
CACAGTTTTA GAGAACAATT GTTATAATTA AATGATAAGG TAGAATATTT 
2901 
CTGCATATAA ATTCTGGCTG GCGTGGAAAT ATTCTTATTG GTAGAAACAA 
2951 
CTACACCCTG GTCATCATCC TGCCTTTCTC TTTATGGTTA CAATGATATA 
3001 
CACTGTTTGA GATGAGGATA AAATACTCTG AGTCCAAACC GGGCCCCTCT 
3051 
GCTAACCATG TTCATGCCTT CTTCTCTTTC CTACAGCTCC TGGGCAACGT 
3101 
GCTGGTTGTT GTGCTGTCTC ATCATTTTGG CAAAGAATTC TGTAAACATG 
3151 
ACTTCCAAGC TGGCCGTGGC TCTCTTGGCA GCCTTCCTGA TTTCTGCAGC 
3201 
TCTGTGTGAA GGTGCAGTTT TGCCAAGGAG TGCTAAAGAA CTTAGATGTC 
3251 
AGTGCATAAA GACATACTCC AAACCTTTCC ACCCCAAATT TATCAAAGAA 
3301 
CTGAGAGTGA TTGAGAGTGG ACCACACTGC GCCAACACAG AAATTATTGT 
354 
3351 
AAAGCTTTCT GATGGAAGAG AGCTCTGTCT GGACCCCAAG GAAAACTGGG 
3401 
TGCAGAGGGT TGTGGAGAAG TTTTTGAAGA GGGCTGAGAA CTCATAAGAA 
3451 
TTCACTCCTC AGGTGCAGGC TGCCTATCAG AAGGTGGTGG CTGGTGTGGC 
3501 
CAATGCCCTG GCTCACAAAT ACCACTGAGA TCGATCTTTT TCCCTCTGCC 
3551 
AAAAATTATG GGGACATCAT GAAGCCCCTT GAGCATCTGA CTTCTGGCTA 
3601 
ATAAAGGAAA TTTATTTTCA TTGCAATAGT GTGTTGGAAT TTTTTGTGTC 
3651 
TCTCACTCGG AAGGACATAT GGGAGGGCAA ATCATTTAAA ACATCAGAAT 
3701 
GAGTATTTGG TTTAGAGTTT GGCAACATAT GCCCATATGC TGGCTGCCAT 
3751 
GAACAAAGGT TGGCTATAAA GAGGTCATCA GTATATGAAA CAGCCCCCTG 
3801 
CTGTCCATTC CTTATTCCAT AGAAAAGCCT TGACTTGAGG TTAGATTTTT 
3851 
TTTATATTTT GTTTTGTGTT ATTTTTTTCT TTAACATCCC TAAAATTTTC 
3901 
CTTACATGTT TTACTAGCCA GATTTTTCCT CCTCTCCTGA CTACTCCCAG 
3951 
TCATAGCTGT CCCTCTTCTC TTATGGAGAT CCCTCGAGCA TGCATCTAGA 
4001 
GCGGCCGCCA CCGCGGTGGA GCTCCAGCTT TTGTTCCCTT TAGTGAGGGT 
4051 
TAATTGCGCG C 
Black = pBluescript II vector sequence 
Brown = CC10 promoter 
Green = Rabbit beta globin intronic and PolyA sequence 
Blue = Human IL-8 
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Appendix 29. hIL-8 nucleotide/protein sequence 
1- ATG ACT TCC AAG CTG GCC GTG GCT CTC TTG GCA GCC TTC CTG ATT 
1-MT S K L A V A L L A A F L I 
46- TCT GCA GCT CTG TGT GAA GGT GCA GTT TTG CCA AGG AGT GCT AAA 
16-SA AL CEGA V L P R SA K 
91- GAA CTT AGA TGT CAG TGC ATA AAG ACA TAC TCC AAA CCT TTC CAC 
31EL R CQCIK T Y S K P F H 
136- CCC AAA TTT ATC AAA GAA CTG AGA GTG ATT GAG AGT GGA CCA CAC 
46-P K F I K E L R VIES GP H 
181- TGC GCC AAC ACA GAA ATT ATT GTA AAG CTT TCT GAT GGA AGA GAG 
61-CAN T E II V K L S D G R E 
226- CTC TGT CTG GAC CCC AAG GAA AAC TGG GTG CAG AGG GTT GTG GAG 
76-LCLDPK E NWVQR VV E 
271- AAG TTT TTG AAG AGG GCT GAG AAC TCA 
91-K F L K R A E N S 
Red = mutated base pair (T—>C) 
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Appendix 30. Inflammatory cell scoring system 
 
Score 	 Bronchi Blood vessels 
0. 
Bronchi or blood vessel is 
not surrounded by any 
inflammatory cells 
1.  
Bronchi or blood vessels is 
surrounded by the 
occasional inflammatory 
cell 
2.  
Inflammation completely 
surrounds and is 1-4 cells 
in diameter from the edge 
of the bronchi or vessel 
3.  
Inflammation 
completely surrounds 
and is 5 or more cells in 
diameter from the edge 
of the bronchi or vessel 
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